[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fkucaQjVKmf3F_2I_q07mdH0bTf8OC425enKBV-4IUMo":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":86,"rows":93},"Samsung Medical Center",[4],978,false,135,63,13853802,51,571,[14,17,20,23,26,29,32,34],{"name":15,"count":16},"Stroke",38,{"name":18,"count":19},"Coronary Artery Disease",29,{"name":21,"count":22},"Breast Cancer",24,{"name":24,"count":25},"Gastric Cancer",19,{"name":27,"count":28},"Non-small Cell Lung Cancer",13,{"name":30,"count":31},"Hepatocellular Carcinoma",11,{"name":33,"count":31},"Benign Prostatic Hyperplasia",{"name":35,"count":36},"Ischemic Heart Disease",10,[38,43,48,53,58,63,68,72,77,82],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT06977685","Effect of Non-Selective Beta-Blockers on Outcomes in Cirrhosis Patients After Hospitalization: A Retrospective Cohort Using Target Trial Design","2023-10-31","Non-selective beta-blockers",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT06041893","Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide","2025-07-05","ATG-LDPTCy",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT04909164","The Prospective Non-randomized Case-control Study From Real-world Lung Cancer Patients","2025-07-30","Immunnotherapy group",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT04899479","Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention","2025-08-31","SGLT2 inhibitor",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT01632475","Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia","2025-09","Pneumostem®",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT05773950","Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention","2025-12","fosaprepitant",{"nctId":69,"briefTitle":70,"date":66,"intervention":71},"NCT02890953","Efficacy and Safety of Pneumostem® for IVH in Premature Infants (Phase 2a)","Pneumostem",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT04819243","PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study","2025-12-30","Pabociclib, Endocrine(or ET + CDK4\u002F6 inhibitors), Talazoparib, Atezolizumab",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT06115031","Remimazolam vs. Propofol: Impact on Postoperative Delirium in Neurosurgical Patients","2025-12-31","Remimazolam",{"nctId":83,"briefTitle":84,"date":80,"intervention":85},"NCT07068490","Impact of Potassium Competitive Acid Blockers After Percutaneous Coronary Intervention for Efficacy and Safety Outcome: Target Trial Emulation Study.","Routine use of P-CAB on DAPT",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,146,195,233,255,281,305,333,351,378,396,425,443,469,495,513,542,600,630,655,681,707,733,757,783,805,823,849,874,897,923,963,995,1018,1177,1259,1295,1324,1349,1375,1402,1423,1444,1465,1483,1508,1530,1548,1566,1590,1616,1634,1723,1756,1791,1829,1866,1904,1943,1967,1992,2010,2034,2059,2084,2108,2132,2156,2179,2204,2228,2251,2276,2294,2319,2344,2369,2392,2415,2439,2465,2483,2501,2519,2537,2560,2583,2605,2623,2649,2672,2694,2718,2742,2767,2785,2810,2834,2859,2877,2895,2919,2942,2960,2978,3002,3028,3087,3159,3228,3285,3329,3370,3397,3419,3451,3483,3517,3541,3559,3583,3607,3630,3648,3672,3697,3721,3745,3763,3781,3806,3824,3847,3872,3895,3920,3944,3962,3980,4002,4024,4048,4066,4084,4108,4126,4150,4168,4190,4214,4239,4263,4285,4311,4329,4347,4371,4389,4441,4476,4510,4540,4592,4644,4686,4724,4750,4783,4818,4850,4883,4915,4950,4989,5011,5041,5063,5085,5115,5150,5180,5208,5243,5271,5297,5325,5359,5381,5409,5437,5464,5486,5509,5533,5557,5581,5605,5629,5652,5675,5701,5719,5737,5760,5784,5802,5826,5852,5870,5894,5922,5940,5966,5991,6009,6027,6050,6072,6097,6115,6133,6151,6173,6191,6209,6235,6259,6277,6295,6313,6331,6355,6378,6401,6427,6445,6463,6481,6505,6527,6551,6569,6587,6605,6623,6641,6659,6683,6701,6719,6742,6767,6791,6812,6836,6857,6878,6902,6926,6948,6972,6997,7022,7044,7067,7093,7111,7133,7151,7174,7197,7222,7240,7264,7285,7308,7326,7348,7366,7390,7408,7431,7456,7480,7505,7523,7541,7565,7587,7611,7629,7652,7670,7688,7706,7732,7750,7773,7796,7820,7843,7865,7887,7913,7935,7958,7981,8003,8025,8048,8066,8084,8106,8127,8148,8166,8189,8210,8228,8250,8313,8363,8406,8448,8493,8526,8552,8588,8621,8652,8681,8709,8747,8775,8800,8830,8861,8894,8916,8943,8974,9000,9022,9045,9072,9090,9108,9139,9162,9185,9207,9231,9254,9277,9302,9325,9347,9365,9389,9414,9438,9461,9479,9497,9521,9539,9564,9582,9603,9626,9644,9666,9688,9710,9728,9752,9770,9788,9814,9832,9850,9873,9891,9914,9932,9956,9979,9997,10020,10043,10061,10086,10104,10122,10140,10161,10185,10203,10225,10243,10261,10286,10309,10330,10348,10370,10392,10415,10438,10456,10478,10496,10520,10541,10566,10589,10610,10637,10658,10681,10705,10728,10754,10772,10795,10818,10839,10862,10884],{"intervention":57,"totalTrials":95,"cells":96},3,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":129},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":128,"soonestReadout":56},[108,117],{"nctId":54,"briefTitle":55,"status":109,"phases":110,"primaryCompletion":56,"completion":75,"start":111,"enrollment":112,"conditions":113,"interventions":116},"RECRUITING",[91],"2021-07-05",200,[114,115],"Acute Myocardial Infarction","Heart Failure",[57],{"nctId":118,"briefTitle":119,"status":120,"phases":121,"primaryCompletion":80,"completion":122,"start":123,"enrollment":124,"conditions":125,"interventions":127},"NCT06350487","The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction","NOT_YET_RECRUITING",[91],"2026-06-30","2024-05-01",154,[126],"Heart Failure, Preserved Ejection Fraction",[57],2,{"trials":130,"activeCount":99},[131],{"nctId":132,"briefTitle":133,"status":134,"phases":135,"primaryCompletion":136,"completion":136,"start":137,"enrollment":138,"conditions":139,"interventions":143},"NCT07332156","Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas","COMPLETED",[],"2023-12-31","2009-01-01",21692,[140,141,142],"Type 2 Diabetes","COPD (Chronic Obstructive Pulmonary Disease)","Lung Cancer (Diagnosis)",[57,144,145],"Sulfonylureas","DPP4 inhibitors",{"intervention":147,"totalTrials":95,"cells":148},"Propofol",{"EARLY_PHASE1":149,"PHASE1":151,"PHASE2":153,"PHASE3":155,"PHASE4":157,"NA":172},{"trials":150,"activeCount":99},[],{"trials":152,"activeCount":99},[],{"trials":154,"activeCount":99},[],{"trials":156,"activeCount":99},[],{"trials":158,"activeCount":171,"soonestReadout":163},[159],{"nctId":160,"briefTitle":161,"status":109,"phases":162,"primaryCompletion":163,"completion":163,"start":164,"enrollment":165,"conditions":166,"interventions":169},"NCT06330038","Anesthesia and Non-small Cell Lung Cancer Recurrence",[91],"2028-12-31","2024-08-05",5384,[27,167,168],"Surgery","Anesthesia",[147,170],"Inhaled anesthetics",1,{"trials":173,"activeCount":171,"soonestReadout":80},[174,182],{"nctId":78,"briefTitle":79,"status":109,"phases":175,"primaryCompletion":80,"completion":176,"start":177,"enrollment":178,"conditions":179,"interventions":181},[92],"2026-12-31","2024-01-29",696,[180],"Postoperative Delirium",[81,147],{"nctId":183,"briefTitle":184,"status":185,"phases":186,"primaryCompletion":187,"completion":187,"start":188,"enrollment":99,"conditions":189,"interventions":193},"NCT05835713","Total Intravenous Anesthesia for Rigid Bronchoscopy Using Remimazolam","WITHDRAWN",[92],"2024-04","2023-04",[190,191,192],"Respiratory Disease","Tracheal Stenosis","Endobronchial Mass",[194,147],"Remimazolam besylate",{"intervention":196,"totalTrials":128,"cells":197},"Rebamipide 2% ophthalmic solution",{"EARLY_PHASE1":198,"PHASE1":200,"PHASE2":202,"PHASE3":204,"PHASE4":206,"NA":231},{"trials":199,"activeCount":99},[],{"trials":201,"activeCount":99},[],{"trials":203,"activeCount":99},[],{"trials":205,"activeCount":99},[],{"trials":207,"activeCount":171,"soonestReadout":225},[208,221],{"nctId":209,"briefTitle":210,"status":134,"phases":211,"primaryCompletion":212,"completion":212,"start":213,"enrollment":214,"conditions":215,"interventions":218},"NCT07397936","Rebamipide Versus Diquafosol and Cyclosporine for Perioperative Dry Eye in Cataract Surgery",[91],"2025-05-01","2024-08-01",55,[216,217],"Dry Eye Disease (DED)","Cataract",[196,219,220],"Diquafosol 3% ophthalmic solution","Cyclosporine 0.05% ophthalmic solution",{"nctId":222,"briefTitle":223,"status":120,"phases":224,"primaryCompletion":225,"completion":226,"start":227,"enrollment":228,"conditions":229,"interventions":230},"NCT07397949","Rebamipide Versus Diquafosol for Perioperative Dry Eye in Cataract Surgery",[91],"2026-12","2027-03","2026-03",60,[216,217],[196,219],{"trials":232,"activeCount":99},[],{"intervention":219,"totalTrials":128,"cells":234},{"EARLY_PHASE1":235,"PHASE1":237,"PHASE2":239,"PHASE3":241,"PHASE4":243,"NA":253},{"trials":236,"activeCount":99},[],{"trials":238,"activeCount":99},[],{"trials":240,"activeCount":99},[],{"trials":242,"activeCount":99},[],{"trials":244,"activeCount":171,"soonestReadout":225},[245,249],{"nctId":209,"briefTitle":210,"status":134,"phases":246,"primaryCompletion":212,"completion":212,"start":213,"enrollment":214,"conditions":247,"interventions":248},[91],[216,217],[196,219,220],{"nctId":222,"briefTitle":223,"status":120,"phases":250,"primaryCompletion":225,"completion":226,"start":227,"enrollment":228,"conditions":251,"interventions":252},[91],[216,217],[196,219],{"trials":254,"activeCount":99},[],{"intervention":256,"totalTrials":171,"cells":257},"Discontinuation of β-blocker",{"EARLY_PHASE1":258,"PHASE1":260,"PHASE2":262,"PHASE3":264,"PHASE4":266,"NA":279},{"trials":259,"activeCount":99},[],{"trials":261,"activeCount":99},[],{"trials":263,"activeCount":99},[],{"trials":265,"activeCount":99},[],{"trials":267,"activeCount":171,"soonestReadout":272},[268],{"nctId":269,"briefTitle":270,"status":109,"phases":271,"primaryCompletion":272,"completion":273,"start":274,"enrollment":275,"conditions":276,"interventions":278},"NCT04769362","Long-term Beta-blocker Therapy After Acute Myocardial Infarction",[91],"2026-01-31","2026-03-31","2021-05-04",2540,[277],"Myocardial Infarction",[256],{"trials":280,"activeCount":99},[],{"intervention":282,"totalTrials":171,"cells":283},"Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin",{"EARLY_PHASE1":284,"PHASE1":286,"PHASE2":288,"PHASE3":290,"PHASE4":292,"NA":303},{"trials":285,"activeCount":99},[],{"trials":287,"activeCount":99},[],{"trials":289,"activeCount":99},[],{"trials":291,"activeCount":99},[],{"trials":293,"activeCount":171,"soonestReadout":298},[294],{"nctId":295,"briefTitle":296,"status":109,"phases":297,"primaryCompletion":298,"completion":163,"start":299,"enrollment":300,"conditions":301,"interventions":302},"NCT04014803","Aspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion",[91],"2027-06-30","2020-01-13",3500,[18],[282],{"trials":304,"activeCount":99},[],{"intervention":306,"totalTrials":171,"cells":307},"Zastaprazan",{"EARLY_PHASE1":308,"PHASE1":310,"PHASE2":312,"PHASE3":314,"PHASE4":316,"NA":331},{"trials":309,"activeCount":99},[],{"trials":311,"activeCount":99},[],{"trials":313,"activeCount":99},[],{"trials":315,"activeCount":99},[],{"trials":317,"activeCount":171,"soonestReadout":322},[318],{"nctId":319,"briefTitle":320,"status":120,"phases":321,"primaryCompletion":322,"completion":323,"start":324,"enrollment":325,"conditions":326,"interventions":329},"NCT07467213","Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction",[91],"2029-12-31","2030-12-31","2026-04-01",5000,[327,328],"Acute Myocardial Infarction (AMI)","Gastrointestinal Bleeding",[306,330],"Proton Pump Inhibitors",{"trials":332,"activeCount":99},[],{"intervention":330,"totalTrials":171,"cells":334},{"EARLY_PHASE1":335,"PHASE1":337,"PHASE2":339,"PHASE3":341,"PHASE4":343,"NA":349},{"trials":336,"activeCount":99},[],{"trials":338,"activeCount":99},[],{"trials":340,"activeCount":99},[],{"trials":342,"activeCount":99},[],{"trials":344,"activeCount":171,"soonestReadout":322},[345],{"nctId":319,"briefTitle":320,"status":120,"phases":346,"primaryCompletion":322,"completion":323,"start":324,"enrollment":325,"conditions":347,"interventions":348},[91],[327,328],[306,330],{"trials":350,"activeCount":99},[],{"intervention":352,"totalTrials":171,"cells":353},"clopidogrel + aspirin",{"EARLY_PHASE1":354,"PHASE1":356,"PHASE2":358,"PHASE3":360,"PHASE4":362,"NA":376},{"trials":355,"activeCount":99},[],{"trials":357,"activeCount":99},[],{"trials":359,"activeCount":99},[],{"trials":361,"activeCount":99},[],{"trials":363,"activeCount":171,"soonestReadout":368},[364],{"nctId":365,"briefTitle":366,"status":120,"phases":367,"primaryCompletion":368,"completion":322,"start":369,"enrollment":370,"conditions":371,"interventions":374},"NCT06763744","Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR",[91],"2029-07-31","2025-06-01",3000,[372,373],"Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)","High Bleeding Risk",[375,352],"P2Y12 antagonist monotherapy",{"trials":377,"activeCount":99},[],{"intervention":170,"totalTrials":171,"cells":379},{"EARLY_PHASE1":380,"PHASE1":382,"PHASE2":384,"PHASE3":386,"PHASE4":388,"NA":394},{"trials":381,"activeCount":99},[],{"trials":383,"activeCount":99},[],{"trials":385,"activeCount":99},[],{"trials":387,"activeCount":99},[],{"trials":389,"activeCount":171,"soonestReadout":163},[390],{"nctId":160,"briefTitle":161,"status":109,"phases":391,"primaryCompletion":163,"completion":163,"start":164,"enrollment":165,"conditions":392,"interventions":393},[91],[27,167,168],[147,170],{"trials":395,"activeCount":99},[],{"intervention":397,"totalTrials":171,"cells":398},"Guideline directed statin therapy",{"EARLY_PHASE1":399,"PHASE1":401,"PHASE2":403,"PHASE3":405,"PHASE4":407,"NA":423},{"trials":400,"activeCount":99},[],{"trials":402,"activeCount":99},[],{"trials":404,"activeCount":99},[],{"trials":406,"activeCount":99},[],{"trials":408,"activeCount":171,"soonestReadout":413},[409],{"nctId":410,"briefTitle":411,"status":109,"phases":412,"primaryCompletion":413,"completion":414,"start":415,"enrollment":416,"conditions":417,"interventions":421},"NCT05845424","High-intensity Statin and Ezetimibe Therapy for Asymptomatic Patients With Positive Coronary Calcium",[91],"2029-06-30","2030-06-30","2023-07-03",6000,[418,419,420],"Coronary Artery Calcification","Metabolic Syndrome","Dyslipidemias",[397,422],"High intensity statin plus ezetimibe therapy",{"trials":424,"activeCount":99},[],{"intervention":422,"totalTrials":171,"cells":426},{"EARLY_PHASE1":427,"PHASE1":429,"PHASE2":431,"PHASE3":433,"PHASE4":435,"NA":441},{"trials":428,"activeCount":99},[],{"trials":430,"activeCount":99},[],{"trials":432,"activeCount":99},[],{"trials":434,"activeCount":99},[],{"trials":436,"activeCount":171,"soonestReadout":413},[437],{"nctId":410,"briefTitle":411,"status":109,"phases":438,"primaryCompletion":413,"completion":414,"start":415,"enrollment":416,"conditions":439,"interventions":440},[91],[418,419,420],[397,422],{"trials":442,"activeCount":99},[],{"intervention":444,"totalTrials":171,"cells":445},"This study aims to evaluate the efficacy and safety of a 14-day triple therapy regimen consisting of Zastaprazan 20 mg, clarithromycin, and amoxicillin for the eradication of Helicobacter pylori.",{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":452,"PHASE4":454,"NA":467},{"trials":447,"activeCount":99},[],{"trials":449,"activeCount":99},[],{"trials":451,"activeCount":99},[],{"trials":453,"activeCount":99},[],{"trials":455,"activeCount":171,"soonestReadout":460},[456],{"nctId":457,"briefTitle":458,"status":120,"phases":459,"primaryCompletion":460,"completion":461,"start":462,"enrollment":463,"conditions":464,"interventions":466},"NCT07115173","Clinical Trial to Evaluate the Efficacy of Probit-Based Triple Therapy for Helicobacter Pylori Eradication",[91],"2027-06-01","2027-12-31","2025-12-01",103,[465],"Helicobacter Infection",[444],{"trials":468,"activeCount":99},[],{"intervention":470,"totalTrials":171,"cells":471},"Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day",{"EARLY_PHASE1":472,"PHASE1":474,"PHASE2":476,"PHASE3":478,"PHASE4":480,"NA":493},{"trials":473,"activeCount":99},[],{"trials":475,"activeCount":99},[],{"trials":477,"activeCount":99},[],{"trials":479,"activeCount":99},[],{"trials":481,"activeCount":171,"soonestReadout":487},[482],{"nctId":483,"briefTitle":484,"status":485,"phases":486,"primaryCompletion":487,"completion":487,"start":488,"enrollment":489,"conditions":490,"interventions":491},"NCT03169985","Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque","ACTIVE_NOT_RECRUITING",[91],"2027-01-28","2017-07-12",280,[18],[470,492],"Rosuvastatin 20 mg orally once a day",{"trials":494,"activeCount":99},[],{"intervention":492,"totalTrials":171,"cells":496},{"EARLY_PHASE1":497,"PHASE1":499,"PHASE2":501,"PHASE3":503,"PHASE4":505,"NA":511},{"trials":498,"activeCount":99},[],{"trials":500,"activeCount":99},[],{"trials":502,"activeCount":99},[],{"trials":504,"activeCount":99},[],{"trials":506,"activeCount":171,"soonestReadout":487},[507],{"nctId":483,"briefTitle":484,"status":485,"phases":508,"primaryCompletion":487,"completion":487,"start":488,"enrollment":489,"conditions":509,"interventions":510},[91],[18],[470,492],{"trials":512,"activeCount":99},[],{"intervention":375,"totalTrials":128,"cells":514},{"EARLY_PHASE1":515,"PHASE1":517,"PHASE2":519,"PHASE3":521,"PHASE4":523,"NA":529},{"trials":516,"activeCount":99},[],{"trials":518,"activeCount":99},[],{"trials":520,"activeCount":99},[],{"trials":522,"activeCount":99},[],{"trials":524,"activeCount":171,"soonestReadout":368},[525],{"nctId":365,"briefTitle":366,"status":120,"phases":526,"primaryCompletion":368,"completion":322,"start":369,"enrollment":370,"conditions":527,"interventions":528},[91],[372,373],[375,352],{"trials":530,"activeCount":99},[531],{"nctId":532,"briefTitle":533,"status":534,"phases":535,"primaryCompletion":536,"completion":537,"start":538,"enrollment":370,"conditions":539,"interventions":540},"NCT02079194","Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES","UNKNOWN",[92],"2018-07-07","2020-07-07","2014-03-18",[18],[375,541],"aspirin plus P2Y12 antagonist",{"intervention":543,"totalTrials":544,"cells":545},"Normal saline",4,{"EARLY_PHASE1":546,"PHASE1":548,"PHASE2":550,"PHASE3":570,"PHASE4":572,"NA":574},{"trials":547,"activeCount":99},[],{"trials":549,"activeCount":99},[],{"trials":551,"activeCount":171,"soonestReadout":66},[552,563],{"nctId":553,"briefTitle":554,"status":134,"phases":555,"primaryCompletion":556,"completion":556,"start":557,"enrollment":558,"conditions":559,"interventions":561},"NCT02128191","No Treatment Versus Oral Ibuprofen Treatment for Patent Ductus Arteriosus in Preterm Infants",[89],"2019-08","2014-07",142,[560],"Bronchopulmonary Dysplasia (BPD)",[562,543],"Oral ibuprofen",{"nctId":69,"briefTitle":70,"status":485,"phases":564,"primaryCompletion":66,"completion":66,"start":565,"enrollment":566,"conditions":567,"interventions":569},[89],"2017-03-28",22,[568],"Cell Transplantation",[71,543],{"trials":571,"activeCount":99},[],{"trials":573,"activeCount":99},[],{"trials":575,"activeCount":171,"soonestReadout":66},[576,590],{"nctId":577,"briefTitle":578,"status":534,"phases":579,"primaryCompletion":580,"completion":581,"start":582,"enrollment":583,"conditions":584,"interventions":586},"NCT06090955","Modulating Surgery-Induced Blood-Brain Barrier Disruption in Elderly",[92],"2024-11-30","2024-12-31","2023-10-25",108,[585],"Delirium, Postoperative",[587,588,589],"Dexmedetomidine Injection [Precedex]","Lidocaine IV","normal saline",{"nctId":64,"briefTitle":65,"status":591,"phases":592,"primaryCompletion":66,"completion":66,"start":593,"enrollment":594,"conditions":595,"interventions":599},"ENROLLING_BY_INVITATION",[92],"2023-08-18",144,[596,597,598],"Postoperative Nausea and Vomiting","Gynecologic Surgical Procedures","Laparoscopy",[67,589],{"intervention":601,"totalTrials":128,"cells":602},"pneumostem",{"EARLY_PHASE1":603,"PHASE1":605,"PHASE2":618,"PHASE3":624,"PHASE4":626,"NA":628},{"trials":604,"activeCount":99},[],{"trials":606,"activeCount":99},[607],{"nctId":608,"briefTitle":609,"status":134,"phases":610,"primaryCompletion":611,"completion":612,"start":613,"enrollment":614,"conditions":615,"interventions":617},"NCT02274428","Phase 1 Clinical Trial of PNEUMOSTEM® Treatment in Premature Infants With Intraventricular Hemorrhage",[88],"2016-02","2016-12","2014-10",9,[616],"Mesenchymal Stromal Cells",[601],{"trials":619,"activeCount":171,"soonestReadout":66},[620],{"nctId":69,"briefTitle":70,"status":485,"phases":621,"primaryCompletion":66,"completion":66,"start":565,"enrollment":566,"conditions":622,"interventions":623},[89],[568],[71,543],{"trials":625,"activeCount":99},[],{"trials":627,"activeCount":99},[],{"trials":629,"activeCount":99},[],{"intervention":631,"totalTrials":171,"cells":632},"Rivoceranib",{"EARLY_PHASE1":633,"PHASE1":635,"PHASE2":637,"PHASE3":649,"PHASE4":651,"NA":653},{"trials":634,"activeCount":99},[],{"trials":636,"activeCount":99},[],{"trials":638,"activeCount":171,"soonestReadout":643},[639],{"nctId":640,"briefTitle":641,"status":120,"phases":642,"primaryCompletion":643,"completion":644,"start":123,"enrollment":645,"conditions":646,"interventions":648},"NCT06200233","Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor",[89],"2026-03-01","2026-12-01",40,[647],"Thymic Epithelial Tumor",[631],{"trials":650,"activeCount":99},[],{"trials":652,"activeCount":99},[],{"trials":654,"activeCount":99},[],{"intervention":656,"totalTrials":171,"cells":657},"Patritumab Deruxtecan",{"EARLY_PHASE1":658,"PHASE1":660,"PHASE2":662,"PHASE3":675,"PHASE4":677,"NA":679},{"trials":659,"activeCount":99},[],{"trials":661,"activeCount":99},[],{"trials":663,"activeCount":171,"soonestReadout":668},[664],{"nctId":665,"briefTitle":666,"status":109,"phases":667,"primaryCompletion":668,"completion":669,"start":670,"enrollment":671,"conditions":672,"interventions":674},"NCT06383884","Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion",[89],"2027-04-30","2029-04-30","2024-08-13",30,[673],"Solid Tumor, Adult",[656],{"trials":676,"activeCount":99},[],{"trials":678,"activeCount":99},[],{"trials":680,"activeCount":99},[],{"intervention":682,"totalTrials":171,"cells":683},"Osimertinib 80 MG",{"EARLY_PHASE1":684,"PHASE1":686,"PHASE2":688,"PHASE3":701,"PHASE4":703,"NA":705},{"trials":685,"activeCount":99},[],{"trials":687,"activeCount":99},[],{"trials":689,"activeCount":171,"soonestReadout":694},[690],{"nctId":691,"briefTitle":692,"status":109,"phases":693,"primaryCompletion":694,"completion":695,"start":696,"enrollment":697,"conditions":698,"interventions":700},"NCT04591002","Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)",[89],"2027-09-01","2027-12-01","2022-09-11",43,[699],"Lung Cancer",[682],{"trials":702,"activeCount":99},[],{"trials":704,"activeCount":99},[],{"trials":706,"activeCount":99},[],{"intervention":708,"totalTrials":171,"cells":709},"Tepotinib",{"EARLY_PHASE1":710,"PHASE1":712,"PHASE2":714,"PHASE3":727,"PHASE4":729,"NA":731},{"trials":711,"activeCount":99},[],{"trials":713,"activeCount":99},[],{"trials":715,"activeCount":171,"soonestReadout":720},[716],{"nctId":717,"briefTitle":718,"status":109,"phases":719,"primaryCompletion":720,"completion":720,"start":721,"enrollment":722,"conditions":723,"interventions":725},"NCT06106802","Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment",[89],"2029-09-30","2024-06-11",47,[724],"Non-Small Cell Lung Cancer Metastatic",[726,708],"Lazertinib",{"trials":728,"activeCount":99},[],{"trials":730,"activeCount":99},[],{"trials":732,"activeCount":99},[],{"intervention":734,"totalTrials":171,"cells":735},"Glofitamab",{"EARLY_PHASE1":736,"PHASE1":738,"PHASE2":740,"PHASE3":751,"PHASE4":753,"NA":755},{"trials":737,"activeCount":99},[],{"trials":739,"activeCount":99},[],{"trials":741,"activeCount":171,"soonestReadout":122},[742],{"nctId":743,"briefTitle":744,"status":485,"phases":745,"primaryCompletion":122,"completion":746,"start":747,"enrollment":671,"conditions":748,"interventions":750},"NCT06552572","Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy",[89],"2028-12-30","2024-11-26",[749],"Diffuse Large B Cell Lymphoma",[734],{"trials":752,"activeCount":99},[],{"trials":754,"activeCount":99},[],{"trials":756,"activeCount":99},[],{"intervention":758,"totalTrials":171,"cells":759},"Tisleizumab",{"EARLY_PHASE1":760,"PHASE1":762,"PHASE2":764,"PHASE3":777,"PHASE4":779,"NA":781},{"trials":761,"activeCount":99},[],{"trials":763,"activeCount":99},[],{"trials":765,"activeCount":171,"soonestReadout":770},[766],{"nctId":767,"briefTitle":768,"status":120,"phases":769,"primaryCompletion":770,"completion":771,"start":772,"enrollment":773,"conditions":774,"interventions":776},"NCT07300891","T Cell Inflamed Gene Expression Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for Refractory Solid Cancer Patients Unexposed to Immunotherapy",[89],"2027-01-31","2028-01-31","2026-08",72,[775],"Refractory Solid Cancer Patients Unexposed to Immunotherapy",[758],{"trials":778,"activeCount":99},[],{"trials":780,"activeCount":99},[],{"trials":782,"activeCount":99},[],{"intervention":76,"totalTrials":171,"cells":784},{"EARLY_PHASE1":785,"PHASE1":787,"PHASE2":789,"PHASE3":799,"PHASE4":801,"NA":803},{"trials":786,"activeCount":99},[],{"trials":788,"activeCount":99},[],{"trials":790,"activeCount":171,"soonestReadout":75},[791],{"nctId":73,"briefTitle":74,"status":109,"phases":792,"primaryCompletion":75,"completion":461,"start":793,"enrollment":794,"conditions":795,"interventions":797},[89],"2021-08-25",178,[796],"Premenopausal HR+\u002FHER2- Metastatic Breast Cancer",[76,798],"Pabociclib, Endocrine(or ET + CDK4\u002F6 inhibitors), Talazoparib,",{"trials":800,"activeCount":99},[],{"trials":802,"activeCount":99},[],{"trials":804,"activeCount":99},[],{"intervention":798,"totalTrials":171,"cells":806},{"EARLY_PHASE1":807,"PHASE1":809,"PHASE2":811,"PHASE3":817,"PHASE4":819,"NA":821},{"trials":808,"activeCount":99},[],{"trials":810,"activeCount":99},[],{"trials":812,"activeCount":171,"soonestReadout":75},[813],{"nctId":73,"briefTitle":74,"status":109,"phases":814,"primaryCompletion":75,"completion":461,"start":793,"enrollment":794,"conditions":815,"interventions":816},[89],[796],[76,798],{"trials":818,"activeCount":99},[],{"trials":820,"activeCount":99},[],{"trials":822,"activeCount":99},[],{"intervention":824,"totalTrials":171,"cells":825},"concurrent chemotherapy",{"EARLY_PHASE1":826,"PHASE1":828,"PHASE2":830,"PHASE3":843,"PHASE4":845,"NA":847},{"trials":827,"activeCount":99},[],{"trials":829,"activeCount":99},[],{"trials":831,"activeCount":171,"soonestReadout":836},[832],{"nctId":833,"briefTitle":834,"status":109,"phases":835,"primaryCompletion":836,"completion":837,"start":838,"enrollment":839,"conditions":840,"interventions":842},"NCT07439497","Definitive Hypofractionated Intensity-modulated Radiation Theraphy With Concurrent Chemotherapy in Cervical Cancer",[89],"2026-05-30","2028-05-30","2025-12-09",34,[841],"Cervical Cancer",[824],{"trials":844,"activeCount":99},[],{"trials":846,"activeCount":99},[],{"trials":848,"activeCount":99},[],{"intervention":850,"totalTrials":171,"cells":851},"Selinexor",{"EARLY_PHASE1":852,"PHASE1":854,"PHASE2":856,"PHASE3":868,"PHASE4":870,"NA":872},{"trials":853,"activeCount":99},[],{"trials":855,"activeCount":99},[],{"trials":857,"activeCount":171,"soonestReadout":746},[858],{"nctId":859,"briefTitle":860,"status":109,"phases":861,"primaryCompletion":746,"completion":746,"start":123,"enrollment":862,"conditions":863,"interventions":867},"NCT06552559","Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma",[88,89],37,[864,865,866],"B-cell Lymphoma Recurrent","B-cell Lymphoma Refractory","CNS Metastases",[850],{"trials":869,"activeCount":99},[],{"trials":871,"activeCount":99},[],{"trials":873,"activeCount":99},[],{"intervention":875,"totalTrials":171,"cells":876},"Osimertinib 80Mg Tab",{"EARLY_PHASE1":877,"PHASE1":879,"PHASE2":881,"PHASE3":891,"PHASE4":893,"NA":895},{"trials":878,"activeCount":99},[],{"trials":880,"activeCount":99},[],{"trials":882,"activeCount":171,"soonestReadout":694},[883],{"nctId":884,"briefTitle":885,"status":109,"phases":886,"primaryCompletion":694,"completion":695,"start":696,"enrollment":887,"conditions":888,"interventions":890},"NCT05528458","Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma",[89],59,[889],"Lung Adenocarcinoma",[875],{"trials":892,"activeCount":99},[],{"trials":894,"activeCount":99},[],{"trials":896,"activeCount":99},[],{"intervention":898,"totalTrials":171,"cells":899},"Avelumab 10 mg\u002Fkg",{"EARLY_PHASE1":900,"PHASE1":902,"PHASE2":904,"PHASE3":917,"PHASE4":919,"NA":921},{"trials":901,"activeCount":99},[],{"trials":903,"activeCount":99},[],{"trials":905,"activeCount":171,"soonestReadout":910},[906],{"nctId":907,"briefTitle":908,"status":109,"phases":909,"primaryCompletion":910,"completion":911,"start":912,"enrollment":913,"conditions":914,"interventions":916},"NCT07225374","Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC",[89],"2026-07-01","2029-07-02","2025-09-16",48,[915],"Upper Tract Urothelial Carcinoma",[898],{"trials":918,"activeCount":99},[],{"trials":920,"activeCount":99},[],{"trials":922,"activeCount":99},[],{"intervention":726,"totalTrials":95,"cells":924},{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":929,"PHASE3":947,"PHASE4":949,"NA":951},{"trials":926,"activeCount":99},[],{"trials":928,"activeCount":99},[],{"trials":930,"activeCount":171,"soonestReadout":720},[931,935],{"nctId":717,"briefTitle":718,"status":109,"phases":932,"primaryCompletion":720,"completion":720,"start":721,"enrollment":722,"conditions":933,"interventions":934},[89],[724],[726,708],{"nctId":936,"briefTitle":937,"status":534,"phases":938,"primaryCompletion":939,"completion":940,"start":941,"enrollment":942,"conditions":943,"interventions":946},"NCT05701384","Lazertinib 160mg in EGFR T790M NSCLC",[89],"2024-01-31","2025-01-31","2023-02-01",117,[944,945],"Lung Cancer Stage IV","EGFR T790M",[726],{"trials":948,"activeCount":99},[],{"trials":950,"activeCount":99},[],{"trials":952,"activeCount":99},[953],{"nctId":954,"briefTitle":955,"status":534,"phases":956,"primaryCompletion":957,"completion":957,"start":958,"enrollment":959,"conditions":960,"interventions":962},"NCT05377788","Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer",[],"2024-06-30","2022-07-31",900,[961,945],"Metastatic Lung Non-Small Cell Carcinoma",[726],{"intervention":62,"totalTrials":128,"cells":964},{"EARLY_PHASE1":965,"PHASE1":967,"PHASE2":980,"PHASE3":982,"PHASE4":984,"NA":986},{"trials":966,"activeCount":99},[],{"trials":968,"activeCount":171,"soonestReadout":225},[969],{"nctId":970,"briefTitle":971,"status":120,"phases":972,"primaryCompletion":225,"completion":973,"start":227,"enrollment":974,"conditions":975,"interventions":978},"NCT07368088","PNEUMOSTEM® for Improving Respiratory Outcomes in Very Premature Infants Diagnosed With Early Pulmonary Arterial Hypertension",[88],"2027-07",12,[976,977],"Pulmonary Arterial Hypertension (PAH)","Premature Infants",[979],"PNEUMOSTEM®",{"trials":981,"activeCount":99},[],{"trials":983,"activeCount":99},[],{"trials":985,"activeCount":99},[],{"trials":987,"activeCount":171,"soonestReadout":61},[988],{"nctId":59,"briefTitle":60,"status":485,"phases":989,"primaryCompletion":61,"completion":990,"start":991,"enrollment":614,"conditions":992,"interventions":994},[],"2026-09","2011-09",[993],"Bronchopulmonary Dysplasia",[62],{"intervention":996,"totalTrials":171,"cells":997},"ET-STEM",{"EARLY_PHASE1":998,"PHASE1":1000,"PHASE2":1010,"PHASE3":1012,"PHASE4":1014,"NA":1016},{"trials":999,"activeCount":99},[],{"trials":1001,"activeCount":171,"soonestReadout":176},[1002],{"nctId":1003,"briefTitle":1004,"status":485,"phases":1005,"primaryCompletion":176,"completion":176,"start":1006,"enrollment":974,"conditions":1007,"interventions":1009},"NCT05315661","The Safety and The Efficacy Evaluation of ET-STEM in Patients With Frontotemporal Dementia",[88],"2022-07-06",[1008],"Frontotemporal Dementia",[996],{"trials":1011,"activeCount":99},[],{"trials":1013,"activeCount":99},[],{"trials":1015,"activeCount":99},[],{"trials":1017,"activeCount":99},[],{"intervention":1019,"totalTrials":31,"cells":1020},"Etoposide",{"EARLY_PHASE1":1021,"PHASE1":1023,"PHASE2":1025,"PHASE3":1161,"PHASE4":1163,"NA":1165},{"trials":1022,"activeCount":99},[],{"trials":1024,"activeCount":99},[],{"trials":1026,"activeCount":99},[1027,1045,1055,1069,1082,1092,1120,1130,1142,1151],{"nctId":1028,"briefTitle":1029,"status":534,"phases":1030,"primaryCompletion":1031,"completion":1032,"start":1033,"enrollment":1034,"conditions":1035,"interventions":1037},"NCT02784015","Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma",[89],"2020-05","2023-05","2016-05",41,[1036],"Unresectable Localized Soft Tissue Sarcoma",[1038,1019,1039,1040,1041,1042,1043,1044],"Cisplatin","Doxorubicin","Cyclophosphamide","Ifosfamide","Carboplatin","Thiotepa","Melphalan",{"nctId":1046,"briefTitle":1047,"status":534,"phases":1048,"primaryCompletion":1049,"start":1050,"enrollment":645,"conditions":1051,"interventions":1053},"NCT02782754","Chemotherapy Plus Reduced Radiotherapy in Intracranial Germinoma",[89],"2017-12","2013-01",[1052],"Intracranial Germinoma",[1042,1019,1040,1054],"Bleomycin",{"nctId":1056,"briefTitle":1057,"status":534,"phases":1058,"primaryCompletion":1059,"completion":1060,"start":1061,"enrollment":1062,"conditions":1063,"interventions":1065},"NCT02544425","VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)",[89],"2021-08-31","2021-11-30","2016-02-21",27,[1064],"Extranodal NK-T-Cell Lymphoma",[1019,1041,1066,1067,1068,1044],"Dexamethasone","L-asparaginase","Busulfan",{"nctId":1070,"briefTitle":1071,"status":534,"phases":1072,"primaryCompletion":1073,"completion":1074,"start":1075,"enrollment":1076,"conditions":1077,"interventions":1079},"NCT02771743","Response-based Treatment of High-risk Neuroblastoma",[89],"2020-03","2023-03","2015-04",54,[1078],"Newly Diagnosed High Risk Neuroblastoma",[1038,1039,1019,1040,1041,1042,1080,1081],"Interleukin-2","Isotretinoin",{"nctId":1083,"briefTitle":1084,"status":134,"phases":1085,"primaryCompletion":1086,"completion":1087,"start":1088,"enrollment":645,"conditions":1089,"interventions":1091},"NCT00793845","Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma",[89],"2015-01","2018-01","2008-08",[1090],"Neuroblastoma",[1040,1019,1042,1043,1044],{"nctId":1093,"briefTitle":1094,"status":534,"phases":1095,"primaryCompletion":1096,"completion":1097,"start":1098,"enrollment":1099,"conditions":1100,"interventions":1105},"NCT02638428","Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy",[89],"2021-12","2023-12","2015-12",90,[1101,1102,1103,1104],"Relapsed Pediatric Solid Tumor","Refractory Pediatric Solid Tumor","Relapsed Pediatric AML","Refractory Pediatric AML",[1041,1042,1019,1106,1107,1108,1109,1110,1111,1112,1113,1114,1115,1116,1117,1118,1119],"Fludarabine","Cytarabine","Pazopanib","Sorafenib","Axitinib","Crizotinib","Dasatinib","Erlotinib","Everolimus","Imatinib","Ruxolitinib","Vandetanib","Vemurafenib","Trastuzumab",{"nctId":1121,"briefTitle":1122,"status":534,"phases":1123,"primaryCompletion":1124,"completion":1125,"start":1126,"enrollment":1127,"conditions":1128,"interventions":1129},"NCT03628131","Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed\u002FRefractory Solid Tumors",[88,89],"2023-07","2025-07","2018-10",46,[1101,1102],[1108,1041,1042,1019],{"nctId":1131,"briefTitle":1132,"status":534,"phases":1133,"primaryCompletion":1134,"start":1135,"enrollment":1136,"conditions":1137,"interventions":1139},"NCT02848183","Optimal Treatment Strategy Based on for Pediatric AML",[89],"2020-12","2016-01",350,[1138],"Pediatric Acute Myeloid Leukemia",[1107,1140,1141,1019],"Idarubicin","Mitoxantrone",{"nctId":1143,"briefTitle":1144,"status":534,"phases":1145,"primaryCompletion":1146,"completion":1147,"start":137,"enrollment":645,"conditions":1148,"interventions":1150},"NCT03061656","Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma",[89],"2013-12-31","2018-12-31",[1149],"High Risk Neuroblastoma",[1040,1042,1019,1043,1044],{"nctId":1152,"briefTitle":1153,"status":534,"phases":1154,"primaryCompletion":1155,"completion":1074,"start":1156,"enrollment":1157,"conditions":1158,"interventions":1160},"NCT02784054","Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor",[89],"2021-03","2014-04",25,[1159],"Intracranial Non-germinomatous Germ Cell Tumor",[1042,1019,1040,1054,1043,1044],{"trials":1162,"activeCount":99},[],{"trials":1164,"activeCount":99},[],{"trials":1166,"activeCount":171,"soonestReadout":163},[1167],{"nctId":1168,"briefTitle":1169,"status":109,"phases":1170,"primaryCompletion":163,"completion":163,"start":1171,"enrollment":1172,"conditions":1173,"interventions":1175},"NCT03117010","Prospective Cohort for Adult Hemophagocytosis",[],"2017-01-01",81,[1174],"Hemophagocytic Lymphohistiocytoses",[1176,1019],"Steroids",{"intervention":1038,"totalTrials":1178,"cells":1179},7,{"EARLY_PHASE1":1180,"PHASE1":1182,"PHASE2":1184,"PHASE3":1242,"PHASE4":1244,"NA":1246},{"trials":1181,"activeCount":99},[],{"trials":1183,"activeCount":99},[],{"trials":1185,"activeCount":99},[1186,1190,1202,1214,1218,1230],{"nctId":1028,"briefTitle":1029,"status":534,"phases":1187,"primaryCompletion":1031,"completion":1032,"start":1033,"enrollment":1034,"conditions":1188,"interventions":1189},[89],[1036],[1038,1019,1039,1040,1041,1042,1043,1044],{"nctId":1191,"briefTitle":1192,"status":534,"phases":1193,"primaryCompletion":1194,"completion":1195,"start":1196,"enrollment":1197,"conditions":1198,"interventions":1200},"NCT03050437","A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI",[89],"2017-02","2017-03","2013-03",96,[1199],"Carcinoma, Non-Small-Cell Lung",[1038,1201],"Pemetrexed",{"nctId":1203,"briefTitle":1204,"status":534,"phases":1205,"primaryCompletion":1206,"completion":1207,"start":1208,"enrollment":1209,"conditions":1210,"interventions":1212},"NCT03061630","A Prospective Study of Neoadjuvant Chemotherapy With Gemcitabine\u002FPlatinum in Muscle-Invasive or Locally-Advanced Urothelial Carcinoma of Bladder",[89],"2022-03","2022-06","2017-02-15",49,[1211],"Urinary Bladder",[1213,1038],"Gemcitabine",{"nctId":1070,"briefTitle":1071,"status":534,"phases":1215,"primaryCompletion":1073,"completion":1074,"start":1075,"enrollment":1076,"conditions":1216,"interventions":1217},[89],[1078],[1038,1039,1019,1040,1041,1042,1080,1081],{"nctId":1219,"briefTitle":1220,"status":534,"phases":1221,"primaryCompletion":1222,"completion":1223,"start":1224,"enrollment":1225,"conditions":1226,"interventions":1228},"NCT01171781","A Randomized Phase II Study of Concurrent Chemoradiation With Every 3 Week of Cisplatin vs With Weekly Cisplatin in Locally Advanced Nasopharyngeal Carcinoma",[89],"2012-06","2014-06","2009-11",110,[1227],"Nasophayngeal Carcinoma Between Stage II and IVb",[1229,1229],"cisplatin",{"nctId":1231,"briefTitle":1232,"status":534,"phases":1233,"primaryCompletion":1234,"completion":1235,"start":1236,"enrollment":862,"conditions":1237,"interventions":1239},"NCT03053856","Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients",[89],"2021-05-13","2021-08-13","2017-02-14",[1238],"Stage IIIA Non-small Cell Lung Cancer",[1240,1038,1241],"Pembrolizumab","Paclitaxel",{"trials":1243,"activeCount":99},[],{"trials":1245,"activeCount":99},[],{"trials":1247,"activeCount":171,"soonestReadout":80},[1248],{"nctId":1249,"briefTitle":1250,"status":485,"phases":1251,"primaryCompletion":80,"completion":1252,"start":1253,"enrollment":1254,"conditions":1255,"interventions":1257},"NCT03306901","Chemoradiotherapy Versus Esophagectomy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma",[92],"2033-12-31","2017-10-20",240,[1256],"Esophageal Cancer",[1258,1038],"5-fluorouracil",{"intervention":1260,"totalTrials":128,"cells":1261},"Chemotherapy",{"EARLY_PHASE1":1262,"PHASE1":1264,"PHASE2":1266,"PHASE3":1268,"PHASE4":1280,"NA":1282},{"trials":1263,"activeCount":99},[],{"trials":1265,"activeCount":99},[],{"trials":1267,"activeCount":99},[],{"trials":1269,"activeCount":99},[1270],{"nctId":1271,"briefTitle":1272,"status":134,"phases":1273,"primaryCompletion":1274,"completion":1275,"start":1276,"enrollment":112,"conditions":1277,"interventions":1279},"NCT00821990","Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer",[90],"2010-09","2011-06","2008-09",[1278],"Advanced Gastric Cancer",[1260],{"trials":1281,"activeCount":99},[],{"trials":1283,"activeCount":171,"soonestReadout":1288},[1284],{"nctId":1285,"briefTitle":1286,"status":109,"phases":1287,"primaryCompletion":1288,"completion":1288,"start":1289,"enrollment":1290,"conditions":1291,"interventions":1294},"NCT03117036","Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III",[],"2026-12-28","2017-03-01",600,[1292,1293],"Lymphoma, Non-Hodgkin","Lymphoma, Hodgkin",[1260],{"intervention":81,"totalTrials":128,"cells":1296},{"EARLY_PHASE1":1297,"PHASE1":1299,"PHASE2":1301,"PHASE3":1303,"PHASE4":1316,"NA":1318},{"trials":1298,"activeCount":99},[],{"trials":1300,"activeCount":99},[],{"trials":1302,"activeCount":99},[],{"trials":1304,"activeCount":99},[1305],{"nctId":1306,"briefTitle":1307,"status":134,"phases":1308,"primaryCompletion":1309,"completion":1309,"start":1310,"enrollment":1311,"conditions":1312,"interventions":1314},"NCT05836545","Remimazolam Versus Midaszolam for Sedation in Diagnostic Upper Gastrointestinal Endoscopy",[90],"2024-01-06","2023-04-05",132,[1313],"Healthy",[81,1315],"Midazolam",{"trials":1317,"activeCount":99},[],{"trials":1319,"activeCount":171,"soonestReadout":80},[1320],{"nctId":78,"briefTitle":79,"status":109,"phases":1321,"primaryCompletion":80,"completion":176,"start":177,"enrollment":178,"conditions":1322,"interventions":1323},[92],[180],[81,147],{"intervention":1325,"totalTrials":171,"cells":1326},"tumor-infiltrating lymphocyte",{"EARLY_PHASE1":1327,"PHASE1":1329,"PHASE2":1331,"PHASE3":1333,"PHASE4":1335,"NA":1337},{"trials":1328,"activeCount":99},[],{"trials":1330,"activeCount":99},[],{"trials":1332,"activeCount":99},[],{"trials":1334,"activeCount":99},[],{"trials":1336,"activeCount":99},[],{"trials":1338,"activeCount":171,"soonestReadout":1343},[1339],{"nctId":1340,"briefTitle":1341,"status":120,"phases":1342,"primaryCompletion":1343,"completion":1344,"start":1345,"enrollment":614,"conditions":1346,"interventions":1348},"NCT07028008","Evaluate the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocyte in Patients With Refractory Melanoma Who Failed to Immune Checkpoint Inhibitors",[92],"2027-05-28","2029-05-28","2025-10-15",[1347],"Melanoma",[1325],{"intervention":1350,"totalTrials":171,"cells":1351},"Anti-arrhythmic drugs for rhythm control",{"EARLY_PHASE1":1352,"PHASE1":1354,"PHASE2":1356,"PHASE3":1358,"PHASE4":1360,"NA":1362},{"trials":1353,"activeCount":99},[],{"trials":1355,"activeCount":99},[],{"trials":1357,"activeCount":99},[],{"trials":1359,"activeCount":99},[],{"trials":1361,"activeCount":99},[],{"trials":1363,"activeCount":171,"soonestReadout":1368},[1364],{"nctId":1365,"briefTitle":1366,"status":109,"phases":1367,"primaryCompletion":1368,"completion":1368,"start":1369,"enrollment":1370,"conditions":1371,"interventions":1374},"NCT07607093","Efficacy of Early Rhythm Control in AF With TR Patients",[],"2027-02-28","2026-02-18",5800,[1372,1373],"Atrial Fibrillation (AF)","Tricuspid Regurgitation (TR)",[1350],{"intervention":1376,"totalTrials":171,"cells":1377},"Standard Medical Therapy",{"EARLY_PHASE1":1378,"PHASE1":1380,"PHASE2":1382,"PHASE3":1384,"PHASE4":1386,"NA":1388},{"trials":1379,"activeCount":99},[],{"trials":1381,"activeCount":99},[],{"trials":1383,"activeCount":99},[],{"trials":1385,"activeCount":99},[],{"trials":1387,"activeCount":99},[],{"trials":1389,"activeCount":171,"soonestReadout":1394},[1390],{"nctId":1391,"briefTitle":1392,"status":109,"phases":1393,"primaryCompletion":1394,"completion":1395,"start":1396,"enrollment":1397,"conditions":1398,"interventions":1401},"NCT07393412","Identifying Risk Factors and Predicting Future Health Outcomes for Korean Patients With Heart and Blood Vessel Diseases: A Long-term Follow-up Study",[],"2026-11-27","2040-12-31","2026-02-02",800000,[1399,1400],"Cardiovascular Diseases (CVD)","Cerebro Vascular Disease",[1376],{"intervention":52,"totalTrials":171,"cells":1403},{"EARLY_PHASE1":1404,"PHASE1":1406,"PHASE2":1408,"PHASE3":1410,"PHASE4":1412,"NA":1414},{"trials":1405,"activeCount":99},[],{"trials":1407,"activeCount":99},[],{"trials":1409,"activeCount":99},[],{"trials":1411,"activeCount":99},[],{"trials":1413,"activeCount":99},[],{"trials":1415,"activeCount":171,"soonestReadout":51},[1416],{"nctId":49,"briefTitle":50,"status":485,"phases":1417,"primaryCompletion":51,"completion":462,"start":1418,"enrollment":1419,"conditions":1420,"interventions":1422},[],"2021-06-15",1500,[1421],"Non-small Cell Lung Cancer (NSCLC)",[52],{"intervention":47,"totalTrials":171,"cells":1424},{"EARLY_PHASE1":1425,"PHASE1":1427,"PHASE2":1429,"PHASE3":1431,"PHASE4":1433,"NA":1435},{"trials":1426,"activeCount":99},[],{"trials":1428,"activeCount":99},[],{"trials":1430,"activeCount":99},[],{"trials":1432,"activeCount":99},[],{"trials":1434,"activeCount":99},[],{"trials":1436,"activeCount":171,"soonestReadout":46},[1437],{"nctId":44,"briefTitle":45,"status":109,"phases":1438,"primaryCompletion":46,"completion":80,"start":1439,"enrollment":1440,"conditions":1441,"interventions":1443},[],"2023-05-29",20,[1442],"Haploidentical Hematopoietic Stem Cell Transplantation",[47],{"intervention":85,"totalTrials":171,"cells":1445},{"EARLY_PHASE1":1446,"PHASE1":1448,"PHASE2":1450,"PHASE3":1452,"PHASE4":1454,"NA":1456},{"trials":1447,"activeCount":99},[],{"trials":1449,"activeCount":99},[],{"trials":1451,"activeCount":99},[],{"trials":1453,"activeCount":99},[],{"trials":1455,"activeCount":99},[],{"trials":1457,"activeCount":171,"soonestReadout":80},[1458],{"nctId":83,"briefTitle":84,"status":109,"phases":1459,"primaryCompletion":80,"completion":80,"start":1460,"enrollment":1461,"conditions":1462,"interventions":1463},[],"2024-10-22",100000,[18],[85,1464],"Guideline Directed Medical Therapy",{"intervention":1464,"totalTrials":171,"cells":1466},{"EARLY_PHASE1":1467,"PHASE1":1469,"PHASE2":1471,"PHASE3":1473,"PHASE4":1475,"NA":1477},{"trials":1468,"activeCount":99},[],{"trials":1470,"activeCount":99},[],{"trials":1472,"activeCount":99},[],{"trials":1474,"activeCount":99},[],{"trials":1476,"activeCount":99},[],{"trials":1478,"activeCount":171,"soonestReadout":80},[1479],{"nctId":83,"briefTitle":84,"status":109,"phases":1480,"primaryCompletion":80,"completion":80,"start":1460,"enrollment":1461,"conditions":1481,"interventions":1482},[],[18],[85,1464],{"intervention":1484,"totalTrials":171,"cells":1485},"Insomnia medication",{"EARLY_PHASE1":1486,"PHASE1":1488,"PHASE2":1490,"PHASE3":1492,"PHASE4":1494,"NA":1496},{"trials":1487,"activeCount":99},[],{"trials":1489,"activeCount":99},[],{"trials":1491,"activeCount":99},[],{"trials":1493,"activeCount":99},[],{"trials":1495,"activeCount":99},[],{"trials":1497,"activeCount":171,"soonestReadout":1502},[1498],{"nctId":1499,"briefTitle":1500,"status":120,"phases":1501,"primaryCompletion":1502,"completion":122,"start":1503,"enrollment":1504,"conditions":1505,"interventions":1507},"NCT07416617","Impact of New-onset Insomnia After Coronary Revascularization for Patients With Acute Myocardial Infarction",[],"2026-05-31","2026-02-12",235342,[114,1506],"Insomina",[1484],{"intervention":42,"totalTrials":171,"cells":1509},{"EARLY_PHASE1":1510,"PHASE1":1512,"PHASE2":1514,"PHASE3":1516,"PHASE4":1518,"NA":1520},{"trials":1511,"activeCount":99},[],{"trials":1513,"activeCount":99},[],{"trials":1515,"activeCount":99},[],{"trials":1517,"activeCount":99},[],{"trials":1519,"activeCount":99},[],{"trials":1521,"activeCount":171,"soonestReadout":41},[1522],{"nctId":39,"briefTitle":40,"status":485,"phases":1523,"primaryCompletion":41,"completion":80,"start":1524,"enrollment":1525,"conditions":1526,"interventions":1529},[],"2013-01-01",7725,[1527,1528],"Cirrhosis","Decompensated Cirrhosis of Liver",[42],{"intervention":67,"totalTrials":171,"cells":1531},{"EARLY_PHASE1":1532,"PHASE1":1534,"PHASE2":1536,"PHASE3":1538,"PHASE4":1540,"NA":1542},{"trials":1533,"activeCount":99},[],{"trials":1535,"activeCount":99},[],{"trials":1537,"activeCount":99},[],{"trials":1539,"activeCount":99},[],{"trials":1541,"activeCount":99},[],{"trials":1543,"activeCount":171,"soonestReadout":66},[1544],{"nctId":64,"briefTitle":65,"status":591,"phases":1545,"primaryCompletion":66,"completion":66,"start":593,"enrollment":594,"conditions":1546,"interventions":1547},[92],[596,597,598],[67,589],{"intervention":1258,"totalTrials":171,"cells":1549},{"EARLY_PHASE1":1550,"PHASE1":1552,"PHASE2":1554,"PHASE3":1556,"PHASE4":1558,"NA":1560},{"trials":1551,"activeCount":99},[],{"trials":1553,"activeCount":99},[],{"trials":1555,"activeCount":99},[],{"trials":1557,"activeCount":99},[],{"trials":1559,"activeCount":99},[],{"trials":1561,"activeCount":171,"soonestReadout":80},[1562],{"nctId":1249,"briefTitle":1250,"status":485,"phases":1563,"primaryCompletion":80,"completion":1252,"start":1253,"enrollment":1254,"conditions":1564,"interventions":1565},[92],[1256],[1258,1038],{"intervention":1567,"totalTrials":171,"cells":1568},"Immunochemotherapy",{"EARLY_PHASE1":1569,"PHASE1":1571,"PHASE2":1573,"PHASE3":1575,"PHASE4":1577,"NA":1579},{"trials":1570,"activeCount":99},[],{"trials":1572,"activeCount":99},[],{"trials":1574,"activeCount":99},[],{"trials":1576,"activeCount":99},[],{"trials":1578,"activeCount":99},[],{"trials":1580,"activeCount":171,"soonestReadout":746},[1581],{"nctId":1582,"briefTitle":1583,"status":109,"phases":1584,"primaryCompletion":746,"completion":746,"start":1585,"enrollment":1586,"conditions":1587,"interventions":1589},"NCT07032103","Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study IV",[],"2022-06-01",2000,[1588],"Lymphoma",[1567],{"intervention":1591,"totalTrials":171,"cells":1592},"early rhythm control group",{"EARLY_PHASE1":1593,"PHASE1":1595,"PHASE2":1597,"PHASE3":1599,"PHASE4":1601,"NA":1603},{"trials":1594,"activeCount":99},[],{"trials":1596,"activeCount":99},[],{"trials":1598,"activeCount":99},[],{"trials":1600,"activeCount":99},[],{"trials":1602,"activeCount":99},[],{"trials":1604,"activeCount":171,"soonestReadout":1609},[1605],{"nctId":1606,"briefTitle":1607,"status":109,"phases":1608,"primaryCompletion":1609,"completion":322,"start":1610,"enrollment":1611,"conditions":1612,"interventions":1615},"NCT07447297","Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial Fibrillation",[92],"2027-12-15","2024-01-02",520,[1372,1613,1614],"Diseases of the Circulatory System","Atrial Flutter",[1591],{"intervention":1176,"totalTrials":171,"cells":1617},{"EARLY_PHASE1":1618,"PHASE1":1620,"PHASE2":1622,"PHASE3":1624,"PHASE4":1626,"NA":1628},{"trials":1619,"activeCount":99},[],{"trials":1621,"activeCount":99},[],{"trials":1623,"activeCount":99},[],{"trials":1625,"activeCount":99},[],{"trials":1627,"activeCount":99},[],{"trials":1629,"activeCount":171,"soonestReadout":163},[1630],{"nctId":1168,"briefTitle":1169,"status":109,"phases":1631,"primaryCompletion":163,"completion":163,"start":1171,"enrollment":1172,"conditions":1632,"interventions":1633},[],[1174],[1176,1019],{"intervention":1240,"totalTrials":1635,"cells":1636},8,{"EARLY_PHASE1":1637,"PHASE1":1639,"PHASE2":1641,"PHASE3":1706,"PHASE4":1708,"NA":1721},{"trials":1638,"activeCount":99},[],{"trials":1640,"activeCount":99},[],{"trials":1642,"activeCount":99},[1643,1654,1662,1672,1681,1692,1696],{"nctId":1644,"briefTitle":1645,"status":134,"phases":1646,"primaryCompletion":1096,"completion":1096,"start":1647,"enrollment":1648,"conditions":1649,"interventions":1652},"NCT02589496","Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis",[89],"2016-03-26",80,[1650,1651],"Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma",[1653],"pembrolizumab",{"nctId":1655,"briefTitle":1656,"status":134,"phases":1657,"primaryCompletion":1658,"completion":1658,"start":1659,"enrollment":228,"conditions":1660,"interventions":1661},"NCT03163992","Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib",[89],"2021-05-17","2017-12-26",[30],[1240],{"nctId":1663,"briefTitle":1664,"status":534,"phases":1665,"primaryCompletion":1666,"completion":1667,"start":1668,"enrollment":1669,"conditions":1670,"interventions":1671},"NCT04249739","Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin\u002FCapecitabine HER2 Positive",[89],"2024-02-06","2025-03","2020-09-29",93,[24],[1240],{"nctId":1673,"briefTitle":1674,"status":534,"phases":1675,"primaryCompletion":1676,"completion":1677,"start":1678,"enrollment":645,"conditions":1679,"interventions":1680},"NCT03858582","neoadjuvant_thymic Epithelial Tumor",[89],"2022-04-01","2023-04-01","2019-04-29",[647],[1653],{"nctId":1682,"briefTitle":1683,"status":134,"phases":1684,"primaryCompletion":1685,"completion":1686,"start":1687,"enrollment":1688,"conditions":1689,"interventions":1691},"NCT02607631","A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor",[89],"2018-02","2018-08","2015-11",33,[1690],"Thymic Epithelial Tumors",[1240],{"nctId":1231,"briefTitle":1232,"status":534,"phases":1693,"primaryCompletion":1234,"completion":1235,"start":1236,"enrollment":862,"conditions":1694,"interventions":1695},[89],[1238],[1240,1038,1241],{"nctId":1697,"briefTitle":1698,"status":534,"phases":1699,"primaryCompletion":1700,"completion":1060,"start":1701,"enrollment":1702,"conditions":1703,"interventions":1705},"NCT03254004","Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm",[89],"2021-03-30","2018-10-08",70,[1704],"Lung Adenocarcinoma, Stage I",[1240],{"trials":1707,"activeCount":99},[],{"trials":1709,"activeCount":99},[1710],{"nctId":1711,"briefTitle":1712,"status":134,"phases":1713,"primaryCompletion":1714,"completion":1715,"start":1716,"enrollment":1717,"conditions":1718,"interventions":1720},"NCT03134456","Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX",[91],"2019-07-08","2023-07-13","2018-05-14",50,[1719],"Metastatic Non-Small Cell Lung Carcinoma",[1240],{"trials":1722,"activeCount":99},[],{"intervention":1724,"totalTrials":128,"cells":1725},"Nilotinib",{"EARLY_PHASE1":1726,"PHASE1":1728,"PHASE2":1730,"PHASE3":1742,"PHASE4":1744,"NA":1754},{"trials":1727,"activeCount":99},[],{"trials":1729,"activeCount":99},[],{"trials":1731,"activeCount":99},[1732],{"nctId":1733,"briefTitle":1734,"status":134,"phases":1735,"primaryCompletion":1736,"completion":1737,"start":1738,"enrollment":1688,"conditions":1739,"interventions":1741},"NCT01099514","Study of Nilotinib in Metastatic Melanoma With KIT Aberrations",[89],"2013-12","2015-06","2009-08",[1740],"Metastatic Melanoma With KIT Aberration",[1724],{"trials":1743,"activeCount":99},[],{"trials":1745,"activeCount":99},[1746],{"nctId":1747,"briefTitle":1748,"status":534,"phases":1749,"primaryCompletion":1685,"completion":1750,"start":1075,"enrollment":645,"conditions":1751,"interventions":1753},"NCT02389920","Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP\u002FAP Intolerant to Dasatinib",[91],"2018-12",[1752],"Leukemia, Chronic Myeloid",[1724],{"trials":1755,"activeCount":99},[],{"intervention":1757,"totalTrials":128,"cells":1758},"Cilostazol",{"EARLY_PHASE1":1759,"PHASE1":1761,"PHASE2":1772,"PHASE3":1774,"PHASE4":1776,"NA":1789},{"trials":1760,"activeCount":99},[],{"trials":1762,"activeCount":99},[1763],{"nctId":1764,"briefTitle":1765,"status":134,"phases":1766,"primaryCompletion":1767,"completion":1736,"start":1222,"enrollment":9,"conditions":1768,"interventions":1769},"NCT01870466","Pharmacodynamic Drug Interaction Between Cilostazol and Statins",[88],"2013-09",[1313],[1757,1770,1771],"Simvastatin","Rosuvastatin",{"trials":1773,"activeCount":99},[],{"trials":1775,"activeCount":99},[],{"trials":1777,"activeCount":99},[1778],{"nctId":1779,"briefTitle":1780,"status":534,"phases":1781,"primaryCompletion":1782,"completion":1783,"start":1784,"enrollment":1785,"conditions":1786,"interventions":1788},"NCT00938522","Efficacy Study of Cilostazol Loading in Elective Percutaneous Coronary Intervention",[91],"2010-12","2011-10","2009-07",400,[1787],"Angioplasty, Transluminal, Percutaneous Coronary",[1757],{"trials":1790,"activeCount":99},[],{"intervention":1792,"totalTrials":128,"cells":1793},"Clopidogrel",{"EARLY_PHASE1":1794,"PHASE1":1796,"PHASE2":1798,"PHASE3":1800,"PHASE4":1811,"NA":1827},{"trials":1795,"activeCount":99},[],{"trials":1797,"activeCount":99},[],{"trials":1799,"activeCount":99},[],{"trials":1801,"activeCount":99},[1802],{"nctId":1803,"briefTitle":1804,"status":534,"phases":1805,"primaryCompletion":1049,"completion":1049,"start":1223,"enrollment":1806,"conditions":1807,"interventions":1809},"NCT02133989","Clopidogrel Resistance and Embolism in Carotid Artery Stenting",[90],86,[1808],"Carotid Stenosis",[1810,1792],"Ticlopidine + Ginko biloba",{"trials":1812,"activeCount":99},[1813],{"nctId":1814,"briefTitle":1815,"status":1816,"phases":1817,"primaryCompletion":1818,"completion":1819,"start":1820,"enrollment":1157,"conditions":1821,"interventions":1824},"NCT03119012","P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold","TERMINATED",[91],"2017-12-18","2018-02-09","2017-04-19",[18,1822,1823],"Stents","Atherosclerosis",[1792,1825,1826],"Ticagrelor","Aspirin",{"trials":1828,"activeCount":99},[],{"intervention":1830,"totalTrials":128,"cells":1831},"celecoxib",{"EARLY_PHASE1":1832,"PHASE1":1834,"PHASE2":1848,"PHASE3":1850,"PHASE4":1852,"NA":1864},{"trials":1833,"activeCount":99},[],{"trials":1835,"activeCount":99},[1836],{"nctId":1837,"briefTitle":1838,"status":134,"phases":1839,"primaryCompletion":1840,"completion":1840,"start":1841,"enrollment":1842,"conditions":1843,"interventions":1845},"NCT03822520","Clinical Study to Evaluate Effect on QT\u002FQTc Interval After Multiple Dose of Celecoxib",[88],"2018-05-25","2017-06-30",28,[1844],"Qt Interval, Variation in",[1846,1847],"Celecoxib","Moxifloxacin",{"trials":1849,"activeCount":99},[],{"trials":1851,"activeCount":99},[],{"trials":1853,"activeCount":99},[1854],{"nctId":1855,"briefTitle":1856,"status":185,"phases":1857,"primaryCompletion":1858,"start":1859,"enrollment":99,"conditions":1860,"interventions":1861},"NCT00687388","The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia",[91],"2012-03","2008-05",[33],[1862,1830,1863],"selective alpha 1-blockers","alpha-blocker and NSAID",{"trials":1865,"activeCount":99},[],{"intervention":1867,"totalTrials":128,"cells":1868},"Enoxaparin",{"EARLY_PHASE1":1869,"PHASE1":1871,"PHASE2":1873,"PHASE3":1875,"PHASE4":1888,"NA":1902},{"trials":1870,"activeCount":99},[],{"trials":1872,"activeCount":99},[],{"trials":1874,"activeCount":99},[],{"trials":1876,"activeCount":99},[1877],{"nctId":1878,"briefTitle":1879,"status":534,"phases":1880,"primaryCompletion":1881,"completion":1882,"start":1883,"enrollment":645,"conditions":1884,"interventions":1886},"NCT03570281","Edoxaban for the Treatment of Coagulopathy in Patients With Active Cancer and Acute Ischemic Stroke: a Pilot Study. (ENCHASE Study)",[89,90],"2020-05-31","2020-11-30","2018-06-15",[1885],"Correction of Cancer-related Coagulopathy With Novel Oral Anticoagulant (Edoxaban)",[1887,1867],"Edoxaban",{"trials":1889,"activeCount":99},[1890],{"nctId":1891,"briefTitle":1892,"status":134,"phases":1893,"primaryCompletion":1050,"completion":1050,"start":1894,"enrollment":1895,"conditions":1896,"interventions":1900},"NCT02379663","Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty",[91],"2012-01",639,[1897,1898,1899],"Osteoarthritis, Hip","Femur Head Necrosis","Femoral Neck Fractures",[1901,1867],"Rivaroxaban",{"trials":1903,"activeCount":99},[],{"intervention":1905,"totalTrials":128,"cells":1906},"Itraconazole",{"EARLY_PHASE1":1907,"PHASE1":1909,"PHASE2":1911,"PHASE3":1913,"PHASE4":1915,"NA":1941},{"trials":1908,"activeCount":99},[],{"trials":1910,"activeCount":99},[],{"trials":1912,"activeCount":99},[],{"trials":1914,"activeCount":99},[],{"trials":1916,"activeCount":99},[1917,1926],{"nctId":1918,"briefTitle":1919,"status":1816,"phases":1920,"primaryCompletion":1782,"completion":1782,"start":1921,"enrollment":1922,"conditions":1923,"interventions":1925},"NCT01282879","Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients",[91],"2009-12",36,[1924],"Graft vs Host Disease",[1905],{"nctId":1927,"briefTitle":1928,"status":134,"phases":1929,"primaryCompletion":1930,"completion":1931,"start":1932,"enrollment":1933,"conditions":1934,"interventions":1939},"NCT00336531","Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation",[91],"2008-06","2008-10","2006-04",100,[1090,1935,1936,1937,1938],"Brain Tumor","Retinoblastoma","Wilms Tumor","Mycoses",[1940],"itraconazole",{"trials":1942,"activeCount":99},[],{"intervention":1944,"totalTrials":171,"cells":1945},"mirabegron 50mg",{"EARLY_PHASE1":1946,"PHASE1":1948,"PHASE2":1950,"PHASE3":1952,"PHASE4":1954,"NA":1965},{"trials":1947,"activeCount":99},[],{"trials":1949,"activeCount":99},[],{"trials":1951,"activeCount":99},[],{"trials":1953,"activeCount":99},[],{"trials":1955,"activeCount":99},[1956],{"nctId":1957,"briefTitle":1958,"status":134,"phases":1959,"primaryCompletion":1960,"completion":1049,"start":1737,"enrollment":1961,"conditions":1962,"interventions":1964},"NCT02468375","Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.",[91],"2017-10",434,[1963],"Overactive Bladder",[1944],{"trials":1966,"activeCount":99},[],{"intervention":1968,"totalTrials":171,"cells":1969},"Add Vildagliptin",{"EARLY_PHASE1":1970,"PHASE1":1972,"PHASE2":1974,"PHASE3":1976,"PHASE4":1978,"NA":1990},{"trials":1971,"activeCount":99},[],{"trials":1973,"activeCount":99},[],{"trials":1975,"activeCount":99},[],{"trials":1977,"activeCount":99},[],{"trials":1979,"activeCount":99},[1980],{"nctId":1981,"briefTitle":1982,"status":134,"phases":1983,"primaryCompletion":1984,"completion":1984,"start":1985,"enrollment":839,"conditions":1986,"interventions":1988},"NCT01404676","The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes",[91],"2012-05","2010-06",[1987],"Type 2 Diabetes Mellitus",[1968,1989],"Add Glimepiride",{"trials":1991,"activeCount":99},[],{"intervention":1989,"totalTrials":171,"cells":1993},{"EARLY_PHASE1":1994,"PHASE1":1996,"PHASE2":1998,"PHASE3":2000,"PHASE4":2002,"NA":2008},{"trials":1995,"activeCount":99},[],{"trials":1997,"activeCount":99},[],{"trials":1999,"activeCount":99},[],{"trials":2001,"activeCount":99},[],{"trials":2003,"activeCount":99},[2004],{"nctId":1981,"briefTitle":1982,"status":134,"phases":2005,"primaryCompletion":1984,"completion":1984,"start":1985,"enrollment":839,"conditions":2006,"interventions":2007},[91],[1987],[1968,1989],{"trials":2009,"activeCount":99},[],{"intervention":2011,"totalTrials":171,"cells":2012},"Alfuzosin",{"EARLY_PHASE1":2013,"PHASE1":2015,"PHASE2":2017,"PHASE3":2019,"PHASE4":2021,"NA":2032},{"trials":2014,"activeCount":99},[],{"trials":2016,"activeCount":99},[],{"trials":2018,"activeCount":99},[],{"trials":2020,"activeCount":99},[],{"trials":2022,"activeCount":99},[2023],{"nctId":2024,"briefTitle":2025,"status":134,"phases":2026,"primaryCompletion":1088,"completion":1088,"start":2027,"enrollment":2028,"conditions":2029,"interventions":2031},"NCT00836823","Evaluation of Symptom-specific Goal Achievement",[91],"2005-12",130,[33,2030],"Lower Urinary Tract Symptoms",[2011],{"trials":2033,"activeCount":99},[],{"intervention":2035,"totalTrials":171,"cells":2036},"Cyclosporine microemulsion",{"EARLY_PHASE1":2037,"PHASE1":2039,"PHASE2":2041,"PHASE3":2043,"PHASE4":2045,"NA":2057},{"trials":2038,"activeCount":99},[],{"trials":2040,"activeCount":99},[],{"trials":2042,"activeCount":99},[],{"trials":2044,"activeCount":99},[],{"trials":2046,"activeCount":99},[2047],{"nctId":2048,"briefTitle":2049,"status":134,"phases":2050,"primaryCompletion":2051,"completion":2052,"start":2053,"enrollment":645,"conditions":2054,"interventions":2056},"NCT04426240","The Effect of Cyclosporin Before Cataract Surgery",[91],"2022-01-26","2022-04-19","2020-08-03",[2055],"Dry Eye Syndromes",[2035],{"trials":2058,"activeCount":99},[],{"intervention":2060,"totalTrials":171,"cells":2061},"Mircera",{"EARLY_PHASE1":2062,"PHASE1":2064,"PHASE2":2066,"PHASE3":2068,"PHASE4":2070,"NA":2082},{"trials":2063,"activeCount":99},[],{"trials":2065,"activeCount":99},[],{"trials":2067,"activeCount":99},[],{"trials":2069,"activeCount":99},[],{"trials":2071,"activeCount":99},[2072],{"nctId":2073,"briefTitle":2074,"status":534,"phases":2075,"primaryCompletion":2076,"completion":2077,"start":1196,"enrollment":2078,"conditions":2079,"interventions":2081},"NCT01807481","Phase IV Study to Evaluate the Efficacy and Safety of Mircera in PD",[91],"2015-02","2015-08",101,[2080],"PD",[2060],{"trials":2083,"activeCount":99},[],{"intervention":2085,"totalTrials":171,"cells":2086},"Lanreotide",{"EARLY_PHASE1":2087,"PHASE1":2089,"PHASE2":2091,"PHASE3":2093,"PHASE4":2095,"NA":2106},{"trials":2088,"activeCount":99},[],{"trials":2090,"activeCount":99},[],{"trials":2092,"activeCount":99},[],{"trials":2094,"activeCount":99},[],{"trials":2096,"activeCount":99},[2097],{"nctId":2098,"briefTitle":2099,"status":534,"phases":2100,"primaryCompletion":2101,"completion":2101,"start":2102,"enrollment":1842,"conditions":2103,"interventions":2105},"NCT03083210","Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET",[91],"2020-02","2017-07-05",[2104],"Neuroendocrine Tumors",[2085],{"trials":2107,"activeCount":99},[],{"intervention":2109,"totalTrials":171,"cells":2110},"Sarpogrelate",{"EARLY_PHASE1":2111,"PHASE1":2113,"PHASE2":2115,"PHASE3":2117,"PHASE4":2119,"NA":2130},{"trials":2112,"activeCount":99},[],{"trials":2114,"activeCount":99},[],{"trials":2116,"activeCount":99},[],{"trials":2118,"activeCount":99},[],{"trials":2120,"activeCount":99},[2121],{"nctId":2122,"briefTitle":2123,"status":534,"phases":2124,"primaryCompletion":1147,"completion":1147,"start":2125,"enrollment":112,"conditions":2126,"interventions":2128},"NCT01674686","The Effect of Sarpogrelate and High Dose Statin on the Reduction of Coronary Spasm",[91],"2012-08-01",[2127],"Variant Angina",[2109,2129],"Atorvastatin",{"trials":2131,"activeCount":99},[],{"intervention":2133,"totalTrials":171,"cells":2134},"naftopidil 75mg",{"EARLY_PHASE1":2135,"PHASE1":2137,"PHASE2":2139,"PHASE3":2141,"PHASE4":2143,"NA":2154},{"trials":2136,"activeCount":99},[],{"trials":2138,"activeCount":99},[],{"trials":2140,"activeCount":99},[],{"trials":2142,"activeCount":99},[],{"trials":2144,"activeCount":99},[2145],{"nctId":2146,"briefTitle":2147,"status":534,"phases":2148,"primaryCompletion":2076,"completion":1075,"start":2149,"enrollment":2028,"conditions":2150,"interventions":2153},"NCT02011737","Naftopidil 75mg for Improving Clearance of Urinary Stones",[91],"2014-02",[2151,2152],"Kidney Calculi","Ureter Calculi",[2133],{"trials":2155,"activeCount":99},[],{"intervention":2157,"totalTrials":171,"cells":2158},"Desmopressin",{"EARLY_PHASE1":2159,"PHASE1":2161,"PHASE2":2163,"PHASE3":2165,"PHASE4":2167,"NA":2177},{"trials":2160,"activeCount":99},[],{"trials":2162,"activeCount":99},[],{"trials":2164,"activeCount":99},[],{"trials":2166,"activeCount":99},[],{"trials":2168,"activeCount":99},[2169],{"nctId":2170,"briefTitle":2171,"status":134,"phases":2172,"primaryCompletion":2027,"completion":2027,"start":2173,"enrollment":463,"conditions":2174,"interventions":2176},"NCT00902655","Desmopressin in the Treatment of Mixed Nocturia With Nocturnal Polyuria and Low Nocturnal Bladder Capacity",[91],"2004-04",[2175],"Nocturia",[2157],{"trials":2178,"activeCount":99},[],{"intervention":2180,"totalTrials":171,"cells":2181},"Paxil CR",{"EARLY_PHASE1":2182,"PHASE1":2184,"PHASE2":2186,"PHASE3":2188,"PHASE4":2190,"NA":2202},{"trials":2183,"activeCount":99},[],{"trials":2185,"activeCount":99},[],{"trials":2187,"activeCount":99},[],{"trials":2189,"activeCount":99},[],{"trials":2191,"activeCount":99},[2192],{"nctId":2193,"briefTitle":2194,"status":134,"phases":2195,"primaryCompletion":2196,"completion":2197,"start":2198,"enrollment":862,"conditions":2199,"interventions":2201},"NCT00767754","Changes of Cerebral Glucose Metabolism After 12 Weeks of Paroxetine Treatment in Panic Disorder",[91],"2007-06","2008-12","2007-01",[2200],"Panic Disorder",[2180],{"trials":2203,"activeCount":99},[],{"intervention":2205,"totalTrials":171,"cells":2206},"Propiverine hydrochloride",{"EARLY_PHASE1":2207,"PHASE1":2209,"PHASE2":2211,"PHASE3":2213,"PHASE4":2215,"NA":2226},{"trials":2208,"activeCount":99},[],{"trials":2210,"activeCount":99},[],{"trials":2212,"activeCount":99},[],{"trials":2214,"activeCount":99},[],{"trials":2216,"activeCount":99},[2217],{"nctId":2218,"briefTitle":2219,"status":134,"phases":2220,"primaryCompletion":2221,"completion":2221,"start":2222,"enrollment":2223,"conditions":2224,"interventions":2225},"NCT00903045","Urinary Urgency Outcomes Following Propiverine Treatment for an Overactive Bladder",[91],"2006-08","2005-01",264,[1963],[2205],{"trials":2227,"activeCount":99},[],{"intervention":2229,"totalTrials":171,"cells":2230},"Duration of DAPT",{"EARLY_PHASE1":2231,"PHASE1":2233,"PHASE2":2235,"PHASE3":2237,"PHASE4":2239,"NA":2249},{"trials":2232,"activeCount":99},[],{"trials":2234,"activeCount":99},[],{"trials":2236,"activeCount":99},[],{"trials":2238,"activeCount":99},[],{"trials":2240,"activeCount":99},[2241],{"nctId":2242,"briefTitle":2243,"status":1816,"phases":2244,"primaryCompletion":2245,"completion":2245,"start":2246,"enrollment":1933,"conditions":2247,"interventions":2248},"NCT05066789","CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 4",[91],"2024-03-22","2022-01-17",[18],[2229],{"trials":2250,"activeCount":99},[],{"intervention":2252,"totalTrials":171,"cells":2253},"Agiocur Pregranules",{"EARLY_PHASE1":2254,"PHASE1":2256,"PHASE2":2258,"PHASE3":2260,"PHASE4":2262,"NA":2274},{"trials":2255,"activeCount":99},[],{"trials":2257,"activeCount":99},[],{"trials":2259,"activeCount":99},[],{"trials":2261,"activeCount":99},[],{"trials":2263,"activeCount":99},[2264],{"nctId":2265,"briefTitle":2266,"status":134,"phases":2267,"primaryCompletion":2268,"completion":2269,"start":2149,"enrollment":2270,"conditions":2271,"interventions":2273},"NCT03552991","Effects of Dietary Fiber on Glucose Control in Subjects With Type 2 Diabetes Mellitus",[91],"2015-10","2018-05-31",14,[2272],"Diabetes Mellitus, Type 2",[2252],{"trials":2275,"activeCount":99},[],{"intervention":220,"totalTrials":171,"cells":2277},{"EARLY_PHASE1":2278,"PHASE1":2280,"PHASE2":2282,"PHASE3":2284,"PHASE4":2286,"NA":2292},{"trials":2279,"activeCount":99},[],{"trials":2281,"activeCount":99},[],{"trials":2283,"activeCount":99},[],{"trials":2285,"activeCount":99},[],{"trials":2287,"activeCount":99},[2288],{"nctId":209,"briefTitle":210,"status":134,"phases":2289,"primaryCompletion":212,"completion":212,"start":213,"enrollment":214,"conditions":2290,"interventions":2291},[91],[216,217],[196,219,220],{"trials":2293,"activeCount":99},[],{"intervention":2295,"totalTrials":171,"cells":2296},"Ecabet",{"EARLY_PHASE1":2297,"PHASE1":2299,"PHASE2":2301,"PHASE3":2303,"PHASE4":2305,"NA":2317},{"trials":2298,"activeCount":99},[],{"trials":2300,"activeCount":99},[],{"trials":2302,"activeCount":99},[],{"trials":2304,"activeCount":99},[],{"trials":2306,"activeCount":99},[2307],{"nctId":2308,"briefTitle":2309,"status":534,"phases":2310,"primaryCompletion":1858,"completion":1858,"start":2311,"enrollment":1099,"conditions":2312,"interventions":2316},"NCT01308177","Efficacy of Ecabet Sodium and Proton Pump Inhibitor Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection",[91],"2011-03",[2313,2314,2315],"Delayed Bleeding,","Healing Ulcer","Quality of Ulcer",[2295],{"trials":2318,"activeCount":99},[],{"intervention":2320,"totalTrials":171,"cells":2321},"Tianeptine",{"EARLY_PHASE1":2322,"PHASE1":2324,"PHASE2":2326,"PHASE3":2328,"PHASE4":2330,"NA":2342},{"trials":2323,"activeCount":99},[],{"trials":2325,"activeCount":99},[],{"trials":2327,"activeCount":99},[],{"trials":2329,"activeCount":99},[],{"trials":2331,"activeCount":99},[2332],{"nctId":2333,"briefTitle":2334,"status":134,"phases":2335,"primaryCompletion":2336,"completion":2336,"start":2311,"enrollment":2337,"conditions":2338,"interventions":2340},"NCT01309776","Comparison of Tianeptine Versus Escitalopram Patients Major Depressive Disorder",[91],"2012-09",164,[2339],"Major Depressive Disorder",[2320,2341],"Escitalopram",{"trials":2343,"activeCount":99},[],{"intervention":2345,"totalTrials":171,"cells":2346},"hyaluronic acid and chondroitin sulphate",{"EARLY_PHASE1":2347,"PHASE1":2349,"PHASE2":2351,"PHASE3":2353,"PHASE4":2355,"NA":2367},{"trials":2348,"activeCount":99},[],{"trials":2350,"activeCount":99},[],{"trials":2352,"activeCount":99},[],{"trials":2354,"activeCount":99},[],{"trials":2356,"activeCount":99},[2357],{"nctId":2358,"briefTitle":2359,"status":134,"phases":2360,"primaryCompletion":1087,"completion":2361,"start":2362,"enrollment":2363,"conditions":2364,"interventions":2366},"NCT02366676","Efficacy of IARULIL® in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract",[91],"2019-10-30","2014-01",105,[2365],"Recurrent Cystitis",[2345],{"trials":2368,"activeCount":99},[],{"intervention":2370,"totalTrials":171,"cells":2371},"azithromycin, doxycycline",{"EARLY_PHASE1":2372,"PHASE1":2374,"PHASE2":2376,"PHASE3":2378,"PHASE4":2380,"NA":2390},{"trials":2373,"activeCount":99},[],{"trials":2375,"activeCount":99},[],{"trials":2377,"activeCount":99},[],{"trials":2379,"activeCount":99},[],{"trials":2381,"activeCount":99},[2382],{"nctId":2383,"briefTitle":2384,"status":134,"phases":2385,"primaryCompletion":2386,"completion":2386,"start":2198,"enrollment":2387,"conditions":2388,"interventions":2389},"NCT00883818","Microorganism in Overactive Bladder Patients",[91],"2007-12",84,[1963],[2370],{"trials":2391,"activeCount":99},[],{"intervention":2393,"totalTrials":171,"cells":2394},"Cerebrolysin",{"EARLY_PHASE1":2395,"PHASE1":2397,"PHASE2":2399,"PHASE3":2401,"PHASE4":2403,"NA":2413},{"trials":2396,"activeCount":99},[],{"trials":2398,"activeCount":99},[],{"trials":2400,"activeCount":99},[],{"trials":2402,"activeCount":99},[],{"trials":2404,"activeCount":99},[2405],{"nctId":2406,"briefTitle":2407,"status":134,"phases":2408,"primaryCompletion":2409,"completion":2409,"start":2410,"enrollment":1648,"conditions":2411,"interventions":2412},"NCT02768571","Effects of Cerebrolysin Combined With Rehabilitation on Motor Recovery in Stroke",[91],"2019-02-14","2016-03-14",[15],[2393],{"trials":2414,"activeCount":99},[],{"intervention":2416,"totalTrials":171,"cells":2417},"tirofiban",{"EARLY_PHASE1":2418,"PHASE1":2420,"PHASE2":2422,"PHASE3":2424,"PHASE4":2426,"NA":2437},{"trials":2419,"activeCount":99},[],{"trials":2421,"activeCount":99},[],{"trials":2423,"activeCount":99},[],{"trials":2425,"activeCount":99},[],{"trials":2427,"activeCount":99},[2428],{"nctId":2429,"briefTitle":2430,"status":134,"phases":2431,"primaryCompletion":2432,"completion":2433,"start":2434,"enrollment":645,"conditions":2435,"interventions":2436},"NCT00611169","The Effects of Facilitated Percutaeous Coronary Intervention in Acute Myocardial Infarction",[91],"2007-02","2007-08","2006-01",[114],[2416],{"trials":2438,"activeCount":99},[],{"intervention":2440,"totalTrials":171,"cells":2441},"Standard Dose of Myfortic and Reduced Dose of Myfortic",{"EARLY_PHASE1":2442,"PHASE1":2444,"PHASE2":2446,"PHASE3":2448,"PHASE4":2450,"NA":2463},{"trials":2443,"activeCount":99},[],{"trials":2445,"activeCount":99},[],{"trials":2447,"activeCount":99},[],{"trials":2449,"activeCount":99},[],{"trials":2451,"activeCount":99},[2452],{"nctId":2453,"briefTitle":2454,"status":134,"phases":2455,"primaryCompletion":2456,"completion":2456,"start":1275,"enrollment":2457,"conditions":2458,"interventions":2460},"NCT01817322","Kidney Graft Function Under the Immunosuppression Strategies",[91],"2013-08",140,[2459],"Chronic Renal Disease",[2440,2461,2462],"Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group","Basiliximab injected both control group and experimental group",{"trials":2464,"activeCount":99},[],{"intervention":2461,"totalTrials":171,"cells":2466},{"EARLY_PHASE1":2467,"PHASE1":2469,"PHASE2":2471,"PHASE3":2473,"PHASE4":2475,"NA":2481},{"trials":2468,"activeCount":99},[],{"trials":2470,"activeCount":99},[],{"trials":2472,"activeCount":99},[],{"trials":2474,"activeCount":99},[],{"trials":2476,"activeCount":99},[2477],{"nctId":2453,"briefTitle":2454,"status":134,"phases":2478,"primaryCompletion":2456,"completion":2456,"start":1275,"enrollment":2457,"conditions":2479,"interventions":2480},[91],[2459],[2440,2461,2462],{"trials":2482,"activeCount":99},[],{"intervention":2462,"totalTrials":171,"cells":2484},{"EARLY_PHASE1":2485,"PHASE1":2487,"PHASE2":2489,"PHASE3":2491,"PHASE4":2493,"NA":2499},{"trials":2486,"activeCount":99},[],{"trials":2488,"activeCount":99},[],{"trials":2490,"activeCount":99},[],{"trials":2492,"activeCount":99},[],{"trials":2494,"activeCount":99},[2495],{"nctId":2453,"briefTitle":2454,"status":134,"phases":2496,"primaryCompletion":2456,"completion":2456,"start":1275,"enrollment":2457,"conditions":2497,"interventions":2498},[91],[2459],[2440,2461,2462],{"trials":2500,"activeCount":99},[],{"intervention":1862,"totalTrials":171,"cells":2502},{"EARLY_PHASE1":2503,"PHASE1":2505,"PHASE2":2507,"PHASE3":2509,"PHASE4":2511,"NA":2517},{"trials":2504,"activeCount":99},[],{"trials":2506,"activeCount":99},[],{"trials":2508,"activeCount":99},[],{"trials":2510,"activeCount":99},[],{"trials":2512,"activeCount":99},[2513],{"nctId":1855,"briefTitle":1856,"status":185,"phases":2514,"primaryCompletion":1858,"start":1859,"enrollment":99,"conditions":2515,"interventions":2516},[91],[33],[1862,1830,1863],{"trials":2518,"activeCount":99},[],{"intervention":1863,"totalTrials":171,"cells":2520},{"EARLY_PHASE1":2521,"PHASE1":2523,"PHASE2":2525,"PHASE3":2527,"PHASE4":2529,"NA":2535},{"trials":2522,"activeCount":99},[],{"trials":2524,"activeCount":99},[],{"trials":2526,"activeCount":99},[],{"trials":2528,"activeCount":99},[],{"trials":2530,"activeCount":99},[2531],{"nctId":1855,"briefTitle":1856,"status":185,"phases":2532,"primaryCompletion":1858,"start":1859,"enrollment":99,"conditions":2533,"interventions":2534},[91],[33],[1862,1830,1863],{"trials":2536,"activeCount":99},[],{"intervention":2538,"totalTrials":171,"cells":2539},"Tolterodine extended-release (ER) 4mg",{"EARLY_PHASE1":2540,"PHASE1":2542,"PHASE2":2544,"PHASE3":2546,"PHASE4":2548,"NA":2558},{"trials":2541,"activeCount":99},[],{"trials":2543,"activeCount":99},[],{"trials":2545,"activeCount":99},[],{"trials":2547,"activeCount":99},[],{"trials":2549,"activeCount":99},[2550],{"nctId":2551,"briefTitle":2552,"status":134,"phases":2553,"primaryCompletion":1894,"completion":1894,"start":2554,"enrollment":2555,"conditions":2556,"interventions":2557},"NCT00836381","Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder",[91],"2009-02",56,[1963],[2538],{"trials":2559,"activeCount":99},[],{"intervention":2561,"totalTrials":171,"cells":2562},"porcine brain peptide",{"EARLY_PHASE1":2563,"PHASE1":2565,"PHASE2":2567,"PHASE3":2569,"PHASE4":2571,"NA":2581},{"trials":2564,"activeCount":99},[],{"trials":2566,"activeCount":99},[],{"trials":2568,"activeCount":99},[],{"trials":2570,"activeCount":99},[],{"trials":2572,"activeCount":99},[2573],{"nctId":2574,"briefTitle":2575,"status":134,"phases":2576,"primaryCompletion":2362,"completion":2149,"start":2577,"enrollment":2578,"conditions":2579,"interventions":2580},"NCT01996761","Effects of Cerebrolysin on Motor Recovery in Patients With Subacute Stroke",[91],"2011-01",71,[2393],[2561],{"trials":2582,"activeCount":99},[],{"intervention":2584,"totalTrials":171,"cells":2585},"Selective serotonin reuptake inhibitors",{"EARLY_PHASE1":2586,"PHASE1":2588,"PHASE2":2590,"PHASE3":2592,"PHASE4":2594,"NA":2603},{"trials":2587,"activeCount":99},[],{"trials":2589,"activeCount":99},[],{"trials":2591,"activeCount":99},[],{"trials":2593,"activeCount":99},[],{"trials":2595,"activeCount":99},[2596],{"nctId":2597,"briefTitle":2598,"status":134,"phases":2599,"primaryCompletion":1784,"completion":1784,"start":2198,"enrollment":645,"conditions":2600,"interventions":2601},"NCT00902421","Efficacy and Safety of Selective Serotonin Reuptake Inhibitor (SSRI) in Overactive Bladder Patients",[91],[1963],[2584,2602],"Antimuscarinics",{"trials":2604,"activeCount":99},[],{"intervention":2602,"totalTrials":171,"cells":2606},{"EARLY_PHASE1":2607,"PHASE1":2609,"PHASE2":2611,"PHASE3":2613,"PHASE4":2615,"NA":2621},{"trials":2608,"activeCount":99},[],{"trials":2610,"activeCount":99},[],{"trials":2612,"activeCount":99},[],{"trials":2614,"activeCount":99},[],{"trials":2616,"activeCount":99},[2617],{"nctId":2597,"briefTitle":2598,"status":134,"phases":2618,"primaryCompletion":1784,"completion":1784,"start":2198,"enrollment":645,"conditions":2619,"interventions":2620},[91],[1963],[2584,2602],{"trials":2622,"activeCount":99},[],{"intervention":2624,"totalTrials":171,"cells":2625},"ZYDENA TAB.75mg",{"EARLY_PHASE1":2626,"PHASE1":2628,"PHASE2":2630,"PHASE3":2632,"PHASE4":2634,"NA":2647},{"trials":2627,"activeCount":99},[],{"trials":2629,"activeCount":99},[],{"trials":2631,"activeCount":99},[],{"trials":2633,"activeCount":99},[],{"trials":2635,"activeCount":99},[2636],{"nctId":2637,"briefTitle":2638,"status":534,"phases":2639,"primaryCompletion":2640,"completion":2641,"start":2642,"enrollment":2643,"conditions":2644,"interventions":2646},"NCT03142542","The Efficacy and Safety of Udenafil in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy",[91],"2019-05","2019-12","2017-05",99,[2645],"Prostate Cancer With Radical Prostatectomy",[2624],{"trials":2648,"activeCount":99},[],{"intervention":2650,"totalTrials":171,"cells":2651},"aflibercept",{"EARLY_PHASE1":2652,"PHASE1":2654,"PHASE2":2656,"PHASE3":2658,"PHASE4":2660,"NA":2670},{"trials":2653,"activeCount":99},[],{"trials":2655,"activeCount":99},[],{"trials":2657,"activeCount":99},[],{"trials":2659,"activeCount":99},[],{"trials":2661,"activeCount":99},[2662],{"nctId":2663,"briefTitle":2664,"status":134,"phases":2665,"primaryCompletion":2666,"completion":2666,"start":2149,"enrollment":1127,"conditions":2667,"interventions":2669},"NCT02072408","Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy",[91],"2017-11-02",[2668],"Polypoidal Choroidal Vasculopathy Without Active Polyp",[2650],{"trials":2671,"activeCount":99},[],{"intervention":2673,"totalTrials":171,"cells":2674},"Lexapro",{"EARLY_PHASE1":2675,"PHASE1":2677,"PHASE2":2679,"PHASE3":2681,"PHASE4":2683,"NA":2692},{"trials":2676,"activeCount":99},[],{"trials":2678,"activeCount":99},[],{"trials":2680,"activeCount":99},[],{"trials":2682,"activeCount":99},[],{"trials":2684,"activeCount":99},[2685],{"nctId":2686,"briefTitle":2687,"status":134,"phases":2688,"primaryCompletion":2433,"completion":2197,"start":2689,"enrollment":1127,"conditions":2690,"interventions":2691},"NCT00767871","Changes of Cerebral Glucose Metabolism and After 12 Weeks of Escitalpram Treatment in Panic Disorder",[91],"2007-03",[2200],[2673],{"trials":2693,"activeCount":99},[],{"intervention":2695,"totalTrials":171,"cells":2696},"Udenafil",{"EARLY_PHASE1":2697,"PHASE1":2699,"PHASE2":2701,"PHASE3":2703,"PHASE4":2705,"NA":2716},{"trials":2698,"activeCount":99},[],{"trials":2700,"activeCount":99},[],{"trials":2702,"activeCount":99},[],{"trials":2704,"activeCount":99},[],{"trials":2706,"activeCount":99},[2707],{"nctId":2708,"briefTitle":2709,"status":534,"phases":2710,"primaryCompletion":2711,"completion":2711,"start":2712,"enrollment":1702,"conditions":2713,"interventions":2715},"NCT01769482","Understanding of Chest Pain in Microvascular Disease Proved by Cardiac Magnetic Resonance Image",[91],"2014-12","2011-12",[2714],"Microvascular Angina",[2695],{"trials":2717,"activeCount":99},[],{"intervention":2719,"totalTrials":171,"cells":2720},"Indocyanine green",{"EARLY_PHASE1":2721,"PHASE1":2723,"PHASE2":2725,"PHASE3":2727,"PHASE4":2729,"NA":2740},{"trials":2722,"activeCount":99},[],{"trials":2724,"activeCount":99},[],{"trials":2726,"activeCount":99},[],{"trials":2728,"activeCount":99},[],{"trials":2730,"activeCount":99},[2731],{"nctId":2732,"briefTitle":2733,"status":534,"phases":2734,"primaryCompletion":1194,"completion":2735,"start":1033,"enrollment":2736,"conditions":2737,"interventions":2739},"NCT02781259","Selective Lymph Node Dissection Using Fluorescent Dye in Node-positive Breast Cancer",[91],"2017-04",150,[2738],"Breast Neoplasms",[2719],{"trials":2741,"activeCount":99},[],{"intervention":2743,"totalTrials":171,"cells":2744},"Use of prophylactic anticonvulsants",{"EARLY_PHASE1":2745,"PHASE1":2747,"PHASE2":2749,"PHASE3":2751,"PHASE4":2753,"NA":2765},{"trials":2746,"activeCount":99},[],{"trials":2748,"activeCount":99},[],{"trials":2750,"activeCount":99},[],{"trials":2752,"activeCount":99},[],{"trials":2754,"activeCount":99},[2755],{"nctId":2756,"briefTitle":2757,"status":534,"phases":2758,"primaryCompletion":2759,"start":2760,"enrollment":228,"conditions":2761,"interventions":2763},"NCT01083784","The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia",[91],"2012-12","2010-03",[2762],"Cardiac Arrest",[2743,2764],"Control group",{"trials":2766,"activeCount":99},[],{"intervention":2764,"totalTrials":171,"cells":2768},{"EARLY_PHASE1":2769,"PHASE1":2771,"PHASE2":2773,"PHASE3":2775,"PHASE4":2777,"NA":2783},{"trials":2770,"activeCount":99},[],{"trials":2772,"activeCount":99},[],{"trials":2774,"activeCount":99},[],{"trials":2776,"activeCount":99},[],{"trials":2778,"activeCount":99},[2779],{"nctId":2756,"briefTitle":2757,"status":534,"phases":2780,"primaryCompletion":2759,"start":2760,"enrollment":228,"conditions":2781,"interventions":2782},[91],[2762],[2743,2764],{"trials":2784,"activeCount":99},[],{"intervention":2786,"totalTrials":171,"cells":2787},"Naftofidil",{"EARLY_PHASE1":2788,"PHASE1":2790,"PHASE2":2792,"PHASE3":2794,"PHASE4":2796,"NA":2808},{"trials":2789,"activeCount":99},[],{"trials":2791,"activeCount":99},[],{"trials":2793,"activeCount":99},[],{"trials":2795,"activeCount":99},[],{"trials":2797,"activeCount":99},[2798],{"nctId":2799,"briefTitle":2800,"status":134,"phases":2801,"primaryCompletion":612,"completion":2802,"start":1736,"enrollment":2803,"conditions":2804,"interventions":2806},"NCT02034604","Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia",[91],"2017-08",194,[2805],"Neurogenic Lower Urinary Tract Dysfunction",[2786,2807],"Tamsulosin",{"trials":2809,"activeCount":99},[],{"intervention":2811,"totalTrials":171,"cells":2812},"High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg",{"EARLY_PHASE1":2813,"PHASE1":2815,"PHASE2":2817,"PHASE3":2819,"PHASE4":2821,"NA":2832},{"trials":2814,"activeCount":99},[],{"trials":2816,"activeCount":99},[],{"trials":2818,"activeCount":99},[],{"trials":2820,"activeCount":99},[],{"trials":2822,"activeCount":99},[2823],{"nctId":2824,"briefTitle":2825,"status":534,"phases":2826,"primaryCompletion":2827,"completion":2827,"start":2828,"enrollment":1648,"conditions":2829,"interventions":2831},"NCT02458755","Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis",[91],"2018-06","2012-02",[15,2830],"Intracranial Atherosclerosis",[2811],{"trials":2833,"activeCount":99},[],{"intervention":2835,"totalTrials":171,"cells":2836},"combination therapy",{"EARLY_PHASE1":2837,"PHASE1":2839,"PHASE2":2841,"PHASE3":2843,"PHASE4":2845,"NA":2857},{"trials":2838,"activeCount":99},[],{"trials":2840,"activeCount":99},[],{"trials":2842,"activeCount":99},[],{"trials":2844,"activeCount":99},[],{"trials":2846,"activeCount":99},[2847],{"nctId":2848,"briefTitle":2849,"status":134,"phases":2850,"primaryCompletion":2851,"completion":1736,"start":2577,"enrollment":2852,"conditions":2853,"interventions":2854},"NCT01301599","Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH)",[91],"2013-07",308,[33],[2835,2855,2856],"alpha blocker monotherapy","5 alpha reductase inhibitor monotherapy",{"trials":2858,"activeCount":99},[],{"intervention":2855,"totalTrials":171,"cells":2860},{"EARLY_PHASE1":2861,"PHASE1":2863,"PHASE2":2865,"PHASE3":2867,"PHASE4":2869,"NA":2875},{"trials":2862,"activeCount":99},[],{"trials":2864,"activeCount":99},[],{"trials":2866,"activeCount":99},[],{"trials":2868,"activeCount":99},[],{"trials":2870,"activeCount":99},[2871],{"nctId":2848,"briefTitle":2849,"status":134,"phases":2872,"primaryCompletion":2851,"completion":1736,"start":2577,"enrollment":2852,"conditions":2873,"interventions":2874},[91],[33],[2835,2855,2856],{"trials":2876,"activeCount":99},[],{"intervention":2856,"totalTrials":171,"cells":2878},{"EARLY_PHASE1":2879,"PHASE1":2881,"PHASE2":2883,"PHASE3":2885,"PHASE4":2887,"NA":2893},{"trials":2880,"activeCount":99},[],{"trials":2882,"activeCount":99},[],{"trials":2884,"activeCount":99},[],{"trials":2886,"activeCount":99},[],{"trials":2888,"activeCount":99},[2889],{"nctId":2848,"briefTitle":2849,"status":134,"phases":2890,"primaryCompletion":2851,"completion":1736,"start":2577,"enrollment":2852,"conditions":2891,"interventions":2892},[91],[33],[2835,2855,2856],{"trials":2894,"activeCount":99},[],{"intervention":2896,"totalTrials":171,"cells":2897},"Tenofovir disoproxil fumarate",{"EARLY_PHASE1":2898,"PHASE1":2900,"PHASE2":2902,"PHASE3":2904,"PHASE4":2906,"NA":2917},{"trials":2899,"activeCount":99},[],{"trials":2901,"activeCount":99},[],{"trials":2903,"activeCount":99},[],{"trials":2905,"activeCount":99},[],{"trials":2907,"activeCount":99},[2908],{"nctId":2909,"briefTitle":2910,"status":534,"phases":2911,"primaryCompletion":1750,"completion":2912,"start":1086,"enrollment":2913,"conditions":2914,"interventions":2916},"NCT02308319","Prompt Or Watchful Monitoring for Hepatitis B Virus Related Hepatocellular Carcinoma Without Elevated viRal Load",[91],"2019-06",124,[2915],"Carcinoma, Hepatocellular",[2896],{"trials":2918,"activeCount":99},[],{"intervention":2920,"totalTrials":171,"cells":2921},"Dutasteride",{"EARLY_PHASE1":2922,"PHASE1":2924,"PHASE2":2926,"PHASE3":2928,"PHASE4":2930,"NA":2940},{"trials":2923,"activeCount":99},[],{"trials":2925,"activeCount":99},[],{"trials":2927,"activeCount":99},[],{"trials":2929,"activeCount":99},[],{"trials":2931,"activeCount":99},[2932],{"nctId":2933,"briefTitle":2934,"status":134,"phases":2935,"primaryCompletion":2936,"completion":2936,"start":2937,"enrollment":1922,"conditions":2938,"interventions":2939},"NCT00827814","Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic Obstruction",[91],"2009-04","2006-06",[33],[2920],{"trials":2941,"activeCount":99},[],{"intervention":1825,"totalTrials":171,"cells":2943},{"EARLY_PHASE1":2944,"PHASE1":2946,"PHASE2":2948,"PHASE3":2950,"PHASE4":2952,"NA":2958},{"trials":2945,"activeCount":99},[],{"trials":2947,"activeCount":99},[],{"trials":2949,"activeCount":99},[],{"trials":2951,"activeCount":99},[],{"trials":2953,"activeCount":99},[2954],{"nctId":1814,"briefTitle":1815,"status":1816,"phases":2955,"primaryCompletion":1818,"completion":1819,"start":1820,"enrollment":1157,"conditions":2956,"interventions":2957},[91],[18,1822,1823],[1792,1825,1826],{"trials":2959,"activeCount":99},[],{"intervention":1826,"totalTrials":171,"cells":2961},{"EARLY_PHASE1":2962,"PHASE1":2964,"PHASE2":2966,"PHASE3":2968,"PHASE4":2970,"NA":2976},{"trials":2963,"activeCount":99},[],{"trials":2965,"activeCount":99},[],{"trials":2967,"activeCount":99},[],{"trials":2969,"activeCount":99},[],{"trials":2971,"activeCount":99},[2972],{"nctId":1814,"briefTitle":1815,"status":1816,"phases":2973,"primaryCompletion":1818,"completion":1819,"start":1820,"enrollment":1157,"conditions":2974,"interventions":2975},[91],[18,1822,1823],[1792,1825,1826],{"trials":2977,"activeCount":99},[],{"intervention":2979,"totalTrials":171,"cells":2980},"doxazosin plus tolterodine SR",{"EARLY_PHASE1":2981,"PHASE1":2983,"PHASE2":2985,"PHASE3":2987,"PHASE4":2989,"NA":3000},{"trials":2982,"activeCount":99},[],{"trials":2984,"activeCount":99},[],{"trials":2986,"activeCount":99},[],{"trials":2988,"activeCount":99},[],{"trials":2990,"activeCount":99},[2991],{"nctId":2992,"briefTitle":2993,"status":134,"phases":2994,"primaryCompletion":2995,"completion":1223,"start":2996,"enrollment":2997,"conditions":2998,"interventions":2999},"NCT00922506","Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH)",[91],"2014-05","2009-05",83,[1963,33],[2979],{"trials":3001,"activeCount":99},[],{"intervention":3003,"totalTrials":171,"cells":3004},"Pravastatin",{"EARLY_PHASE1":3005,"PHASE1":3007,"PHASE2":3009,"PHASE3":3011,"PHASE4":3013,"NA":3026},{"trials":3006,"activeCount":99},[],{"trials":3008,"activeCount":99},[],{"trials":3010,"activeCount":99},[],{"trials":3012,"activeCount":99},[],{"trials":3014,"activeCount":99},[3015],{"nctId":3016,"briefTitle":3017,"status":134,"phases":3018,"primaryCompletion":3019,"completion":3019,"start":3020,"enrollment":3021,"conditions":3022,"interventions":3025},"NCT02754739","Effect of Pravastatin in the Subjects With Prediabetes or Early Diabetes",[91],"2017-08-31","2014-04-15",44,[3023,3024],"Diabetes Mellitus","Prediabetic State",[3003],{"trials":3027,"activeCount":99},[],{"intervention":1042,"totalTrials":614,"cells":3029},{"EARLY_PHASE1":3030,"PHASE1":3032,"PHASE2":3034,"PHASE3":3068,"PHASE4":3083,"NA":3085},{"trials":3031,"activeCount":99},[],{"trials":3033,"activeCount":99},[],{"trials":3035,"activeCount":99},[3036,3040,3044,3048,3052,3056,3060,3064],{"nctId":1028,"briefTitle":1029,"status":534,"phases":3037,"primaryCompletion":1031,"completion":1032,"start":1033,"enrollment":1034,"conditions":3038,"interventions":3039},[89],[1036],[1038,1019,1039,1040,1041,1042,1043,1044],{"nctId":1046,"briefTitle":1047,"status":534,"phases":3041,"primaryCompletion":1049,"start":1050,"enrollment":645,"conditions":3042,"interventions":3043},[89],[1052],[1042,1019,1040,1054],{"nctId":1070,"briefTitle":1071,"status":534,"phases":3045,"primaryCompletion":1073,"completion":1074,"start":1075,"enrollment":1076,"conditions":3046,"interventions":3047},[89],[1078],[1038,1039,1019,1040,1041,1042,1080,1081],{"nctId":1083,"briefTitle":1084,"status":134,"phases":3049,"primaryCompletion":1086,"completion":1087,"start":1088,"enrollment":645,"conditions":3050,"interventions":3051},[89],[1090],[1040,1019,1042,1043,1044],{"nctId":1093,"briefTitle":1094,"status":534,"phases":3053,"primaryCompletion":1096,"completion":1097,"start":1098,"enrollment":1099,"conditions":3054,"interventions":3055},[89],[1101,1102,1103,1104],[1041,1042,1019,1106,1107,1108,1109,1110,1111,1112,1113,1114,1115,1116,1117,1118,1119],{"nctId":1121,"briefTitle":1122,"status":534,"phases":3057,"primaryCompletion":1124,"completion":1125,"start":1126,"enrollment":1127,"conditions":3058,"interventions":3059},[88,89],[1101,1102],[1108,1041,1042,1019],{"nctId":1143,"briefTitle":1144,"status":534,"phases":3061,"primaryCompletion":1146,"completion":1147,"start":137,"enrollment":645,"conditions":3062,"interventions":3063},[89],[1149],[1040,1042,1019,1043,1044],{"nctId":1152,"briefTitle":1153,"status":534,"phases":3065,"primaryCompletion":1155,"completion":1074,"start":1156,"enrollment":1157,"conditions":3066,"interventions":3067},[89],[1159],[1042,1019,1040,1054,1043,1044],{"trials":3069,"activeCount":99},[3070],{"nctId":3071,"briefTitle":3072,"status":534,"phases":3073,"primaryCompletion":3074,"completion":3075,"start":3076,"enrollment":3077,"conditions":3078,"interventions":3079},"NCT03991403","Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC",[90],"2023-03-11","2024-03-11","2019-08-27",228,[27],[3080,1201,3081,1042,1241,3082],"Atezolizumab","Bevacizumab","Carboplatin or cisplatin",{"trials":3084,"activeCount":99},[],{"trials":3086,"activeCount":99},[],{"intervention":1241,"totalTrials":1178,"cells":3088},{"EARLY_PHASE1":3089,"PHASE1":3091,"PHASE2":3103,"PHASE3":3149,"PHASE4":3155,"NA":3157},{"trials":3090,"activeCount":99},[],{"trials":3092,"activeCount":99},[3093],{"nctId":3094,"briefTitle":3095,"status":134,"phases":3096,"primaryCompletion":1134,"completion":3097,"start":1098,"enrollment":3098,"conditions":3099,"interventions":3101},"NCT02630199","Study of AZD6738, DNA Damage Repair\u002FNovel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer",[88],"2021-04-19",65,[3100],"Refractory Cancer",[3102,1241],"AZD6738",{"trials":3104,"activeCount":99},[3105,3116,3126,3136,3145],{"nctId":3106,"briefTitle":3107,"status":134,"phases":3108,"primaryCompletion":3109,"completion":3109,"start":3110,"enrollment":3111,"conditions":3112,"interventions":3113},"NCT02451956","Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and\u002For PIK3CA Amplification as a Second-line Chemotherapy",[89],"2019-05-24","2015-01-07",21,[1278],[3114,3115],"AZD5363","paclitaxel",{"nctId":3117,"briefTitle":3118,"status":134,"phases":3119,"primaryCompletion":3120,"completion":3120,"start":3121,"enrollment":3122,"conditions":3123,"interventions":3124},"NCT02628951","Ramucirumab\u002FPaclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis",[89],"2019-01-02","2016-05-26",62,[1650,1651],[3125,1241],"Ramucirumab",{"nctId":3127,"briefTitle":3128,"status":134,"phases":3129,"primaryCompletion":2641,"completion":3097,"start":3130,"enrollment":3131,"conditions":3132,"interventions":3134},"NCT02448329","Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy",[89],"2015-01-14",26,[3133],"Advanced Gastric Adenocarcinoma",[3135,3115],"AZD1775",{"nctId":3137,"briefTitle":3138,"status":1816,"phases":3139,"primaryCompletion":3140,"completion":3140,"start":3141,"enrollment":1062,"conditions":3142,"interventions":3143},"NCT02449655","Trial of AZD5363 Plus Paclitaxel \u002FAZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA\u002FMEK\u002FRAS\u002FTP53\u002FMET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy",[89],"2018-07-16","2015-02-12",[3133],[3114,3115,3144,3115],"AZD2014",{"nctId":1231,"briefTitle":1232,"status":534,"phases":3146,"primaryCompletion":1234,"completion":1235,"start":1236,"enrollment":862,"conditions":3147,"interventions":3148},[89],[1238],[1240,1038,1241],{"trials":3150,"activeCount":99},[3151],{"nctId":3071,"briefTitle":3072,"status":534,"phases":3152,"primaryCompletion":3074,"completion":3075,"start":3076,"enrollment":3077,"conditions":3153,"interventions":3154},[90],[27],[3080,1201,3081,1042,1241,3082],{"trials":3156,"activeCount":99},[],{"trials":3158,"activeCount":99},[],{"intervention":1770,"totalTrials":1178,"cells":3160},{"EARLY_PHASE1":3161,"PHASE1":3163,"PHASE2":3178,"PHASE3":3205,"PHASE4":3224,"NA":3226},{"trials":3162,"activeCount":99},[],{"trials":3164,"activeCount":99},[3165,3174],{"nctId":3166,"briefTitle":3167,"status":534,"phases":3168,"primaryCompletion":3169,"completion":1134,"start":3170,"enrollment":614,"conditions":3171,"interventions":3173},"NCT03086291","A Phase I Study of High Dose Simvastatin in Patients With Gastrointestinal Tract Cancer Who Failed to Standard Chemotherapy",[88],"2020-09","2018-01-04",[3172],"Stomach Cancer",[1770],{"nctId":1764,"briefTitle":1765,"status":134,"phases":3175,"primaryCompletion":1767,"completion":1736,"start":1222,"enrollment":9,"conditions":3176,"interventions":3177},[88],[1313],[1757,1770,1771],{"trials":3179,"activeCount":99},[3180,3188,3197],{"nctId":3181,"briefTitle":3182,"status":134,"phases":3183,"primaryCompletion":3184,"completion":3184,"start":1736,"enrollment":697,"conditions":3185,"interventions":3187},"NCT02026583","A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer Patients",[89],"2017-04-28",[3186],"Colorectal Cancer",[1770],{"nctId":3189,"briefTitle":3190,"status":534,"phases":3191,"primaryCompletion":1134,"completion":1134,"start":3192,"enrollment":228,"conditions":3193,"interventions":3195},"NCT02161822","Capecitabine Plus Simvastatin in Locally Advanced Rectal Cancer Patients",[89],"2014-10-01",[3194],"Adenocarcinoma of Rectum",[3196],"simvastatin",{"nctId":3198,"briefTitle":3199,"status":134,"phases":3200,"completion":2433,"start":3201,"enrollment":1717,"conditions":3202,"interventions":3204},"NCT00313859","Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC",[89],"2005-09",[3186,3203],"Metastasis",[3196],{"trials":3206,"activeCount":99},[3207,3215],{"nctId":3208,"briefTitle":3209,"status":134,"phases":3210,"primaryCompletion":3211,"completion":1086,"start":2554,"enrollment":3212,"conditions":3213,"interventions":3214},"NCT01099085","Trial of XP (Capecitabine\u002FCDDP) Simvastatin in Advanced Gastric Cancer Patients",[90],"2013-06",207,[24],[1770],{"nctId":3216,"briefTitle":3217,"status":534,"phases":3218,"primaryCompletion":3219,"completion":2995,"start":3220,"enrollment":3221,"conditions":3222,"interventions":3223},"NCT01238094","Trial of XELIRI\u002FFOLFIRI + Simvastatin Followed by Simvastatin Maintenance in Metastatic Colorectal Cancer",[90],"2013-11","2010-04",258,[3186],[1770],{"trials":3225,"activeCount":99},[],{"trials":3227,"activeCount":99},[],{"intervention":3229,"totalTrials":544,"cells":3230},"Capecitabine",{"EARLY_PHASE1":3231,"PHASE1":3233,"PHASE2":3235,"PHASE3":3269,"PHASE4":3281,"NA":3283},{"trials":3232,"activeCount":99},[],{"trials":3234,"activeCount":99},[],{"trials":3236,"activeCount":99},[3237,3248,3261],{"nctId":3238,"briefTitle":3239,"status":534,"phases":3240,"primaryCompletion":2641,"completion":1134,"start":3241,"enrollment":3242,"conditions":3243,"interventions":3245},"NCT02350686","XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy",[89],"2015-05-14",67,[3244],"Biliary Tract Cancer",[3246,3247],"capecitabine","oxaliplatin",{"nctId":3249,"briefTitle":3250,"status":534,"phases":3251,"primaryCompletion":3252,"completion":3252,"start":3253,"enrollment":3254,"conditions":3255,"interventions":3257},"NCT02592746","A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC",[89],"2021-06","2016-06",182,[3256],"Metastatic Breast Cancer",[3258,3259,3260,3229],"Palbociclib","Exemestane","Leuprolide Acetate",{"nctId":3262,"briefTitle":3263,"status":134,"phases":3264,"primaryCompletion":2456,"completion":1736,"start":3265,"enrollment":887,"conditions":3266,"interventions":3268},"NCT01099527","A Trial of RAD001\u002FCapecitabine in Refractory Gastric Cancer",[88,89],"2009-10",[3267],"Metastatic Gastric Cancer",[1114,3229],{"trials":3270,"activeCount":99},[3271],{"nctId":3272,"briefTitle":3273,"status":534,"phases":3274,"primaryCompletion":3275,"completion":3275,"start":3276,"enrollment":3277,"conditions":3278,"interventions":3279},"NCT04401709","Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer",[90],"2025-03-30","2021-04-01",490,[3244],[3280,3229],"Gemcitabine\u002FCapecitabine",{"trials":3282,"activeCount":99},[],{"trials":3284,"activeCount":99},[],{"intervention":3247,"totalTrials":544,"cells":3286},{"EARLY_PHASE1":3287,"PHASE1":3289,"PHASE2":3291,"PHASE3":3305,"PHASE4":3325,"NA":3327},{"trials":3288,"activeCount":99},[],{"trials":3290,"activeCount":99},[],{"trials":3292,"activeCount":99},[3293,3297],{"nctId":3238,"briefTitle":3239,"status":534,"phases":3294,"primaryCompletion":2641,"completion":1134,"start":3241,"enrollment":3242,"conditions":3295,"interventions":3296},[89],[3244],[3246,3247],{"nctId":3298,"briefTitle":3299,"status":534,"phases":3300,"primaryCompletion":2828,"start":1782,"enrollment":3301,"conditions":3302,"interventions":3304},"NCT01467921","Study of LV5FU2 Versus FOLFOX for Curatively-resected, Node-positive Esophageal Squamous Cell Carcinoma",[89],68,[3303],"Curatively-resected, Node-positive Esophageal Squamous Cell Carcinoma",[3247],{"trials":3306,"activeCount":99},[3307,3316],{"nctId":3308,"briefTitle":3309,"status":534,"phases":3310,"primaryCompletion":612,"completion":1134,"start":3311,"enrollment":1254,"conditions":3312,"interventions":3314},"NCT01470443","Study of GEMOX(Gemcitabine\u002FOxaliplatin) Versus XELOX(Xeloda\u002FOxaliplatin) in Advanced Biliary Tract Carcinoma",[90],"2011-12-28",[3313],"Biliary Tract (Intrahepatic, Extrahepatic Cholangiocarcinoma, Gall Bladder) Cancer",[3315,3315],"Oxaliplatin",{"nctId":3317,"briefTitle":3318,"status":534,"phases":3319,"primaryCompletion":2641,"completion":2641,"start":3320,"enrollment":3321,"conditions":3322,"interventions":3324},"NCT01092481","Study Investigating the Role of Oxaliplatin Duration in Modified FOLFOX-6 or CAPOX Regimen as Adjuvant Colon Cancer Therapy",[90],"2010-01-26",1580,[3323],"Colon Cancer",[3247],{"trials":3326,"activeCount":99},[],{"trials":3328,"activeCount":99},[],{"intervention":1201,"totalTrials":544,"cells":3330},{"EARLY_PHASE1":3331,"PHASE1":3333,"PHASE2":3335,"PHASE3":3360,"PHASE4":3366,"NA":3368},{"trials":3332,"activeCount":99},[],{"trials":3334,"activeCount":99},[],{"trials":3336,"activeCount":99},[3337,3341,3349],{"nctId":1191,"briefTitle":1192,"status":534,"phases":3338,"primaryCompletion":1194,"completion":1195,"start":1196,"enrollment":1197,"conditions":3339,"interventions":3340},[89],[1199],[1038,1201],{"nctId":3342,"briefTitle":3343,"status":534,"phases":3344,"primaryCompletion":3345,"completion":1097,"start":2268,"enrollment":3346,"conditions":3347,"interventions":3348},"NCT02588781","Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study",[89],"2022-12",23,[3186],[1201],{"nctId":3350,"briefTitle":3351,"status":134,"phases":3352,"primaryCompletion":3353,"completion":3354,"start":3355,"enrollment":19,"conditions":3356,"interventions":3358},"NCT03086538","Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy",[89],"2020-01-30","2020-05-25","2017-05-30",[3357],"Colo-rectal Cancer",[1201,3359],"Tarceva 100Mg",{"trials":3361,"activeCount":99},[3362],{"nctId":3071,"briefTitle":3072,"status":534,"phases":3363,"primaryCompletion":3074,"completion":3075,"start":3076,"enrollment":3077,"conditions":3364,"interventions":3365},[90],[27],[3080,1201,3081,1042,1241,3082],{"trials":3367,"activeCount":99},[],{"trials":3369,"activeCount":99},[],{"intervention":3080,"totalTrials":128,"cells":3371},{"EARLY_PHASE1":3372,"PHASE1":3374,"PHASE2":3376,"PHASE3":3387,"PHASE4":3393,"NA":3395},{"trials":3373,"activeCount":99},[],{"trials":3375,"activeCount":99},[],{"trials":3377,"activeCount":99},[3378],{"nctId":3379,"briefTitle":3380,"status":534,"phases":3381,"primaryCompletion":3382,"completion":3382,"start":3383,"enrollment":1127,"conditions":3384,"interventions":3386},"NCT03616691","Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC",[89],"2020-06-30","2018-08-01",[3385],"Non Small Cell Lung Cancer",[3080,3081],{"trials":3388,"activeCount":99},[3389],{"nctId":3071,"briefTitle":3072,"status":534,"phases":3390,"primaryCompletion":3074,"completion":3075,"start":3076,"enrollment":3077,"conditions":3391,"interventions":3392},[90],[27],[3080,1201,3081,1042,1241,3082],{"trials":3394,"activeCount":99},[],{"trials":3396,"activeCount":99},[],{"intervention":3081,"totalTrials":128,"cells":3398},{"EARLY_PHASE1":3399,"PHASE1":3401,"PHASE2":3403,"PHASE3":3409,"PHASE4":3415,"NA":3417},{"trials":3400,"activeCount":99},[],{"trials":3402,"activeCount":99},[],{"trials":3404,"activeCount":99},[3405],{"nctId":3379,"briefTitle":3380,"status":534,"phases":3406,"primaryCompletion":3382,"completion":3382,"start":3383,"enrollment":1127,"conditions":3407,"interventions":3408},[89],[3385],[3080,3081],{"trials":3410,"activeCount":99},[3411],{"nctId":3071,"briefTitle":3072,"status":534,"phases":3412,"primaryCompletion":3074,"completion":3075,"start":3076,"enrollment":3077,"conditions":3413,"interventions":3414},[90],[27],[3080,1201,3081,1042,1241,3082],{"trials":3416,"activeCount":99},[],{"trials":3418,"activeCount":99},[],{"intervention":3420,"totalTrials":128,"cells":3421},"Xeloda",{"EARLY_PHASE1":3422,"PHASE1":3424,"PHASE2":3426,"PHASE3":3428,"PHASE4":3447,"NA":3449},{"trials":3423,"activeCount":99},[],{"trials":3425,"activeCount":99},[],{"trials":3427,"activeCount":99},[],{"trials":3429,"activeCount":99},[3430,3439],{"nctId":3431,"briefTitle":3432,"status":1816,"phases":3433,"primaryCompletion":2995,"completion":3434,"start":3435,"enrollment":36,"conditions":3436,"interventions":3438},"NCT02060669","Xeloda Maintenance Versus BSC in Metastatic Colorectal Cancer",[90],"2014-09","2010-06-20",[3437],"Metastatic Colorectal Cancer",[3420],{"nctId":3440,"briefTitle":3441,"status":185,"phases":3442,"primaryCompletion":2076,"completion":1098,"start":1274,"enrollment":99,"conditions":3443,"interventions":3444},"NCT01470742","Trial Comparing Capecitabine Plus Oxaliplatin (XELOX) and Capecitabine (X) as First-line Chemotherapy in Elderly Patients With Advanced Gastric Cancer",[90],[24],[3445,3446],"XELOX","XELODA",{"trials":3448,"activeCount":99},[],{"trials":3450,"activeCount":99},[],{"intervention":3452,"totalTrials":128,"cells":3453},"TS-1, oxaliplatin",{"EARLY_PHASE1":3454,"PHASE1":3456,"PHASE2":3458,"PHASE3":3469,"PHASE4":3479,"NA":3481},{"trials":3455,"activeCount":99},[],{"trials":3457,"activeCount":99},[],{"trials":3459,"activeCount":99},[3460],{"nctId":3461,"briefTitle":3462,"status":134,"phases":3463,"primaryCompletion":1930,"completion":3464,"start":2221,"enrollment":3465,"conditions":3466,"interventions":3468},"NCT00531245","A Phase I\u002FII Trial of TS-1 and Oxaliplatin in Patients With Advanced Colorectal Cancer",[88,89],"2009-03",77,[3467],"Colorectal Neoplasms",[3452],{"trials":3470,"activeCount":99},[3471],{"nctId":3472,"briefTitle":3473,"status":534,"phases":3474,"primaryCompletion":1134,"completion":1134,"start":3475,"enrollment":3476,"conditions":3477,"interventions":3478},"NCT01761461","Phase III Randomized Trial of Adjuvant Chemotherapy With S-1 vs S-1\u002FOxaliplatin ± Radiotherapy for Completely Resected Gastric Adenocarcinoma : The ARTIST II Trial",[90],"2013-02-06",547,[24],[3452],{"trials":3480,"activeCount":99},[],{"trials":3482,"activeCount":99},[],{"intervention":3484,"totalTrials":128,"cells":3485},"Phenylephrine",{"EARLY_PHASE1":3486,"PHASE1":3488,"PHASE2":3500,"PHASE3":3502,"PHASE4":3513,"NA":3515},{"trials":3487,"activeCount":99},[],{"trials":3489,"activeCount":99},[3490],{"nctId":3491,"briefTitle":3492,"status":534,"phases":3493,"primaryCompletion":1223,"completion":2711,"start":2759,"enrollment":1717,"conditions":3494,"interventions":3497},"NCT02009007","Vasopressors for Cerebral Oxygenation",[88],[3495,3496],"Hypoxia","Hypotension",[3498,3499],"dopamine","phenylephrine",{"trials":3501,"activeCount":99},[],{"trials":3503,"activeCount":99},[3504],{"nctId":3505,"briefTitle":3506,"status":534,"phases":3507,"primaryCompletion":1049,"completion":1049,"start":1222,"enrollment":3508,"conditions":3509,"interventions":3512},"NCT01600235","Safety and Efficacy of Therapeutic INduced HYPERTENSION in Acute Non-cardioembolic Ischemic Stroke (SETIN-HYPERTENSION)",[90],170,[3510,3511],"Stroke, Acute","Progressing Stroke",[3484],{"trials":3514,"activeCount":99},[],{"trials":3516,"activeCount":99},[],{"intervention":3518,"totalTrials":171,"cells":3519},"consolidation chemotherapy with Docetaxel plus cisplatin",{"EARLY_PHASE1":3520,"PHASE1":3522,"PHASE2":3524,"PHASE3":3526,"PHASE4":3537,"NA":3539},{"trials":3521,"activeCount":99},[],{"trials":3523,"activeCount":99},[],{"trials":3525,"activeCount":99},[],{"trials":3527,"activeCount":99},[3528],{"nctId":3529,"briefTitle":3530,"status":134,"phases":3531,"primaryCompletion":1196,"completion":3532,"start":3533,"enrollment":1961,"conditions":3534,"interventions":3535},"NCT00326378","Efficacy Study of Additional Chemotherapy After Concurrent Chemoradiation in Non-small Cell Lung Cancer",[90],"2015-05","2005-10",[1199],[3518,3536],"CCRT arm without consolidation chemotherapy",{"trials":3538,"activeCount":99},[],{"trials":3540,"activeCount":99},[],{"intervention":3536,"totalTrials":171,"cells":3542},{"EARLY_PHASE1":3543,"PHASE1":3545,"PHASE2":3547,"PHASE3":3549,"PHASE4":3555,"NA":3557},{"trials":3544,"activeCount":99},[],{"trials":3546,"activeCount":99},[],{"trials":3548,"activeCount":99},[],{"trials":3550,"activeCount":99},[3551],{"nctId":3529,"briefTitle":3530,"status":134,"phases":3552,"primaryCompletion":1196,"completion":3532,"start":3533,"enrollment":1961,"conditions":3553,"interventions":3554},[90],[1199],[3518,3536],{"trials":3556,"activeCount":99},[],{"trials":3558,"activeCount":99},[],{"intervention":3560,"totalTrials":171,"cells":3561},"Metformin",{"EARLY_PHASE1":3562,"PHASE1":3564,"PHASE2":3566,"PHASE3":3568,"PHASE4":3579,"NA":3581},{"trials":3563,"activeCount":99},[],{"trials":3565,"activeCount":99},[],{"trials":3567,"activeCount":99},[],{"trials":3569,"activeCount":99},[3570],{"nctId":3571,"briefTitle":3572,"status":534,"phases":3573,"primaryCompletion":136,"completion":3574,"start":3575,"enrollment":3465,"conditions":3576,"interventions":3578},"NCT04792749","Clinical Effects of Metformin on Fertility-sparing Treatment for Early Endometrial Cancer",[90],"2024-03-31","2021-06-01",[3577],"Endometrial Cancer Stage I",[3560],{"trials":3580,"activeCount":99},[],{"trials":3582,"activeCount":99},[],{"intervention":3584,"totalTrials":171,"cells":3585},"Pantoprazole",{"EARLY_PHASE1":3586,"PHASE1":3588,"PHASE2":3590,"PHASE3":3592,"PHASE4":3603,"NA":3605},{"trials":3587,"activeCount":99},[],{"trials":3589,"activeCount":99},[],{"trials":3591,"activeCount":99},[],{"trials":3593,"activeCount":99},[3594],{"nctId":3595,"briefTitle":3596,"status":534,"phases":3597,"primaryCompletion":612,"completion":3598,"start":1033,"enrollment":112,"conditions":3599,"interventions":3601},"NCT02533349","Trial of Proton Pump Inhibitor With Prokinetics or Placebo in Patients With Laryngopharyngeal Reflux Disease",[90],"2017-01",[3600],"Laryngopharyngeal Reflux Disease",[3602,3584],"Motilitone",{"trials":3604,"activeCount":99},[],{"trials":3606,"activeCount":99},[],{"intervention":3608,"totalTrials":171,"cells":3609},"Aliskiren",{"EARLY_PHASE1":3610,"PHASE1":3612,"PHASE2":3614,"PHASE3":3616,"PHASE4":3626,"NA":3628},{"trials":3611,"activeCount":99},[],{"trials":3613,"activeCount":99},[],{"trials":3615,"activeCount":99},[],{"trials":3617,"activeCount":99},[3618],{"nctId":3619,"briefTitle":3620,"status":134,"phases":3621,"primaryCompletion":613,"completion":2711,"start":1985,"enrollment":671,"conditions":3622,"interventions":3624},"NCT01715207","Comparison of Aliskiren vs Negative Controls on Aortic Stiffness in Patients With MFS",[90],[3623],"Marfan Syndrome",[3608,3625],"Atenolol",{"trials":3627,"activeCount":99},[],{"trials":3629,"activeCount":99},[],{"intervention":3625,"totalTrials":171,"cells":3631},{"EARLY_PHASE1":3632,"PHASE1":3634,"PHASE2":3636,"PHASE3":3638,"PHASE4":3644,"NA":3646},{"trials":3633,"activeCount":99},[],{"trials":3635,"activeCount":99},[],{"trials":3637,"activeCount":99},[],{"trials":3639,"activeCount":99},[3640],{"nctId":3619,"briefTitle":3620,"status":134,"phases":3641,"primaryCompletion":613,"completion":2711,"start":1985,"enrollment":671,"conditions":3642,"interventions":3643},[90],[3623],[3608,3625],{"trials":3645,"activeCount":99},[],{"trials":3647,"activeCount":99},[],{"intervention":3649,"totalTrials":171,"cells":3650},"gemcitabine , paclitaxel",{"EARLY_PHASE1":3651,"PHASE1":3653,"PHASE2":3655,"PHASE3":3657,"PHASE4":3668,"NA":3670},{"trials":3652,"activeCount":99},[],{"trials":3654,"activeCount":99},[],{"trials":3656,"activeCount":99},[],{"trials":3658,"activeCount":99},[3659],{"nctId":3660,"briefTitle":3661,"status":134,"phases":3662,"primaryCompletion":612,"completion":612,"start":3663,"enrollment":3664,"conditions":3665,"interventions":3667},"NCT00561119","Maintenance Versus Observation After 6 Cycles of Gemcitabine Plus Paclitaxel in Pts With Advanced Breast Cancer",[90],"2007-05",326,[3666],"Advanced Breast Cancer",[3649],{"trials":3669,"activeCount":99},[],{"trials":3671,"activeCount":99},[],{"intervention":3673,"totalTrials":171,"cells":3674},"Usage of Fibrin sealant",{"EARLY_PHASE1":3675,"PHASE1":3677,"PHASE2":3679,"PHASE3":3681,"PHASE4":3693,"NA":3695},{"trials":3676,"activeCount":99},[],{"trials":3678,"activeCount":99},[],{"trials":3680,"activeCount":99},[],{"trials":3682,"activeCount":99},[3683],{"nctId":3684,"briefTitle":3685,"status":134,"phases":3686,"primaryCompletion":2577,"completion":2577,"start":3687,"enrollment":3688,"conditions":3689,"interventions":3692},"NCT01126060","Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain",[90],"2010-02",78,[3690,3691],"Thyroid Carcinoma","Thyroidectomy",[3673],{"trials":3694,"activeCount":99},[],{"trials":3696,"activeCount":99},[],{"intervention":3698,"totalTrials":171,"cells":3699},"Palonosetron",{"EARLY_PHASE1":3700,"PHASE1":3702,"PHASE2":3704,"PHASE3":3706,"PHASE4":3717,"NA":3719},{"trials":3701,"activeCount":99},[],{"trials":3703,"activeCount":99},[],{"trials":3705,"activeCount":99},[],{"trials":3707,"activeCount":99},[3708],{"nctId":3709,"briefTitle":3710,"status":134,"phases":3711,"primaryCompletion":1222,"completion":1222,"start":1894,"enrollment":3712,"conditions":3713,"interventions":3716},"NCT01568268","Therapeutic Efficacy and Safety of Palonosetron in Treatment of Postoperative Nausea and Vomiting",[90],384,[3714,3715],"Laparoscopic Gynecologic, Abdominal, Other Surgery","General Anesthesia",[3698],{"trials":3718,"activeCount":99},[],{"trials":3720,"activeCount":99},[],{"intervention":3722,"totalTrials":171,"cells":3723},"Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg",{"EARLY_PHASE1":3724,"PHASE1":3726,"PHASE2":3728,"PHASE3":3730,"PHASE4":3741,"NA":3743},{"trials":3725,"activeCount":99},[],{"trials":3727,"activeCount":99},[],{"trials":3729,"activeCount":99},[],{"trials":3731,"activeCount":99},[3732],{"nctId":3733,"briefTitle":3734,"status":534,"phases":3735,"primaryCompletion":2077,"start":1767,"enrollment":3736,"conditions":3737,"interventions":3739},"NCT01940952","Zydena on Cognitive Function of Alzheimer's Disease Patients",[90],210,[3738],"Alzheimer's Disease",[3722,3740],"Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg",{"trials":3742,"activeCount":99},[],{"trials":3744,"activeCount":99},[],{"intervention":3740,"totalTrials":171,"cells":3746},{"EARLY_PHASE1":3747,"PHASE1":3749,"PHASE2":3751,"PHASE3":3753,"PHASE4":3759,"NA":3761},{"trials":3748,"activeCount":99},[],{"trials":3750,"activeCount":99},[],{"trials":3752,"activeCount":99},[],{"trials":3754,"activeCount":99},[3755],{"nctId":3733,"briefTitle":3734,"status":534,"phases":3756,"primaryCompletion":2077,"start":1767,"enrollment":3736,"conditions":3757,"interventions":3758},[90],[3738],[3722,3740],{"trials":3760,"activeCount":99},[],{"trials":3762,"activeCount":99},[],{"intervention":3280,"totalTrials":171,"cells":3764},{"EARLY_PHASE1":3765,"PHASE1":3767,"PHASE2":3769,"PHASE3":3771,"PHASE4":3777,"NA":3779},{"trials":3766,"activeCount":99},[],{"trials":3768,"activeCount":99},[],{"trials":3770,"activeCount":99},[],{"trials":3772,"activeCount":99},[3773],{"nctId":3272,"briefTitle":3273,"status":534,"phases":3774,"primaryCompletion":3275,"completion":3275,"start":3276,"enrollment":3277,"conditions":3775,"interventions":3776},[90],[3244],[3280,3229],{"trials":3778,"activeCount":99},[],{"trials":3780,"activeCount":99},[],{"intervention":3782,"totalTrials":171,"cells":3783},"Gemcitabine\u002FOxaliplatin",{"EARLY_PHASE1":3784,"PHASE1":3786,"PHASE2":3788,"PHASE3":3790,"PHASE4":3802,"NA":3804},{"trials":3785,"activeCount":99},[],{"trials":3787,"activeCount":99},[],{"trials":3789,"activeCount":99},[],{"trials":3791,"activeCount":99},[3792],{"nctId":3793,"briefTitle":3794,"status":134,"phases":3795,"primaryCompletion":1894,"completion":1222,"start":3796,"enrollment":3797,"conditions":3798,"interventions":3800},"NCT01149122","Gemcitabine\u002FOxaliplatin (GEMOX) With or Without Erlotinib (Tarceva) in Advanced Biliary Tract Carcinoma",[90],"2009-01",266,[3799],"Unresectable, Metastatic Biliary Tract Carcinoma",[3782,3801],"Gemcitabine\u002FOxaliplatin with Erlotinib",{"trials":3803,"activeCount":99},[],{"trials":3805,"activeCount":99},[],{"intervention":3801,"totalTrials":171,"cells":3807},{"EARLY_PHASE1":3808,"PHASE1":3810,"PHASE2":3812,"PHASE3":3814,"PHASE4":3820,"NA":3822},{"trials":3809,"activeCount":99},[],{"trials":3811,"activeCount":99},[],{"trials":3813,"activeCount":99},[],{"trials":3815,"activeCount":99},[3816],{"nctId":3793,"briefTitle":3794,"status":134,"phases":3817,"primaryCompletion":1894,"completion":1222,"start":3796,"enrollment":3797,"conditions":3818,"interventions":3819},[90],[3799],[3782,3801],{"trials":3821,"activeCount":99},[],{"trials":3823,"activeCount":99},[],{"intervention":3825,"totalTrials":171,"cells":3826},"Tranexamic Acid",{"EARLY_PHASE1":3827,"PHASE1":3829,"PHASE2":3831,"PHASE3":3833,"PHASE4":3843,"NA":3845},{"trials":3828,"activeCount":99},[],{"trials":3830,"activeCount":99},[],{"trials":3832,"activeCount":99},[],{"trials":3834,"activeCount":99},[3835],{"nctId":3836,"briefTitle":3837,"status":534,"phases":3838,"primaryCompletion":612,"completion":612,"start":2268,"enrollment":2736,"conditions":3839,"interventions":3842},"NCT02587845","Use of Transexamic Acid in Hip Replacement",[90],[3840,3841],"Bleeding","Transfusion Related Complication",[3825,3825],{"trials":3844,"activeCount":99},[],{"trials":3846,"activeCount":99},[],{"intervention":3848,"totalTrials":171,"cells":3849},"Ferinject",{"EARLY_PHASE1":3850,"PHASE1":3852,"PHASE2":3854,"PHASE3":3856,"PHASE4":3868,"NA":3870},{"trials":3851,"activeCount":99},[],{"trials":3853,"activeCount":99},[],{"trials":3855,"activeCount":99},[],{"trials":3857,"activeCount":99},[3858],{"nctId":3859,"briefTitle":3860,"status":534,"phases":3861,"primaryCompletion":3862,"completion":3862,"start":3863,"enrollment":3864,"conditions":3865,"interventions":3867},"NCT04187716","Intravenous Iron Injection in Cancer Patients With Anemia",[90],"2020-12-01","2020-02-01",341,[3866],"Cancer Anaemia",[3848],{"trials":3869,"activeCount":99},[],{"trials":3871,"activeCount":99},[],{"intervention":3873,"totalTrials":171,"cells":3874},"cefazolin, erythromycin, clarithromycin",{"EARLY_PHASE1":3875,"PHASE1":3877,"PHASE2":3879,"PHASE3":3881,"PHASE4":3891,"NA":3893},{"trials":3876,"activeCount":99},[],{"trials":3878,"activeCount":99},[],{"trials":3880,"activeCount":99},[],{"trials":3882,"activeCount":99},[3883],{"nctId":3884,"briefTitle":3885,"status":134,"phases":3886,"primaryCompletion":3220,"completion":3220,"start":3887,"enrollment":2078,"conditions":3888,"interventions":3890},"NCT01401179","Antibiotics Study in Preterm Premature Rupture of the Membranes",[90],"2005-04",[3889],"Preterm Premature Rupture of the Membranes",[3873],{"trials":3892,"activeCount":99},[],{"trials":3894,"activeCount":99},[],{"intervention":3896,"totalTrials":171,"cells":3897},"Lanreotide 60Mg Solution for",{"EARLY_PHASE1":3898,"PHASE1":3900,"PHASE2":3902,"PHASE3":3904,"PHASE4":3916,"NA":3918},{"trials":3899,"activeCount":99},[],{"trials":3901,"activeCount":99},[],{"trials":3903,"activeCount":99},[],{"trials":3905,"activeCount":99},[3906],{"nctId":3907,"briefTitle":3908,"status":534,"phases":3909,"primaryCompletion":3910,"completion":3911,"start":3912,"enrollment":1099,"conditions":3913,"interventions":3915},"NCT03439709","Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma",[90],"2022-06-30","2022-12-31","2018-03-01",[3914],"Acromegaly Due to Pituitary Adenoma",[3896],{"trials":3917,"activeCount":99},[],{"trials":3919,"activeCount":99},[],{"intervention":3921,"totalTrials":171,"cells":3922},"Cefazolin",{"EARLY_PHASE1":3923,"PHASE1":3925,"PHASE2":3927,"PHASE3":3929,"PHASE4":3940,"NA":3942},{"trials":3924,"activeCount":99},[],{"trials":3926,"activeCount":99},[],{"trials":3928,"activeCount":99},[],{"trials":3930,"activeCount":99},[3931],{"nctId":3932,"briefTitle":3933,"status":134,"phases":3934,"primaryCompletion":1134,"completion":1096,"start":1783,"enrollment":3935,"conditions":3936,"interventions":3938},"NCT01503606","Duration of Antibiotics Treatment With Cefazolin and Clarithromycin in Women With Preterm Premature Rupture of Membrane",[90],151,[3937],"Preterm Premature Rupture of Membrane",[3921,3939,3921,3939],"Clarithromycin",{"trials":3941,"activeCount":99},[],{"trials":3943,"activeCount":99},[],{"intervention":3939,"totalTrials":171,"cells":3945},{"EARLY_PHASE1":3946,"PHASE1":3948,"PHASE2":3950,"PHASE3":3952,"PHASE4":3958,"NA":3960},{"trials":3947,"activeCount":99},[],{"trials":3949,"activeCount":99},[],{"trials":3951,"activeCount":99},[],{"trials":3953,"activeCount":99},[3954],{"nctId":3932,"briefTitle":3933,"status":134,"phases":3955,"primaryCompletion":1134,"completion":1096,"start":1783,"enrollment":3935,"conditions":3956,"interventions":3957},[90],[3937],[3921,3939,3921,3939],{"trials":3959,"activeCount":99},[],{"trials":3961,"activeCount":99},[],{"intervention":3082,"totalTrials":171,"cells":3963},{"EARLY_PHASE1":3964,"PHASE1":3966,"PHASE2":3968,"PHASE3":3970,"PHASE4":3976,"NA":3978},{"trials":3965,"activeCount":99},[],{"trials":3967,"activeCount":99},[],{"trials":3969,"activeCount":99},[],{"trials":3971,"activeCount":99},[3972],{"nctId":3071,"briefTitle":3072,"status":534,"phases":3973,"primaryCompletion":3074,"completion":3075,"start":3076,"enrollment":3077,"conditions":3974,"interventions":3975},[90],[27],[3080,1201,3081,1042,1241,3082],{"trials":3977,"activeCount":99},[],{"trials":3979,"activeCount":99},[],{"intervention":3981,"totalTrials":171,"cells":3982},"gemcitabine, cisplatin",{"EARLY_PHASE1":3983,"PHASE1":3985,"PHASE2":3987,"PHASE3":3989,"PHASE4":3998,"NA":4000},{"trials":3984,"activeCount":99},[],{"trials":3986,"activeCount":99},[],{"trials":3988,"activeCount":99},[],{"trials":3990,"activeCount":99},[3991],{"nctId":3992,"briefTitle":3993,"status":185,"phases":3994,"primaryCompletion":3995,"completion":3995,"start":1932,"enrollment":99,"conditions":3996,"interventions":3997},"NCT00329472","Efficacy Study of Induction Chemotherapy Before Surgery in Operable Non-small Cell Lung Cancer",[90],"2010-07",[1199],[3981],{"trials":3999,"activeCount":99},[],{"trials":4001,"activeCount":99},[],{"intervention":4003,"totalTrials":171,"cells":4004},"Infliximab",{"EARLY_PHASE1":4005,"PHASE1":4007,"PHASE2":4009,"PHASE3":4011,"PHASE4":4020,"NA":4022},{"trials":4006,"activeCount":99},[],{"trials":4008,"activeCount":99},[],{"trials":4010,"activeCount":99},[],{"trials":4012,"activeCount":99},[4013],{"nctId":4014,"briefTitle":4015,"status":134,"phases":4016,"primaryCompletion":1275,"completion":1275,"start":3265,"enrollment":1440,"conditions":4017,"interventions":4019},"NCT01661257","Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy",[90],[4018],"Crohn's Disease",[4003],{"trials":4021,"activeCount":99},[],{"trials":4023,"activeCount":99},[],{"intervention":4025,"totalTrials":171,"cells":4026},"S-1 & Oxaliplatin",{"EARLY_PHASE1":4027,"PHASE1":4029,"PHASE2":4031,"PHASE3":4033,"PHASE4":4044,"NA":4046},{"trials":4028,"activeCount":99},[],{"trials":4030,"activeCount":99},[],{"trials":4032,"activeCount":99},[],{"trials":4034,"activeCount":99},[4035],{"nctId":4036,"briefTitle":4037,"status":134,"phases":4038,"primaryCompletion":4039,"completion":2577,"start":1930,"enrollment":4040,"conditions":4041,"interventions":4042},"NCT00677443","Study of S-1 and Oxaliplatin (SOX) Versus Capecitabine and Oxaliplatin (COX) in Patients With Advanced Colorectal Cancer",[90],"2009-09",344,[3186],[4025,4043],"Capecitabine & Oxaliplatin",{"trials":4045,"activeCount":99},[],{"trials":4047,"activeCount":99},[],{"intervention":4043,"totalTrials":171,"cells":4049},{"EARLY_PHASE1":4050,"PHASE1":4052,"PHASE2":4054,"PHASE3":4056,"PHASE4":4062,"NA":4064},{"trials":4051,"activeCount":99},[],{"trials":4053,"activeCount":99},[],{"trials":4055,"activeCount":99},[],{"trials":4057,"activeCount":99},[4058],{"nctId":4036,"briefTitle":4037,"status":134,"phases":4059,"primaryCompletion":4039,"completion":2577,"start":1930,"enrollment":4040,"conditions":4060,"interventions":4061},[90],[3186],[4025,4043],{"trials":4063,"activeCount":99},[],{"trials":4065,"activeCount":99},[],{"intervention":1810,"totalTrials":171,"cells":4067},{"EARLY_PHASE1":4068,"PHASE1":4070,"PHASE2":4072,"PHASE3":4074,"PHASE4":4080,"NA":4082},{"trials":4069,"activeCount":99},[],{"trials":4071,"activeCount":99},[],{"trials":4073,"activeCount":99},[],{"trials":4075,"activeCount":99},[4076],{"nctId":1803,"briefTitle":1804,"status":534,"phases":4077,"primaryCompletion":1049,"completion":1049,"start":1223,"enrollment":1806,"conditions":4078,"interventions":4079},[90],[1808],[1810,1792],{"trials":4081,"activeCount":99},[],{"trials":4083,"activeCount":99},[],{"intervention":4085,"totalTrials":171,"cells":4086},"Gemifloxacin-based triple therapy",{"EARLY_PHASE1":4087,"PHASE1":4089,"PHASE2":4091,"PHASE3":4093,"PHASE4":4104,"NA":4106},{"trials":4088,"activeCount":99},[],{"trials":4090,"activeCount":99},[],{"trials":4092,"activeCount":99},[],{"trials":4094,"activeCount":99},[4095],{"nctId":4096,"briefTitle":4097,"status":534,"phases":4098,"primaryCompletion":2077,"completion":2268,"start":2076,"enrollment":4099,"conditions":4100,"interventions":4102},"NCT02368470","Randomized Study on Efficacy of Gemifloxacin-based Regimen for Helicobacter Pylori Infection",[90],252,[4101],"Helicobacter Pylori Infection",[4085,4103],"Standard triple therapy",{"trials":4105,"activeCount":99},[],{"trials":4107,"activeCount":99},[],{"intervention":4103,"totalTrials":171,"cells":4109},{"EARLY_PHASE1":4110,"PHASE1":4112,"PHASE2":4114,"PHASE3":4116,"PHASE4":4122,"NA":4124},{"trials":4111,"activeCount":99},[],{"trials":4113,"activeCount":99},[],{"trials":4115,"activeCount":99},[],{"trials":4117,"activeCount":99},[4118],{"nctId":4096,"briefTitle":4097,"status":534,"phases":4119,"primaryCompletion":2077,"completion":2268,"start":2076,"enrollment":4099,"conditions":4120,"interventions":4121},[90],[4101],[4085,4103],{"trials":4123,"activeCount":99},[],{"trials":4125,"activeCount":99},[],{"intervention":4127,"totalTrials":171,"cells":4128},"Misoprostol",{"EARLY_PHASE1":4129,"PHASE1":4131,"PHASE2":4133,"PHASE3":4135,"PHASE4":4146,"NA":4148},{"trials":4130,"activeCount":99},[],{"trials":4132,"activeCount":99},[],{"trials":4134,"activeCount":99},[],{"trials":4136,"activeCount":99},[4137],{"nctId":4138,"briefTitle":4139,"status":134,"phases":4140,"primaryCompletion":1784,"completion":1784,"start":4141,"enrollment":4142,"conditions":4143,"interventions":4145},"NCT01024270","Cervical Priming With Misoprostol Prior to Operative Hysteroscopy",[90],"2008-07",141,[4144],"Cervical Ripening",[4127],{"trials":4147,"activeCount":99},[],{"trials":4149,"activeCount":99},[],{"intervention":1315,"totalTrials":171,"cells":4151},{"EARLY_PHASE1":4152,"PHASE1":4154,"PHASE2":4156,"PHASE3":4158,"PHASE4":4164,"NA":4166},{"trials":4153,"activeCount":99},[],{"trials":4155,"activeCount":99},[],{"trials":4157,"activeCount":99},[],{"trials":4159,"activeCount":99},[4160],{"nctId":1306,"briefTitle":1307,"status":134,"phases":4161,"primaryCompletion":1309,"completion":1309,"start":1310,"enrollment":1311,"conditions":4162,"interventions":4163},[90],[1313],[81,1315],{"trials":4165,"activeCount":99},[],{"trials":4167,"activeCount":99},[],{"intervention":4169,"totalTrials":171,"cells":4170},"NSAIDS",{"EARLY_PHASE1":4171,"PHASE1":4173,"PHASE2":4175,"PHASE3":4177,"PHASE4":4186,"NA":4188},{"trials":4172,"activeCount":99},[],{"trials":4174,"activeCount":99},[],{"trials":4176,"activeCount":99},[],{"trials":4178,"activeCount":99},[4179],{"nctId":4180,"briefTitle":4181,"status":534,"phases":4182,"primaryCompletion":1135,"start":3434,"enrollment":4183,"conditions":4184,"interventions":4185},"NCT02141139","Perioperative Inflammation and Breast Cancer Outcome",[90],1568,[2738],[4169],{"trials":4187,"activeCount":99},[],{"trials":4189,"activeCount":99},[],{"intervention":4191,"totalTrials":171,"cells":4192},"Vilanterol and Umeclidinium Bromide",{"EARLY_PHASE1":4193,"PHASE1":4195,"PHASE2":4197,"PHASE3":4199,"PHASE4":4210,"NA":4212},{"trials":4194,"activeCount":99},[],{"trials":4196,"activeCount":99},[],{"trials":4198,"activeCount":99},[],{"trials":4200,"activeCount":99},[4201],{"nctId":4202,"briefTitle":4203,"status":534,"phases":4204,"primaryCompletion":4205,"completion":187,"start":3276,"enrollment":4206,"conditions":4207,"interventions":4209},"NCT04536675","Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery",[90],"2023-11",204,[4208,3385],"Chronic Obstructive Pulmonary Disease",[4191],{"trials":4211,"activeCount":99},[],{"trials":4213,"activeCount":99},[],{"intervention":4215,"totalTrials":171,"cells":4216},"Capecitabine, cisplatin, Radiotherapy",{"EARLY_PHASE1":4217,"PHASE1":4219,"PHASE2":4221,"PHASE3":4223,"PHASE4":4235,"NA":4237},{"trials":4218,"activeCount":99},[],{"trials":4220,"activeCount":99},[],{"trials":4222,"activeCount":99},[],{"trials":4224,"activeCount":99},[4225],{"nctId":4226,"briefTitle":4227,"status":134,"phases":4228,"primaryCompletion":4229,"completion":4230,"start":4231,"enrollment":4232,"conditions":4233,"interventions":4234},"NCT00323830","Phase III Randomized Trial of Adjuvant XP Chemotherapy and XP\u002FRT for Resected Gastric Adenocarcinoma",[90],"2008-04","2011-04","2004-10",458,[24,167],[4215],{"trials":4236,"activeCount":99},[],{"trials":4238,"activeCount":99},[],{"intervention":4240,"totalTrials":171,"cells":4241},"PRP",{"EARLY_PHASE1":4242,"PHASE1":4244,"PHASE2":4246,"PHASE3":4248,"PHASE4":4259,"NA":4261},{"trials":4243,"activeCount":99},[],{"trials":4245,"activeCount":99},[],{"trials":4247,"activeCount":99},[],{"trials":4249,"activeCount":99},[4250],{"nctId":4251,"briefTitle":4252,"status":134,"phases":4253,"primaryCompletion":2268,"completion":2268,"start":4254,"enrollment":1225,"conditions":4255,"interventions":4257},"NCT02211521","Comparison of Autologous Platelet-rich Plasma With Hyaluronic Acid for the Treatment of Osteoarthritis of the Knee Joint",[90],"2014-08",[4256],"Osteoarthritis, Knee",[4240,4258],"Hyaluronic acid",{"trials":4260,"activeCount":99},[],{"trials":4262,"activeCount":99},[],{"intervention":4264,"totalTrials":171,"cells":4265},"intraocular injections of bevacizumab",{"EARLY_PHASE1":4266,"PHASE1":4268,"PHASE2":4270,"PHASE3":4272,"PHASE4":4281,"NA":4283},{"trials":4267,"activeCount":99},[],{"trials":4269,"activeCount":99},[],{"trials":4271,"activeCount":99},[],{"trials":4273,"activeCount":99},[4274],{"nctId":4275,"briefTitle":4276,"status":534,"phases":4277,"primaryCompletion":2311,"completion":1858,"start":2760,"enrollment":645,"conditions":4278,"interventions":4280},"NCT01122966","The Effect of Bevacizumab on the Trabeculectomy",[89,90],[4279],"Glaucoma",[4264],{"trials":4282,"activeCount":99},[],{"trials":4284,"activeCount":99},[],{"intervention":4286,"totalTrials":171,"cells":4287},"DP",{"EARLY_PHASE1":4288,"PHASE1":4290,"PHASE2":4292,"PHASE3":4294,"PHASE4":4307,"NA":4309},{"trials":4289,"activeCount":99},[],{"trials":4291,"activeCount":99},[],{"trials":4293,"activeCount":99},[],{"trials":4295,"activeCount":99},[4296],{"nctId":4297,"briefTitle":4298,"status":134,"phases":4299,"primaryCompletion":4300,"completion":4301,"start":4302,"enrollment":112,"conditions":4303,"interventions":4305},"NCT00313872","Phase III Trial of DP Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer",[90],"2009-06","2010-01","2003-05",[24,4304],"Metastases",[4286,4306],"FOLFIRI",{"trials":4308,"activeCount":99},[],{"trials":4310,"activeCount":99},[],{"intervention":4306,"totalTrials":171,"cells":4312},{"EARLY_PHASE1":4313,"PHASE1":4315,"PHASE2":4317,"PHASE3":4319,"PHASE4":4325,"NA":4327},{"trials":4314,"activeCount":99},[],{"trials":4316,"activeCount":99},[],{"trials":4318,"activeCount":99},[],{"trials":4320,"activeCount":99},[4321],{"nctId":4297,"briefTitle":4298,"status":134,"phases":4322,"primaryCompletion":4300,"completion":4301,"start":4302,"enrollment":112,"conditions":4323,"interventions":4324},[90],[24,4304],[4286,4306],{"trials":4326,"activeCount":99},[],{"trials":4328,"activeCount":99},[],{"intervention":3445,"totalTrials":171,"cells":4330},{"EARLY_PHASE1":4331,"PHASE1":4333,"PHASE2":4335,"PHASE3":4337,"PHASE4":4343,"NA":4345},{"trials":4332,"activeCount":99},[],{"trials":4334,"activeCount":99},[],{"trials":4336,"activeCount":99},[],{"trials":4338,"activeCount":99},[4339],{"nctId":3440,"briefTitle":3441,"status":185,"phases":4340,"primaryCompletion":2076,"completion":1098,"start":1274,"enrollment":99,"conditions":4341,"interventions":4342},[90],[24],[3445,3446],{"trials":4344,"activeCount":99},[],{"trials":4346,"activeCount":99},[],{"intervention":4348,"totalTrials":171,"cells":4349},"iressa",{"EARLY_PHASE1":4350,"PHASE1":4352,"PHASE2":4354,"PHASE3":4356,"PHASE4":4367,"NA":4369},{"trials":4351,"activeCount":99},[],{"trials":4353,"activeCount":99},[],{"trials":4355,"activeCount":99},[],{"trials":4357,"activeCount":99},[4358],{"nctId":4359,"briefTitle":4360,"status":534,"phases":4361,"primaryCompletion":4362,"start":1859,"enrollment":4363,"conditions":4364,"interventions":4365},"NCT01066195","Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy",[90],"2010-10",129,[27],[4348,4366],"alimta",{"trials":4368,"activeCount":99},[],{"trials":4370,"activeCount":99},[],{"intervention":4366,"totalTrials":171,"cells":4372},{"EARLY_PHASE1":4373,"PHASE1":4375,"PHASE2":4377,"PHASE3":4379,"PHASE4":4385,"NA":4387},{"trials":4374,"activeCount":99},[],{"trials":4376,"activeCount":99},[],{"trials":4378,"activeCount":99},[],{"trials":4380,"activeCount":99},[4381],{"nctId":4359,"briefTitle":4360,"status":534,"phases":4382,"primaryCompletion":4362,"start":1859,"enrollment":4363,"conditions":4383,"interventions":4384},[90],[27],[4348,4366],{"trials":4386,"activeCount":99},[],{"trials":4388,"activeCount":99},[],{"intervention":1040,"totalTrials":1178,"cells":4390},{"EARLY_PHASE1":4391,"PHASE1":4393,"PHASE2":4395,"PHASE3":4435,"PHASE4":4437,"NA":4439},{"trials":4392,"activeCount":99},[],{"trials":4394,"activeCount":99},[],{"trials":4396,"activeCount":99},[4397,4401,4405,4409,4413,4417,4431],{"nctId":1028,"briefTitle":1029,"status":534,"phases":4398,"primaryCompletion":1031,"completion":1032,"start":1033,"enrollment":1034,"conditions":4399,"interventions":4400},[89],[1036],[1038,1019,1039,1040,1041,1042,1043,1044],{"nctId":1046,"briefTitle":1047,"status":534,"phases":4402,"primaryCompletion":1049,"start":1050,"enrollment":645,"conditions":4403,"interventions":4404},[89],[1052],[1042,1019,1040,1054],{"nctId":1070,"briefTitle":1071,"status":534,"phases":4406,"primaryCompletion":1073,"completion":1074,"start":1075,"enrollment":1076,"conditions":4407,"interventions":4408},[89],[1078],[1038,1039,1019,1040,1041,1042,1080,1081],{"nctId":1083,"briefTitle":1084,"status":134,"phases":4410,"primaryCompletion":1086,"completion":1087,"start":1088,"enrollment":645,"conditions":4411,"interventions":4412},[89],[1090],[1040,1019,1042,1043,1044],{"nctId":1143,"briefTitle":1144,"status":534,"phases":4414,"primaryCompletion":1146,"completion":1147,"start":137,"enrollment":645,"conditions":4415,"interventions":4416},[89],[1149],[1040,1042,1019,1043,1044],{"nctId":4418,"briefTitle":4419,"status":134,"phases":4420,"primaryCompletion":4421,"completion":4422,"start":4423,"enrollment":22,"conditions":4424,"interventions":4426},"NCT02670616","Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma",[89],"2020-06","2020-10","2016-05-01",[4425],"Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma",[4427,4428,1040,1039,4429,4430],"Ibrutinib","Rituximab","vincristine","Prednisolone",{"nctId":1152,"briefTitle":1153,"status":534,"phases":4432,"primaryCompletion":1155,"completion":1074,"start":1156,"enrollment":1157,"conditions":4433,"interventions":4434},[89],[1159],[1042,1019,1040,1054,1043,1044],{"trials":4436,"activeCount":99},[],{"trials":4438,"activeCount":99},[],{"trials":4440,"activeCount":99},[],{"intervention":1041,"totalTrials":4442,"cells":4443},5,{"EARLY_PHASE1":4444,"PHASE1":4446,"PHASE2":4448,"PHASE3":4470,"PHASE4":4472,"NA":4474},{"trials":4445,"activeCount":99},[],{"trials":4447,"activeCount":99},[],{"trials":4449,"activeCount":99},[4450,4454,4458,4462,4466],{"nctId":1028,"briefTitle":1029,"status":534,"phases":4451,"primaryCompletion":1031,"completion":1032,"start":1033,"enrollment":1034,"conditions":4452,"interventions":4453},[89],[1036],[1038,1019,1039,1040,1041,1042,1043,1044],{"nctId":1056,"briefTitle":1057,"status":534,"phases":4455,"primaryCompletion":1059,"completion":1060,"start":1061,"enrollment":1062,"conditions":4456,"interventions":4457},[89],[1064],[1019,1041,1066,1067,1068,1044],{"nctId":1070,"briefTitle":1071,"status":534,"phases":4459,"primaryCompletion":1073,"completion":1074,"start":1075,"enrollment":1076,"conditions":4460,"interventions":4461},[89],[1078],[1038,1039,1019,1040,1041,1042,1080,1081],{"nctId":1093,"briefTitle":1094,"status":534,"phases":4463,"primaryCompletion":1096,"completion":1097,"start":1098,"enrollment":1099,"conditions":4464,"interventions":4465},[89],[1101,1102,1103,1104],[1041,1042,1019,1106,1107,1108,1109,1110,1111,1112,1113,1114,1115,1116,1117,1118,1119],{"nctId":1121,"briefTitle":1122,"status":534,"phases":4467,"primaryCompletion":1124,"completion":1125,"start":1126,"enrollment":1127,"conditions":4468,"interventions":4469},[88,89],[1101,1102],[1108,1041,1042,1019],{"trials":4471,"activeCount":99},[],{"trials":4473,"activeCount":99},[],{"trials":4475,"activeCount":99},[],{"intervention":1044,"totalTrials":4442,"cells":4477},{"EARLY_PHASE1":4478,"PHASE1":4480,"PHASE2":4482,"PHASE3":4504,"PHASE4":4506,"NA":4508},{"trials":4479,"activeCount":99},[],{"trials":4481,"activeCount":99},[],{"trials":4483,"activeCount":99},[4484,4488,4492,4496,4500],{"nctId":1028,"briefTitle":1029,"status":534,"phases":4485,"primaryCompletion":1031,"completion":1032,"start":1033,"enrollment":1034,"conditions":4486,"interventions":4487},[89],[1036],[1038,1019,1039,1040,1041,1042,1043,1044],{"nctId":1056,"briefTitle":1057,"status":534,"phases":4489,"primaryCompletion":1059,"completion":1060,"start":1061,"enrollment":1062,"conditions":4490,"interventions":4491},[89],[1064],[1019,1041,1066,1067,1068,1044],{"nctId":1083,"briefTitle":1084,"status":134,"phases":4493,"primaryCompletion":1086,"completion":1087,"start":1088,"enrollment":645,"conditions":4494,"interventions":4495},[89],[1090],[1040,1019,1042,1043,1044],{"nctId":1143,"briefTitle":1144,"status":534,"phases":4497,"primaryCompletion":1146,"completion":1147,"start":137,"enrollment":645,"conditions":4498,"interventions":4499},[89],[1149],[1040,1042,1019,1043,1044],{"nctId":1152,"briefTitle":1153,"status":534,"phases":4501,"primaryCompletion":1155,"completion":1074,"start":1156,"enrollment":1157,"conditions":4502,"interventions":4503},[89],[1159],[1042,1019,1040,1054,1043,1044],{"trials":4505,"activeCount":99},[],{"trials":4507,"activeCount":99},[],{"trials":4509,"activeCount":99},[],{"intervention":1043,"totalTrials":544,"cells":4511},{"EARLY_PHASE1":4512,"PHASE1":4514,"PHASE2":4516,"PHASE3":4534,"PHASE4":4536,"NA":4538},{"trials":4513,"activeCount":99},[],{"trials":4515,"activeCount":99},[],{"trials":4517,"activeCount":99},[4518,4522,4526,4530],{"nctId":1028,"briefTitle":1029,"status":534,"phases":4519,"primaryCompletion":1031,"completion":1032,"start":1033,"enrollment":1034,"conditions":4520,"interventions":4521},[89],[1036],[1038,1019,1039,1040,1041,1042,1043,1044],{"nctId":1083,"briefTitle":1084,"status":134,"phases":4523,"primaryCompletion":1086,"completion":1087,"start":1088,"enrollment":645,"conditions":4524,"interventions":4525},[89],[1090],[1040,1019,1042,1043,1044],{"nctId":1143,"briefTitle":1144,"status":534,"phases":4527,"primaryCompletion":1146,"completion":1147,"start":137,"enrollment":645,"conditions":4528,"interventions":4529},[89],[1149],[1040,1042,1019,1043,1044],{"nctId":1152,"briefTitle":1153,"status":534,"phases":4531,"primaryCompletion":1155,"completion":1074,"start":1156,"enrollment":1157,"conditions":4532,"interventions":4533},[89],[1159],[1042,1019,1040,1054,1043,1044],{"trials":4535,"activeCount":99},[],{"trials":4537,"activeCount":99},[],{"trials":4539,"activeCount":99},[],{"intervention":4541,"totalTrials":544,"cells":4542},"Docetaxel",{"EARLY_PHASE1":4543,"PHASE1":4545,"PHASE2":4547,"PHASE3":4586,"PHASE4":4588,"NA":4590},{"trials":4544,"activeCount":99},[],{"trials":4546,"activeCount":99},[],{"trials":4548,"activeCount":99},[4549,4559,4567,4577],{"nctId":4550,"briefTitle":4551,"status":134,"phases":4552,"primaryCompletion":3382,"completion":4553,"start":4554,"enrollment":1178,"conditions":4555,"interventions":4556},"NCT02447406","Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment",[88,89],"2020-09-20","2015-04-30",[3133],[4557,4558],"AZD6094","docetaxel",{"nctId":4560,"briefTitle":4561,"status":134,"phases":4562,"primaryCompletion":4563,"completion":4563,"start":4564,"enrollment":128,"conditions":4565,"interventions":4566},"NCT02447380","Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment",[89],"2019-02-18","2017-07-10",[3133],[4557,4541],{"nctId":4568,"briefTitle":4569,"status":134,"phases":4570,"primaryCompletion":4571,"completion":1736,"start":4572,"enrollment":4573,"conditions":4574,"interventions":4576},"NCT01711112","Salvage Docetaxel for Pretreated Urothelial Cancer",[89],"2013-04","2010-08",31,[4575],"Bladder Cancer",[4541],{"nctId":4578,"briefTitle":4579,"status":534,"phases":4580,"primaryCompletion":1206,"completion":1207,"start":4581,"enrollment":4582,"conditions":4583,"interventions":4585},"NCT03061643","An Open Label Phase II Study of Biweekly Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Prostatic Adenocarcinoma",[89],"2017-02-08",42,[4584],"Prostatic Neoplasm",[4541],{"trials":4587,"activeCount":99},[],{"trials":4589,"activeCount":99},[],{"trials":4591,"activeCount":99},[],{"intervention":4593,"totalTrials":544,"cells":4594},"Durvalumab",{"EARLY_PHASE1":4595,"PHASE1":4597,"PHASE2":4599,"PHASE3":4638,"PHASE4":4640,"NA":4642},{"trials":4596,"activeCount":99},[],{"trials":4598,"activeCount":99},[],{"trials":4600,"activeCount":99},[4601,4607,4618,4628],{"nctId":4602,"briefTitle":4603,"status":534,"phases":4604,"primaryCompletion":3252,"completion":1096,"start":611,"enrollment":1806,"conditions":4605,"interventions":4606},"NCT02520453","Adjuvant Durvalumab for Esophageal Cancer",[89],[1256],[4593],{"nctId":4608,"briefTitle":4609,"status":534,"phases":4610,"primaryCompletion":4611,"completion":4612,"start":4613,"enrollment":4614,"conditions":4615,"interventions":4617},"NCT03780608","This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)",[89],"2022-12-01","2023-12-01","2019-07-30",61,[1650,4616],"Malignant Melanoma",[3102,4593],{"nctId":4619,"briefTitle":4620,"status":534,"phases":4621,"primaryCompletion":4622,"completion":4623,"start":4624,"enrollment":645,"conditions":4625,"interventions":4627},"NCT03377400","Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer",[89],"2021-06-30","2021-12-30","2017-12-14",[4626],"Esophageal Squamous Cell Carcinoma",[4593],{"nctId":4629,"briefTitle":4630,"status":534,"phases":4631,"primaryCompletion":4632,"completion":4633,"start":4634,"enrollment":11,"conditions":4635,"interventions":4637},"NCT03585998","Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer",[89],"2021-06-19","2021-12-19","2018-06-19",[4636],"Small Cell Lung Cancer",[4593],{"trials":4639,"activeCount":99},[],{"trials":4641,"activeCount":99},[],{"trials":4643,"activeCount":99},[],{"intervention":1113,"totalTrials":544,"cells":4645},{"EARLY_PHASE1":4646,"PHASE1":4648,"PHASE2":4650,"PHASE3":4680,"PHASE4":4682,"NA":4684},{"trials":4647,"activeCount":99},[],{"trials":4649,"activeCount":99},[],{"trials":4651,"activeCount":99},[4652,4656,4664,4670],{"nctId":1093,"briefTitle":1094,"status":534,"phases":4653,"primaryCompletion":1096,"completion":1097,"start":1098,"enrollment":1099,"conditions":4654,"interventions":4655},[89],[1101,1102,1103,1104],[1041,1042,1019,1106,1107,1108,1109,1110,1111,1112,1113,1114,1115,1116,1117,1118,1119],{"nctId":4657,"briefTitle":4658,"status":134,"phases":4659,"primaryCompletion":1782,"completion":2759,"start":2198,"enrollment":697,"conditions":4660,"interventions":4663},"NCT01130753","Efficacy of Erlotinib in Neoadjuvant Setting in Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer",[89],[4661,1113,4662],"Lung Neoplasms","Neoadjuvant Therapy",[1113],{"nctId":4665,"briefTitle":4666,"status":534,"phases":4667,"primaryCompletion":4572,"start":1738,"enrollment":3346,"conditions":4668,"interventions":4669},"NCT01130779","The Continuation of Erlotinib",[89],[27],[1113],{"nctId":4671,"briefTitle":4672,"status":534,"phases":4673,"primaryCompletion":4674,"completion":4675,"start":4676,"enrollment":3021,"conditions":4677,"interventions":4678},"NCT03110484","Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study",[89],"2023-06-14","2024-06-14","2021-07-09",[3244],[4679,1113],"Pemetrexed 500 MG",{"trials":4681,"activeCount":99},[],{"trials":4683,"activeCount":99},[],{"trials":4685,"activeCount":99},[],{"intervention":1115,"totalTrials":95,"cells":4687},{"EARLY_PHASE1":4688,"PHASE1":4690,"PHASE2":4692,"PHASE3":4718,"PHASE4":4720,"NA":4722},{"trials":4689,"activeCount":99},[],{"trials":4691,"activeCount":99},[],{"trials":4693,"activeCount":99},[4694,4702,4714],{"nctId":4695,"briefTitle":4696,"status":534,"phases":4697,"primaryCompletion":1207,"completion":3345,"start":4698,"enrollment":2270,"conditions":4699,"interventions":4701},"NCT02461849","Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy",[89],"2014-04-04",[4700],"Advanced, Refractory Cancer",[1115],{"nctId":4703,"briefTitle":4704,"status":134,"phases":4705,"primaryCompletion":4706,"completion":4707,"start":1289,"enrollment":4708,"conditions":4709,"interventions":4711},"NCT03170180","Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer",[89],"2021-10-31","2021-12-28",66,[4710],"Stomach Neoplasms",[4712,4713,1115],"Sunitinib","Gefitinib",{"nctId":1093,"briefTitle":1094,"status":534,"phases":4715,"primaryCompletion":1096,"completion":1097,"start":1098,"enrollment":1099,"conditions":4716,"interventions":4717},[89],[1101,1102,1103,1104],[1041,1042,1019,1106,1107,1108,1109,1110,1111,1112,1113,1114,1115,1116,1117,1118,1119],{"trials":4719,"activeCount":99},[],{"trials":4721,"activeCount":99},[],{"trials":4723,"activeCount":99},[],{"intervention":1039,"totalTrials":95,"cells":4725},{"EARLY_PHASE1":4726,"PHASE1":4728,"PHASE2":4730,"PHASE3":4744,"PHASE4":4746,"NA":4748},{"trials":4727,"activeCount":99},[],{"trials":4729,"activeCount":99},[],{"trials":4731,"activeCount":99},[4732,4736,4740],{"nctId":1028,"briefTitle":1029,"status":534,"phases":4733,"primaryCompletion":1031,"completion":1032,"start":1033,"enrollment":1034,"conditions":4734,"interventions":4735},[89],[1036],[1038,1019,1039,1040,1041,1042,1043,1044],{"nctId":1070,"briefTitle":1071,"status":534,"phases":4737,"primaryCompletion":1073,"completion":1074,"start":1075,"enrollment":1076,"conditions":4738,"interventions":4739},[89],[1078],[1038,1039,1019,1040,1041,1042,1080,1081],{"nctId":4418,"briefTitle":4419,"status":134,"phases":4741,"primaryCompletion":4421,"completion":4422,"start":4423,"enrollment":22,"conditions":4742,"interventions":4743},[89],[4425],[4427,4428,1040,1039,4429,4430],{"trials":4745,"activeCount":99},[],{"trials":4747,"activeCount":99},[],{"trials":4749,"activeCount":99},[],{"intervention":3144,"totalTrials":95,"cells":4751},{"EARLY_PHASE1":4752,"PHASE1":4754,"PHASE2":4756,"PHASE3":4777,"PHASE4":4779,"NA":4781},{"trials":4753,"activeCount":99},[],{"trials":4755,"activeCount":99},[],{"trials":4757,"activeCount":99},[4758,4766,4770],{"nctId":4759,"briefTitle":4760,"status":1816,"phases":4761,"primaryCompletion":4762,"completion":4762,"start":4763,"enrollment":171,"conditions":4764,"interventions":4765},"NCT03061708","Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line Therapy",[89],"2018-11-16","2017-02-01",[4710],[3144],{"nctId":3137,"briefTitle":3138,"status":1816,"phases":4767,"primaryCompletion":3140,"completion":3140,"start":3141,"enrollment":1062,"conditions":4768,"interventions":4769},[89],[3133],[3114,3115,3144,3115],{"nctId":4771,"briefTitle":4772,"status":1816,"phases":4773,"primaryCompletion":4762,"completion":4762,"start":4763,"enrollment":171,"conditions":4774,"interventions":4776},"NCT03082833","Phase II Trial of AZD2014 in TSC1\u002F2 Mutated or TSC1\u002F2 Null GC Patients as Second-line Chemotherapy",[89],[4775],"Cancer of Stomach",[3144],{"trials":4778,"activeCount":99},[],{"trials":4780,"activeCount":99},[],{"trials":4782,"activeCount":99},[],{"intervention":3258,"totalTrials":95,"cells":4784},{"EARLY_PHASE1":4785,"PHASE1":4787,"PHASE2":4789,"PHASE3":4812,"PHASE4":4814,"NA":4816},{"trials":4786,"activeCount":99},[],{"trials":4788,"activeCount":99},[],{"trials":4790,"activeCount":99},[4791,4795,4802],{"nctId":3249,"briefTitle":3250,"status":534,"phases":4792,"primaryCompletion":3252,"completion":3252,"start":3253,"enrollment":3254,"conditions":4793,"interventions":4794},[89],[3256],[3258,3259,3260,3229],{"nctId":4796,"briefTitle":4797,"status":534,"phases":4798,"primaryCompletion":2641,"completion":1134,"start":2802,"enrollment":1688,"conditions":4799,"interventions":4801},"NCT03219554","A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor",[89],[4800],"Thymic Cancer",[3258],{"nctId":4803,"briefTitle":4804,"status":534,"phases":4805,"primaryCompletion":4806,"completion":4807,"start":4808,"enrollment":4809,"conditions":4810,"interventions":4811},"NCT04247633","High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)",[89],"2023-02","2025-02","2020-02-11",578,[21],[3258],{"trials":4813,"activeCount":99},[],{"trials":4815,"activeCount":99},[],{"trials":4817,"activeCount":99},[],{"intervention":1114,"totalTrials":95,"cells":4819},{"EARLY_PHASE1":4820,"PHASE1":4822,"PHASE2":4824,"PHASE3":4844,"PHASE4":4846,"NA":4848},{"trials":4821,"activeCount":99},[],{"trials":4823,"activeCount":99},[],{"trials":4825,"activeCount":99},[4826,4836,4840],{"nctId":4827,"briefTitle":4828,"status":134,"phases":4829,"primaryCompletion":4830,"completion":4831,"start":2076,"enrollment":36,"conditions":4832,"interventions":4834},"NCT02449538","Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors",[89],"2016-04","2016-08",[4833],"Solid Tumor",[4835],"everolimus",{"nctId":1093,"briefTitle":1094,"status":534,"phases":4837,"primaryCompletion":1096,"completion":1097,"start":1098,"enrollment":1099,"conditions":4838,"interventions":4839},[89],[1101,1102,1103,1104],[1041,1042,1019,1106,1107,1108,1109,1110,1111,1112,1113,1114,1115,1116,1117,1118,1119],{"nctId":3262,"briefTitle":3263,"status":134,"phases":4841,"primaryCompletion":2456,"completion":1736,"start":3265,"enrollment":887,"conditions":4842,"interventions":4843},[88,89],[3267],[1114,3229],{"trials":4845,"activeCount":99},[],{"trials":4847,"activeCount":99},[],{"trials":4849,"activeCount":99},[],{"intervention":3135,"totalTrials":95,"cells":4851},{"EARLY_PHASE1":4852,"PHASE1":4854,"PHASE2":4856,"PHASE3":4877,"PHASE4":4879,"NA":4881},{"trials":4853,"activeCount":99},[],{"trials":4855,"activeCount":99},[],{"trials":4857,"activeCount":99},[4858,4867,4871],{"nctId":4859,"briefTitle":4860,"status":1816,"phases":4861,"primaryCompletion":4862,"completion":4863,"start":4864,"enrollment":1178,"conditions":4865,"interventions":4866},"NCT02688907","Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation",[89],"2017-12-27","2018-09-12","2016-06-07",[4636],[3135],{"nctId":3127,"briefTitle":3128,"status":134,"phases":4868,"primaryCompletion":2641,"completion":3097,"start":3130,"enrollment":3131,"conditions":4869,"interventions":4870},[89],[3133],[3135,3115],{"nctId":4872,"briefTitle":4873,"status":134,"phases":4874,"primaryCompletion":1126,"completion":1126,"start":1098,"enrollment":22,"conditions":4875,"interventions":4876},"NCT02593019","Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients",[89],[4636],[3135],{"trials":4878,"activeCount":99},[],{"trials":4880,"activeCount":99},[],{"trials":4882,"activeCount":99},[],{"intervention":3102,"totalTrials":95,"cells":4884},{"EARLY_PHASE1":4885,"PHASE1":4887,"PHASE2":4893,"PHASE3":4909,"PHASE4":4911,"NA":4913},{"trials":4886,"activeCount":99},[],{"trials":4888,"activeCount":99},[4889],{"nctId":3094,"briefTitle":3095,"status":134,"phases":4890,"primaryCompletion":1134,"completion":3097,"start":1098,"enrollment":3098,"conditions":4891,"interventions":4892},[88],[3100],[3102,1241],{"trials":4894,"activeCount":99},[4895,4905],{"nctId":4896,"briefTitle":4897,"status":134,"phases":4898,"primaryCompletion":4899,"completion":4899,"start":4900,"enrollment":3131,"conditions":4901,"interventions":4903},"NCT03428607","Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]",[89],"2021-01-15","2018-10-17",[4902],"SCLC",[3102,4904],"Olaparib",{"nctId":4608,"briefTitle":4609,"status":534,"phases":4906,"primaryCompletion":4611,"completion":4612,"start":4613,"enrollment":4614,"conditions":4907,"interventions":4908},[89],[1650,4616],[3102,4593],{"trials":4910,"activeCount":99},[],{"trials":4912,"activeCount":99},[],{"trials":4914,"activeCount":99},[],{"intervention":4713,"totalTrials":95,"cells":4916},{"EARLY_PHASE1":4917,"PHASE1":4919,"PHASE2":4921,"PHASE3":4944,"PHASE4":4946,"NA":4948},{"trials":4918,"activeCount":99},[],{"trials":4920,"activeCount":99},[],{"trials":4922,"activeCount":99},[4923,4927,4935],{"nctId":4703,"briefTitle":4704,"status":134,"phases":4924,"primaryCompletion":4706,"completion":4707,"start":1289,"enrollment":4708,"conditions":4925,"interventions":4926},[89],[4710],[4712,4713,1115],{"nctId":4928,"briefTitle":4929,"status":134,"phases":4930,"primaryCompletion":4421,"completion":3862,"start":4931,"enrollment":4932,"conditions":4933,"interventions":4934},"NCT02447419","Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors",[89],"2014-12-03",16,[4833],[4713],{"nctId":4936,"briefTitle":4937,"status":534,"phases":4938,"primaryCompletion":4939,"completion":1147,"start":4940,"enrollment":1933,"conditions":4941,"interventions":4942},"NCT03399669","The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation",[89],"2018-06-30","2015-02-17",[27],[4943],"gefitinib",{"trials":4945,"activeCount":99},[],{"trials":4947,"activeCount":99},[],{"trials":4949,"activeCount":99},[],{"intervention":4951,"totalTrials":95,"cells":4952},"Vistusertib",{"EARLY_PHASE1":4953,"PHASE1":4955,"PHASE2":4957,"PHASE3":4983,"PHASE4":4985,"NA":4987},{"trials":4954,"activeCount":99},[],{"trials":4956,"activeCount":99},[],{"trials":4958,"activeCount":99},[4959,4967,4973],{"nctId":4960,"briefTitle":4961,"status":185,"phases":4962,"primaryCompletion":4963,"completion":4963,"start":4964,"enrollment":99,"conditions":4965,"interventions":4966},"NCT03166176","Phase II Trial of Vistusertib（AZD2014） Single Agent in TSC1or 2 Null or TSC 1\u002F2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy",[89],"2018-07-31","2018-03",[4833],[4951],{"nctId":4968,"briefTitle":4969,"status":185,"phases":4970,"primaryCompletion":2827,"completion":4963,"start":4964,"enrollment":99,"conditions":4971,"interventions":4972},"NCT03166904","Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy",[89],[4833],[4951],{"nctId":4974,"briefTitle":4975,"status":1816,"phases":4976,"primaryCompletion":4977,"completion":4978,"start":4979,"enrollment":544,"conditions":4980,"interventions":4981},"NCT03106155","Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification",[89],"2018-05-03","2018-06-29","2017-08-02",[4636],[4982],"vistusertib",{"trials":4984,"activeCount":99},[],{"trials":4986,"activeCount":99},[],{"trials":4988,"activeCount":99},[],{"intervention":1054,"totalTrials":128,"cells":4990},{"EARLY_PHASE1":4991,"PHASE1":4993,"PHASE2":4995,"PHASE3":5005,"PHASE4":5007,"NA":5009},{"trials":4992,"activeCount":99},[],{"trials":4994,"activeCount":99},[],{"trials":4996,"activeCount":99},[4997,5001],{"nctId":1046,"briefTitle":1047,"status":534,"phases":4998,"primaryCompletion":1049,"start":1050,"enrollment":645,"conditions":4999,"interventions":5000},[89],[1052],[1042,1019,1040,1054],{"nctId":1152,"briefTitle":1153,"status":534,"phases":5002,"primaryCompletion":1155,"completion":1074,"start":1156,"enrollment":1157,"conditions":5003,"interventions":5004},[89],[1159],[1042,1019,1040,1054,1043,1044],{"trials":5006,"activeCount":99},[],{"trials":5008,"activeCount":99},[],{"trials":5010,"activeCount":99},[],{"intervention":5012,"totalTrials":128,"cells":5013},"Nivolumab",{"EARLY_PHASE1":5014,"PHASE1":5016,"PHASE2":5018,"PHASE3":5035,"PHASE4":5037,"NA":5039},{"trials":5015,"activeCount":99},[],{"trials":5017,"activeCount":99},[],{"trials":5019,"activeCount":99},[5020,5027],{"nctId":5021,"briefTitle":5022,"status":185,"phases":5023,"primaryCompletion":1031,"completion":5024,"start":1031,"enrollment":99,"conditions":5025,"interventions":5026},"NCT03758729","Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.",[89],"2020-05-11",[1347],[5012],{"nctId":5028,"briefTitle":5029,"status":534,"phases":5030,"primaryCompletion":5031,"completion":958,"start":5032,"enrollment":1440,"conditions":5033,"interventions":5034},"NCT03987815","Neoadjuvant Nivolumab for Operable Esophageal Carcinoma",[89],"2021-12-31","2019-08-01",[4626],[5012],{"trials":5036,"activeCount":99},[],{"trials":5038,"activeCount":99},[],{"trials":5040,"activeCount":99},[],{"intervention":3114,"totalTrials":128,"cells":5042},{"EARLY_PHASE1":5043,"PHASE1":5045,"PHASE2":5047,"PHASE3":5057,"PHASE4":5059,"NA":5061},{"trials":5044,"activeCount":99},[],{"trials":5046,"activeCount":99},[],{"trials":5048,"activeCount":99},[5049,5053],{"nctId":3106,"briefTitle":3107,"status":134,"phases":5050,"primaryCompletion":3109,"completion":3109,"start":3110,"enrollment":3111,"conditions":5051,"interventions":5052},[89],[1278],[3114,3115],{"nctId":3137,"briefTitle":3138,"status":1816,"phases":5054,"primaryCompletion":3140,"completion":3140,"start":3141,"enrollment":1062,"conditions":5055,"interventions":5056},[89],[3133],[3114,3115,3144,3115],{"trials":5058,"activeCount":99},[],{"trials":5060,"activeCount":99},[],{"trials":5062,"activeCount":99},[],{"intervention":4557,"totalTrials":128,"cells":5064},{"EARLY_PHASE1":5065,"PHASE1":5067,"PHASE2":5069,"PHASE3":5079,"PHASE4":5081,"NA":5083},{"trials":5066,"activeCount":99},[],{"trials":5068,"activeCount":99},[],{"trials":5070,"activeCount":99},[5071,5075],{"nctId":4550,"briefTitle":4551,"status":134,"phases":5072,"primaryCompletion":3382,"completion":4553,"start":4554,"enrollment":1178,"conditions":5073,"interventions":5074},[88,89],[3133],[4557,4558],{"nctId":4560,"briefTitle":4561,"status":134,"phases":5076,"primaryCompletion":4563,"completion":4563,"start":4564,"enrollment":128,"conditions":5077,"interventions":5078},[89],[3133],[4557,4541],{"trials":5080,"activeCount":99},[],{"trials":5082,"activeCount":99},[],{"trials":5084,"activeCount":99},[],{"intervention":5086,"totalTrials":128,"cells":5087},"Vactosertib",{"EARLY_PHASE1":5088,"PHASE1":5090,"PHASE2":5099,"PHASE3":5109,"PHASE4":5111,"NA":5113},{"trials":5089,"activeCount":99},[],{"trials":5091,"activeCount":99},[5092],{"nctId":5093,"briefTitle":5094,"status":534,"phases":5095,"primaryCompletion":3345,"completion":1074,"start":3097,"enrollment":22,"conditions":5096,"interventions":5098},"NCT04258072","Vactosertib With Nal-IRI\u002FFL in Metastatic Pancreatic Ductal Adenocarcinoma.",[88],[5097],"Pancreas Cancer",[5086],{"trials":5100,"activeCount":99},[5101],{"nctId":5102,"briefTitle":5103,"status":534,"phases":5104,"primaryCompletion":1097,"completion":5105,"start":5106,"enrollment":697,"conditions":5107,"interventions":5108},"NCT04656002","As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers",[89],"2024-12","2022-10",[24],[5086],{"trials":5110,"activeCount":99},[],{"trials":5112,"activeCount":99},[],{"trials":5114,"activeCount":99},[],{"intervention":5116,"totalTrials":128,"cells":5117},"AZD9291",{"EARLY_PHASE1":5118,"PHASE1":5120,"PHASE2":5122,"PHASE3":5144,"PHASE4":5146,"NA":5148},{"trials":5119,"activeCount":99},[],{"trials":5121,"activeCount":99},[],{"trials":5123,"activeCount":99},[5124,5133],{"nctId":5125,"briefTitle":5126,"status":534,"phases":5127,"primaryCompletion":5128,"completion":5129,"start":5130,"enrollment":862,"conditions":5131,"interventions":5132},"NCT03424759","Uncommon EGFR AZD9291",[89],"2017-12-31","2019-07-31","2016-01-01",[3385],[5116],{"nctId":5134,"briefTitle":5135,"status":534,"phases":5136,"primaryCompletion":5137,"completion":5031,"start":5138,"enrollment":1648,"conditions":5139,"interventions":5143},"NCT03257124","Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and\u002For LMS",[89],"2019-08-31","2017-05-08",[5140,5141,5142],"Non-Small Cell Lung Cancer With EGFR T790M Mutation","With Brain and\u002For Leptomeningeal Metastasis","Failed Tyrosine Kinase Inhibitors",[5116],{"trials":5145,"activeCount":99},[],{"trials":5147,"activeCount":99},[],{"trials":5149,"activeCount":99},[],{"intervention":1213,"totalTrials":128,"cells":5151},{"EARLY_PHASE1":5152,"PHASE1":5154,"PHASE2":5156,"PHASE3":5174,"PHASE4":5176,"NA":5178},{"trials":5153,"activeCount":99},[],{"trials":5155,"activeCount":99},[],{"trials":5157,"activeCount":99},[5158,5162],{"nctId":1203,"briefTitle":1204,"status":534,"phases":5159,"primaryCompletion":1206,"completion":1207,"start":1208,"enrollment":1209,"conditions":5160,"interventions":5161},[89],[1211],[1213,1038],{"nctId":5163,"briefTitle":5164,"status":134,"phases":5165,"primaryCompletion":5166,"completion":5166,"start":5167,"enrollment":5168,"conditions":5169,"interventions":5171},"NCT02426281","Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma",[89],"2022-09-30","2015-06-04",111,[5170],"Pancreatic Ductal Adenocarcinoma",[5172,5173],"nab-paclitaxel","gemcitabine",{"trials":5175,"activeCount":99},[],{"trials":5177,"activeCount":99},[],{"trials":5179,"activeCount":99},[],{"intervention":5181,"totalTrials":128,"cells":5182},"crizotinib",{"EARLY_PHASE1":5183,"PHASE1":5185,"PHASE2":5187,"PHASE3":5202,"PHASE4":5204,"NA":5206},{"trials":5184,"activeCount":99},[],{"trials":5186,"activeCount":99},[],{"trials":5188,"activeCount":99},[5189,5198],{"nctId":5190,"briefTitle":5191,"status":134,"phases":5192,"primaryCompletion":1135,"completion":5193,"start":5194,"enrollment":128,"conditions":5195,"interventions":5197},"NCT02435108","A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy",[89],"2016-07-15","2014-05-15",[5196],"c-MET Positive Gastric Cancer",[5181],{"nctId":1093,"briefTitle":1094,"status":534,"phases":5199,"primaryCompletion":1096,"completion":1097,"start":1098,"enrollment":1099,"conditions":5200,"interventions":5201},[89],[1101,1102,1103,1104],[1041,1042,1019,1106,1107,1108,1109,1110,1111,1112,1113,1114,1115,1116,1117,1118,1119],{"trials":5203,"activeCount":99},[],{"trials":5205,"activeCount":99},[],{"trials":5207,"activeCount":99},[],{"intervention":5209,"totalTrials":128,"cells":5210},"Avelumab",{"EARLY_PHASE1":5211,"PHASE1":5213,"PHASE2":5215,"PHASE3":5237,"PHASE4":5239,"NA":5241},{"trials":5212,"activeCount":99},[],{"trials":5214,"activeCount":99},[],{"trials":5216,"activeCount":99},[5217,5226],{"nctId":5218,"briefTitle":5219,"status":134,"phases":5220,"primaryCompletion":5221,"completion":5221,"start":5222,"enrollment":2270,"conditions":5223,"interventions":5225},"NCT03147404","Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes",[89],"2019-07-22","2017-12-28",[5224],"Neuroendocrine Carcinoma, Grade 3",[5209],{"nctId":5227,"briefTitle":5228,"status":534,"phases":5229,"primaryCompletion":5230,"completion":5231,"start":5232,"enrollment":3111,"conditions":5233,"interventions":5235},"NCT03439501","Avelumab in Relapsed or Refractory Extranodal Natural Killer\u002FT-cell Lymphoma[AVENT STUDY]",[89],"2022-01-30","2022-03-30","2018-01-16",[5234],"Lymphoma, Extranodal NK-T-Cell",[5236],"avelumab",{"trials":5238,"activeCount":99},[],{"trials":5240,"activeCount":99},[],{"trials":5242,"activeCount":99},[],{"intervention":1771,"totalTrials":128,"cells":5244},{"EARLY_PHASE1":5245,"PHASE1":5247,"PHASE2":5253,"PHASE3":5265,"PHASE4":5267,"NA":5269},{"trials":5246,"activeCount":99},[],{"trials":5248,"activeCount":99},[5249],{"nctId":1764,"briefTitle":1765,"status":134,"phases":5250,"primaryCompletion":1767,"completion":1736,"start":1222,"enrollment":9,"conditions":5251,"interventions":5252},[88],[1313],[1757,1770,1771],{"trials":5254,"activeCount":99},[5255],{"nctId":5256,"briefTitle":5257,"status":534,"phases":5258,"primaryCompletion":1686,"completion":1686,"start":2077,"enrollment":5259,"conditions":5260,"interventions":5262},"NCT02516826","The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease",[89],504,[5261],"Coronary Syndrome",[1771,5263,5264],"Olmesartan","Combination",{"trials":5266,"activeCount":99},[],{"trials":5268,"activeCount":99},[],{"trials":5270,"activeCount":99},[],{"intervention":4904,"totalTrials":128,"cells":5272},{"EARLY_PHASE1":5273,"PHASE1":5275,"PHASE2":5277,"PHASE3":5291,"PHASE4":5293,"NA":5295},{"trials":5274,"activeCount":99},[],{"trials":5276,"activeCount":99},[],{"trials":5278,"activeCount":99},[5279,5283],{"nctId":4896,"briefTitle":4897,"status":134,"phases":5280,"primaryCompletion":4899,"completion":4899,"start":4900,"enrollment":3131,"conditions":5281,"interventions":5282},[89],[4902],[3102,4904],{"nctId":5284,"briefTitle":5285,"status":134,"phases":5286,"primaryCompletion":5287,"completion":5287,"start":4831,"enrollment":5288,"conditions":5289,"interventions":5290},"NCT03009682","Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1\u002F2 Mutations, ATM Deficiency or MRE11A Mutations",[89],"2021-01",15,[4636],[4904],{"trials":5292,"activeCount":99},[],{"trials":5294,"activeCount":99},[],{"trials":5296,"activeCount":99},[],{"intervention":1066,"totalTrials":128,"cells":5298},{"EARLY_PHASE1":5299,"PHASE1":5301,"PHASE2":5303,"PHASE3":5319,"PHASE4":5321,"NA":5323},{"trials":5300,"activeCount":99},[],{"trials":5302,"activeCount":99},[],{"trials":5304,"activeCount":99},[5305,5309],{"nctId":1056,"briefTitle":1057,"status":534,"phases":5306,"primaryCompletion":1059,"completion":1060,"start":1061,"enrollment":1062,"conditions":5307,"interventions":5308},[89],[1064],[1019,1041,1066,1067,1068,1044],{"nctId":5310,"briefTitle":5311,"status":534,"phases":5312,"primaryCompletion":957,"completion":957,"start":5313,"enrollment":1688,"conditions":5314,"interventions":5316},"NCT05509374","Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone",[89],"2021-10-28",[5315],"Multiple Myeloma",[5317,5318,1066],"Carfilzomib 56 MG [Kyprolis]","Pomalidomide",{"trials":5320,"activeCount":99},[],{"trials":5322,"activeCount":99},[],{"trials":5324,"activeCount":99},[],{"intervention":5326,"totalTrials":128,"cells":5327},"Lapatinib",{"EARLY_PHASE1":5328,"PHASE1":5330,"PHASE2":5332,"PHASE3":5353,"PHASE4":5355,"NA":5357},{"trials":5329,"activeCount":99},[],{"trials":5331,"activeCount":99},[],{"trials":5333,"activeCount":99},[5334,5345],{"nctId":5335,"briefTitle":5336,"status":134,"phases":5337,"primaryCompletion":5338,"completion":5339,"start":5340,"enrollment":5341,"conditions":5342,"interventions":5344},"NCT02015169","Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis",[89],"2017-07-17","2017-11-17","2012-07-09",32,[5343],"HER2-positive Gastric Cancer Patients With Liver Metastasis",[5326],{"nctId":5346,"briefTitle":5347,"status":134,"phases":5348,"primaryCompletion":1135,"completion":5349,"start":4931,"enrollment":1178,"conditions":5350,"interventions":5352},"NCT02342587","Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer",[89],"2016-08-21",[5351],"HER2-positive Refractory Advanced Cancer",[5326],{"trials":5354,"activeCount":99},[],{"trials":5356,"activeCount":99},[],{"trials":5358,"activeCount":99},[],{"intervention":1107,"totalTrials":128,"cells":5360},{"EARLY_PHASE1":5361,"PHASE1":5363,"PHASE2":5365,"PHASE3":5375,"PHASE4":5377,"NA":5379},{"trials":5362,"activeCount":99},[],{"trials":5364,"activeCount":99},[],{"trials":5366,"activeCount":99},[5367,5371],{"nctId":1093,"briefTitle":1094,"status":534,"phases":5368,"primaryCompletion":1096,"completion":1097,"start":1098,"enrollment":1099,"conditions":5369,"interventions":5370},[89],[1101,1102,1103,1104],[1041,1042,1019,1106,1107,1108,1109,1110,1111,1112,1113,1114,1115,1116,1117,1118,1119],{"nctId":1131,"briefTitle":1132,"status":534,"phases":5372,"primaryCompletion":1134,"start":1135,"enrollment":1136,"conditions":5373,"interventions":5374},[89],[1138],[1107,1140,1141,1019],{"trials":5376,"activeCount":99},[],{"trials":5378,"activeCount":99},[],{"trials":5380,"activeCount":99},[],{"intervention":1116,"totalTrials":128,"cells":5382},{"EARLY_PHASE1":5383,"PHASE1":5385,"PHASE2":5387,"PHASE3":5403,"PHASE4":5405,"NA":5407},{"trials":5384,"activeCount":99},[],{"trials":5386,"activeCount":99},[],{"trials":5388,"activeCount":99},[5389,5393],{"nctId":1093,"briefTitle":1094,"status":534,"phases":5390,"primaryCompletion":1096,"completion":1097,"start":1098,"enrollment":1099,"conditions":5391,"interventions":5392},[89],[1101,1102,1103,1104],[1041,1042,1019,1106,1107,1108,1109,1110,1111,1112,1113,1114,1115,1116,1117,1118,1119],{"nctId":5394,"briefTitle":5395,"status":134,"phases":5396,"primaryCompletion":1841,"completion":5397,"start":5398,"enrollment":1440,"conditions":5399,"interventions":5402},"NCT01965119","Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma",[89],"2018-09-18","2013-11-15",[5400,5401],"Relapsed or Refractory Hodgkin Lymphoma","Primary Mediastinal Large B-cell Lymphoma",[1116],{"trials":5404,"activeCount":99},[],{"trials":5406,"activeCount":99},[],{"trials":5408,"activeCount":99},[],{"intervention":1117,"totalTrials":128,"cells":5410},{"EARLY_PHASE1":5411,"PHASE1":5413,"PHASE2":5415,"PHASE3":5431,"PHASE4":5433,"NA":5435},{"trials":5412,"activeCount":99},[],{"trials":5414,"activeCount":99},[],{"trials":5416,"activeCount":99},[5417,5421],{"nctId":1093,"briefTitle":1094,"status":534,"phases":5418,"primaryCompletion":1096,"completion":1097,"start":1098,"enrollment":1099,"conditions":5419,"interventions":5420},[89],[1101,1102,1103,1104],[1041,1042,1019,1106,1107,1108,1109,1110,1111,1112,1113,1114,1115,1116,1117,1118,1119],{"nctId":5422,"briefTitle":5423,"status":134,"phases":5424,"primaryCompletion":5425,"completion":5426,"start":5427,"enrollment":5428,"conditions":5429,"interventions":5430},"NCT01823068","Vandetanib in Advanced NSCLC With RET Rearrangement",[89],"2014-12-29","2018-03-16","2014-11-03",17,[3385],[1117],{"trials":5432,"activeCount":99},[],{"trials":5434,"activeCount":99},[],{"trials":5436,"activeCount":99},[],{"intervention":4428,"totalTrials":128,"cells":5438},{"EARLY_PHASE1":5439,"PHASE1":5441,"PHASE2":5443,"PHASE3":5458,"PHASE4":5460,"NA":5462},{"trials":5440,"activeCount":99},[],{"trials":5442,"activeCount":99},[],{"trials":5444,"activeCount":99},[5445,5454],{"nctId":5446,"briefTitle":5447,"status":134,"phases":5448,"primaryCompletion":5449,"start":3796,"enrollment":5450,"conditions":5451,"interventions":5453},"NCT01054781","Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)",[89],"2010-11",91,[5452],"Diffuse Large B-cell Lymphoma (DLBCL)",[4428],{"nctId":4418,"briefTitle":4419,"status":134,"phases":5455,"primaryCompletion":4421,"completion":4422,"start":4423,"enrollment":22,"conditions":5456,"interventions":5457},[89],[4425],[4427,4428,1040,1039,4429,4430],{"trials":5459,"activeCount":99},[],{"trials":5461,"activeCount":99},[],{"trials":5463,"activeCount":99},[],{"intervention":5465,"totalTrials":171,"cells":5466},"Dovitinib",{"EARLY_PHASE1":5467,"PHASE1":5469,"PHASE2":5471,"PHASE3":5480,"PHASE4":5482,"NA":5484},{"trials":5468,"activeCount":99},[],{"trials":5470,"activeCount":99},[],{"trials":5472,"activeCount":99},[5473],{"nctId":5474,"briefTitle":5475,"status":534,"phases":5476,"primaryCompletion":1086,"start":1196,"enrollment":1062,"conditions":5477,"interventions":5479},"NCT01861197","Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer",[89],[5478],"Squamous NSCLC",[5465],{"trials":5481,"activeCount":99},[],{"trials":5483,"activeCount":99},[],{"trials":5485,"activeCount":99},[],{"intervention":5487,"totalTrials":171,"cells":5488},"Fludarabine, Mitoxantrone, Dexamethasone, Vorinostat",{"EARLY_PHASE1":5489,"PHASE1":5491,"PHASE2":5493,"PHASE3":5503,"PHASE4":5505,"NA":5507},{"trials":5490,"activeCount":99},[],{"trials":5492,"activeCount":99},[],{"trials":5494,"activeCount":99},[5495],{"nctId":5496,"briefTitle":5497,"status":1816,"phases":5498,"primaryCompletion":5499,"completion":611,"start":1222,"enrollment":1440,"conditions":5500,"interventions":5502},"NCT01578343","Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma",[89],"2015-09",[5501],"Mantle Cell Lymphoma",[5487],{"trials":5504,"activeCount":99},[],{"trials":5506,"activeCount":99},[],{"trials":5508,"activeCount":99},[],{"intervention":5510,"totalTrials":171,"cells":5511},"Gemcitabine\u002FDocetaxel",{"EARLY_PHASE1":5512,"PHASE1":5514,"PHASE2":5516,"PHASE3":5527,"PHASE4":5529,"NA":5531},{"trials":5513,"activeCount":99},[],{"trials":5515,"activeCount":99},[],{"trials":5517,"activeCount":99},[5518],{"nctId":5519,"briefTitle":5520,"status":134,"phases":5521,"primaryCompletion":2149,"completion":1086,"start":5522,"enrollment":22,"conditions":5523,"interventions":5526},"NCT01469598","Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer",[89],"2011-08",[5524,5525],"Metastatic Carcinoma","Recurrent Esophageal Squamous Cell Carcinoma",[5510],{"trials":5528,"activeCount":99},[],{"trials":5530,"activeCount":99},[],{"trials":5532,"activeCount":99},[],{"intervention":5534,"totalTrials":171,"cells":5535},"gemcitabine\u002Fdocetaxel combination",{"EARLY_PHASE1":5536,"PHASE1":5538,"PHASE2":5540,"PHASE3":5551,"PHASE4":5553,"NA":5555},{"trials":5537,"activeCount":99},[],{"trials":5539,"activeCount":99},[],{"trials":5541,"activeCount":99},[5542],{"nctId":5543,"briefTitle":5544,"status":534,"phases":5545,"primaryCompletion":5546,"completion":5547,"start":2268,"enrollment":19,"conditions":5548,"interventions":5550},"NCT02590055","Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary",[89],"2018-09","2019-09",[5549],"Carcinoma of Unknown Primary",[5534],{"trials":5552,"activeCount":99},[],{"trials":5554,"activeCount":99},[],{"trials":5556,"activeCount":99},[],{"intervention":5558,"totalTrials":171,"cells":5559},"Gemcitabine, Cisplatin, and Nab-Paclitaxe",{"EARLY_PHASE1":5560,"PHASE1":5562,"PHASE2":5564,"PHASE3":5575,"PHASE4":5577,"NA":5579},{"trials":5561,"activeCount":99},[],{"trials":5563,"activeCount":99},[],{"trials":5565,"activeCount":99},[5566],{"nctId":5567,"briefTitle":5568,"status":185,"phases":5569,"primaryCompletion":5570,"completion":5570,"start":5571,"enrollment":99,"conditions":5572,"interventions":5574},"NCT04546828","A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea",[89],"2021-08-18","2021-02-01",[5573],"Intrahepatic Cholangiocarcinoma",[5558],{"trials":5576,"activeCount":99},[],{"trials":5578,"activeCount":99},[],{"trials":5580,"activeCount":99},[],{"intervention":5582,"totalTrials":171,"cells":5583},"bortezomib\u002Fdexamethasone",{"EARLY_PHASE1":5584,"PHASE1":5586,"PHASE2":5588,"PHASE3":5599,"PHASE4":5601,"NA":5603},{"trials":5585,"activeCount":99},[],{"trials":5587,"activeCount":99},[],{"trials":5589,"activeCount":99},[5590],{"nctId":5591,"briefTitle":5592,"status":134,"phases":5593,"primaryCompletion":5594,"completion":5594,"start":5595,"enrollment":5341,"conditions":5596,"interventions":5598},"NCT03487133","Bortezomib\u002FDexamethasone Therapy in Patients With Relapsed and\u002For Refractory Cutaneous T-cell Lymphoma",[89],"2020-09-30","2017-09-19",[5597],"Relapsed and\u002For Refractory Cutaneous T-cell Lymphoma",[5582],{"trials":5600,"activeCount":99},[],{"trials":5602,"activeCount":99},[],{"trials":5604,"activeCount":99},[],{"intervention":5606,"totalTrials":171,"cells":5607},"docetaxel plus Cisplatin",{"EARLY_PHASE1":5608,"PHASE1":5610,"PHASE2":5612,"PHASE3":5623,"PHASE4":5625,"NA":5627},{"trials":5609,"activeCount":99},[],{"trials":5611,"activeCount":99},[],{"trials":5613,"activeCount":99},[5614],{"nctId":5615,"briefTitle":5616,"status":534,"phases":5617,"primaryCompletion":5618,"completion":1032,"start":5619,"enrollment":4582,"conditions":5620,"interventions":5622},"NCT05008237","Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study",[89],"2022-05","2014-05-02",[5621],"Salivary Gland Cancer",[5606],{"trials":5624,"activeCount":99},[],{"trials":5626,"activeCount":99},[],{"trials":5628,"activeCount":99},[],{"intervention":5630,"totalTrials":171,"cells":5631},"AZD2811",{"EARLY_PHASE1":5632,"PHASE1":5634,"PHASE2":5636,"PHASE3":5646,"PHASE4":5648,"NA":5650},{"trials":5633,"activeCount":99},[],{"trials":5635,"activeCount":99},[],{"trials":5637,"activeCount":99},[5638],{"nctId":5639,"briefTitle":5640,"status":1816,"phases":5641,"primaryCompletion":1701,"completion":5642,"start":5643,"enrollment":5288,"conditions":5644,"interventions":5645},"NCT03366675","AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3]",[89],"2018-10-29","2017-12-01",[4636],[5630],{"trials":5647,"activeCount":99},[],{"trials":5649,"activeCount":99},[],{"trials":5651,"activeCount":99},[],{"intervention":5653,"totalTrials":171,"cells":5654},"BCD chemotherapy",{"EARLY_PHASE1":5655,"PHASE1":5657,"PHASE2":5659,"PHASE3":5669,"PHASE4":5671,"NA":5673},{"trials":5656,"activeCount":99},[],{"trials":5658,"activeCount":99},[],{"trials":5660,"activeCount":99},[5661],{"nctId":5662,"briefTitle":5663,"status":134,"phases":5664,"primaryCompletion":5665,"completion":5665,"start":3532,"enrollment":671,"conditions":5666,"interventions":5668},"NCT02424045","Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma",[89],"2017-09",[5667],"T-cell Lymphoma",[5653],{"trials":5670,"activeCount":99},[],{"trials":5672,"activeCount":99},[],{"trials":5674,"activeCount":99},[],{"intervention":5676,"totalTrials":171,"cells":5677},"GC1118",{"EARLY_PHASE1":5678,"PHASE1":5680,"PHASE2":5682,"PHASE3":5695,"PHASE4":5697,"NA":5699},{"trials":5679,"activeCount":99},[],{"trials":5681,"activeCount":99},[],{"trials":5683,"activeCount":99},[5684],{"nctId":5685,"briefTitle":5686,"status":134,"phases":5687,"primaryCompletion":5688,"completion":5689,"start":5690,"enrollment":28,"conditions":5691,"interventions":5694},"NCT03618667","GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification",[89],"2018-09-08","2022-04-28","2018-01-22",[5692,5693],"Glioblastoma, Adult","EGFR Amplification",[5676],{"trials":5696,"activeCount":99},[],{"trials":5698,"activeCount":99},[],{"trials":5700,"activeCount":99},[],{"intervention":3259,"totalTrials":171,"cells":5702},{"EARLY_PHASE1":5703,"PHASE1":5705,"PHASE2":5707,"PHASE3":5713,"PHASE4":5715,"NA":5717},{"trials":5704,"activeCount":99},[],{"trials":5706,"activeCount":99},[],{"trials":5708,"activeCount":99},[5709],{"nctId":3249,"briefTitle":3250,"status":534,"phases":5710,"primaryCompletion":3252,"completion":3252,"start":3253,"enrollment":3254,"conditions":5711,"interventions":5712},[89],[3256],[3258,3259,3260,3229],{"trials":5714,"activeCount":99},[],{"trials":5716,"activeCount":99},[],{"trials":5718,"activeCount":99},[],{"intervention":3260,"totalTrials":171,"cells":5720},{"EARLY_PHASE1":5721,"PHASE1":5723,"PHASE2":5725,"PHASE3":5731,"PHASE4":5733,"NA":5735},{"trials":5722,"activeCount":99},[],{"trials":5724,"activeCount":99},[],{"trials":5726,"activeCount":99},[5727],{"nctId":3249,"briefTitle":3250,"status":534,"phases":5728,"primaryCompletion":3252,"completion":3252,"start":3253,"enrollment":3254,"conditions":5729,"interventions":5730},[89],[3256],[3258,3259,3260,3229],{"trials":5732,"activeCount":99},[],{"trials":5734,"activeCount":99},[],{"trials":5736,"activeCount":99},[],{"intervention":5738,"totalTrials":171,"cells":5739},"MK3475",{"EARLY_PHASE1":5740,"PHASE1":5742,"PHASE2":5744,"PHASE3":5754,"PHASE4":5756,"NA":5758},{"trials":5741,"activeCount":99},[],{"trials":5743,"activeCount":99},[],{"trials":5745,"activeCount":99},[5746],{"nctId":5747,"briefTitle":5748,"status":134,"phases":5749,"primaryCompletion":4623,"completion":5750,"start":5751,"enrollment":1688,"conditions":5752,"interventions":5753},"NCT03110328","Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes",[89],"2022-03-24","2018-02-07",[3244],[5738],{"trials":5755,"activeCount":99},[],{"trials":5757,"activeCount":99},[],{"trials":5759,"activeCount":99},[],{"intervention":5761,"totalTrials":171,"cells":5762},"Capecitabine\u002FCisplatin",{"EARLY_PHASE1":5763,"PHASE1":5765,"PHASE2":5767,"PHASE3":5778,"PHASE4":5780,"NA":5782},{"trials":5764,"activeCount":99},[],{"trials":5766,"activeCount":99},[],{"trials":5768,"activeCount":99},[5769],{"nctId":5770,"briefTitle":5771,"status":134,"phases":5772,"primaryCompletion":1767,"completion":2995,"start":1276,"enrollment":5773,"conditions":5774,"interventions":5776},"NCT01474642","Phase II Trial of XP Versus XG in Advanced Esophageal Squamous Cell Carcinoma",[89],64,[5775],"Advanced or Recurrent Esophageal Squamous Cell Carcinoma",[5761,5777],"Capecitabine\u002FPaditaxel",{"trials":5779,"activeCount":99},[],{"trials":5781,"activeCount":99},[],{"trials":5783,"activeCount":99},[],{"intervention":5777,"totalTrials":171,"cells":5785},{"EARLY_PHASE1":5786,"PHASE1":5788,"PHASE2":5790,"PHASE3":5796,"PHASE4":5798,"NA":5800},{"trials":5787,"activeCount":99},[],{"trials":5789,"activeCount":99},[],{"trials":5791,"activeCount":99},[5792],{"nctId":5770,"briefTitle":5771,"status":134,"phases":5793,"primaryCompletion":1767,"completion":2995,"start":1276,"enrollment":5773,"conditions":5794,"interventions":5795},[89],[5775],[5761,5777],{"trials":5797,"activeCount":99},[],{"trials":5799,"activeCount":99},[],{"trials":5801,"activeCount":99},[],{"intervention":5803,"totalTrials":171,"cells":5804},"neoadjuvant docetaxel\u002Fcisplatin",{"EARLY_PHASE1":5805,"PHASE1":5807,"PHASE2":5809,"PHASE3":5820,"PHASE4":5822,"NA":5824},{"trials":5806,"activeCount":99},[],{"trials":5808,"activeCount":99},[],{"trials":5810,"activeCount":99},[5811],{"nctId":5812,"briefTitle":5813,"status":134,"phases":5814,"primaryCompletion":5815,"completion":5816,"start":2432,"enrollment":1062,"conditions":5817,"interventions":5819},"NCT01312324","Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer",[89],"2015-07","2016-03",[5818],"Locally Advanced Stage III or IV Thymic Cancer",[5803],{"trials":5821,"activeCount":99},[],{"trials":5823,"activeCount":99},[],{"trials":5825,"activeCount":99},[],{"intervention":5827,"totalTrials":171,"cells":5828},"Docetaxel + Sunitinib",{"EARLY_PHASE1":5829,"PHASE1":5831,"PHASE2":5833,"PHASE3":5846,"PHASE4":5848,"NA":5850},{"trials":5830,"activeCount":99},[],{"trials":5832,"activeCount":99},[],{"trials":5834,"activeCount":99},[5835],{"nctId":5836,"briefTitle":5837,"status":134,"phases":5838,"primaryCompletion":5839,"completion":5840,"start":5841,"enrollment":5842,"conditions":5843,"interventions":5844},"NCT01238055","Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer",[89],"2012-04","2012-10","2008-11",116,[1278],[5827,5845],"Docetaxel only",{"trials":5847,"activeCount":99},[],{"trials":5849,"activeCount":99},[],{"trials":5851,"activeCount":99},[],{"intervention":5845,"totalTrials":171,"cells":5853},{"EARLY_PHASE1":5854,"PHASE1":5856,"PHASE2":5858,"PHASE3":5864,"PHASE4":5866,"NA":5868},{"trials":5855,"activeCount":99},[],{"trials":5857,"activeCount":99},[],{"trials":5859,"activeCount":99},[5860],{"nctId":5836,"briefTitle":5837,"status":134,"phases":5861,"primaryCompletion":5839,"completion":5840,"start":5841,"enrollment":5842,"conditions":5862,"interventions":5863},[89],[1278],[5827,5845],{"trials":5865,"activeCount":99},[],{"trials":5867,"activeCount":99},[],{"trials":5869,"activeCount":99},[],{"intervention":5871,"totalTrials":171,"cells":5872},"Lenalidomide 25mg",{"EARLY_PHASE1":5873,"PHASE1":5875,"PHASE2":5877,"PHASE3":5888,"PHASE4":5890,"NA":5892},{"trials":5874,"activeCount":99},[],{"trials":5876,"activeCount":99},[],{"trials":5878,"activeCount":99},[5879],{"nctId":5880,"briefTitle":5881,"status":534,"phases":5882,"primaryCompletion":5883,"completion":4205,"start":4762,"enrollment":5884,"conditions":5885,"interventions":5887},"NCT03730740","Phase II of Lenalidomide After Salvage Therapy in R\u002FR Non-Hodgkin T-cell Lymphoma",[89],"2021-11",79,[5886],"Relapsed and\u002For Refractory Non-Hodgkin T-cell Lymphoma",[5871],{"trials":5889,"activeCount":99},[],{"trials":5891,"activeCount":99},[],{"trials":5893,"activeCount":99},[],{"intervention":5895,"totalTrials":171,"cells":5896},"Evogliptin",{"EARLY_PHASE1":5897,"PHASE1":5899,"PHASE2":5901,"PHASE3":5916,"PHASE4":5918,"NA":5920},{"trials":5898,"activeCount":99},[],{"trials":5900,"activeCount":99},[],{"trials":5902,"activeCount":99},[5903],{"nctId":5904,"briefTitle":5905,"status":134,"phases":5906,"primaryCompletion":5907,"completion":5907,"start":5908,"enrollment":5909,"conditions":5910,"interventions":5914},"NCT03667300","Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency",[89],"2019-05-14","2017-03-16",209,[5911,5912,5913],"Type2 Diabetes Mellitus","Albuminuria","Renal Insufficiency",[5895,5915],"Linagliptin",{"trials":5917,"activeCount":99},[],{"trials":5919,"activeCount":99},[],{"trials":5921,"activeCount":99},[],{"intervention":5915,"totalTrials":171,"cells":5923},{"EARLY_PHASE1":5924,"PHASE1":5926,"PHASE2":5928,"PHASE3":5934,"PHASE4":5936,"NA":5938},{"trials":5925,"activeCount":99},[],{"trials":5927,"activeCount":99},[],{"trials":5929,"activeCount":99},[5930],{"nctId":5904,"briefTitle":5905,"status":134,"phases":5931,"primaryCompletion":5907,"completion":5907,"start":5908,"enrollment":5909,"conditions":5932,"interventions":5933},[89],[5911,5912,5913],[5895,5915],{"trials":5935,"activeCount":99},[],{"trials":5937,"activeCount":99},[],{"trials":5939,"activeCount":99},[],{"intervention":5941,"totalTrials":171,"cells":5942},"L-Ascorbic Acid",{"EARLY_PHASE1":5943,"PHASE1":5945,"PHASE2":5947,"PHASE3":5960,"PHASE4":5962,"NA":5964},{"trials":5944,"activeCount":99},[],{"trials":5946,"activeCount":99},[],{"trials":5948,"activeCount":99},[5949],{"nctId":5950,"briefTitle":5951,"status":5952,"phases":5953,"completion":5954,"start":5955,"enrollment":1157,"conditions":5956,"interventions":5959},"NCT00329498","L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic Syndromes","SUSPENDED",[89],"2005-08","1998-05",[5957,5958],"Acute Myeloid Leukemia","Myelodysplastic Syndrome",[5941],{"trials":5961,"activeCount":99},[],{"trials":5963,"activeCount":99},[],{"trials":5965,"activeCount":99},[],{"intervention":5967,"totalTrials":171,"cells":5968},"Enzalutamide",{"EARLY_PHASE1":5969,"PHASE1":5971,"PHASE2":5973,"PHASE3":5985,"PHASE4":5987,"NA":5989},{"trials":5970,"activeCount":99},[],{"trials":5972,"activeCount":99},[],{"trials":5974,"activeCount":99},[5975],{"nctId":5976,"briefTitle":5977,"status":534,"phases":5978,"primaryCompletion":5979,"completion":5980,"start":5981,"enrollment":11,"conditions":5982,"interventions":5984},"NCT06015321","An Open Label Phase II Study of First-Line Maintenance Enzalutamide Following Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Castration-Naive Prostatic Adenocarcinoma",[89],"2025-10-31","2026-04-30","2023-10-01",[5983],"Prostatic Adenocarcinoma",[5967],{"trials":5986,"activeCount":99},[],{"trials":5988,"activeCount":99},[],{"trials":5990,"activeCount":99},[],{"intervention":5263,"totalTrials":171,"cells":5992},{"EARLY_PHASE1":5993,"PHASE1":5995,"PHASE2":5997,"PHASE3":6003,"PHASE4":6005,"NA":6007},{"trials":5994,"activeCount":99},[],{"trials":5996,"activeCount":99},[],{"trials":5998,"activeCount":99},[5999],{"nctId":5256,"briefTitle":5257,"status":534,"phases":6000,"primaryCompletion":1686,"completion":1686,"start":2077,"enrollment":5259,"conditions":6001,"interventions":6002},[89],[5261],[1771,5263,5264],{"trials":6004,"activeCount":99},[],{"trials":6006,"activeCount":99},[],{"trials":6008,"activeCount":99},[],{"intervention":5264,"totalTrials":171,"cells":6010},{"EARLY_PHASE1":6011,"PHASE1":6013,"PHASE2":6015,"PHASE3":6021,"PHASE4":6023,"NA":6025},{"trials":6012,"activeCount":99},[],{"trials":6014,"activeCount":99},[],{"trials":6016,"activeCount":99},[6017],{"nctId":5256,"briefTitle":5257,"status":534,"phases":6018,"primaryCompletion":1686,"completion":1686,"start":2077,"enrollment":5259,"conditions":6019,"interventions":6020},[89],[5261],[1771,5263,5264],{"trials":6022,"activeCount":99},[],{"trials":6024,"activeCount":99},[],{"trials":6026,"activeCount":99},[],{"intervention":6028,"totalTrials":171,"cells":6029},"Durvalumab Plus Tremelimumab",{"EARLY_PHASE1":6030,"PHASE1":6032,"PHASE2":6034,"PHASE3":6044,"PHASE4":6046,"NA":6048},{"trials":6031,"activeCount":99},[],{"trials":6033,"activeCount":99},[],{"trials":6035,"activeCount":99},[6036],{"nctId":6037,"briefTitle":6038,"status":534,"phases":6039,"primaryCompletion":4622,"completion":1206,"start":6040,"enrollment":4573,"conditions":6041,"interventions":6043},"NCT03450967","Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC",[89],"2018-04-11",[6042],"Head and Neck Squamous Cell Carcinoma",[6028],{"trials":6045,"activeCount":99},[],{"trials":6047,"activeCount":99},[],{"trials":6049,"activeCount":99},[],{"intervention":6051,"totalTrials":171,"cells":6052},"docetaxel, oxaliplatin",{"EARLY_PHASE1":6053,"PHASE1":6055,"PHASE2":6057,"PHASE3":6066,"PHASE4":6068,"NA":6070},{"trials":6054,"activeCount":99},[],{"trials":6056,"activeCount":99},[],{"trials":6058,"activeCount":99},[6059],{"nctId":6060,"briefTitle":6061,"status":134,"phases":6062,"primaryCompletion":6063,"completion":1930,"start":2434,"enrollment":3301,"conditions":6064,"interventions":6065},"NCT00533533","A Phase I\u002FII Trial of Docetaxel and Oxaliplatin in Patients With Advanced Gastric Cancer",[88,89],"2008-03",[24],[6051],{"trials":6067,"activeCount":99},[],{"trials":6069,"activeCount":99},[],{"trials":6071,"activeCount":99},[],{"intervention":6073,"totalTrials":171,"cells":6074},"Zydena",{"EARLY_PHASE1":6075,"PHASE1":6077,"PHASE2":6079,"PHASE3":6091,"PHASE4":6093,"NA":6095},{"trials":6076,"activeCount":99},[],{"trials":6078,"activeCount":99},[],{"trials":6080,"activeCount":99},[6081],{"nctId":6082,"briefTitle":6083,"status":534,"phases":6084,"primaryCompletion":1858,"completion":6085,"start":6086,"enrollment":1648,"conditions":6087,"interventions":6090},"NCT01466543","Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity",[89],"2012-11","2011-11",[6088,6089],"Vascular Dementia","Subcortical Vascular Dementia",[6073],{"trials":6092,"activeCount":99},[],{"trials":6094,"activeCount":99},[],{"trials":6096,"activeCount":99},[],{"intervention":1067,"totalTrials":171,"cells":6098},{"EARLY_PHASE1":6099,"PHASE1":6101,"PHASE2":6103,"PHASE3":6109,"PHASE4":6111,"NA":6113},{"trials":6100,"activeCount":99},[],{"trials":6102,"activeCount":99},[],{"trials":6104,"activeCount":99},[6105],{"nctId":1056,"briefTitle":1057,"status":534,"phases":6106,"primaryCompletion":1059,"completion":1060,"start":1061,"enrollment":1062,"conditions":6107,"interventions":6108},[89],[1064],[1019,1041,1066,1067,1068,1044],{"trials":6110,"activeCount":99},[],{"trials":6112,"activeCount":99},[],{"trials":6114,"activeCount":99},[],{"intervention":1068,"totalTrials":171,"cells":6116},{"EARLY_PHASE1":6117,"PHASE1":6119,"PHASE2":6121,"PHASE3":6127,"PHASE4":6129,"NA":6131},{"trials":6118,"activeCount":99},[],{"trials":6120,"activeCount":99},[],{"trials":6122,"activeCount":99},[6123],{"nctId":1056,"briefTitle":1057,"status":534,"phases":6124,"primaryCompletion":1059,"completion":1060,"start":1061,"enrollment":1062,"conditions":6125,"interventions":6126},[89],[1064],[1019,1041,1066,1067,1068,1044],{"trials":6128,"activeCount":99},[],{"trials":6130,"activeCount":99},[],{"trials":6132,"activeCount":99},[],{"intervention":562,"totalTrials":171,"cells":6134},{"EARLY_PHASE1":6135,"PHASE1":6137,"PHASE2":6139,"PHASE3":6145,"PHASE4":6147,"NA":6149},{"trials":6136,"activeCount":99},[],{"trials":6138,"activeCount":99},[],{"trials":6140,"activeCount":99},[6141],{"nctId":553,"briefTitle":554,"status":134,"phases":6142,"primaryCompletion":556,"completion":556,"start":557,"enrollment":558,"conditions":6143,"interventions":6144},[89],[560],[562,543],{"trials":6146,"activeCount":99},[],{"trials":6148,"activeCount":99},[],{"trials":6150,"activeCount":99},[],{"intervention":6152,"totalTrials":171,"cells":6153},"Gemcitabine TS-1",{"EARLY_PHASE1":6154,"PHASE1":6156,"PHASE2":6158,"PHASE3":6167,"PHASE4":6169,"NA":6171},{"trials":6155,"activeCount":99},[],{"trials":6157,"activeCount":99},[],{"trials":6159,"activeCount":99},[6160],{"nctId":6161,"briefTitle":6162,"status":1816,"phases":6163,"primaryCompletion":1921,"completion":1921,"start":6164,"enrollment":25,"conditions":6165,"interventions":6166},"NCT01171755","Phase II Study of Gemcitabine and TS-1 in Biliary Trat Cancer",[89],"2008-02",[3244],[6152],{"trials":6168,"activeCount":99},[],{"trials":6170,"activeCount":99},[],{"trials":6172,"activeCount":99},[],{"intervention":1080,"totalTrials":171,"cells":6174},{"EARLY_PHASE1":6175,"PHASE1":6177,"PHASE2":6179,"PHASE3":6185,"PHASE4":6187,"NA":6189},{"trials":6176,"activeCount":99},[],{"trials":6178,"activeCount":99},[],{"trials":6180,"activeCount":99},[6181],{"nctId":1070,"briefTitle":1071,"status":534,"phases":6182,"primaryCompletion":1073,"completion":1074,"start":1075,"enrollment":1076,"conditions":6183,"interventions":6184},[89],[1078],[1038,1039,1019,1040,1041,1042,1080,1081],{"trials":6186,"activeCount":99},[],{"trials":6188,"activeCount":99},[],{"trials":6190,"activeCount":99},[],{"intervention":1081,"totalTrials":171,"cells":6192},{"EARLY_PHASE1":6193,"PHASE1":6195,"PHASE2":6197,"PHASE3":6203,"PHASE4":6205,"NA":6207},{"trials":6194,"activeCount":99},[],{"trials":6196,"activeCount":99},[],{"trials":6198,"activeCount":99},[6199],{"nctId":1070,"briefTitle":1071,"status":534,"phases":6200,"primaryCompletion":1073,"completion":1074,"start":1075,"enrollment":1076,"conditions":6201,"interventions":6202},[89],[1078],[1038,1039,1019,1040,1041,1042,1080,1081],{"trials":6204,"activeCount":99},[],{"trials":6206,"activeCount":99},[],{"trials":6208,"activeCount":99},[],{"intervention":6210,"totalTrials":171,"cells":6211},"fludarabine phosphate, busulfan",{"EARLY_PHASE1":6212,"PHASE1":6214,"PHASE2":6216,"PHASE3":6229,"PHASE4":6231,"NA":6233},{"trials":6213,"activeCount":99},[],{"trials":6215,"activeCount":99},[],{"trials":6217,"activeCount":99},[6218],{"nctId":6219,"briefTitle":6220,"status":534,"phases":6221,"primaryCompletion":2712,"completion":2759,"start":1088,"enrollment":6222,"conditions":6223,"interventions":6228},"NCT00815568","Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI)",[89],114,[6224,6225,6226,6227,1588],"AML","MDS","ALL","CML",[6210],{"trials":6230,"activeCount":99},[],{"trials":6232,"activeCount":99},[],{"trials":6234,"activeCount":99},[],{"intervention":6236,"totalTrials":171,"cells":6237},"Fluorouracil",{"EARLY_PHASE1":6238,"PHASE1":6240,"PHASE2":6242,"PHASE3":6253,"PHASE4":6255,"NA":6257},{"trials":6239,"activeCount":99},[],{"trials":6241,"activeCount":99},[],{"trials":6243,"activeCount":99},[6244],{"nctId":6245,"briefTitle":6246,"status":185,"phases":6247,"primaryCompletion":6248,"completion":6248,"start":6248,"enrollment":99,"conditions":6249,"interventions":6250},"NCT03110510","FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study",[89],"2019-09-06",[3244],[6236,6251,6252],"Irinotecan Hydrochloride","leucovorin calcium",{"trials":6254,"activeCount":99},[],{"trials":6256,"activeCount":99},[],{"trials":6258,"activeCount":99},[],{"intervention":6251,"totalTrials":171,"cells":6260},{"EARLY_PHASE1":6261,"PHASE1":6263,"PHASE2":6265,"PHASE3":6271,"PHASE4":6273,"NA":6275},{"trials":6262,"activeCount":99},[],{"trials":6264,"activeCount":99},[],{"trials":6266,"activeCount":99},[6267],{"nctId":6245,"briefTitle":6246,"status":185,"phases":6268,"primaryCompletion":6248,"completion":6248,"start":6248,"enrollment":99,"conditions":6269,"interventions":6270},[89],[3244],[6236,6251,6252],{"trials":6272,"activeCount":99},[],{"trials":6274,"activeCount":99},[],{"trials":6276,"activeCount":99},[],{"intervention":6252,"totalTrials":171,"cells":6278},{"EARLY_PHASE1":6279,"PHASE1":6281,"PHASE2":6283,"PHASE3":6289,"PHASE4":6291,"NA":6293},{"trials":6280,"activeCount":99},[],{"trials":6282,"activeCount":99},[],{"trials":6284,"activeCount":99},[6285],{"nctId":6245,"briefTitle":6246,"status":185,"phases":6286,"primaryCompletion":6248,"completion":6248,"start":6248,"enrollment":99,"conditions":6287,"interventions":6288},[89],[3244],[6236,6251,6252],{"trials":6290,"activeCount":99},[],{"trials":6292,"activeCount":99},[],{"trials":6294,"activeCount":99},[],{"intervention":5317,"totalTrials":171,"cells":6296},{"EARLY_PHASE1":6297,"PHASE1":6299,"PHASE2":6301,"PHASE3":6307,"PHASE4":6309,"NA":6311},{"trials":6298,"activeCount":99},[],{"trials":6300,"activeCount":99},[],{"trials":6302,"activeCount":99},[6303],{"nctId":5310,"briefTitle":5311,"status":534,"phases":6304,"primaryCompletion":957,"completion":957,"start":5313,"enrollment":1688,"conditions":6305,"interventions":6306},[89],[5315],[5317,5318,1066],{"trials":6308,"activeCount":99},[],{"trials":6310,"activeCount":99},[],{"trials":6312,"activeCount":99},[],{"intervention":5318,"totalTrials":171,"cells":6314},{"EARLY_PHASE1":6315,"PHASE1":6317,"PHASE2":6319,"PHASE3":6325,"PHASE4":6327,"NA":6329},{"trials":6316,"activeCount":99},[],{"trials":6318,"activeCount":99},[],{"trials":6320,"activeCount":99},[6321],{"nctId":5310,"briefTitle":5311,"status":534,"phases":6322,"primaryCompletion":957,"completion":957,"start":5313,"enrollment":1688,"conditions":6323,"interventions":6324},[89],[5315],[5317,5318,1066],{"trials":6326,"activeCount":99},[],{"trials":6328,"activeCount":99},[],{"trials":6330,"activeCount":99},[],{"intervention":6332,"totalTrials":171,"cells":6333},"Autologous dendritic cell",{"EARLY_PHASE1":6334,"PHASE1":6336,"PHASE2":6338,"PHASE3":6349,"PHASE4":6351,"NA":6353},{"trials":6335,"activeCount":99},[],{"trials":6337,"activeCount":99},[],{"trials":6339,"activeCount":99},[6340],{"nctId":6341,"briefTitle":6342,"status":134,"phases":6343,"primaryCompletion":6344,"completion":6344,"start":6345,"enrollment":974,"conditions":6346,"interventions":6348},"NCT01171729","Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer",[88,89],"2010-05","2006-07",[6347],"Prostatic Cancer",[6332],{"trials":6350,"activeCount":99},[],{"trials":6352,"activeCount":99},[],{"trials":6354,"activeCount":99},[],{"intervention":6356,"totalTrials":171,"cells":6357},"BAVC-C+Durvalumab",{"EARLY_PHASE1":6358,"PHASE1":6360,"PHASE2":6362,"PHASE3":6372,"PHASE4":6374,"NA":6376},{"trials":6359,"activeCount":99},[],{"trials":6361,"activeCount":99},[],{"trials":6363,"activeCount":99},[6364],{"nctId":6365,"briefTitle":6366,"status":534,"phases":6367,"primaryCompletion":6368,"completion":6368,"start":6369,"enrollment":862,"conditions":6370,"interventions":6371},"NCT04800978","Combination of Durvalumab and BVAC-C in Patients With HPV 16 or 18 Positive Cervical Cancer Failure to First-Line Platinum-based Chemotherapy",[89],"2024-08-31","2021-06-14",[841],[6356],{"trials":6373,"activeCount":99},[],{"trials":6375,"activeCount":99},[],{"trials":6377,"activeCount":99},[],{"intervention":6379,"totalTrials":171,"cells":6380},"tipifarnib",{"EARLY_PHASE1":6381,"PHASE1":6383,"PHASE2":6385,"PHASE3":6395,"PHASE4":6397,"NA":6399},{"trials":6382,"activeCount":99},[],{"trials":6384,"activeCount":99},[],{"trials":6386,"activeCount":99},[6387],{"nctId":6388,"briefTitle":6389,"status":534,"phases":6390,"primaryCompletion":1206,"completion":1207,"start":6391,"enrollment":25,"conditions":6392,"interventions":6394},"NCT02535650","Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma",[89],"2015-11-12",[6393],"Urothelial Carcinoma",[6379],{"trials":6396,"activeCount":99},[],{"trials":6398,"activeCount":99},[],{"trials":6400,"activeCount":99},[],{"intervention":6402,"totalTrials":171,"cells":6403},"Fulvestrant plus Goserelin",{"EARLY_PHASE1":6404,"PHASE1":6406,"PHASE2":6408,"PHASE3":6421,"PHASE4":6423,"NA":6425},{"trials":6405,"activeCount":99},[],{"trials":6407,"activeCount":99},[],{"trials":6409,"activeCount":99},[6410],{"nctId":6411,"briefTitle":6412,"status":534,"phases":6413,"primaryCompletion":2827,"completion":2641,"start":1782,"enrollment":6414,"conditions":6415,"interventions":6418},"NCT01266213","Fulvestrant (F)\u002FGoserelin (G) vs Anastrozole (A)\u002FG vs G for Premenopausal Women",[89],147,[3256,6416,6417],"Estrogen Receptor Positive Tumor","Breast Cancer Nos Premenopausal",[6402,6419,6420],"Anastrozole plus Goserelin","Goserelin",{"trials":6422,"activeCount":99},[],{"trials":6424,"activeCount":99},[],{"trials":6426,"activeCount":99},[],{"intervention":6419,"totalTrials":171,"cells":6428},{"EARLY_PHASE1":6429,"PHASE1":6431,"PHASE2":6433,"PHASE3":6439,"PHASE4":6441,"NA":6443},{"trials":6430,"activeCount":99},[],{"trials":6432,"activeCount":99},[],{"trials":6434,"activeCount":99},[6435],{"nctId":6411,"briefTitle":6412,"status":534,"phases":6436,"primaryCompletion":2827,"completion":2641,"start":1782,"enrollment":6414,"conditions":6437,"interventions":6438},[89],[3256,6416,6417],[6402,6419,6420],{"trials":6440,"activeCount":99},[],{"trials":6442,"activeCount":99},[],{"trials":6444,"activeCount":99},[],{"intervention":6420,"totalTrials":171,"cells":6446},{"EARLY_PHASE1":6447,"PHASE1":6449,"PHASE2":6451,"PHASE3":6457,"PHASE4":6459,"NA":6461},{"trials":6448,"activeCount":99},[],{"trials":6450,"activeCount":99},[],{"trials":6452,"activeCount":99},[6453],{"nctId":6411,"briefTitle":6412,"status":534,"phases":6454,"primaryCompletion":2827,"completion":2641,"start":1782,"enrollment":6414,"conditions":6455,"interventions":6456},[89],[3256,6416,6417],[6402,6419,6420],{"trials":6458,"activeCount":99},[],{"trials":6460,"activeCount":99},[],{"trials":6462,"activeCount":99},[],{"intervention":5172,"totalTrials":171,"cells":6464},{"EARLY_PHASE1":6465,"PHASE1":6467,"PHASE2":6469,"PHASE3":6475,"PHASE4":6477,"NA":6479},{"trials":6466,"activeCount":99},[],{"trials":6468,"activeCount":99},[],{"trials":6470,"activeCount":99},[6471],{"nctId":5163,"briefTitle":5164,"status":134,"phases":6472,"primaryCompletion":5166,"completion":5166,"start":5167,"enrollment":5168,"conditions":6473,"interventions":6474},[89],[5170],[5172,5173],{"trials":6476,"activeCount":99},[],{"trials":6478,"activeCount":99},[],{"trials":6480,"activeCount":99},[],{"intervention":6482,"totalTrials":171,"cells":6483},"Lenalidomide maintenance",{"EARLY_PHASE1":6484,"PHASE1":6486,"PHASE2":6488,"PHASE3":6499,"PHASE4":6501,"NA":6503},{"trials":6485,"activeCount":99},[],{"trials":6487,"activeCount":99},[],{"trials":6489,"activeCount":99},[6490],{"nctId":6491,"briefTitle":6492,"status":534,"phases":6493,"primaryCompletion":6494,"completion":66,"start":6495,"enrollment":6496,"conditions":6497,"interventions":6498},"NCT05497102","Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT",[89],"2024-05","2021-11-08",58,[5315],[6482],{"trials":6500,"activeCount":99},[],{"trials":6502,"activeCount":99},[],{"trials":6504,"activeCount":99},[],{"intervention":6506,"totalTrials":171,"cells":6507},"Romiplostim",{"EARLY_PHASE1":6508,"PHASE1":6510,"PHASE2":6512,"PHASE3":6521,"PHASE4":6523,"NA":6525},{"trials":6509,"activeCount":99},[],{"trials":6511,"activeCount":99},[],{"trials":6513,"activeCount":99},[6514],{"nctId":6515,"briefTitle":6516,"status":534,"phases":6517,"primaryCompletion":1098,"completion":1135,"start":1086,"enrollment":1440,"conditions":6518,"interventions":6520},"NCT02338414","An Observational Study to Evaluate the Efficacy of Biweekly Romiplostim in Adult Patients With ITP",[89],[6519],"Immune Thrombocytopenia",[6506],{"trials":6522,"activeCount":99},[],{"trials":6524,"activeCount":99},[],{"trials":6526,"activeCount":99},[],{"intervention":6528,"totalTrials":171,"cells":6529},"Gemcitabine+simvastatin",{"EARLY_PHASE1":6530,"PHASE1":6532,"PHASE2":6534,"PHASE3":6545,"PHASE4":6547,"NA":6549},{"trials":6531,"activeCount":99},[],{"trials":6533,"activeCount":99},[],{"trials":6535,"activeCount":99},[6536],{"nctId":6537,"briefTitle":6538,"status":134,"phases":6539,"primaryCompletion":1767,"completion":2149,"start":1931,"enrollment":6540,"conditions":6541,"interventions":6543},"NCT00944463","Trial of Simvastatin and Gemcitabine in Pancreatic Cancer Patients",[89],106,[6542],"Pancreatic Cancer",[6528,6544],"Gemcitabine+Placebo",{"trials":6546,"activeCount":99},[],{"trials":6548,"activeCount":99},[],{"trials":6550,"activeCount":99},[],{"intervention":6544,"totalTrials":171,"cells":6552},{"EARLY_PHASE1":6553,"PHASE1":6555,"PHASE2":6557,"PHASE3":6563,"PHASE4":6565,"NA":6567},{"trials":6554,"activeCount":99},[],{"trials":6556,"activeCount":99},[],{"trials":6558,"activeCount":99},[6559],{"nctId":6537,"briefTitle":6538,"status":134,"phases":6560,"primaryCompletion":1767,"completion":2149,"start":1931,"enrollment":6540,"conditions":6561,"interventions":6562},[89],[6542],[6528,6544],{"trials":6564,"activeCount":99},[],{"trials":6566,"activeCount":99},[],{"trials":6568,"activeCount":99},[],{"intervention":1106,"totalTrials":171,"cells":6570},{"EARLY_PHASE1":6571,"PHASE1":6573,"PHASE2":6575,"PHASE3":6581,"PHASE4":6583,"NA":6585},{"trials":6572,"activeCount":99},[],{"trials":6574,"activeCount":99},[],{"trials":6576,"activeCount":99},[6577],{"nctId":1093,"briefTitle":1094,"status":534,"phases":6578,"primaryCompletion":1096,"completion":1097,"start":1098,"enrollment":1099,"conditions":6579,"interventions":6580},[89],[1101,1102,1103,1104],[1041,1042,1019,1106,1107,1108,1109,1110,1111,1112,1113,1114,1115,1116,1117,1118,1119],{"trials":6582,"activeCount":99},[],{"trials":6584,"activeCount":99},[],{"trials":6586,"activeCount":99},[],{"intervention":1110,"totalTrials":171,"cells":6588},{"EARLY_PHASE1":6589,"PHASE1":6591,"PHASE2":6593,"PHASE3":6599,"PHASE4":6601,"NA":6603},{"trials":6590,"activeCount":99},[],{"trials":6592,"activeCount":99},[],{"trials":6594,"activeCount":99},[6595],{"nctId":1093,"briefTitle":1094,"status":534,"phases":6596,"primaryCompletion":1096,"completion":1097,"start":1098,"enrollment":1099,"conditions":6597,"interventions":6598},[89],[1101,1102,1103,1104],[1041,1042,1019,1106,1107,1108,1109,1110,1111,1112,1113,1114,1115,1116,1117,1118,1119],{"trials":6600,"activeCount":99},[],{"trials":6602,"activeCount":99},[],{"trials":6604,"activeCount":99},[],{"intervention":1112,"totalTrials":171,"cells":6606},{"EARLY_PHASE1":6607,"PHASE1":6609,"PHASE2":6611,"PHASE3":6617,"PHASE4":6619,"NA":6621},{"trials":6608,"activeCount":99},[],{"trials":6610,"activeCount":99},[],{"trials":6612,"activeCount":99},[6613],{"nctId":1093,"briefTitle":1094,"status":534,"phases":6614,"primaryCompletion":1096,"completion":1097,"start":1098,"enrollment":1099,"conditions":6615,"interventions":6616},[89],[1101,1102,1103,1104],[1041,1042,1019,1106,1107,1108,1109,1110,1111,1112,1113,1114,1115,1116,1117,1118,1119],{"trials":6618,"activeCount":99},[],{"trials":6620,"activeCount":99},[],{"trials":6622,"activeCount":99},[],{"intervention":1118,"totalTrials":171,"cells":6624},{"EARLY_PHASE1":6625,"PHASE1":6627,"PHASE2":6629,"PHASE3":6635,"PHASE4":6637,"NA":6639},{"trials":6626,"activeCount":99},[],{"trials":6628,"activeCount":99},[],{"trials":6630,"activeCount":99},[6631],{"nctId":1093,"briefTitle":1094,"status":534,"phases":6632,"primaryCompletion":1096,"completion":1097,"start":1098,"enrollment":1099,"conditions":6633,"interventions":6634},[89],[1101,1102,1103,1104],[1041,1042,1019,1106,1107,1108,1109,1110,1111,1112,1113,1114,1115,1116,1117,1118,1119],{"trials":6636,"activeCount":99},[],{"trials":6638,"activeCount":99},[],{"trials":6640,"activeCount":99},[],{"intervention":1119,"totalTrials":171,"cells":6642},{"EARLY_PHASE1":6643,"PHASE1":6645,"PHASE2":6647,"PHASE3":6653,"PHASE4":6655,"NA":6657},{"trials":6644,"activeCount":99},[],{"trials":6646,"activeCount":99},[],{"trials":6648,"activeCount":99},[6649],{"nctId":1093,"briefTitle":1094,"status":534,"phases":6650,"primaryCompletion":1096,"completion":1097,"start":1098,"enrollment":1099,"conditions":6651,"interventions":6652},[89],[1101,1102,1103,1104],[1041,1042,1019,1106,1107,1108,1109,1110,1111,1112,1113,1114,1115,1116,1117,1118,1119],{"trials":6654,"activeCount":99},[],{"trials":6656,"activeCount":99},[],{"trials":6658,"activeCount":99},[],{"intervention":6660,"totalTrials":171,"cells":6661},"Gemcitabine plus cisplatin",{"EARLY_PHASE1":6662,"PHASE1":6664,"PHASE2":6666,"PHASE3":6677,"PHASE4":6679,"NA":6681},{"trials":6663,"activeCount":99},[],{"trials":6665,"activeCount":99},[],{"trials":6667,"activeCount":99},[6668],{"nctId":6669,"briefTitle":6670,"status":534,"phases":6671,"primaryCompletion":1736,"start":6672,"enrollment":6673,"conditions":6674,"interventions":6675},"NCT01401192","Pemetrexed\u002FCisplatin Versus Gemcitabine\u002FCisplatin According to Thymidylate Synthase Expression",[89],"2011-07",304,[27],[6660,6676,6676,6660],"pemetrexed plus cisplatin",{"trials":6678,"activeCount":99},[],{"trials":6680,"activeCount":99},[],{"trials":6682,"activeCount":99},[],{"intervention":6676,"totalTrials":171,"cells":6684},{"EARLY_PHASE1":6685,"PHASE1":6687,"PHASE2":6689,"PHASE3":6695,"PHASE4":6697,"NA":6699},{"trials":6686,"activeCount":99},[],{"trials":6688,"activeCount":99},[],{"trials":6690,"activeCount":99},[6691],{"nctId":6669,"briefTitle":6670,"status":534,"phases":6692,"primaryCompletion":1736,"start":6672,"enrollment":6673,"conditions":6693,"interventions":6694},[89],[27],[6660,6676,6676,6660],{"trials":6696,"activeCount":99},[],{"trials":6698,"activeCount":99},[],{"trials":6700,"activeCount":99},[],{"intervention":3125,"totalTrials":171,"cells":6702},{"EARLY_PHASE1":6703,"PHASE1":6705,"PHASE2":6707,"PHASE3":6713,"PHASE4":6715,"NA":6717},{"trials":6704,"activeCount":99},[],{"trials":6706,"activeCount":99},[],{"trials":6708,"activeCount":99},[6709],{"nctId":3117,"briefTitle":3118,"status":134,"phases":6710,"primaryCompletion":3120,"completion":3120,"start":3121,"enrollment":3122,"conditions":6711,"interventions":6712},[89],[1650,1651],[3125,1241],{"trials":6714,"activeCount":99},[],{"trials":6716,"activeCount":99},[],{"trials":6718,"activeCount":99},[],{"intervention":6720,"totalTrials":171,"cells":6721},"Bortezomib, Lenalidomide, Dexamethasone",{"EARLY_PHASE1":6722,"PHASE1":6724,"PHASE2":6726,"PHASE3":6736,"PHASE4":6738,"NA":6740},{"trials":6723,"activeCount":99},[],{"trials":6725,"activeCount":99},[],{"trials":6727,"activeCount":99},[6728],{"nctId":6729,"briefTitle":6730,"status":534,"phases":6731,"primaryCompletion":6732,"completion":1667,"start":6733,"enrollment":1209,"conditions":6734,"interventions":6735},"NCT04277845","Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple Myeloma",[89],"2022-03-23","2020-08-06",[5315],[6720],{"trials":6737,"activeCount":99},[],{"trials":6739,"activeCount":99},[],{"trials":6741,"activeCount":99},[],{"intervention":6743,"totalTrials":171,"cells":6744},"Dacomitinib",{"EARLY_PHASE1":6745,"PHASE1":6747,"PHASE2":6749,"PHASE3":6761,"PHASE4":6763,"NA":6765},{"trials":6746,"activeCount":99},[],{"trials":6748,"activeCount":99},[],{"trials":6750,"activeCount":99},[6751],{"nctId":6752,"briefTitle":6753,"status":534,"phases":6754,"primaryCompletion":6755,"completion":6756,"start":6757,"enrollment":671,"conditions":6758,"interventions":6760},"NCT04675008","Central Nervous System(CNS) Efficacy of Dacomitinib",[89],"2022-09-01","2023-03-01","2020-12-07",[3385,6759],"Brain Metastases",[6743],{"trials":6762,"activeCount":99},[],{"trials":6764,"activeCount":99},[],{"trials":6766,"activeCount":99},[],{"intervention":6768,"totalTrials":171,"cells":6769},"Ferinject®",{"EARLY_PHASE1":6770,"PHASE1":6772,"PHASE2":6774,"PHASE3":6785,"PHASE4":6787,"NA":6789},{"trials":6771,"activeCount":99},[],{"trials":6773,"activeCount":99},[],{"trials":6775,"activeCount":99},[6776],{"nctId":6777,"briefTitle":6778,"status":534,"phases":6779,"primaryCompletion":1960,"completion":1049,"start":6780,"enrollment":1933,"conditions":6781,"interventions":6784},"NCT02599012","The Efficacy of Intravenous Iron for the Treatment of Anemia in Cancer Patients",[89],"2015-09-12",[6782,6783],"Cancer","Anemia",[6768],{"trials":6786,"activeCount":99},[],{"trials":6788,"activeCount":99},[],{"trials":6790,"activeCount":99},[],{"intervention":6792,"totalTrials":171,"cells":6793},"MG4101",{"EARLY_PHASE1":6794,"PHASE1":6796,"PHASE2":6798,"PHASE3":6806,"PHASE4":6808,"NA":6810},{"trials":6795,"activeCount":99},[],{"trials":6797,"activeCount":99},[],{"trials":6799,"activeCount":99},[6800],{"nctId":6801,"briefTitle":6802,"status":134,"phases":6803,"primaryCompletion":2268,"completion":2268,"start":4254,"enrollment":4442,"conditions":6804,"interventions":6805},"NCT02008929","to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell)",[89],[30],[6792],{"trials":6807,"activeCount":99},[],{"trials":6809,"activeCount":99},[],{"trials":6811,"activeCount":99},[],{"intervention":6813,"totalTrials":171,"cells":6814},"Capecitabine plus cisplatin",{"EARLY_PHASE1":6815,"PHASE1":6817,"PHASE2":6819,"PHASE3":6830,"PHASE4":6832,"NA":6834},{"trials":6816,"activeCount":99},[],{"trials":6818,"activeCount":99},[],{"trials":6820,"activeCount":99},[6821],{"nctId":6822,"briefTitle":6823,"status":534,"phases":6824,"primaryCompletion":1960,"completion":1750,"start":1931,"enrollment":6825,"conditions":6826,"interventions":6829},"NCT00816634","Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma",[89],94,[6827,6828,5775],"First Line Chemotherapy","Capecitabine Plus Cisplatin Versus Capecitabine Plus Paclitaxel",[6813],{"trials":6831,"activeCount":99},[],{"trials":6833,"activeCount":99},[],{"trials":6835,"activeCount":99},[],{"intervention":6837,"totalTrials":171,"cells":6838},"Salvage reinduction chemotherapy including Gemtuzumab ozogamicin, Idarubicin and Cytarabine and Vorinostat",{"EARLY_PHASE1":6839,"PHASE1":6841,"PHASE2":6843,"PHASE3":6851,"PHASE4":6853,"NA":6855},{"trials":6840,"activeCount":99},[],{"trials":6842,"activeCount":99},[],{"trials":6844,"activeCount":99},[6845],{"nctId":6846,"briefTitle":6847,"status":534,"phases":6848,"enrollment":1062,"conditions":6849,"interventions":6850},"NCT01039363","Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia",[89],[5957],[6837],{"trials":6852,"activeCount":99},[],{"trials":6854,"activeCount":99},[],{"trials":6856,"activeCount":99},[],{"intervention":6858,"totalTrials":171,"cells":6859},"Pazopanib in combination with capecitabine and oxaliplatin",{"EARLY_PHASE1":6860,"PHASE1":6862,"PHASE2":6864,"PHASE3":6872,"PHASE4":6874,"NA":6876},{"trials":6861,"activeCount":99},[],{"trials":6863,"activeCount":99},[],{"trials":6865,"activeCount":99},[6866],{"nctId":6867,"briefTitle":6868,"status":134,"phases":6869,"primaryCompletion":1737,"completion":1098,"start":1782,"enrollment":4708,"conditions":6870,"interventions":6871},"NCT01130805","A Study of Pazopanib With CAPEOX in AGC Patients",[89],[24],[6858],{"trials":6873,"activeCount":99},[],{"trials":6875,"activeCount":99},[],{"trials":6877,"activeCount":99},[],{"intervention":6879,"totalTrials":171,"cells":6880},"Volitinib",{"EARLY_PHASE1":6881,"PHASE1":6883,"PHASE2":6885,"PHASE3":6896,"PHASE4":6898,"NA":6900},{"trials":6882,"activeCount":99},[],{"trials":6884,"activeCount":99},[],{"trials":6886,"activeCount":99},[6887],{"nctId":6888,"briefTitle":6889,"status":134,"phases":6890,"primaryCompletion":6891,"completion":6892,"start":6893,"enrollment":4932,"conditions":6894,"interventions":6895},"NCT02449551","Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment",[89],"2020-12-30","2021-08-27","2016-02-10",[3133],[6879],{"trials":6897,"activeCount":99},[],{"trials":6899,"activeCount":99},[],{"trials":6901,"activeCount":99},[],{"intervention":6903,"totalTrials":171,"cells":6904},"Amlodipine-losartan",{"EARLY_PHASE1":6905,"PHASE1":6907,"PHASE2":6909,"PHASE3":6920,"PHASE4":6922,"NA":6924},{"trials":6906,"activeCount":99},[],{"trials":6908,"activeCount":99},[],{"trials":6910,"activeCount":99},[6911],{"nctId":6912,"briefTitle":6913,"status":534,"phases":6914,"primaryCompletion":1097,"completion":5105,"start":6915,"enrollment":1933,"conditions":6916,"interventions":6918},"NCT05212597","Open Label RCT for Chronic Severe AR : Entresto vs. CCB\u002FARB",[89],"2022-01-12",[6917],"Aortic Valve Insufficiency",[6919,6903],"Sacubitril-valsartan",{"trials":6921,"activeCount":99},[],{"trials":6923,"activeCount":99},[],{"trials":6925,"activeCount":99},[],{"intervention":6927,"totalTrials":171,"cells":6928},"Amikacin",{"EARLY_PHASE1":6929,"PHASE1":6931,"PHASE2":6933,"PHASE3":6942,"PHASE4":6944,"NA":6946},{"trials":6930,"activeCount":99},[],{"trials":6932,"activeCount":99},[],{"trials":6934,"activeCount":99},[6935],{"nctId":6936,"briefTitle":6937,"status":185,"phases":6938,"primaryCompletion":1098,"completion":4830,"start":2828,"enrollment":99,"conditions":6939,"interventions":6941},"NCT01528930","Inhaled Amikacin Treatment for Nontuberculous Mycobacterial Lung Disease",[89],[6940],"Pulmonary Non-tuberculous Mycobacterial Lung Disease",[6927],{"trials":6943,"activeCount":99},[],{"trials":6945,"activeCount":99},[],{"trials":6947,"activeCount":99},[],{"intervention":6949,"totalTrials":171,"cells":6950},"salvage iressa",{"EARLY_PHASE1":6951,"PHASE1":6953,"PHASE2":6955,"PHASE3":6966,"PHASE4":6968,"NA":6970},{"trials":6952,"activeCount":99},[],{"trials":6954,"activeCount":99},[],{"trials":6956,"activeCount":99},[6957],{"nctId":6958,"briefTitle":6959,"status":534,"phases":6960,"primaryCompletion":6961,"start":1274,"enrollment":6962,"conditions":6963,"interventions":6965},"NCT01312337","Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)",[89],"2012-08",92,[6964],"Nonsmall Cell Lung Cancer",[6949],{"trials":6967,"activeCount":99},[],{"trials":6969,"activeCount":99},[],{"trials":6971,"activeCount":99},[],{"intervention":6973,"totalTrials":171,"cells":6974},"Human umbilical cord blood-derived mesenchymal stem cells",{"EARLY_PHASE1":6975,"PHASE1":6977,"PHASE2":6979,"PHASE3":6991,"PHASE4":6993,"NA":6995},{"trials":6976,"activeCount":99},[],{"trials":6978,"activeCount":99},[],{"trials":6980,"activeCount":99},[6981],{"nctId":6982,"briefTitle":6983,"status":534,"phases":6984,"primaryCompletion":2759,"completion":2759,"start":1894,"enrollment":671,"conditions":6985,"interventions":6990},"NCT01549665","Umbilical Cord Blood-derived Mesenchymal Stem Cells for the Treatment of Steroid-refractory Acute or Chronic Graft-versus-host-disease",[88,89],[6986,6987,6988,6989],"Graft-Versus-Host Disease","GVHD","Allogeneic Hematopoietic Transplant","Disorder Related to Transplantation",[6973],{"trials":6992,"activeCount":99},[],{"trials":6994,"activeCount":99},[],{"trials":6996,"activeCount":99},[],{"intervention":6998,"totalTrials":171,"cells":6999},"Atorvastatin 10mg",{"EARLY_PHASE1":7000,"PHASE1":7002,"PHASE2":7004,"PHASE3":7016,"PHASE4":7018,"NA":7020},{"trials":7001,"activeCount":99},[],{"trials":7003,"activeCount":99},[],{"trials":7005,"activeCount":99},[7006],{"nctId":7007,"briefTitle":7008,"status":534,"phases":7009,"primaryCompletion":7010,"completion":940,"start":7011,"enrollment":1922,"conditions":7012,"interventions":7015},"NCT05483894","Atorvastatin Use and Portal Hypertension in Patients With Hepatitis B Virus-related Liver Cirrhosis: A Randomized Controlled Trial",[89],"2024-07-31","2022-08-01",[7013,7014],"Hepatitis B","Portal Hypertension",[6998],{"trials":7017,"activeCount":99},[],{"trials":7019,"activeCount":99},[],{"trials":7021,"activeCount":99},[],{"intervention":7023,"totalTrials":171,"cells":7024},"cetuximab\u002Firinotecan\u002Fsimvastatin",{"EARLY_PHASE1":7025,"PHASE1":7027,"PHASE2":7029,"PHASE3":7038,"PHASE4":7040,"NA":7042},{"trials":7026,"activeCount":99},[],{"trials":7028,"activeCount":99},[],{"trials":7030,"activeCount":99},[7031],{"nctId":7032,"briefTitle":7033,"status":134,"phases":7034,"primaryCompletion":2336,"completion":2759,"start":5449,"enrollment":7035,"conditions":7036,"interventions":7037},"NCT01281761","Simvastatin + Cetuximab\u002FIrinotecan in K-ras Mutant Colorectal Cancer (CRC)",[89],52,[3437],[7023],{"trials":7039,"activeCount":99},[],{"trials":7041,"activeCount":99},[],{"trials":7043,"activeCount":99},[],{"intervention":7045,"totalTrials":171,"cells":7046},"alfuzosin hydrochloride XL 10mg",{"EARLY_PHASE1":7047,"PHASE1":7049,"PHASE2":7051,"PHASE3":7061,"PHASE4":7063,"NA":7065},{"trials":7048,"activeCount":99},[],{"trials":7050,"activeCount":99},[],{"trials":7052,"activeCount":99},[7053],{"nctId":7054,"briefTitle":7055,"status":134,"phases":7056,"primaryCompletion":3464,"completion":1921,"start":1930,"enrollment":7057,"conditions":7058,"interventions":7060},"NCT00679315","Efficacy and Safety of Alfuzosin for the Treatment of Voiding Dysfunction in Female",[89],190,[7059],"Voiding Dysfunction",[7045],{"trials":7062,"activeCount":99},[],{"trials":7064,"activeCount":99},[],{"trials":7066,"activeCount":99},[],{"intervention":7068,"totalTrials":171,"cells":7069},"CHOP",{"EARLY_PHASE1":7070,"PHASE1":7072,"PHASE2":7074,"PHASE3":7087,"PHASE4":7089,"NA":7091},{"trials":7071,"activeCount":99},[],{"trials":7073,"activeCount":99},[],{"trials":7075,"activeCount":99},[7076],{"nctId":7077,"briefTitle":7078,"status":534,"phases":7079,"primaryCompletion":3910,"completion":7080,"start":7081,"enrollment":7082,"conditions":7083,"interventions":7085},"NCT02445404","Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL",[89],"2023-06-30","2015-09-23",134,[7084],"Peripheral T-cell Lymphoma",[7068,7086],"fractionated ICED",{"trials":7088,"activeCount":99},[],{"trials":7090,"activeCount":99},[],{"trials":7092,"activeCount":99},[],{"intervention":7086,"totalTrials":171,"cells":7094},{"EARLY_PHASE1":7095,"PHASE1":7097,"PHASE2":7099,"PHASE3":7105,"PHASE4":7107,"NA":7109},{"trials":7096,"activeCount":99},[],{"trials":7098,"activeCount":99},[],{"trials":7100,"activeCount":99},[7101],{"nctId":7077,"briefTitle":7078,"status":534,"phases":7102,"primaryCompletion":3910,"completion":7080,"start":7081,"enrollment":7082,"conditions":7103,"interventions":7104},[89],[7084],[7068,7086],{"trials":7106,"activeCount":99},[],{"trials":7108,"activeCount":99},[],{"trials":7110,"activeCount":99},[],{"intervention":7112,"totalTrials":171,"cells":7113},"Epirubicin",{"EARLY_PHASE1":7114,"PHASE1":7116,"PHASE2":7118,"PHASE3":7127,"PHASE4":7129,"NA":7131},{"trials":7115,"activeCount":99},[],{"trials":7117,"activeCount":99},[],{"trials":7119,"activeCount":99},[7120],{"nctId":7121,"briefTitle":7122,"status":134,"phases":7123,"primaryCompletion":3265,"completion":3265,"start":4229,"enrollment":5450,"conditions":7124,"interventions":7125},"NCT00743964","Phase II Study of Epirubicin, Cisplatin and Capecitabine (ECX) Versus Cisplatin and Capecitabine (CX) for Advanced Gastric Cancer (AGC)",[89],[1278],[7112,7126],"Cisplatin, capecitabine",{"trials":7128,"activeCount":99},[],{"trials":7130,"activeCount":99},[],{"trials":7132,"activeCount":99},[],{"intervention":7126,"totalTrials":171,"cells":7134},{"EARLY_PHASE1":7135,"PHASE1":7137,"PHASE2":7139,"PHASE3":7145,"PHASE4":7147,"NA":7149},{"trials":7136,"activeCount":99},[],{"trials":7138,"activeCount":99},[],{"trials":7140,"activeCount":99},[7141],{"nctId":7121,"briefTitle":7122,"status":134,"phases":7142,"primaryCompletion":3265,"completion":3265,"start":4229,"enrollment":5450,"conditions":7143,"interventions":7144},[89],[1278],[7112,7126],{"trials":7146,"activeCount":99},[],{"trials":7148,"activeCount":99},[],{"trials":7150,"activeCount":99},[],{"intervention":7152,"totalTrials":171,"cells":7153},"docetaxel plus selumetinib",{"EARLY_PHASE1":7154,"PHASE1":7156,"PHASE2":7158,"PHASE3":7168,"PHASE4":7170,"NA":7172},{"trials":7155,"activeCount":99},[],{"trials":7157,"activeCount":99},[],{"trials":7159,"activeCount":99},[7160],{"nctId":7161,"briefTitle":7162,"status":134,"phases":7163,"primaryCompletion":7164,"completion":7164,"start":7165,"enrollment":1157,"conditions":7166,"interventions":7167},"NCT02448290","Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low\u002FHigh MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy",[89],"2018-05-17","2014-11-12",[1650],[7152],{"trials":7169,"activeCount":99},[],{"trials":7171,"activeCount":99},[],{"trials":7173,"activeCount":99},[],{"intervention":7175,"totalTrials":171,"cells":7176},"Docetaxel, Cisplatin",{"EARLY_PHASE1":7177,"PHASE1":7179,"PHASE2":7181,"PHASE3":7191,"PHASE4":7193,"NA":7195},{"trials":7178,"activeCount":99},[],{"trials":7180,"activeCount":99},[],{"trials":7182,"activeCount":99},[7183],{"nctId":7184,"briefTitle":7185,"status":534,"phases":7186,"primaryCompletion":7187,"start":6345,"enrollment":11,"conditions":7188,"interventions":7190},"NCT01312311","Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer",[89],"2011-05",[7189],"Nasopharyngeal Cancer",[7175],{"trials":7192,"activeCount":99},[],{"trials":7194,"activeCount":99},[],{"trials":7196,"activeCount":99},[],{"intervention":7198,"totalTrials":171,"cells":7199},"TAHP and AHP",{"EARLY_PHASE1":7200,"PHASE1":7202,"PHASE2":7204,"PHASE3":7216,"PHASE4":7218,"NA":7220},{"trials":7201,"activeCount":99},[],{"trials":7203,"activeCount":99},[],{"trials":7205,"activeCount":99},[7206],{"nctId":7207,"briefTitle":7208,"status":534,"phases":7209,"primaryCompletion":7210,"completion":7210,"start":7211,"enrollment":3242,"conditions":7212,"interventions":7214},"NCT03881878","TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery",[88,89],"2022-10-31","2019-05-27",[7213],"HER2-positive Breast Cancer",[7198,7215],"TAHP plus AC and AHP",{"trials":7217,"activeCount":99},[],{"trials":7219,"activeCount":99},[],{"trials":7221,"activeCount":99},[],{"intervention":7215,"totalTrials":171,"cells":7223},{"EARLY_PHASE1":7224,"PHASE1":7226,"PHASE2":7228,"PHASE3":7234,"PHASE4":7236,"NA":7238},{"trials":7225,"activeCount":99},[],{"trials":7227,"activeCount":99},[],{"trials":7229,"activeCount":99},[7230],{"nctId":7207,"briefTitle":7208,"status":534,"phases":7231,"primaryCompletion":7210,"completion":7210,"start":7211,"enrollment":3242,"conditions":7232,"interventions":7233},[88,89],[7213],[7198,7215],{"trials":7235,"activeCount":99},[],{"trials":7237,"activeCount":99},[],{"trials":7239,"activeCount":99},[],{"intervention":7241,"totalTrials":171,"cells":7242},"refametinib",{"EARLY_PHASE1":7243,"PHASE1":7245,"PHASE2":7247,"PHASE3":7258,"PHASE4":7260,"NA":7262},{"trials":7244,"activeCount":99},[],{"trials":7246,"activeCount":99},[],{"trials":7248,"activeCount":99},[7249],{"nctId":7250,"briefTitle":7251,"status":134,"phases":7252,"primaryCompletion":7253,"completion":7254,"start":7255,"enrollment":544,"conditions":7256,"interventions":7257},"NCT02346032","Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma",[89],"2016-09-30","2016-10-13","2015-06-30",[3244],[7241],{"trials":7259,"activeCount":99},[],{"trials":7261,"activeCount":99},[],{"trials":7263,"activeCount":99},[],{"intervention":7265,"totalTrials":171,"cells":7266},"Poziotinib",{"EARLY_PHASE1":7267,"PHASE1":7269,"PHASE2":7271,"PHASE3":7279,"PHASE4":7281,"NA":7283},{"trials":7268,"activeCount":99},[],{"trials":7270,"activeCount":99},[],{"trials":7272,"activeCount":99},[7273],{"nctId":7274,"briefTitle":7275,"status":134,"phases":7276,"primaryCompletion":2101,"completion":2101,"start":5499,"enrollment":4442,"conditions":7277,"interventions":7278},"NCT02544997","A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway",[89],[3256],[7265],{"trials":7280,"activeCount":99},[],{"trials":7282,"activeCount":99},[],{"trials":7284,"activeCount":99},[],{"intervention":7286,"totalTrials":171,"cells":7287},"neoadjuvant docetaxel\u002Fcisplatin\u002Ffluorouracil",{"EARLY_PHASE1":7288,"PHASE1":7290,"PHASE2":7292,"PHASE3":7302,"PHASE4":7304,"NA":7306},{"trials":7289,"activeCount":99},[],{"trials":7291,"activeCount":99},[],{"trials":7293,"activeCount":99},[7294],{"nctId":7295,"briefTitle":7296,"status":134,"phases":7297,"primaryCompletion":5816,"completion":1750,"start":5449,"enrollment":645,"conditions":7298,"interventions":7300},"NCT01312350","Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)",[89],[7299],"Hypopharyngeal Cancer",[7286,7301],"No treatment before definitive CCRT",{"trials":7303,"activeCount":99},[],{"trials":7305,"activeCount":99},[],{"trials":7307,"activeCount":99},[],{"intervention":7301,"totalTrials":171,"cells":7309},{"EARLY_PHASE1":7310,"PHASE1":7312,"PHASE2":7314,"PHASE3":7320,"PHASE4":7322,"NA":7324},{"trials":7311,"activeCount":99},[],{"trials":7313,"activeCount":99},[],{"trials":7315,"activeCount":99},[7316],{"nctId":7295,"briefTitle":7296,"status":134,"phases":7317,"primaryCompletion":5816,"completion":1750,"start":5449,"enrollment":645,"conditions":7318,"interventions":7319},[89],[7299],[7286,7301],{"trials":7321,"activeCount":99},[],{"trials":7323,"activeCount":99},[],{"trials":7325,"activeCount":99},[],{"intervention":7327,"totalTrials":171,"cells":7328},"Concurrent Radiotherapy (RT)\u002Fcisplatin, VIPD",{"EARLY_PHASE1":7329,"PHASE1":7331,"PHASE2":7333,"PHASE3":7342,"PHASE4":7344,"NA":7346},{"trials":7330,"activeCount":99},[],{"trials":7332,"activeCount":99},[],{"trials":7334,"activeCount":99},[7335],{"nctId":7336,"briefTitle":7337,"status":134,"phases":7338,"primaryCompletion":3464,"completion":1784,"start":1932,"conditions":7339,"interventions":7341},"NCT00418535","Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)\u002FT-cell Lymphoma",[89],[7340],"Lymphoma, T-Cell",[7327],{"trials":7343,"activeCount":99},[],{"trials":7345,"activeCount":99},[],{"trials":7347,"activeCount":99},[],{"intervention":4679,"totalTrials":171,"cells":7349},{"EARLY_PHASE1":7350,"PHASE1":7352,"PHASE2":7354,"PHASE3":7360,"PHASE4":7362,"NA":7364},{"trials":7351,"activeCount":99},[],{"trials":7353,"activeCount":99},[],{"trials":7355,"activeCount":99},[7356],{"nctId":4671,"briefTitle":4672,"status":534,"phases":7357,"primaryCompletion":4674,"completion":4675,"start":4676,"enrollment":3021,"conditions":7358,"interventions":7359},[89],[3244],[4679,1113],{"trials":7361,"activeCount":99},[],{"trials":7363,"activeCount":99},[],{"trials":7365,"activeCount":99},[],{"intervention":7367,"totalTrials":171,"cells":7368},"Vismodegib 150 mg",{"EARLY_PHASE1":7369,"PHASE1":7371,"PHASE2":7373,"PHASE3":7384,"PHASE4":7386,"NA":7388},{"trials":7370,"activeCount":99},[],{"trials":7372,"activeCount":99},[],{"trials":7374,"activeCount":99},[7375],{"nctId":7376,"briefTitle":7377,"status":134,"phases":7378,"primaryCompletion":7379,"completion":7380,"start":7381,"enrollment":36,"conditions":7382,"interventions":7383},"NCT03052478","Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression",[89],"2019-12-31","2020-09-10","2017-02-10",[4710],[7367],{"trials":7385,"activeCount":99},[],{"trials":7387,"activeCount":99},[],{"trials":7389,"activeCount":99},[],{"intervention":3359,"totalTrials":171,"cells":7391},{"EARLY_PHASE1":7392,"PHASE1":7394,"PHASE2":7396,"PHASE3":7402,"PHASE4":7404,"NA":7406},{"trials":7393,"activeCount":99},[],{"trials":7395,"activeCount":99},[],{"trials":7397,"activeCount":99},[7398],{"nctId":3350,"briefTitle":3351,"status":134,"phases":7399,"primaryCompletion":3353,"completion":3354,"start":3355,"enrollment":19,"conditions":7400,"interventions":7401},[89],[3357],[1201,3359],{"trials":7403,"activeCount":99},[],{"trials":7405,"activeCount":99},[],{"trials":7407,"activeCount":99},[],{"intervention":7409,"totalTrials":171,"cells":7410},"Velcade",{"EARLY_PHASE1":7411,"PHASE1":7413,"PHASE2":7415,"PHASE3":7425,"PHASE4":7427,"NA":7429},{"trials":7412,"activeCount":99},[],{"trials":7414,"activeCount":99},[],{"trials":7416,"activeCount":99},[7417],{"nctId":7418,"briefTitle":7419,"status":134,"phases":7420,"primaryCompletion":4039,"completion":3265,"start":1932,"enrollment":214,"conditions":7421,"interventions":7424},"NCT00374699","Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)\u002FT Cell Lymphomas",[88,89],[7422,7423],"Peripheral T-Cell Lymphomas","Non-Hodgkin Lymphoma",[7409],{"trials":7426,"activeCount":99},[],{"trials":7428,"activeCount":99},[],{"trials":7430,"activeCount":99},[],{"intervention":7432,"totalTrials":171,"cells":7433},"RAD001",{"EARLY_PHASE1":7434,"PHASE1":7436,"PHASE2":7438,"PHASE3":7450,"PHASE4":7452,"NA":7454},{"trials":7435,"activeCount":99},[],{"trials":7437,"activeCount":99},[],{"trials":7439,"activeCount":99},[7440],{"nctId":7441,"briefTitle":7442,"status":134,"phases":7443,"primaryCompletion":2711,"completion":2711,"start":3995,"enrollment":1127,"conditions":7444,"interventions":7449},"NCT01198665","RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas",[88,89],[7445,7446,7447,7448],"Peripheral T Cell Lymphoma Unspecified","Anaplastic Large Cell Lymphoma, ALK-negative","Angioimmunoblastic T Cell Lymphoma","Cutaneous T Cell Lymphoma",[7432],{"trials":7451,"activeCount":99},[],{"trials":7453,"activeCount":99},[],{"trials":7455,"activeCount":99},[],{"intervention":7457,"totalTrials":171,"cells":7458},"CCRT with weekly docetaxel & cisplatin",{"EARLY_PHASE1":7459,"PHASE1":7461,"PHASE2":7463,"PHASE3":7474,"PHASE4":7476,"NA":7478},{"trials":7460,"activeCount":99},[],{"trials":7462,"activeCount":99},[],{"trials":7464,"activeCount":99},[7465],{"nctId":7466,"briefTitle":7467,"status":134,"phases":7468,"primaryCompletion":7469,"completion":7469,"start":7470,"enrollment":3021,"conditions":7471,"interventions":7473},"NCT01126008","Concomitant Chemoradiotherapy (CCRT) With Weekly Docetaxel and Cisplatin for Locally Advanced Head and Neck Cancer",[89],"2016-04-15","2009-11-16",[7472],"Head and Neck Cancer",[7457],{"trials":7475,"activeCount":99},[],{"trials":7477,"activeCount":99},[],{"trials":7479,"activeCount":99},[],{"intervention":7481,"totalTrials":171,"cells":7482},"Pegteograstim",{"EARLY_PHASE1":7483,"PHASE1":7485,"PHASE2":7487,"PHASE3":7499,"PHASE4":7501,"NA":7503},{"trials":7484,"activeCount":99},[],{"trials":7486,"activeCount":99},[],{"trials":7488,"activeCount":99},[7489],{"nctId":7490,"briefTitle":7491,"status":534,"phases":7492,"primaryCompletion":1126,"completion":7493,"start":7494,"enrollment":839,"conditions":7495,"interventions":7498},"NCT02787876","Pegteograstim in Children With Solid Tumors",[89],"2018-11","2016-10-04",[7496,7497],"Chemotherapy Induced Neutropenia","Pediatric Solid Tumor",[7481],{"trials":7500,"activeCount":99},[],{"trials":7502,"activeCount":99},[],{"trials":7504,"activeCount":99},[],{"intervention":1140,"totalTrials":171,"cells":7506},{"EARLY_PHASE1":7507,"PHASE1":7509,"PHASE2":7511,"PHASE3":7517,"PHASE4":7519,"NA":7521},{"trials":7508,"activeCount":99},[],{"trials":7510,"activeCount":99},[],{"trials":7512,"activeCount":99},[7513],{"nctId":1131,"briefTitle":1132,"status":534,"phases":7514,"primaryCompletion":1134,"start":1135,"enrollment":1136,"conditions":7515,"interventions":7516},[89],[1138],[1107,1140,1141,1019],{"trials":7518,"activeCount":99},[],{"trials":7520,"activeCount":99},[],{"trials":7522,"activeCount":99},[],{"intervention":1141,"totalTrials":171,"cells":7524},{"EARLY_PHASE1":7525,"PHASE1":7527,"PHASE2":7529,"PHASE3":7535,"PHASE4":7537,"NA":7539},{"trials":7526,"activeCount":99},[],{"trials":7528,"activeCount":99},[],{"trials":7530,"activeCount":99},[7531],{"nctId":1131,"briefTitle":1132,"status":534,"phases":7532,"primaryCompletion":1134,"start":1135,"enrollment":1136,"conditions":7533,"interventions":7534},[89],[1138],[1107,1140,1141,1019],{"trials":7536,"activeCount":99},[],{"trials":7538,"activeCount":99},[],{"trials":7540,"activeCount":99},[],{"intervention":7542,"totalTrials":171,"cells":7543},"Bortezomib",{"EARLY_PHASE1":7544,"PHASE1":7546,"PHASE2":7548,"PHASE3":7559,"PHASE4":7561,"NA":7563},{"trials":7545,"activeCount":99},[],{"trials":7547,"activeCount":99},[],{"trials":7549,"activeCount":99},[7550],{"nctId":7551,"briefTitle":7552,"status":534,"phases":7553,"primaryCompletion":7554,"completion":7555,"start":7556,"enrollment":887,"conditions":7557,"interventions":7558},"NCT01965977","Bortezomib Maintenance in High Risk DLBCL",[89],"2018-10-30","2021-10-30","2015-04-08",[749],[7542],{"trials":7560,"activeCount":99},[],{"trials":7562,"activeCount":99},[],{"trials":7564,"activeCount":99},[],{"intervention":7566,"totalTrials":171,"cells":7567},"Gilotrif",{"EARLY_PHASE1":7568,"PHASE1":7570,"PHASE2":7572,"PHASE3":7581,"PHASE4":7583,"NA":7585},{"trials":7569,"activeCount":99},[],{"trials":7571,"activeCount":99},[],{"trials":7573,"activeCount":99},[7574],{"nctId":7575,"briefTitle":7576,"status":134,"phases":7577,"primaryCompletion":2711,"completion":7578,"start":6672,"enrollment":1717,"conditions":7579,"interventions":7580},"NCT02747953","Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib",[89],"2016-11",[27],[7566],{"trials":7582,"activeCount":99},[],{"trials":7584,"activeCount":99},[],{"trials":7586,"activeCount":99},[],{"intervention":7588,"totalTrials":171,"cells":7589},"Pemetrexed, Carboplatin, Pembrolizumab",{"EARLY_PHASE1":7590,"PHASE1":7592,"PHASE2":7594,"PHASE3":7605,"PHASE4":7607,"NA":7609},{"trials":7591,"activeCount":99},[],{"trials":7593,"activeCount":99},[],{"trials":7595,"activeCount":99},[7596],{"nctId":7597,"briefTitle":7598,"status":134,"phases":7599,"primaryCompletion":957,"completion":7600,"start":7601,"enrollment":28,"conditions":7602,"interventions":7603},"NCT04967417","Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain Metastases",[89],"2024-12-02","2022-05-26",[27],[7588,7604],"Paclitaxel, Carboplatin, Pembrolizumab",{"trials":7606,"activeCount":99},[],{"trials":7608,"activeCount":99},[],{"trials":7610,"activeCount":99},[],{"intervention":7604,"totalTrials":171,"cells":7612},{"EARLY_PHASE1":7613,"PHASE1":7615,"PHASE2":7617,"PHASE3":7623,"PHASE4":7625,"NA":7627},{"trials":7614,"activeCount":99},[],{"trials":7616,"activeCount":99},[],{"trials":7618,"activeCount":99},[7619],{"nctId":7597,"briefTitle":7598,"status":134,"phases":7620,"primaryCompletion":957,"completion":7600,"start":7601,"enrollment":28,"conditions":7621,"interventions":7622},[89],[27],[7588,7604],{"trials":7624,"activeCount":99},[],{"trials":7626,"activeCount":99},[],{"trials":7628,"activeCount":99},[],{"intervention":7630,"totalTrials":171,"cells":7631},"pembrolizumab plus ramucirumab",{"EARLY_PHASE1":7632,"PHASE1":7634,"PHASE2":7636,"PHASE3":7646,"PHASE4":7648,"NA":7650},{"trials":7633,"activeCount":99},[],{"trials":7635,"activeCount":99},[],{"trials":7637,"activeCount":99},[7638],{"nctId":7639,"briefTitle":7640,"status":534,"phases":7641,"primaryCompletion":4611,"completion":4611,"start":7642,"enrollment":7643,"conditions":7644,"interventions":7645},"NCT04632459","Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer",[89],"2021-06-16",35,[24],[7630],{"trials":7647,"activeCount":99},[],{"trials":7649,"activeCount":99},[],{"trials":7651,"activeCount":99},[],{"intervention":4427,"totalTrials":171,"cells":7653},{"EARLY_PHASE1":7654,"PHASE1":7656,"PHASE2":7658,"PHASE3":7664,"PHASE4":7666,"NA":7668},{"trials":7655,"activeCount":99},[],{"trials":7657,"activeCount":99},[],{"trials":7659,"activeCount":99},[7660],{"nctId":4418,"briefTitle":4419,"status":134,"phases":7661,"primaryCompletion":4421,"completion":4422,"start":4423,"enrollment":22,"conditions":7662,"interventions":7663},[89],[4425],[4427,4428,1040,1039,4429,4430],{"trials":7665,"activeCount":99},[],{"trials":7667,"activeCount":99},[],{"trials":7669,"activeCount":99},[],{"intervention":4429,"totalTrials":171,"cells":7671},{"EARLY_PHASE1":7672,"PHASE1":7674,"PHASE2":7676,"PHASE3":7682,"PHASE4":7684,"NA":7686},{"trials":7673,"activeCount":99},[],{"trials":7675,"activeCount":99},[],{"trials":7677,"activeCount":99},[7678],{"nctId":4418,"briefTitle":4419,"status":134,"phases":7679,"primaryCompletion":4421,"completion":4422,"start":4423,"enrollment":22,"conditions":7680,"interventions":7681},[89],[4425],[4427,4428,1040,1039,4429,4430],{"trials":7683,"activeCount":99},[],{"trials":7685,"activeCount":99},[],{"trials":7687,"activeCount":99},[],{"intervention":4430,"totalTrials":171,"cells":7689},{"EARLY_PHASE1":7690,"PHASE1":7692,"PHASE2":7694,"PHASE3":7700,"PHASE4":7702,"NA":7704},{"trials":7691,"activeCount":99},[],{"trials":7693,"activeCount":99},[],{"trials":7695,"activeCount":99},[7696],{"nctId":4418,"briefTitle":4419,"status":134,"phases":7697,"primaryCompletion":4421,"completion":4422,"start":4423,"enrollment":22,"conditions":7698,"interventions":7699},[89],[4425],[4427,4428,1040,1039,4429,4430],{"trials":7701,"activeCount":99},[],{"trials":7703,"activeCount":99},[],{"trials":7705,"activeCount":99},[],{"intervention":7707,"totalTrials":171,"cells":7708},"nanoxel",{"EARLY_PHASE1":7709,"PHASE1":7711,"PHASE2":7713,"PHASE3":7726,"PHASE4":7728,"NA":7730},{"trials":7710,"activeCount":99},[],{"trials":7712,"activeCount":99},[],{"trials":7714,"activeCount":99},[7715],{"nctId":7716,"briefTitle":7717,"status":534,"phases":7718,"primaryCompletion":7719,"completion":7720,"start":7721,"enrollment":1034,"conditions":7722,"interventions":7724},"NCT03614364","Combination of Nanoxel and Herzuma in Salivary Duct Carcinoma",[89],"2022-09","2023-08","2018-09-20",[7723],"Salivary Duct Carcinoma",[7707,7725],"herzuma",{"trials":7727,"activeCount":99},[],{"trials":7729,"activeCount":99},[],{"trials":7731,"activeCount":99},[],{"intervention":7725,"totalTrials":171,"cells":7733},{"EARLY_PHASE1":7734,"PHASE1":7736,"PHASE2":7738,"PHASE3":7744,"PHASE4":7746,"NA":7748},{"trials":7735,"activeCount":99},[],{"trials":7737,"activeCount":99},[],{"trials":7739,"activeCount":99},[7740],{"nctId":7716,"briefTitle":7717,"status":534,"phases":7741,"primaryCompletion":7719,"completion":7720,"start":7721,"enrollment":1034,"conditions":7742,"interventions":7743},[89],[7723],[7707,7725],{"trials":7745,"activeCount":99},[],{"trials":7747,"activeCount":99},[],{"trials":7749,"activeCount":99},[],{"intervention":7751,"totalTrials":171,"cells":7752},"FOLFOX6\u002Fcetuximab",{"EARLY_PHASE1":7753,"PHASE1":7755,"PHASE2":7757,"PHASE3":7767,"PHASE4":7769,"NA":7771},{"trials":7754,"activeCount":99},[],{"trials":7756,"activeCount":99},[],{"trials":7758,"activeCount":99},[7759],{"nctId":7760,"briefTitle":7761,"status":134,"phases":7762,"primaryCompletion":1894,"completion":1222,"start":1930,"enrollment":7763,"conditions":7764,"interventions":7766},"NCT00743678","Neoadjuvant FOLFOX6 + Cetuximab in Patients With Colorectal Cancer and Unresectable Liver Metastasis",[89],73,[3186,7765],"Unresectable Liver Metastasis",[7751],{"trials":7768,"activeCount":99},[],{"trials":7770,"activeCount":99},[],{"trials":7772,"activeCount":99},[],{"intervention":7774,"totalTrials":171,"cells":7775},"afatinib",{"EARLY_PHASE1":7776,"PHASE1":7778,"PHASE2":7780,"PHASE3":7790,"PHASE4":7792,"NA":7794},{"trials":7777,"activeCount":99},[],{"trials":7779,"activeCount":99},[],{"trials":7781,"activeCount":99},[7782],{"nctId":7783,"briefTitle":7784,"status":534,"phases":7785,"primaryCompletion":3532,"completion":1033,"start":7786,"enrollment":1717,"conditions":7787,"interventions":7789},"NCT01861223","Afatinib Plus Nimotuzumb for NSCLC",[88,89],"2013-05",[7788],"NSCLC",[7774],{"trials":7791,"activeCount":99},[],{"trials":7793,"activeCount":99},[],{"trials":7795,"activeCount":99},[],{"intervention":7797,"totalTrials":171,"cells":7798},"Aprepitant\u002FRamosetron\u002FDexamethasone",{"EARLY_PHASE1":7799,"PHASE1":7801,"PHASE2":7803,"PHASE3":7814,"PHASE4":7816,"NA":7818},{"trials":7800,"activeCount":99},[],{"trials":7802,"activeCount":99},[],{"trials":7804,"activeCount":99},[7805],{"nctId":7806,"briefTitle":7807,"status":134,"phases":7808,"primaryCompletion":1783,"completion":5839,"start":6344,"enrollment":7809,"conditions":7810,"interventions":7813},"NCT01012336","Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane\u002FCarboplatin",[89],89,[7811,7812],"Chemotherapy-Induced Nausea and Vomiting","Ovarian Cancer",[7797],{"trials":7815,"activeCount":99},[],{"trials":7817,"activeCount":99},[],{"trials":7819,"activeCount":99},[],{"intervention":7821,"totalTrials":171,"cells":7822},"chemotherapy only",{"EARLY_PHASE1":7823,"PHASE1":7825,"PHASE2":7827,"PHASE3":7837,"PHASE4":7839,"NA":7841},{"trials":7824,"activeCount":99},[],{"trials":7826,"activeCount":99},[],{"trials":7828,"activeCount":99},[7829],{"nctId":7830,"briefTitle":7831,"status":134,"phases":7832,"primaryCompletion":7833,"completion":7833,"start":7834,"enrollment":5428,"conditions":7835,"interventions":7836},"NCT01066234","Adjuvant CCRT vs CT in Minimal N2 NSCLC",[89],"2021-01-18","2017-10-23",[27],[7821],{"trials":7838,"activeCount":99},[],{"trials":7840,"activeCount":99},[],{"trials":7842,"activeCount":99},[],{"intervention":7844,"totalTrials":171,"cells":7845},"Brentuximab vedotin",{"EARLY_PHASE1":7846,"PHASE1":7848,"PHASE2":7850,"PHASE3":7859,"PHASE4":7861,"NA":7863},{"trials":7847,"activeCount":99},[],{"trials":7849,"activeCount":99},[],{"trials":7851,"activeCount":99},[7852],{"nctId":7853,"briefTitle":7854,"status":134,"phases":7855,"primaryCompletion":1049,"completion":5546,"start":7856,"enrollment":1688,"conditions":7857,"interventions":7858},"NCT02280785","Brentuximab Vedotin for Relapsed\u002FRefractory CD30-positive Non-Hodgkin Lymphomas",[89],"2014-11",[7423],[7844],{"trials":7860,"activeCount":99},[],{"trials":7862,"activeCount":99},[],{"trials":7864,"activeCount":99},[],{"intervention":7866,"totalTrials":171,"cells":7867},"MTX, MVD, VIA",{"EARLY_PHASE1":7868,"PHASE1":7870,"PHASE2":7872,"PHASE3":7881,"PHASE4":7883,"NA":7885},{"trials":7869,"activeCount":99},[],{"trials":7871,"activeCount":99},[],{"trials":7873,"activeCount":99},[7874],{"nctId":7875,"briefTitle":7876,"status":134,"phases":7877,"primaryCompletion":1984,"completion":1984,"start":4301,"enrollment":1922,"conditions":7878,"interventions":7880},"NCT01083342","High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study",[89],[7879],"CNS Lymphoma",[7866],{"trials":7882,"activeCount":99},[],{"trials":7884,"activeCount":99},[],{"trials":7886,"activeCount":99},[],{"intervention":7888,"totalTrials":171,"cells":7889},"Pembrolizumab plus chemotherapy",{"EARLY_PHASE1":7890,"PHASE1":7892,"PHASE2":7894,"PHASE3":7907,"PHASE4":7909,"NA":7911},{"trials":7891,"activeCount":99},[],{"trials":7893,"activeCount":99},[],{"trials":7895,"activeCount":99},[7896],{"nctId":7897,"briefTitle":7898,"status":534,"phases":7899,"primaryCompletion":7900,"completion":7901,"start":7902,"enrollment":7903,"conditions":7904,"interventions":7906},"NCT03656094","Chemotherapy With Pembrolizumab Continuation After Progression to PD-1\u002FL1 Inhibitors",[89],"2020-11-01","2021-11-01","2018-11-01",98,[7905],"Non-small Cell Lung Cancer Metastatic",[7888],{"trials":7908,"activeCount":99},[],{"trials":7910,"activeCount":99},[],{"trials":7912,"activeCount":99},[],{"intervention":7914,"totalTrials":171,"cells":7915},"80mg Osimertinib",{"EARLY_PHASE1":7916,"PHASE1":7918,"PHASE2":7920,"PHASE3":7929,"PHASE4":7931,"NA":7933},{"trials":7917,"activeCount":99},[],{"trials":7919,"activeCount":99},[],{"trials":7921,"activeCount":99},[7922],{"nctId":7923,"briefTitle":7924,"status":134,"phases":7925,"primaryCompletion":582,"completion":582,"start":7926,"enrollment":7763,"conditions":7927,"interventions":7928},"NCT04563871","Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)",[89],"2020-11-17",[1421],[7914],{"trials":7930,"activeCount":99},[],{"trials":7932,"activeCount":99},[],{"trials":7934,"activeCount":99},[],{"intervention":7936,"totalTrials":171,"cells":7937},"BIBF1120",{"EARLY_PHASE1":7938,"PHASE1":7940,"PHASE2":7942,"PHASE3":7952,"PHASE4":7954,"NA":7956},{"trials":7939,"activeCount":99},[],{"trials":7941,"activeCount":99},[],{"trials":7943,"activeCount":99},[7944],{"nctId":7945,"briefTitle":7946,"status":534,"phases":7947,"primaryCompletion":7948,"completion":3598,"start":7856,"enrollment":1440,"conditions":7949,"interventions":7951},"NCT02558387","Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck",[89],"2016-07",[7950],"Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck",[7936],{"trials":7953,"activeCount":99},[],{"trials":7955,"activeCount":99},[],{"trials":7957,"activeCount":99},[],{"intervention":7959,"totalTrials":171,"cells":7960},"Oxaliplatin, S-1, radiotherapy",{"EARLY_PHASE1":7961,"PHASE1":7963,"PHASE2":7965,"PHASE3":7975,"PHASE4":7977,"NA":7979},{"trials":7962,"activeCount":99},[],{"trials":7964,"activeCount":99},[],{"trials":7966,"activeCount":99},[7967],{"nctId":7968,"briefTitle":7969,"status":1816,"phases":7970,"primaryCompletion":6085,"completion":6085,"start":3464,"enrollment":671,"conditions":7971,"interventions":7974},"NCT01106066","Phase I\u002FII Study of Neoadjuvant Chemoradiotherapy With S-1\u002F Oxaliplatin in Patients With Gastric Cancer: Randomized Phase II Study of S-1\u002FRT vs. S-1\u002FOxaliplatin\u002FRT",[88,89],[7972,7973],"Phase I: To Determine the Maximum Tolerated Dose (MTD)","Phase II: To Assess the Pathologic CR Rate and Feasibility Following Neoadjuvant Chemoradiation Therapy With S1\u002FOxaliplatin",[7959],{"trials":7976,"activeCount":99},[],{"trials":7978,"activeCount":99},[],{"trials":7980,"activeCount":99},[],{"intervention":7982,"totalTrials":171,"cells":7983},"irinotecan",{"EARLY_PHASE1":7984,"PHASE1":7986,"PHASE2":7995,"PHASE3":7997,"PHASE4":7999,"NA":8001},{"trials":7985,"activeCount":99},[],{"trials":7987,"activeCount":99},[7988],{"nctId":7989,"briefTitle":7990,"status":134,"phases":7991,"primaryCompletion":7992,"completion":2433,"start":4231,"enrollment":5428,"conditions":7993,"interventions":7994},"NCT00539877","Phase I Study of Interperitoneal Chenotherapy in Patients With Gastric Adenocarainoma With Peritoneal Seeding",[88],"2006-12",[4710],[7982],{"trials":7996,"activeCount":99},[],{"trials":7998,"activeCount":99},[],{"trials":8000,"activeCount":99},[],{"trials":8002,"activeCount":99},[],{"intervention":8004,"totalTrials":171,"cells":8005},"Endoscopic ultrasonography-guided double ethanol lavage",{"EARLY_PHASE1":8006,"PHASE1":8008,"PHASE2":8017,"PHASE3":8019,"PHASE4":8021,"NA":8023},{"trials":8007,"activeCount":99},[],{"trials":8009,"activeCount":99},[8010],{"nctId":8011,"briefTitle":8012,"status":534,"phases":8013,"primaryCompletion":4831,"completion":4831,"start":613,"enrollment":645,"conditions":8014,"interventions":8016},"NCT02213419","Endoscopic Ultrasonography-guided Double Ethanol Lavage for Pancreatic Cysts: a Prospective Cohort Study",[88],[8015],"Pancreatic Mucinous-Cystic Neoplasm",[8004],{"trials":8018,"activeCount":99},[],{"trials":8020,"activeCount":99},[],{"trials":8022,"activeCount":99},[],{"trials":8024,"activeCount":99},[],{"intervention":8026,"totalTrials":171,"cells":8027},"Sitagliptin",{"EARLY_PHASE1":8028,"PHASE1":8030,"PHASE2":8040,"PHASE3":8042,"PHASE4":8044,"NA":8046},{"trials":8029,"activeCount":99},[],{"trials":8031,"activeCount":99},[8032],{"nctId":8033,"briefTitle":8034,"status":134,"phases":8035,"primaryCompletion":4230,"completion":4230,"start":6344,"enrollment":3131,"conditions":8036,"interventions":8037},"NCT01422590","Pharmacodynamics of Mitiglinide\u002FSitagliptin Compared to Mitiglinide and Sitagliptin",[88],[1987],[8026,8038,8039],"Mitiglinide","Sitagliptin, Mitiglinide",{"trials":8041,"activeCount":99},[],{"trials":8043,"activeCount":99},[],{"trials":8045,"activeCount":99},[],{"trials":8047,"activeCount":99},[],{"intervention":8038,"totalTrials":171,"cells":8049},{"EARLY_PHASE1":8050,"PHASE1":8052,"PHASE2":8058,"PHASE3":8060,"PHASE4":8062,"NA":8064},{"trials":8051,"activeCount":99},[],{"trials":8053,"activeCount":99},[8054],{"nctId":8033,"briefTitle":8034,"status":134,"phases":8055,"primaryCompletion":4230,"completion":4230,"start":6344,"enrollment":3131,"conditions":8056,"interventions":8057},[88],[1987],[8026,8038,8039],{"trials":8059,"activeCount":99},[],{"trials":8061,"activeCount":99},[],{"trials":8063,"activeCount":99},[],{"trials":8065,"activeCount":99},[],{"intervention":8039,"totalTrials":171,"cells":8067},{"EARLY_PHASE1":8068,"PHASE1":8070,"PHASE2":8076,"PHASE3":8078,"PHASE4":8080,"NA":8082},{"trials":8069,"activeCount":99},[],{"trials":8071,"activeCount":99},[8072],{"nctId":8033,"briefTitle":8034,"status":134,"phases":8073,"primaryCompletion":4230,"completion":4230,"start":6344,"enrollment":3131,"conditions":8074,"interventions":8075},[88],[1987],[8026,8038,8039],{"trials":8077,"activeCount":99},[],{"trials":8079,"activeCount":99},[],{"trials":8081,"activeCount":99},[],{"trials":8083,"activeCount":99},[],{"intervention":8085,"totalTrials":171,"cells":8086},"JX-594",{"EARLY_PHASE1":8087,"PHASE1":8089,"PHASE2":8098,"PHASE3":8100,"PHASE4":8102,"NA":8104},{"trials":8088,"activeCount":99},[],{"trials":8090,"activeCount":99},[8091],{"nctId":8092,"briefTitle":8093,"status":134,"phases":8094,"primaryCompletion":5840,"completion":1086,"start":3995,"enrollment":5288,"conditions":8095,"interventions":8097},"NCT01469611","A Trial of JX-594 in Refractory Colorectal Carcinoma",[88],[8096],"Colorectal Carcinoma",[8085],{"trials":8099,"activeCount":99},[],{"trials":8101,"activeCount":99},[],{"trials":8103,"activeCount":99},[],{"trials":8105,"activeCount":99},[],{"intervention":8107,"totalTrials":171,"cells":8108},"simvastatin\u002Fcilostazol",{"EARLY_PHASE1":8109,"PHASE1":8111,"PHASE2":8119,"PHASE3":8121,"PHASE4":8123,"NA":8125},{"trials":8110,"activeCount":99},[],{"trials":8112,"activeCount":99},[8113],{"nctId":8114,"briefTitle":8115,"status":134,"phases":8116,"primaryCompletion":991,"completion":991,"start":1275,"enrollment":1440,"conditions":8117,"interventions":8118},"NCT01383395","Effect of Cilostazol on the Pharmacokinetics of Simvastatin",[88],[1313],[8107],{"trials":8120,"activeCount":99},[],{"trials":8122,"activeCount":99},[],{"trials":8124,"activeCount":99},[],{"trials":8126,"activeCount":99},[],{"intervention":8128,"totalTrials":171,"cells":8129},"taxol plus everolimus",{"EARLY_PHASE1":8130,"PHASE1":8132,"PHASE2":8140,"PHASE3":8142,"PHASE4":8144,"NA":8146},{"trials":8131,"activeCount":99},[],{"trials":8133,"activeCount":99},[8134],{"nctId":8135,"briefTitle":8136,"status":134,"phases":8137,"primaryCompletion":1984,"completion":4571,"start":1921,"enrollment":3111,"conditions":8138,"interventions":8139},"NCT01079481","Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer",[88],[4636],[8128],{"trials":8141,"activeCount":99},[],{"trials":8143,"activeCount":99},[],{"trials":8145,"activeCount":99},[],{"trials":8147,"activeCount":99},[],{"intervention":1847,"totalTrials":171,"cells":8149},{"EARLY_PHASE1":8150,"PHASE1":8152,"PHASE2":8158,"PHASE3":8160,"PHASE4":8162,"NA":8164},{"trials":8151,"activeCount":99},[],{"trials":8153,"activeCount":99},[8154],{"nctId":1837,"briefTitle":1838,"status":134,"phases":8155,"primaryCompletion":1840,"completion":1840,"start":1841,"enrollment":1842,"conditions":8156,"interventions":8157},[88],[1844],[1846,1847],{"trials":8159,"activeCount":99},[],{"trials":8161,"activeCount":99},[],{"trials":8163,"activeCount":99},[],{"trials":8165,"activeCount":99},[],{"intervention":8167,"totalTrials":171,"cells":8168},"intravitreal triamcinolone acetonide",{"EARLY_PHASE1":8169,"PHASE1":8171,"PHASE2":8181,"PHASE3":8183,"PHASE4":8185,"NA":8187},{"trials":8170,"activeCount":99},[],{"trials":8172,"activeCount":99},[8173],{"nctId":8174,"briefTitle":8175,"status":134,"phases":8176,"completion":8177,"start":3887,"conditions":8178,"interventions":8180},"NCT00371410","Sequentially Combined Vitrectomy, IVTA and Macular Focal Laser Photocoagulation for Diabetic Macular Edema",[88],"2007-10",[8179],"Diabetic Macular Edema",[8167],{"trials":8182,"activeCount":99},[],{"trials":8184,"activeCount":99},[],{"trials":8186,"activeCount":99},[],{"trials":8188,"activeCount":99},[],{"intervention":8190,"totalTrials":171,"cells":8191},"sorafenib, TS-1",{"EARLY_PHASE1":8192,"PHASE1":8194,"PHASE2":8202,"PHASE3":8204,"PHASE4":8206,"NA":8208},{"trials":8193,"activeCount":99},[],{"trials":8195,"activeCount":99},[8196],{"nctId":8197,"briefTitle":8198,"status":134,"phases":8199,"primaryCompletion":1274,"completion":991,"start":4039,"enrollment":1440,"conditions":8200,"interventions":8201},"NCT01131689","Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma",[88],[30],[8190],{"trials":8203,"activeCount":99},[],{"trials":8205,"activeCount":99},[],{"trials":8207,"activeCount":99},[],{"trials":8209,"activeCount":99},[],{"intervention":3498,"totalTrials":171,"cells":8211},{"EARLY_PHASE1":8212,"PHASE1":8214,"PHASE2":8220,"PHASE3":8222,"PHASE4":8224,"NA":8226},{"trials":8213,"activeCount":99},[],{"trials":8215,"activeCount":99},[8216],{"nctId":3491,"briefTitle":3492,"status":534,"phases":8217,"primaryCompletion":1223,"completion":2711,"start":2759,"enrollment":1717,"conditions":8218,"interventions":8219},[88],[3495,3496],[3498,3499],{"trials":8221,"activeCount":99},[],{"trials":8223,"activeCount":99},[],{"trials":8225,"activeCount":99},[],{"trials":8227,"activeCount":99},[],{"intervention":8229,"totalTrials":171,"cells":8230},"Romidepsin",{"EARLY_PHASE1":8231,"PHASE1":8240,"PHASE2":8242,"PHASE3":8244,"PHASE4":8246,"NA":8248},{"trials":8232,"activeCount":99},[8233],{"nctId":8234,"briefTitle":8235,"status":134,"phases":8236,"primaryCompletion":2851,"completion":2851,"start":2851,"enrollment":4932,"conditions":8237,"interventions":8239},"NCT01913119","A Pilot Study of Romidepsin in Relapsed or Refractory Extranodal NK\u002FT-cell Lymphoma",[87],[8238],"Histologically Proven Extranodal NKTcell Lymphoma",[8229],{"trials":8241,"activeCount":99},[],{"trials":8243,"activeCount":99},[],{"trials":8245,"activeCount":99},[],{"trials":8247,"activeCount":99},[],{"trials":8249,"activeCount":99},[],{"intervention":1108,"totalTrials":1178,"cells":8251},{"EARLY_PHASE1":8252,"PHASE1":8254,"PHASE2":8256,"PHASE3":8291,"PHASE4":8293,"NA":8295},{"trials":8253,"activeCount":99},[],{"trials":8255,"activeCount":99},[],{"trials":8257,"activeCount":99},[8258,8265,8272,8276,8280],{"nctId":8259,"briefTitle":8260,"status":134,"phases":8261,"primaryCompletion":1194,"completion":1049,"start":3211,"enrollment":8262,"conditions":8263,"interventions":8264},"NCT01797874","Pazopanib Maintenance for SCLC",[89],97,[4902],[1108],{"nctId":8266,"briefTitle":8267,"status":134,"phases":8268,"primaryCompletion":1858,"completion":1196,"start":3220,"enrollment":862,"conditions":8269,"interventions":8271},"NCT01099540","Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor",[89],[8270],"Neuroendocrine Tumor",[1108],{"nctId":1093,"briefTitle":1094,"status":534,"phases":8273,"primaryCompletion":1096,"completion":1097,"start":1098,"enrollment":1099,"conditions":8274,"interventions":8275},[89],[1101,1102,1103,1104],[1041,1042,1019,1106,1107,1108,1109,1110,1111,1112,1113,1114,1115,1116,1117,1118,1119],{"nctId":1121,"briefTitle":1122,"status":534,"phases":8277,"primaryCompletion":1124,"completion":1125,"start":1126,"enrollment":1127,"conditions":8278,"interventions":8279},[88,89],[1101,1102],[1108,1041,1042,1019],{"nctId":8281,"briefTitle":8282,"status":134,"phases":8283,"primaryCompletion":8284,"completion":8285,"start":8286,"enrollment":36,"conditions":8287,"interventions":8289},"NCT01538238","pazopanib_NCRCC,Ph2 STUDY",[89],"2015-02-28","2015-11-14","2012-05-02",[8288],"Locally Advanced or Metastatic Non-clear Cell Type Renal Cell Carcinoma",[8290],"pazopanib",{"trials":8292,"activeCount":99},[],{"trials":8294,"activeCount":99},[],{"trials":8296,"activeCount":99},[8297,8305],{"nctId":8298,"briefTitle":8299,"status":134,"phases":8300,"primaryCompletion":5232,"completion":8301,"start":1033,"enrollment":128,"conditions":8302,"interventions":8304},"NCT02691767","Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors",[92],"2020-02-13",[8303],"Refractory Solid Tumors",[8290],{"nctId":8306,"briefTitle":8307,"status":134,"phases":8308,"primaryCompletion":8309,"completion":1685,"start":8310,"enrollment":128,"conditions":8311,"interventions":8312},"NCT02450136","Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors",[92],"2017-07-30","2015-10-08",[8303],[8290],{"intervention":8314,"totalTrials":544,"cells":8315},"SSRI treated group",{"EARLY_PHASE1":8316,"PHASE1":8318,"PHASE2":8320,"PHASE3":8322,"PHASE4":8324,"NA":8326},{"trials":8317,"activeCount":99},[],{"trials":8319,"activeCount":99},[],{"trials":8321,"activeCount":99},[],{"trials":8323,"activeCount":99},[],{"trials":8325,"activeCount":99},[],{"trials":8327,"activeCount":99},[8328,8340,8349,8356],{"nctId":8329,"briefTitle":8330,"status":534,"phases":8331,"primaryCompletion":8332,"completion":612,"start":8333,"enrollment":8334,"conditions":8335,"interventions":8339},"NCT01237275","Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients",[92],"2003-12","1999-10",300,[8336,8337,8338],"Depression","Continuous Antidepressant Abuse","Adverse Reaction to Drug",[8314],{"nctId":8341,"briefTitle":8342,"status":534,"phases":8343,"primaryCompletion":1750,"completion":1750,"start":8344,"enrollment":8345,"conditions":8346,"interventions":8347},"NCT00817375","Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients",[92],"2003-02",1000,[8336,8338],[8314,8348],"non-SSRI treated group",{"nctId":8350,"briefTitle":8351,"status":534,"phases":8352,"primaryCompletion":1750,"completion":1750,"start":8344,"enrollment":8345,"conditions":8353,"interventions":8355},"NCT01228357","Predict Antidepressant Responsiveness Using Pharmacogenomics",[92],[8336,8354],"Depressive Symptoms",[8314,8348],{"nctId":8357,"briefTitle":8358,"status":534,"phases":8359,"primaryCompletion":612,"completion":4964,"start":1932,"enrollment":8345,"conditions":8360,"interventions":8362},"NCT00817011","Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness",[92],[8336,8361],"Antidepressant Drug Adverse Reaction",[8314,8348],{"intervention":4712,"totalTrials":544,"cells":8364},{"EARLY_PHASE1":8365,"PHASE1":8367,"PHASE2":8369,"PHASE3":8382,"PHASE4":8384,"NA":8395},{"trials":8366,"activeCount":99},[],{"trials":8368,"activeCount":99},[],{"trials":8370,"activeCount":99},[8371,8378],{"nctId":8372,"briefTitle":8373,"status":134,"phases":8374,"primaryCompletion":1894,"completion":2828,"start":3464,"enrollment":887,"conditions":8375,"interventions":8377},"NCT01082809","Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma",[89],[8376],"Advanced Biliary Tract Adenocarcinoma",[4712],{"nctId":4703,"briefTitle":4704,"status":134,"phases":8379,"primaryCompletion":4706,"completion":4707,"start":1289,"enrollment":4708,"conditions":8380,"interventions":8381},[89],[4710],[4712,4713,1115],{"trials":8383,"activeCount":99},[],{"trials":8385,"activeCount":99},[8386],{"nctId":8387,"briefTitle":8388,"status":134,"phases":8389,"primaryCompletion":8390,"completion":8391,"start":8392,"enrollment":171,"conditions":8393,"interventions":8394},"NCT02691793","Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors",[91],"2019-08-30","2019-11-19","2017-11-20",[8303],[4712],{"trials":8396,"activeCount":99},[8397],{"nctId":8398,"briefTitle":8399,"status":134,"phases":8400,"primaryCompletion":8390,"completion":8401,"start":8402,"enrollment":171,"conditions":8403,"interventions":8404},"NCT02450123","Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors",[92],"2019-11-05","2016-03-23",[8303],[8405],"sunitinib",{"intervention":1109,"totalTrials":544,"cells":8407},{"EARLY_PHASE1":8408,"PHASE1":8410,"PHASE2":8412,"PHASE3":8426,"PHASE4":8428,"NA":8430},{"trials":8409,"activeCount":99},[],{"trials":8411,"activeCount":99},[],{"trials":8413,"activeCount":99},[8414,8418],{"nctId":1093,"briefTitle":1094,"status":534,"phases":8415,"primaryCompletion":1096,"completion":1097,"start":1098,"enrollment":1099,"conditions":8416,"interventions":8417},[89],[1101,1102,1103,1104],[1041,1042,1019,1106,1107,1108,1109,1110,1111,1112,1113,1114,1115,1116,1117,1118,1119],{"nctId":8419,"briefTitle":8420,"status":134,"phases":8421,"primaryCompletion":1782,"completion":5522,"start":1224,"enrollment":8422,"conditions":8423,"interventions":8425},"NCT01091207","Sorafenib for Imatinib\u002FSunitinib-failed GIST",[89],39,[8424],"Gastrointestinal Stromal Tumors",[1109],{"trials":8427,"activeCount":99},[],{"trials":8429,"activeCount":99},[],{"trials":8431,"activeCount":99},[8432,8439],{"nctId":8433,"briefTitle":8434,"status":185,"phases":8435,"primaryCompletion":1750,"completion":8391,"start":8436,"enrollment":99,"conditions":8437,"interventions":8438},"NCT02691780","Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors",[92],"2016-12-23",[8303],[1109],{"nctId":8440,"briefTitle":8441,"status":134,"phases":8442,"primaryCompletion":4831,"completion":8443,"start":8444,"enrollment":171,"conditions":8445,"interventions":8446},"NCT02450149","Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors",[92],"2016-08-09","2016-05-30",[8303],[8447],"sorafenib",{"intervention":8449,"totalTrials":544,"cells":8450},"atorvastatin",{"EARLY_PHASE1":8451,"PHASE1":8453,"PHASE2":8455,"PHASE3":8457,"PHASE4":8459,"NA":8474},{"trials":8452,"activeCount":99},[],{"trials":8454,"activeCount":99},[],{"trials":8456,"activeCount":99},[],{"trials":8458,"activeCount":99},[],{"trials":8460,"activeCount":99},[8461,8465],{"nctId":2122,"briefTitle":2123,"status":534,"phases":8462,"primaryCompletion":1147,"completion":1147,"start":2125,"enrollment":112,"conditions":8463,"interventions":8464},[91],[2127],[2109,2129],{"nctId":8466,"briefTitle":8467,"status":534,"phases":8468,"primaryCompletion":1921,"completion":1782,"start":8469,"enrollment":8470,"conditions":8471,"interventions":8473},"NCT00620204","Efficacy Study of Atorvastatin to Treat Variant Angina",[91],"2008-01",136,[8472],"Angina Pectoris, Variant",[8449],{"trials":8475,"activeCount":99},[8476,8484],{"nctId":8477,"briefTitle":8478,"status":134,"phases":8479,"primaryCompletion":2554,"completion":1738,"start":8480,"enrollment":8481,"conditions":8482,"interventions":8483},"NCT00610870","Effect of Atorvastatin Administration Before Primary Percutaneous Coronary Intervention",[92],"2007-07",173,[1787],[8449],{"nctId":8485,"briefTitle":8486,"status":134,"phases":8487,"primaryCompletion":8488,"completion":3663,"start":8489,"enrollment":2913,"conditions":8490,"interventions":8492},"NCT00611143","Atorvastatin for Prevention of Postoperative Atrial Fibrillation After Off-Pump Coronary Artery Bypass Grafting Surgery",[92],"2007-04","2006-05",[8491],"Coronary Artery Bypass",[8449],{"intervention":3602,"totalTrials":95,"cells":8494},{"EARLY_PHASE1":8495,"PHASE1":8497,"PHASE2":8499,"PHASE3":8501,"PHASE4":8507,"NA":8509},{"trials":8496,"activeCount":99},[],{"trials":8498,"activeCount":99},[],{"trials":8500,"activeCount":99},[],{"trials":8502,"activeCount":99},[8503],{"nctId":3595,"briefTitle":3596,"status":534,"phases":8504,"primaryCompletion":612,"completion":3598,"start":1033,"enrollment":112,"conditions":8505,"interventions":8506},[90],[3600],[3602,3584],{"trials":8508,"activeCount":99},[],{"trials":8510,"activeCount":99},[8511,8519],{"nctId":8512,"briefTitle":8513,"status":134,"phases":8514,"primaryCompletion":8515,"completion":1736,"start":2456,"enrollment":645,"conditions":8516,"interventions":8518},"NCT02091635","Efficacy of Motilitone on Gastric Accommodation in Healthy Adult Patients: Evaluation Using MRI Method",[92],"2013-10",[8517],"Dyspepsia",[3602],{"nctId":8520,"briefTitle":8521,"status":534,"phases":8522,"primaryCompletion":2076,"completion":2076,"start":1223,"enrollment":3688,"conditions":8523,"interventions":8524},"NCT02151708","Efficacy of Motilitone on Gastric Emptying in Patients With Functional Dyspepsia: Evaluation Using MRI Method",[92],[8517],[8525],"motilitone",{"intervention":8348,"totalTrials":95,"cells":8527},{"EARLY_PHASE1":8528,"PHASE1":8530,"PHASE2":8532,"PHASE3":8534,"PHASE4":8536,"NA":8538},{"trials":8529,"activeCount":99},[],{"trials":8531,"activeCount":99},[],{"trials":8533,"activeCount":99},[],{"trials":8535,"activeCount":99},[],{"trials":8537,"activeCount":99},[],{"trials":8539,"activeCount":99},[8540,8544,8548],{"nctId":8341,"briefTitle":8342,"status":534,"phases":8541,"primaryCompletion":1750,"completion":1750,"start":8344,"enrollment":8345,"conditions":8542,"interventions":8543},[92],[8336,8338],[8314,8348],{"nctId":8350,"briefTitle":8351,"status":534,"phases":8545,"primaryCompletion":1750,"completion":1750,"start":8344,"enrollment":8345,"conditions":8546,"interventions":8547},[92],[8336,8354],[8314,8348],{"nctId":8357,"briefTitle":8358,"status":534,"phases":8549,"primaryCompletion":612,"completion":4964,"start":1932,"enrollment":8345,"conditions":8550,"interventions":8551},[92],[8336,8361],[8314,8348],{"intervention":8553,"totalTrials":95,"cells":8554},"donepezil",{"EARLY_PHASE1":8555,"PHASE1":8557,"PHASE2":8559,"PHASE3":8561,"PHASE4":8563,"NA":8565},{"trials":8556,"activeCount":99},[],{"trials":8558,"activeCount":99},[],{"trials":8560,"activeCount":99},[],{"trials":8562,"activeCount":99},[],{"trials":8564,"activeCount":99},[],{"trials":8566,"activeCount":99},[8567,8574,8581],{"nctId":8568,"briefTitle":8569,"status":534,"phases":8570,"conditions":8571,"interventions":8572},"NCT00530478","Effect of Donepezil on the Reorganization of Cognitive Neural Network in Patients With Post-Stroke Cognitive Impairment",[92],[15],[8573],"Donepezil",{"nctId":8575,"briefTitle":8576,"status":134,"phases":8577,"primaryCompletion":2936,"completion":2936,"start":6164,"enrollment":773,"conditions":8578,"interventions":8580},"NCT01023425","Clinical Trial of Donepezil Between the Naive Group and the Switching Group",[92],[3738,8579],"Dementia",[8553],{"nctId":8582,"briefTitle":8583,"status":134,"phases":8584,"primaryCompletion":1985,"completion":1985,"start":2689,"enrollment":8585,"conditions":8586,"interventions":8587},"NCT01023867","Clinical Trial of Donepezil Between the Patients With Alzheimer's Disease and Mixed Dementia",[92],88,[3738,8579],[8553],{"intervention":8589,"totalTrials":128,"cells":8590},"sirolimus",{"EARLY_PHASE1":8591,"PHASE1":8593,"PHASE2":8595,"PHASE3":8597,"PHASE4":8599,"NA":8610},{"trials":8592,"activeCount":99},[],{"trials":8594,"activeCount":99},[],{"trials":8596,"activeCount":99},[],{"trials":8598,"activeCount":99},[],{"trials":8600,"activeCount":99},[8601],{"nctId":8602,"briefTitle":8603,"status":134,"phases":8604,"primaryCompletion":6891,"completion":8605,"start":8606,"enrollment":8607,"conditions":8608,"interventions":8609},"NCT02688881","Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors",[91],"2021-02-24","2017-02-05",6,[8303],[8589],{"trials":8611,"activeCount":99},[8612],{"nctId":8613,"briefTitle":8614,"status":134,"phases":8615,"primaryCompletion":8616,"completion":8617,"start":8618,"enrollment":4442,"conditions":8619,"interventions":8620},"NCT02449564","The Pilot Study Evaluate the Safety and Efficacy of Sirolimus in Patients With PIK3CA Mutation and\u002For PIK3CA Amplification Refractory Solid Tumors",[92],"2017-09-27","2017-11-03","2014-11-24",[4833],[8589],{"intervention":8622,"totalTrials":128,"cells":8623},"methylprednisolone",{"EARLY_PHASE1":8624,"PHASE1":8626,"PHASE2":8628,"PHASE3":8630,"PHASE4":8632,"NA":8634},{"trials":8625,"activeCount":99},[],{"trials":8627,"activeCount":99},[],{"trials":8629,"activeCount":99},[],{"trials":8631,"activeCount":99},[],{"trials":8633,"activeCount":99},[],{"trials":8635,"activeCount":99},[8636,8644],{"nctId":8637,"briefTitle":8638,"status":534,"phases":8639,"primaryCompletion":8640,"completion":8640,"start":4830,"enrollment":112,"conditions":8641,"interventions":8643},"NCT02733510","The Impact of Early Protocol Biopsy in Kidney Transplant",[],"2019-04",[8642],"Chronic Renal Failure",[8622],{"nctId":8645,"briefTitle":8646,"status":534,"phases":8647,"primaryCompletion":8648,"completion":8648,"start":611,"enrollment":124,"conditions":8649,"interventions":8650},"NCT02664493","The Effect of Steroid Pulse Therapy for the Reduction of Acute Rejection Episode in Subclinical Borderline Changes",[92],"2020-07",[8642],[8651],"Methylprednisolone",{"intervention":8653,"totalTrials":128,"cells":8654},"Sacubitril-Valsartan",{"EARLY_PHASE1":8655,"PHASE1":8657,"PHASE2":8659,"PHASE3":8665,"PHASE4":8667,"NA":8669},{"trials":8656,"activeCount":99},[],{"trials":8658,"activeCount":99},[],{"trials":8660,"activeCount":99},[8661],{"nctId":6912,"briefTitle":6913,"status":534,"phases":8662,"primaryCompletion":1097,"completion":5105,"start":6915,"enrollment":1933,"conditions":8663,"interventions":8664},[89],[6917],[6919,6903],{"trials":8666,"activeCount":99},[],{"trials":8668,"activeCount":99},[],{"trials":8670,"activeCount":99},[8671],{"nctId":8672,"briefTitle":8673,"status":534,"phases":8674,"primaryCompletion":8675,"completion":4807,"start":8676,"enrollment":1933,"conditions":8677,"interventions":8679},"NCT04803175","Sacubitril\u002FValsartan Versus Valsartan in Heart Failure With Improved Ejection Fraction",[],"2024-02","2021-03-16",[8678],"Heart Failure, Systolic",[8653,8680],"Valsartan",{"intervention":8680,"totalTrials":128,"cells":8682},{"EARLY_PHASE1":8683,"PHASE1":8685,"PHASE2":8687,"PHASE3":8689,"PHASE4":8691,"NA":8703},{"trials":8684,"activeCount":99},[],{"trials":8686,"activeCount":99},[],{"trials":8688,"activeCount":99},[],{"trials":8690,"activeCount":99},[],{"trials":8692,"activeCount":99},[8693],{"nctId":8694,"briefTitle":8695,"status":534,"phases":8696,"primaryCompletion":2712,"completion":2712,"start":3464,"enrollment":8697,"conditions":8698,"interventions":8701},"NCT00858299","The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria",[91],500,[8699,8700],"Chronic Kidney Disease","Proteinuria",[8702],"valsartan",{"trials":8704,"activeCount":99},[8705],{"nctId":8672,"briefTitle":8673,"status":534,"phases":8706,"primaryCompletion":8675,"completion":4807,"start":8676,"enrollment":1933,"conditions":8707,"interventions":8708},[],[8678],[8653,8680],{"intervention":8710,"totalTrials":128,"cells":8711},"Dexmedetomidine",{"EARLY_PHASE1":8712,"PHASE1":8714,"PHASE2":8716,"PHASE3":8718,"PHASE4":8720,"NA":8722},{"trials":8713,"activeCount":99},[],{"trials":8715,"activeCount":99},[],{"trials":8717,"activeCount":99},[],{"trials":8719,"activeCount":99},[],{"trials":8721,"activeCount":99},[],{"trials":8723,"activeCount":99},[8724,8734],{"nctId":8725,"briefTitle":8726,"status":134,"phases":8727,"primaryCompletion":2759,"completion":2759,"start":1858,"enrollment":3465,"conditions":8728,"interventions":8733},"NCT01572454","Comparison of Dexmedetomidine and Remifentanil Infusion During CABG",[92],[8729,8730,8731,8710,8732],"Coronary Artery Bypass Graft","Hypokalemia","Cardiac Arrhythmia","Remifentanil",[8710,8732],{"nctId":8735,"briefTitle":8736,"status":134,"phases":8737,"primaryCompletion":8738,"completion":8738,"start":2336,"enrollment":8739,"conditions":8740,"interventions":8746},"NCT01688648","Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft",[92],"2013-02",160,[8741,8729,8710,8742,8743,8744,8745],"Unstable Angina","Lidocaine","Myocardial Injury","Arrhythmia","Blood Electrolyte Balance",[8742,8710],{"intervention":8732,"totalTrials":128,"cells":8748},{"EARLY_PHASE1":8749,"PHASE1":8751,"PHASE2":8753,"PHASE3":8755,"PHASE4":8757,"NA":8759},{"trials":8750,"activeCount":99},[],{"trials":8752,"activeCount":99},[],{"trials":8754,"activeCount":99},[],{"trials":8756,"activeCount":99},[],{"trials":8758,"activeCount":99},[],{"trials":8760,"activeCount":99},[8761,8765],{"nctId":8725,"briefTitle":8726,"status":134,"phases":8762,"primaryCompletion":2759,"completion":2759,"start":1858,"enrollment":3465,"conditions":8763,"interventions":8764},[92],[8729,8730,8731,8710,8732],[8710,8732],{"nctId":8766,"briefTitle":8767,"status":134,"phases":8768,"primaryCompletion":8769,"completion":8770,"start":8771,"enrollment":228,"conditions":8772,"interventions":8774},"NCT03756233","Gradual Withdrawal of Remifentanil Infusion Reduced Postoperative Pain and Opioid Requirement During Breast Surgery",[92],"2019-07-01","2019-07-03","2018-11-26",[8773],"Pain, Postoperative",[8732],{"intervention":2341,"totalTrials":128,"cells":8776},{"EARLY_PHASE1":8777,"PHASE1":8779,"PHASE2":8781,"PHASE3":8783,"PHASE4":8785,"NA":8791},{"trials":8778,"activeCount":99},[],{"trials":8780,"activeCount":99},[],{"trials":8782,"activeCount":99},[],{"trials":8784,"activeCount":99},[],{"trials":8786,"activeCount":99},[8787],{"nctId":2333,"briefTitle":2334,"status":134,"phases":8788,"primaryCompletion":2336,"completion":2336,"start":2311,"enrollment":2337,"conditions":8789,"interventions":8790},[91],[2339],[2320,2341],{"trials":8792,"activeCount":99},[8793],{"nctId":8794,"briefTitle":8795,"status":534,"phases":8796,"primaryCompletion":1783,"completion":612,"start":2197,"enrollment":8797,"conditions":8798,"interventions":8799},"NCT00935246","Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning",[92],202,[8336,8337,8338],[2341],{"intervention":1901,"totalTrials":128,"cells":8801},{"EARLY_PHASE1":8802,"PHASE1":8804,"PHASE2":8806,"PHASE3":8808,"PHASE4":8810,"NA":8816},{"trials":8803,"activeCount":99},[],{"trials":8805,"activeCount":99},[],{"trials":8807,"activeCount":99},[],{"trials":8809,"activeCount":99},[],{"trials":8811,"activeCount":99},[8812],{"nctId":1891,"briefTitle":1892,"status":134,"phases":8813,"primaryCompletion":1050,"completion":1050,"start":1894,"enrollment":1895,"conditions":8814,"interventions":8815},[91],[1897,1898,1899],[1901,1867],{"trials":8817,"activeCount":99},[8818],{"nctId":8819,"briefTitle":8820,"status":534,"phases":8821,"primaryCompletion":8822,"completion":8823,"start":8824,"enrollment":8825,"conditions":8826,"interventions":8829},"NCT04096547","Rivaroxaban in Elderly NVAF Patients With or Without Renal Impairment",[],"2022-02-28","2022-08-30","2019-09-25",1200,[8827,1901,8828,5913],"Atrial Fibrillation","Elderly",[1901],{"intervention":588,"totalTrials":128,"cells":8831},{"EARLY_PHASE1":8832,"PHASE1":8834,"PHASE2":8836,"PHASE3":8838,"PHASE4":8840,"NA":8842},{"trials":8833,"activeCount":99},[],{"trials":8835,"activeCount":99},[],{"trials":8837,"activeCount":99},[],{"trials":8839,"activeCount":99},[],{"trials":8841,"activeCount":99},[],{"trials":8843,"activeCount":99},[8844,8857],{"nctId":8845,"briefTitle":8846,"status":134,"phases":8847,"primaryCompletion":8848,"completion":8849,"start":8850,"enrollment":6222,"conditions":8851,"interventions":8854},"NCT05742438","Effects of Dexmedetomidine\u002FLidocaine\u002FIntrathecal Morphine on Cancer Metastasis Biomarker After Colorectal Surgery",[92],"2023-07-05","2023-08-05","2023-04-12",[3186,168,8852,8853],"Cancer Metastatic","Inflammation",[588,8855,8856],"Dexmedetomidine IV","intrathecal morphine",{"nctId":577,"briefTitle":578,"status":534,"phases":8858,"primaryCompletion":580,"completion":581,"start":582,"enrollment":583,"conditions":8859,"interventions":8860},[92],[585],[587,588,589],{"intervention":8862,"totalTrials":128,"cells":8863},"Cartistem",{"EARLY_PHASE1":8864,"PHASE1":8873,"PHASE2":8875,"PHASE3":8877,"PHASE4":8879,"NA":8881},{"trials":8865,"activeCount":99},[8866],{"nctId":8867,"briefTitle":8868,"status":534,"phases":8869,"primaryCompletion":2077,"completion":1098,"start":2759,"enrollment":1842,"conditions":8870,"interventions":8872},"NCT02338375","Safety and Efficacy of Allogenic Umbilical Cord Blood-derived Mesenchymal Stem Cell Product",[87],[8871],"Osteochondral Lesion of Talus",[8862],{"trials":8874,"activeCount":99},[],{"trials":8876,"activeCount":99},[],{"trials":8878,"activeCount":99},[],{"trials":8880,"activeCount":99},[],{"trials":8882,"activeCount":99},[8883],{"nctId":8884,"briefTitle":8885,"status":134,"phases":8886,"primaryCompletion":8887,"completion":8888,"start":8889,"enrollment":671,"conditions":8890,"interventions":8892},"NCT02755376","Development of Novel Strategy for Treatment of Anterior Cruciate Ligament (ACL) Injury Using Stem Cell",[92],"2016-04-28","2018-12-01","2014-01-01",[8891],"Deficiency of Anterior Cruciate Ligament",[8862,8893],"hyaluronic acid",{"intervention":4258,"totalTrials":128,"cells":8895},{"EARLY_PHASE1":8896,"PHASE1":8898,"PHASE2":8900,"PHASE3":8902,"PHASE4":8908,"NA":8910},{"trials":8897,"activeCount":99},[],{"trials":8899,"activeCount":99},[],{"trials":8901,"activeCount":99},[],{"trials":8903,"activeCount":99},[8904],{"nctId":4251,"briefTitle":4252,"status":134,"phases":8905,"primaryCompletion":2268,"completion":2268,"start":4254,"enrollment":1225,"conditions":8906,"interventions":8907},[90],[4256],[4240,4258],{"trials":8909,"activeCount":99},[],{"trials":8911,"activeCount":99},[8912],{"nctId":8884,"briefTitle":8885,"status":134,"phases":8913,"primaryCompletion":8887,"completion":8888,"start":8889,"enrollment":671,"conditions":8914,"interventions":8915},[92],[8891],[8862,8893],{"intervention":1887,"totalTrials":128,"cells":8917},{"EARLY_PHASE1":8918,"PHASE1":8920,"PHASE2":8922,"PHASE3":8924,"PHASE4":8930,"NA":8932},{"trials":8919,"activeCount":99},[],{"trials":8921,"activeCount":99},[],{"trials":8923,"activeCount":99},[],{"trials":8925,"activeCount":99},[8926],{"nctId":1878,"briefTitle":1879,"status":534,"phases":8927,"primaryCompletion":1881,"completion":1882,"start":1883,"enrollment":645,"conditions":8928,"interventions":8929},[89,90],[1885],[1887,1867],{"trials":8931,"activeCount":99},[],{"trials":8933,"activeCount":99},[8934],{"nctId":8935,"briefTitle":8936,"status":134,"phases":8937,"primaryCompletion":3382,"completion":8938,"start":5643,"enrollment":228,"conditions":8939,"interventions":8941},"NCT04121767","Safety and Efficacy of Edoxaban in Thoracoscopic Ablation",[92],"2020-07-10",[8827,8940],"Anticoagulants and Bleeding Disorders",[1887,8942],"Warfarin",{"intervention":8944,"totalTrials":128,"cells":8945},"aspirin, clopidogrel",{"EARLY_PHASE1":8946,"PHASE1":8948,"PHASE2":8950,"PHASE3":8952,"PHASE4":8954,"NA":8956},{"trials":8947,"activeCount":99},[],{"trials":8949,"activeCount":99},[],{"trials":8951,"activeCount":99},[],{"trials":8953,"activeCount":99},[],{"trials":8955,"activeCount":99},[],{"trials":8957,"activeCount":99},[8958,8966],{"nctId":8959,"briefTitle":8960,"status":134,"phases":8961,"primaryCompletion":2197,"completion":2554,"start":6164,"enrollment":1648,"conditions":8962,"interventions":8964},"NCT00620646","The Comparison of Effects Between Increased Dose of Clopidogrel and Addition of Cilostazol",[92],[8963],"Clopidogrel Non-Responsiveness",[8944,8965],"aspirin, clopidogrel, cilostazol",{"nctId":8967,"briefTitle":8968,"status":134,"phases":8969,"primaryCompletion":4229,"completion":2936,"start":8970,"enrollment":8825,"conditions":8971,"interventions":8972},"NCT00418860","The Optimal Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent",[92],"2006-09",[18],[8973],"Aspirin, Clopidogrel",{"intervention":2807,"totalTrials":128,"cells":8975},{"EARLY_PHASE1":8976,"PHASE1":8978,"PHASE2":8980,"PHASE3":8982,"PHASE4":8984,"NA":8990},{"trials":8977,"activeCount":99},[],{"trials":8979,"activeCount":99},[],{"trials":8981,"activeCount":99},[],{"trials":8983,"activeCount":99},[],{"trials":8985,"activeCount":99},[8986],{"nctId":2799,"briefTitle":2800,"status":134,"phases":8987,"primaryCompletion":612,"completion":2802,"start":1736,"enrollment":2803,"conditions":8988,"interventions":8989},[91],[2805],[2786,2807],{"trials":8991,"activeCount":99},[8992],{"nctId":8993,"briefTitle":8994,"status":534,"phases":8995,"primaryCompletion":6086,"start":1738,"enrollment":8996,"conditions":8997,"interventions":8998},"NCT00954889","Clinical Effect and Safety of Tamsulosin 0.4mg in Patients With LUTS\u002FBPH Refractory to Tamsulosin 0.2mg",[92],220,[33],[8999],"tamsulosin",{"intervention":9001,"totalTrials":171,"cells":9002},"Photofrin",{"EARLY_PHASE1":9003,"PHASE1":9005,"PHASE2":9007,"PHASE3":9009,"PHASE4":9011,"NA":9013},{"trials":9004,"activeCount":99},[],{"trials":9006,"activeCount":99},[],{"trials":9008,"activeCount":99},[],{"trials":9010,"activeCount":99},[],{"trials":9012,"activeCount":99},[],{"trials":9014,"activeCount":99},[9015],{"nctId":9016,"briefTitle":9017,"status":134,"phases":9018,"primaryCompletion":2311,"completion":2311,"start":4039,"enrollment":31,"conditions":9019,"interventions":9021},"NCT01506115","Safety and Efficacy of Photodynamic Therapy for Bile Duct Invasion of Hepatocellular Carcinoma",[92],[30,9020],"Obstructive Jaundice",[9001],{"intervention":9023,"totalTrials":171,"cells":9024},"Sonazoid",{"EARLY_PHASE1":9025,"PHASE1":9027,"PHASE2":9029,"PHASE3":9031,"PHASE4":9033,"NA":9035},{"trials":9026,"activeCount":99},[],{"trials":9028,"activeCount":99},[],{"trials":9030,"activeCount":99},[],{"trials":9032,"activeCount":99},[],{"trials":9034,"activeCount":99},[],{"trials":9036,"activeCount":99},[9037],{"nctId":9038,"briefTitle":9039,"status":134,"phases":9040,"primaryCompletion":9041,"completion":9041,"start":1033,"enrollment":3122,"conditions":9042,"interventions":9044},"NCT02737865","Superb Microvascular Imaging in Focal Nodular Hyperplasia",[92],"2019-04-25",[9043],"Focal Nodular Hyperplasia",[9023],{"intervention":9046,"totalTrials":171,"cells":9047},"2L PEG-Asc",{"EARLY_PHASE1":9048,"PHASE1":9050,"PHASE2":9052,"PHASE3":9054,"PHASE4":9056,"NA":9058},{"trials":9049,"activeCount":99},[],{"trials":9051,"activeCount":99},[],{"trials":9053,"activeCount":99},[],{"trials":9055,"activeCount":99},[],{"trials":9057,"activeCount":99},[],{"trials":9059,"activeCount":99},[9060],{"nctId":9061,"briefTitle":9062,"status":134,"phases":9063,"primaryCompletion":9064,"completion":9064,"start":9065,"enrollment":9066,"conditions":9067,"interventions":9069},"NCT03849196","Effectiveness of Bisacodyl Suppository Agent for Dose Reduction of Low Dose PEG",[92],"2018-01-30","2017-07-31",168,[9068],"Bowel Preparation",[9046,9070,9071],"Bisacodyl 10Mg Suppository","1L PEG-Asc",{"intervention":9070,"totalTrials":171,"cells":9073},{"EARLY_PHASE1":9074,"PHASE1":9076,"PHASE2":9078,"PHASE3":9080,"PHASE4":9082,"NA":9084},{"trials":9075,"activeCount":99},[],{"trials":9077,"activeCount":99},[],{"trials":9079,"activeCount":99},[],{"trials":9081,"activeCount":99},[],{"trials":9083,"activeCount":99},[],{"trials":9085,"activeCount":99},[9086],{"nctId":9061,"briefTitle":9062,"status":134,"phases":9087,"primaryCompletion":9064,"completion":9064,"start":9065,"enrollment":9066,"conditions":9088,"interventions":9089},[92],[9068],[9046,9070,9071],{"intervention":9071,"totalTrials":171,"cells":9091},{"EARLY_PHASE1":9092,"PHASE1":9094,"PHASE2":9096,"PHASE3":9098,"PHASE4":9100,"NA":9102},{"trials":9093,"activeCount":99},[],{"trials":9095,"activeCount":99},[],{"trials":9097,"activeCount":99},[],{"trials":9099,"activeCount":99},[],{"trials":9101,"activeCount":99},[],{"trials":9103,"activeCount":99},[9104],{"nctId":9061,"briefTitle":9062,"status":134,"phases":9105,"primaryCompletion":9064,"completion":9064,"start":9065,"enrollment":9066,"conditions":9106,"interventions":9107},[92],[9068],[9046,9070,9071],{"intervention":9109,"totalTrials":171,"cells":9110},"DAPT, Statin",{"EARLY_PHASE1":9111,"PHASE1":9113,"PHASE2":9115,"PHASE3":9117,"PHASE4":9119,"NA":9121},{"trials":9112,"activeCount":99},[],{"trials":9114,"activeCount":99},[],{"trials":9116,"activeCount":99},[],{"trials":9118,"activeCount":99},[],{"trials":9120,"activeCount":99},[],{"trials":9122,"activeCount":99},[9123],{"nctId":9124,"briefTitle":9125,"status":134,"phases":9126,"primaryCompletion":9127,"completion":9128,"start":9129,"enrollment":9130,"conditions":9131,"interventions":9138},"NCT03785509","The Compliance of DAPT and Statins on Clinical Outcomes in Percutaneous Coronary Intervention Patients",[],"2018-02-06","2018-11-30","2017-04-06",47291,[9132,9133,9134,9135,9136,9137],"Platelet Aggregation Inhibitors","Hydroxymethylglutaryl-coa Reductase Inhibitors","Compliance, Medication","Adherence, Medication","Persistence, Medication","Percutaneous Coronary Intervention",[9109],{"intervention":9140,"totalTrials":171,"cells":9141},"Spinal anesthesia",{"EARLY_PHASE1":9142,"PHASE1":9144,"PHASE2":9146,"PHASE3":9148,"PHASE4":9150,"NA":9152},{"trials":9143,"activeCount":99},[],{"trials":9145,"activeCount":99},[],{"trials":9147,"activeCount":99},[],{"trials":9149,"activeCount":99},[],{"trials":9151,"activeCount":99},[],{"trials":9153,"activeCount":99},[9154],{"nctId":9155,"briefTitle":9156,"status":134,"phases":9157,"primaryCompletion":2759,"completion":2759,"start":1984,"enrollment":5909,"conditions":9158,"interventions":9161},"NCT01609517","The Influence of Body-mass Index on the Outcome of Spinal Anesthesia for Total Knee Replacement Arthroplasty",[],[9159,9160],"Spinal Anesthesia","Success or Failure of Spinal Anesthesia",[9140],{"intervention":9163,"totalTrials":171,"cells":9164},"EVONAIL® solution",{"EARLY_PHASE1":9165,"PHASE1":9167,"PHASE2":9169,"PHASE3":9171,"PHASE4":9173,"NA":9175},{"trials":9166,"activeCount":99},[],{"trials":9168,"activeCount":99},[],{"trials":9170,"activeCount":99},[],{"trials":9172,"activeCount":99},[],{"trials":9174,"activeCount":99},[],{"trials":9176,"activeCount":99},[9177],{"nctId":9178,"briefTitle":9179,"status":134,"phases":9180,"primaryCompletion":3253,"completion":9181,"start":2077,"enrollment":1933,"conditions":9182,"interventions":9184},"NCT02670603","A Trial of Evonail® Solution for Prevention or Treatment of Onycholysis",[92],"2016-09",[21,9183],"Docetaxel Chemotherapy",[9163],{"intervention":9186,"totalTrials":171,"cells":9187},"Oxybutinin, Fesoterodine, Solifenacin, Propiverin, Trospium",{"EARLY_PHASE1":9188,"PHASE1":9190,"PHASE2":9192,"PHASE3":9194,"PHASE4":9196,"NA":9198},{"trials":9189,"activeCount":99},[],{"trials":9191,"activeCount":99},[],{"trials":9193,"activeCount":99},[],{"trials":9195,"activeCount":99},[],{"trials":9197,"activeCount":99},[],{"trials":9199,"activeCount":99},[9200],{"nctId":9201,"briefTitle":9202,"status":134,"phases":9203,"primaryCompletion":1687,"completion":611,"start":3687,"enrollment":9204,"conditions":9205,"interventions":9206},"NCT01499069","Urinary Nerve Growth Factor (NGF), Prostaglandin E2 (PGE2)and Adenosine Triphosphate (ATP): Potential Biomarkers in Overactive Bladder Patients",[92],191,[1963],[9186],{"intervention":9208,"totalTrials":171,"cells":9209},"Amitriptyline",{"EARLY_PHASE1":9210,"PHASE1":9212,"PHASE2":9214,"PHASE3":9216,"PHASE4":9218,"NA":9220},{"trials":9211,"activeCount":99},[],{"trials":9213,"activeCount":99},[],{"trials":9215,"activeCount":99},[],{"trials":9217,"activeCount":99},[],{"trials":9219,"activeCount":99},[],{"trials":9221,"activeCount":99},[9222],{"nctId":9223,"briefTitle":9224,"status":534,"phases":9225,"primaryCompletion":4831,"completion":9226,"start":1135,"enrollment":9227,"conditions":9228,"interventions":9230},"NCT02638870","Colonoscopy-related Pain Predicts the Treatment Response of Amitriptyline in Patients With Irritable Bowel Syndrome",[],"2016-10",118,[9229],"Irritable Bowel Syndrome",[9208],{"intervention":9232,"totalTrials":171,"cells":9233},"Optimal medical treatment",{"EARLY_PHASE1":9234,"PHASE1":9236,"PHASE2":9238,"PHASE3":9240,"PHASE4":9242,"NA":9244},{"trials":9235,"activeCount":99},[],{"trials":9237,"activeCount":99},[],{"trials":9239,"activeCount":99},[],{"trials":9241,"activeCount":99},[],{"trials":9243,"activeCount":99},[],{"trials":9245,"activeCount":99},[9246],{"nctId":9247,"briefTitle":9248,"status":534,"phases":9249,"primaryCompletion":136,"completion":581,"start":9250,"enrollment":8345,"conditions":9251,"interventions":9253},"NCT04143893","The Current Status and Clinical Outcomes of Patients With Cardiogenic Shock II",[],"2019-05-30",[9252],"Cardiogenic Shock",[9232],{"intervention":9255,"totalTrials":171,"cells":9256},"Antiviral treatment in combination with low-dose gemcitabine",{"EARLY_PHASE1":9257,"PHASE1":9259,"PHASE2":9261,"PHASE3":9263,"PHASE4":9265,"NA":9267},{"trials":9258,"activeCount":99},[],{"trials":9260,"activeCount":99},[],{"trials":9262,"activeCount":99},[],{"trials":9264,"activeCount":99},[],{"trials":9266,"activeCount":99},[],{"trials":9268,"activeCount":99},[9269],{"nctId":9270,"briefTitle":9271,"status":185,"phases":9272,"primaryCompletion":9273,"completion":9273,"start":9274,"enrollment":99,"conditions":9275,"interventions":9276},"NCT05431244","Pilot Study of Antiviral Treatment in Combination With Low-dose Gemcitabine in EBV-associated Gastric Cancer (EBVaGC)",[92],"2024-07-01","2022-07-01",[24],[9255],{"intervention":9278,"totalTrials":171,"cells":9279},"LDL reduction therapy",{"EARLY_PHASE1":9280,"PHASE1":9282,"PHASE2":9284,"PHASE3":9286,"PHASE4":9288,"NA":9290},{"trials":9281,"activeCount":99},[],{"trials":9283,"activeCount":99},[],{"trials":9285,"activeCount":99},[],{"trials":9287,"activeCount":99},[],{"trials":9289,"activeCount":99},[],{"trials":9291,"activeCount":99},[9292],{"nctId":9293,"briefTitle":9294,"status":134,"phases":9295,"primaryCompletion":581,"completion":9296,"start":9297,"enrollment":9298,"conditions":9299,"interventions":9301},"NCT06338956","Optimal Attained LDL-Cholesterol Levels in Patients Who Achieved ≥50% LDL Reduction After PCI",[],"2025-05-15","2024-01-01",135877,[18,9300],"Hyperlipidemias",[9278],{"intervention":9303,"totalTrials":171,"cells":9304},"Antiplatelet Agents",{"EARLY_PHASE1":9305,"PHASE1":9307,"PHASE2":9309,"PHASE3":9311,"PHASE4":9313,"NA":9315},{"trials":9306,"activeCount":99},[],{"trials":9308,"activeCount":99},[],{"trials":9310,"activeCount":99},[],{"trials":9312,"activeCount":99},[],{"trials":9314,"activeCount":99},[],{"trials":9316,"activeCount":99},[9317],{"nctId":9318,"briefTitle":9319,"status":134,"phases":9320,"primaryCompletion":581,"completion":581,"start":1524,"enrollment":9321,"conditions":9322,"interventions":9324},"NCT06281041","Nationwide Cohort Study of Antiplatelet Agents as Primary Prevention",[],4657,[18,9323],"Coronary Artery Stenosis",[9303],{"intervention":9326,"totalTrials":171,"cells":9327},"Ibuprofen",{"EARLY_PHASE1":9328,"PHASE1":9330,"PHASE2":9332,"PHASE3":9334,"PHASE4":9336,"NA":9338},{"trials":9329,"activeCount":99},[],{"trials":9331,"activeCount":99},[],{"trials":9333,"activeCount":99},[],{"trials":9335,"activeCount":99},[],{"trials":9337,"activeCount":99},[],{"trials":9339,"activeCount":99},[9340],{"nctId":9341,"briefTitle":9342,"status":134,"phases":9343,"primaryCompletion":557,"completion":557,"start":1223,"enrollment":1099,"conditions":9344,"interventions":9345},"NCT02461056","Synergistic Effect of Ibuprofen and Hydromorphone for Postoperative Pain",[92],[21],[9326,9346],"Hydromorphone",{"intervention":9346,"totalTrials":171,"cells":9348},{"EARLY_PHASE1":9349,"PHASE1":9351,"PHASE2":9353,"PHASE3":9355,"PHASE4":9357,"NA":9359},{"trials":9350,"activeCount":99},[],{"trials":9352,"activeCount":99},[],{"trials":9354,"activeCount":99},[],{"trials":9356,"activeCount":99},[],{"trials":9358,"activeCount":99},[],{"trials":9360,"activeCount":99},[9361],{"nctId":9341,"briefTitle":9342,"status":134,"phases":9362,"primaryCompletion":557,"completion":557,"start":1223,"enrollment":1099,"conditions":9363,"interventions":9364},[92],[21],[9326,9346],{"intervention":9366,"totalTrials":171,"cells":9367},"Any treatment for cluster headache",{"EARLY_PHASE1":9368,"PHASE1":9370,"PHASE2":9372,"PHASE3":9374,"PHASE4":9376,"NA":9378},{"trials":9369,"activeCount":99},[],{"trials":9371,"activeCount":99},[],{"trials":9373,"activeCount":99},[],{"trials":9375,"activeCount":99},[],{"trials":9377,"activeCount":99},[],{"trials":9379,"activeCount":99},[9380],{"nctId":9381,"briefTitle":9382,"status":534,"phases":9383,"primaryCompletion":9384,"completion":9384,"start":4830,"enrollment":1702,"conditions":9385,"interventions":9388},"NCT02895256","Long-term Prognosis of Cluster Headache: a Retrospective Cohort Study",[],"2021-04",[9386,9387],"Cluster Headache","Disease Course",[9366],{"intervention":9390,"totalTrials":171,"cells":9391},"Omapone Peri 724mL or Winuf Peri 654mL",{"EARLY_PHASE1":9392,"PHASE1":9394,"PHASE2":9396,"PHASE3":9398,"PHASE4":9400,"NA":9402},{"trials":9393,"activeCount":99},[],{"trials":9395,"activeCount":99},[],{"trials":9397,"activeCount":99},[],{"trials":9399,"activeCount":99},[],{"trials":9401,"activeCount":99},[],{"trials":9403,"activeCount":99},[9404],{"nctId":9405,"briefTitle":9406,"status":134,"phases":9407,"primaryCompletion":9408,"completion":136,"start":9409,"enrollment":8262,"conditions":9410,"interventions":9413},"NCT04259307","Effect of Intensive Nutritional Support in Subacute Stroke Patient",[92],"2023-08-31","2020-01-29",[15,9411,9412],"Rehabilitation","Nutrition",[9390],{"intervention":9415,"totalTrials":171,"cells":9416},"Tamoxifen Oral",{"EARLY_PHASE1":9417,"PHASE1":9419,"PHASE2":9421,"PHASE3":9423,"PHASE4":9425,"NA":9427},{"trials":9418,"activeCount":99},[],{"trials":9420,"activeCount":99},[],{"trials":9422,"activeCount":99},[],{"trials":9424,"activeCount":99},[],{"trials":9426,"activeCount":99},[],{"trials":9428,"activeCount":99},[9429],{"nctId":9430,"briefTitle":9431,"status":534,"phases":9432,"primaryCompletion":9433,"completion":9433,"start":9434,"enrollment":1440,"conditions":9435,"interventions":9437},"NCT04116827","Sleep and Activity Patterns in Pre-menopausal Breast Cancer Patients on Tamoxifen Using a Wrist-worn Internet of Things Device",[],"2020-12-31","2018-08-10",[9436,21],"Sleep Disorder",[9415],{"intervention":9439,"totalTrials":171,"cells":9440},"immune check point inhibitors",{"EARLY_PHASE1":9441,"PHASE1":9443,"PHASE2":9445,"PHASE3":9447,"PHASE4":9449,"NA":9451},{"trials":9442,"activeCount":99},[],{"trials":9444,"activeCount":99},[],{"trials":9446,"activeCount":99},[],{"trials":9448,"activeCount":99},[],{"trials":9450,"activeCount":99},[],{"trials":9452,"activeCount":99},[9453],{"nctId":9454,"briefTitle":9455,"status":134,"phases":9456,"primaryCompletion":581,"completion":581,"start":9457,"enrollment":2913,"conditions":9458,"interventions":9460},"NCT07009600","Conversion Surgery After Target Therapy or Immunotherapy in Stage IV Gastric Cancer",[],"2010-01-01",[9459],"Gastric Cancer Stage IV",[9439],{"intervention":144,"totalTrials":171,"cells":9462},{"EARLY_PHASE1":9463,"PHASE1":9465,"PHASE2":9467,"PHASE3":9469,"PHASE4":9471,"NA":9473},{"trials":9464,"activeCount":99},[],{"trials":9466,"activeCount":99},[],{"trials":9468,"activeCount":99},[],{"trials":9470,"activeCount":99},[],{"trials":9472,"activeCount":99},[],{"trials":9474,"activeCount":99},[9475],{"nctId":132,"briefTitle":133,"status":134,"phases":9476,"primaryCompletion":136,"completion":136,"start":137,"enrollment":138,"conditions":9477,"interventions":9478},[],[140,141,142],[57,144,145],{"intervention":145,"totalTrials":171,"cells":9480},{"EARLY_PHASE1":9481,"PHASE1":9483,"PHASE2":9485,"PHASE3":9487,"PHASE4":9489,"NA":9491},{"trials":9482,"activeCount":99},[],{"trials":9484,"activeCount":99},[],{"trials":9486,"activeCount":99},[],{"trials":9488,"activeCount":99},[],{"trials":9490,"activeCount":99},[],{"trials":9492,"activeCount":99},[9493],{"nctId":132,"briefTitle":133,"status":134,"phases":9494,"primaryCompletion":136,"completion":136,"start":137,"enrollment":138,"conditions":9495,"interventions":9496},[],[140,141,142],[57,144,145],{"intervention":9498,"totalTrials":171,"cells":9499},"Mycophenolate mofetil, Corticosteroids",{"EARLY_PHASE1":9500,"PHASE1":9502,"PHASE2":9504,"PHASE3":9506,"PHASE4":9508,"NA":9510},{"trials":9501,"activeCount":99},[],{"trials":9503,"activeCount":99},[],{"trials":9505,"activeCount":99},[],{"trials":9507,"activeCount":99},[],{"trials":9509,"activeCount":99},[],{"trials":9511,"activeCount":99},[9512],{"nctId":9513,"briefTitle":9514,"status":534,"phases":9515,"primaryCompletion":1685,"completion":1685,"start":2149,"enrollment":9516,"conditions":9517,"interventions":9519},"NCT02095418","Comparison of New-onset Diabetes After Transplantation Between Two Steroid Withdrawal Group With CellCept",[92],152,[9518],"Diabetes",[9498,9520],"Corticosteroids, Mycophenolate mofetil",{"intervention":9520,"totalTrials":171,"cells":9522},{"EARLY_PHASE1":9523,"PHASE1":9525,"PHASE2":9527,"PHASE3":9529,"PHASE4":9531,"NA":9533},{"trials":9524,"activeCount":99},[],{"trials":9526,"activeCount":99},[],{"trials":9528,"activeCount":99},[],{"trials":9530,"activeCount":99},[],{"trials":9532,"activeCount":99},[],{"trials":9534,"activeCount":99},[9535],{"nctId":9513,"briefTitle":9514,"status":534,"phases":9536,"primaryCompletion":1685,"completion":1685,"start":2149,"enrollment":9516,"conditions":9537,"interventions":9538},[92],[9518],[9498,9520],{"intervention":9540,"totalTrials":171,"cells":9541},"Omega 3",{"EARLY_PHASE1":9542,"PHASE1":9544,"PHASE2":9546,"PHASE3":9548,"PHASE4":9550,"NA":9552},{"trials":9543,"activeCount":99},[],{"trials":9545,"activeCount":99},[],{"trials":9547,"activeCount":99},[],{"trials":9549,"activeCount":99},[],{"trials":9551,"activeCount":99},[],{"trials":9553,"activeCount":99},[9554],{"nctId":9555,"briefTitle":9556,"status":534,"phases":9557,"primaryCompletion":9558,"completion":9559,"start":9560,"enrollment":671,"conditions":9561,"interventions":9563},"NCT04411615","Effect of Re-esterified Triglyceride (rTG) Form Omega-3 Supplements on Dry Eye Following Cataract Surgery",[92],"2020-08-01","2021-02-28","2020-07-01",[9562],"Dry Eye",[9540],{"intervention":8742,"totalTrials":171,"cells":9565},{"EARLY_PHASE1":9566,"PHASE1":9568,"PHASE2":9570,"PHASE3":9572,"PHASE4":9574,"NA":9576},{"trials":9567,"activeCount":99},[],{"trials":9569,"activeCount":99},[],{"trials":9571,"activeCount":99},[],{"trials":9573,"activeCount":99},[],{"trials":9575,"activeCount":99},[],{"trials":9577,"activeCount":99},[9578],{"nctId":8735,"briefTitle":8736,"status":134,"phases":9579,"primaryCompletion":8738,"completion":8738,"start":2336,"enrollment":8739,"conditions":9580,"interventions":9581},[92],[8741,8729,8710,8742,8743,8744,8745],[8742,8710],{"intervention":9583,"totalTrials":171,"cells":9584},"spliceosome",{"EARLY_PHASE1":9585,"PHASE1":9587,"PHASE2":9589,"PHASE3":9591,"PHASE4":9593,"NA":9595},{"trials":9586,"activeCount":99},[],{"trials":9588,"activeCount":99},[],{"trials":9590,"activeCount":99},[],{"trials":9592,"activeCount":99},[],{"trials":9594,"activeCount":99},[],{"trials":9596,"activeCount":99},[9597],{"nctId":9598,"briefTitle":9599,"status":134,"phases":9600,"primaryCompletion":8515,"completion":2149,"start":1894,"enrollment":6496,"conditions":9601,"interventions":9602},"NCT02060409","Prognostic Molecular Markers in Patients With Myelodysplastic Syndrome",[],[5958],[9583],{"intervention":9604,"totalTrials":171,"cells":9605},"antidepressant response",{"EARLY_PHASE1":9606,"PHASE1":9608,"PHASE2":9610,"PHASE3":9612,"PHASE4":9614,"NA":9616},{"trials":9607,"activeCount":99},[],{"trials":9609,"activeCount":99},[],{"trials":9611,"activeCount":99},[],{"trials":9613,"activeCount":99},[],{"trials":9615,"activeCount":99},[],{"trials":9617,"activeCount":99},[9618],{"nctId":9619,"briefTitle":9620,"status":534,"phases":9621,"primaryCompletion":1750,"completion":1750,"start":9622,"enrollment":8334,"conditions":9623,"interventions":9624},"NCT01352572","Effects of Antidepressant on Postsynaptic Signal Transduction in Serotonergic System of Depressed Patients",[92],"2002-01",[8336],[9604,9625],"antidepressant non-response",{"intervention":9625,"totalTrials":171,"cells":9627},{"EARLY_PHASE1":9628,"PHASE1":9630,"PHASE2":9632,"PHASE3":9634,"PHASE4":9636,"NA":9638},{"trials":9629,"activeCount":99},[],{"trials":9631,"activeCount":99},[],{"trials":9633,"activeCount":99},[],{"trials":9635,"activeCount":99},[],{"trials":9637,"activeCount":99},[],{"trials":9639,"activeCount":99},[9640],{"nctId":9619,"briefTitle":9620,"status":534,"phases":9641,"primaryCompletion":1750,"completion":1750,"start":9622,"enrollment":8334,"conditions":9642,"interventions":9643},[92],[8336],[9604,9625],{"intervention":9645,"totalTrials":171,"cells":9646},"Genetic test",{"EARLY_PHASE1":9647,"PHASE1":9649,"PHASE2":9651,"PHASE3":9653,"PHASE4":9655,"NA":9657},{"trials":9648,"activeCount":99},[],{"trials":9650,"activeCount":99},[],{"trials":9652,"activeCount":99},[],{"trials":9654,"activeCount":99},[],{"trials":9656,"activeCount":99},[],{"trials":9658,"activeCount":99},[9659],{"nctId":9660,"briefTitle":9661,"status":534,"phases":9662,"primaryCompletion":9663,"completion":1097,"start":3219,"enrollment":112,"conditions":9664,"interventions":9665},"NCT02299622","Personalized Sequence for Thoracic, Esophageal, and H&N Cancer",[],"2022-11",[699],[9645],{"intervention":9667,"totalTrials":171,"cells":9668},"Chemotherapy with or without radiotherapy",{"EARLY_PHASE1":9669,"PHASE1":9671,"PHASE2":9673,"PHASE3":9675,"PHASE4":9677,"NA":9679},{"trials":9670,"activeCount":99},[],{"trials":9672,"activeCount":99},[],{"trials":9674,"activeCount":99},[],{"trials":9676,"activeCount":99},[],{"trials":9678,"activeCount":99},[],{"trials":9680,"activeCount":99},[9681],{"nctId":9682,"briefTitle":9683,"status":134,"phases":9684,"primaryCompletion":2712,"completion":2712,"start":1276,"enrollment":9685,"conditions":9686,"interventions":9687},"NCT00822731","Samsung Medical Center-Lymphoma Cohort Study",[92],953,[1588],[9667],{"intervention":9689,"totalTrials":171,"cells":9690},"Propafenone",{"EARLY_PHASE1":9691,"PHASE1":9693,"PHASE2":9695,"PHASE3":9697,"PHASE4":9699,"NA":9701},{"trials":9692,"activeCount":99},[],{"trials":9694,"activeCount":99},[],{"trials":9696,"activeCount":99},[],{"trials":9698,"activeCount":99},[],{"trials":9700,"activeCount":99},[],{"trials":9702,"activeCount":99},[9703],{"nctId":9704,"briefTitle":9705,"status":134,"phases":9706,"primaryCompletion":8515,"completion":8515,"start":7187,"enrollment":7903,"conditions":9707,"interventions":9708},"NCT01991119","Efficacy of Propafenone Versus Dronedarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation",[92],[8827],[9689,9709],"Dronedarone",{"intervention":9709,"totalTrials":171,"cells":9711},{"EARLY_PHASE1":9712,"PHASE1":9714,"PHASE2":9716,"PHASE3":9718,"PHASE4":9720,"NA":9722},{"trials":9713,"activeCount":99},[],{"trials":9715,"activeCount":99},[],{"trials":9717,"activeCount":99},[],{"trials":9719,"activeCount":99},[],{"trials":9721,"activeCount":99},[],{"trials":9723,"activeCount":99},[9724],{"nctId":9704,"briefTitle":9705,"status":134,"phases":9725,"primaryCompletion":8515,"completion":8515,"start":7187,"enrollment":7903,"conditions":9726,"interventions":9727},[92],[8827],[9689,9709],{"intervention":9729,"totalTrials":171,"cells":9730},"bladder tissue of Interstitial Cystitis and normal bladder tissue",{"EARLY_PHASE1":9731,"PHASE1":9733,"PHASE2":9735,"PHASE3":9737,"PHASE4":9739,"NA":9741},{"trials":9732,"activeCount":99},[],{"trials":9734,"activeCount":99},[],{"trials":9736,"activeCount":99},[],{"trials":9738,"activeCount":99},[],{"trials":9740,"activeCount":99},[],{"trials":9742,"activeCount":99},[9743],{"nctId":9744,"briefTitle":9745,"status":134,"phases":9746,"primaryCompletion":136,"completion":9747,"start":9748,"enrollment":2270,"conditions":9749,"interventions":9751},"NCT03523559","Genetic and Histopathologic Characteristics of Interstitial Cystitis",[],"2024-02-29","2018-03-31",[9750],"Interstitial Cystitis",[9729],{"intervention":194,"totalTrials":171,"cells":9753},{"EARLY_PHASE1":9754,"PHASE1":9756,"PHASE2":9758,"PHASE3":9760,"PHASE4":9762,"NA":9764},{"trials":9755,"activeCount":99},[],{"trials":9757,"activeCount":99},[],{"trials":9759,"activeCount":99},[],{"trials":9761,"activeCount":99},[],{"trials":9763,"activeCount":99},[],{"trials":9765,"activeCount":99},[9766],{"nctId":183,"briefTitle":184,"status":185,"phases":9767,"primaryCompletion":187,"completion":187,"start":188,"enrollment":99,"conditions":9768,"interventions":9769},[92],[190,191,192],[194,147],{"intervention":541,"totalTrials":171,"cells":9771},{"EARLY_PHASE1":9772,"PHASE1":9774,"PHASE2":9776,"PHASE3":9778,"PHASE4":9780,"NA":9782},{"trials":9773,"activeCount":99},[],{"trials":9775,"activeCount":99},[],{"trials":9777,"activeCount":99},[],{"trials":9779,"activeCount":99},[],{"trials":9781,"activeCount":99},[],{"trials":9783,"activeCount":99},[9784],{"nctId":532,"briefTitle":533,"status":534,"phases":9785,"primaryCompletion":536,"completion":537,"start":538,"enrollment":370,"conditions":9786,"interventions":9787},[92],[18],[375,541],{"intervention":9789,"totalTrials":171,"cells":9790},"patient controlled analgesia",{"EARLY_PHASE1":9791,"PHASE1":9793,"PHASE2":9795,"PHASE3":9797,"PHASE4":9799,"NA":9801},{"trials":9792,"activeCount":99},[],{"trials":9794,"activeCount":99},[],{"trials":9796,"activeCount":99},[],{"trials":9798,"activeCount":99},[],{"trials":9800,"activeCount":99},[],{"trials":9802,"activeCount":99},[9803],{"nctId":9804,"briefTitle":9805,"status":134,"phases":9806,"primaryCompletion":9807,"completion":9808,"start":9809,"enrollment":7809,"conditions":9810,"interventions":9813},"NCT03240562","Ultrasound-guided Block for Thoracic Surgery Pain",[92],"2017-11-30","2017-12-30","2017-08-03",[9811,9812],"Postoperative Pain","Thoracic Cancer",[9789],{"intervention":8855,"totalTrials":171,"cells":9815},{"EARLY_PHASE1":9816,"PHASE1":9818,"PHASE2":9820,"PHASE3":9822,"PHASE4":9824,"NA":9826},{"trials":9817,"activeCount":99},[],{"trials":9819,"activeCount":99},[],{"trials":9821,"activeCount":99},[],{"trials":9823,"activeCount":99},[],{"trials":9825,"activeCount":99},[],{"trials":9827,"activeCount":99},[9828],{"nctId":8845,"briefTitle":8846,"status":134,"phases":9829,"primaryCompletion":8848,"completion":8849,"start":8850,"enrollment":6222,"conditions":9830,"interventions":9831},[92],[3186,168,8852,8853],[588,8855,8856],{"intervention":8856,"totalTrials":171,"cells":9833},{"EARLY_PHASE1":9834,"PHASE1":9836,"PHASE2":9838,"PHASE3":9840,"PHASE4":9842,"NA":9844},{"trials":9835,"activeCount":99},[],{"trials":9837,"activeCount":99},[],{"trials":9839,"activeCount":99},[],{"trials":9841,"activeCount":99},[],{"trials":9843,"activeCount":99},[],{"trials":9845,"activeCount":99},[9846],{"nctId":8845,"briefTitle":8846,"status":134,"phases":9847,"primaryCompletion":8848,"completion":8849,"start":8850,"enrollment":6222,"conditions":9848,"interventions":9849},[92],[3186,168,8852,8853],[588,8855,8856],{"intervention":9851,"totalTrials":171,"cells":9852},"Methylphenidate",{"EARLY_PHASE1":9853,"PHASE1":9855,"PHASE2":9857,"PHASE3":9859,"PHASE4":9861,"NA":9863},{"trials":9854,"activeCount":99},[],{"trials":9856,"activeCount":99},[],{"trials":9858,"activeCount":99},[],{"trials":9860,"activeCount":99},[],{"trials":9862,"activeCount":99},[],{"trials":9864,"activeCount":99},[9865],{"nctId":9866,"briefTitle":9867,"status":534,"phases":9868,"primaryCompletion":2077,"completion":1098,"start":1050,"enrollment":1127,"conditions":9869,"interventions":9871},"NCT02482649","EAA\u002FTherapy for Treating Children With ADHD",[92],[9870],"Attention Deficit Hyperactivity Disorder",[9851,9872],"Atomoxetine",{"intervention":9872,"totalTrials":171,"cells":9874},{"EARLY_PHASE1":9875,"PHASE1":9877,"PHASE2":9879,"PHASE3":9881,"PHASE4":9883,"NA":9885},{"trials":9876,"activeCount":99},[],{"trials":9878,"activeCount":99},[],{"trials":9880,"activeCount":99},[],{"trials":9882,"activeCount":99},[],{"trials":9884,"activeCount":99},[],{"trials":9886,"activeCount":99},[9887],{"nctId":9866,"briefTitle":9867,"status":534,"phases":9888,"primaryCompletion":2077,"completion":1098,"start":1050,"enrollment":1127,"conditions":9889,"interventions":9890},[92],[9870],[9851,9872],{"intervention":9892,"totalTrials":171,"cells":9893},"Pregabalin",{"EARLY_PHASE1":9894,"PHASE1":9896,"PHASE2":9898,"PHASE3":9900,"PHASE4":9902,"NA":9904},{"trials":9895,"activeCount":99},[],{"trials":9897,"activeCount":99},[],{"trials":9899,"activeCount":99},[],{"trials":9901,"activeCount":99},[],{"trials":9903,"activeCount":99},[],{"trials":9905,"activeCount":99},[9906],{"nctId":9907,"briefTitle":9908,"status":534,"phases":9909,"primaryCompletion":6086,"completion":2712,"start":1274,"enrollment":1933,"conditions":9910,"interventions":9912},"NCT01370915","Perioperative Administration of Pregabalin for Pain After Septoplasty",[92],[9911],"Deviated Nasal Septum",[9892,9913],"Vitamin complex",{"intervention":9913,"totalTrials":171,"cells":9915},{"EARLY_PHASE1":9916,"PHASE1":9918,"PHASE2":9920,"PHASE3":9922,"PHASE4":9924,"NA":9926},{"trials":9917,"activeCount":99},[],{"trials":9919,"activeCount":99},[],{"trials":9921,"activeCount":99},[],{"trials":9923,"activeCount":99},[],{"trials":9925,"activeCount":99},[],{"trials":9927,"activeCount":99},[9928],{"nctId":9907,"briefTitle":9908,"status":534,"phases":9929,"primaryCompletion":6086,"completion":2712,"start":1274,"enrollment":1933,"conditions":9930,"interventions":9931},[92],[9911],[9892,9913],{"intervention":9933,"totalTrials":171,"cells":9934},"human Wharton's jelly-derived mesenchymal stem cells",{"EARLY_PHASE1":9935,"PHASE1":9937,"PHASE2":9939,"PHASE3":9941,"PHASE4":9943,"NA":9945},{"trials":9936,"activeCount":99},[],{"trials":9938,"activeCount":99},[],{"trials":9940,"activeCount":99},[],{"trials":9942,"activeCount":99},[],{"trials":9944,"activeCount":99},[],{"trials":9946,"activeCount":99},[9947],{"nctId":9948,"briefTitle":9949,"status":134,"phases":9950,"primaryCompletion":9951,"completion":9951,"start":9952,"enrollment":95,"conditions":9953,"interventions":9955},"NCT06218134","Evaluate the Safety and Potential Efficacy of Human Wharton's Jelly-derived Mesenchymal Stem Cells With Charcot-Marie-Tooth Disease Type 1E",[92],"2024-10-28","2024-05-23",[9954],"Charcot-Marie-Tooth Disease, Type 1",[9933],{"intervention":9957,"totalTrials":171,"cells":9958},"responders",{"EARLY_PHASE1":9959,"PHASE1":9961,"PHASE2":9963,"PHASE3":9965,"PHASE4":9967,"NA":9969},{"trials":9960,"activeCount":99},[],{"trials":9962,"activeCount":99},[],{"trials":9964,"activeCount":99},[],{"trials":9966,"activeCount":99},[],{"trials":9968,"activeCount":99},[],{"trials":9970,"activeCount":99},[9971],{"nctId":9972,"briefTitle":9973,"status":534,"phases":9974,"primaryCompletion":2689,"completion":1750,"start":9975,"enrollment":8345,"conditions":9976,"interventions":9977},"NCT01352559","Prediction of Antidepressant Response Using Pharmacogenetics and Peripheral Lymphocytic Phenotype",[92],"2001-11",[8336],[9957,9978],"non-responders",{"intervention":9978,"totalTrials":171,"cells":9980},{"EARLY_PHASE1":9981,"PHASE1":9983,"PHASE2":9985,"PHASE3":9987,"PHASE4":9989,"NA":9991},{"trials":9982,"activeCount":99},[],{"trials":9984,"activeCount":99},[],{"trials":9986,"activeCount":99},[],{"trials":9988,"activeCount":99},[],{"trials":9990,"activeCount":99},[],{"trials":9992,"activeCount":99},[9993],{"nctId":9972,"briefTitle":9973,"status":534,"phases":9994,"primaryCompletion":2689,"completion":1750,"start":9975,"enrollment":8345,"conditions":9995,"interventions":9996},[92],[8336],[9957,9978],{"intervention":9998,"totalTrials":171,"cells":9999},"Pralatrexate",{"EARLY_PHASE1":10000,"PHASE1":10002,"PHASE2":10004,"PHASE3":10006,"PHASE4":10008,"NA":10010},{"trials":10001,"activeCount":99},[],{"trials":10003,"activeCount":99},[],{"trials":10005,"activeCount":99},[],{"trials":10007,"activeCount":99},[],{"trials":10009,"activeCount":99},[],{"trials":10011,"activeCount":99},[10012],{"nctId":10013,"briefTitle":10014,"status":134,"phases":10015,"primaryCompletion":1841,"completion":1841,"start":10016,"enrollment":1688,"conditions":10017,"interventions":10019},"NCT03356678","Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma",[],"2016-09-23",[10018],"Relapsed or Refractory Peripheral T-cell Lymphoma",[9998],{"intervention":10021,"totalTrials":171,"cells":10022},"Vasopressin",{"EARLY_PHASE1":10023,"PHASE1":10025,"PHASE2":10027,"PHASE3":10029,"PHASE4":10031,"NA":10033},{"trials":10024,"activeCount":99},[],{"trials":10026,"activeCount":99},[],{"trials":10028,"activeCount":99},[],{"trials":10030,"activeCount":99},[],{"trials":10032,"activeCount":99},[],{"trials":10034,"activeCount":99},[10035],{"nctId":10036,"briefTitle":10037,"status":1816,"phases":10038,"primaryCompletion":1736,"completion":1736,"start":2712,"enrollment":3688,"conditions":10039,"interventions":10041},"NCT01493102","Discontinuation Order of Vasopressors in Septic Shock",[92],[10040],"Septic Shock",[10021,10042],"Norepinephrine",{"intervention":10042,"totalTrials":171,"cells":10044},{"EARLY_PHASE1":10045,"PHASE1":10047,"PHASE2":10049,"PHASE3":10051,"PHASE4":10053,"NA":10055},{"trials":10046,"activeCount":99},[],{"trials":10048,"activeCount":99},[],{"trials":10050,"activeCount":99},[],{"trials":10052,"activeCount":99},[],{"trials":10054,"activeCount":99},[],{"trials":10056,"activeCount":99},[10057],{"nctId":10036,"briefTitle":10037,"status":1816,"phases":10058,"primaryCompletion":1736,"completion":1736,"start":2712,"enrollment":3688,"conditions":10059,"interventions":10060},[92],[10040],[10021,10042],{"intervention":10062,"totalTrials":171,"cells":10063},"Intensive lipid lowering plus Omega3-fatty acid",{"EARLY_PHASE1":10064,"PHASE1":10066,"PHASE2":10068,"PHASE3":10070,"PHASE4":10072,"NA":10074},{"trials":10065,"activeCount":99},[],{"trials":10067,"activeCount":99},[],{"trials":10069,"activeCount":99},[],{"trials":10071,"activeCount":99},[],{"trials":10073,"activeCount":99},[],{"trials":10075,"activeCount":99},[10076],{"nctId":10077,"briefTitle":10078,"status":534,"phases":10079,"primaryCompletion":3687,"start":4141,"enrollment":228,"conditions":10080,"interventions":10082},"NCT00760786","Effects of Intensive Lipid Lowering and Omega-3 Fatty Acid on Composition of Coronary Atherosclerotic Plaque",[92],[10081],"Acute Coronary Syndrome",[10062,10083,10084,10085],"Moderate lipid lowering plus Omega3-fatty acid","Intensive lipid lowering plus placebo","Moderate lipid lowering plus placebo",{"intervention":10083,"totalTrials":171,"cells":10087},{"EARLY_PHASE1":10088,"PHASE1":10090,"PHASE2":10092,"PHASE3":10094,"PHASE4":10096,"NA":10098},{"trials":10089,"activeCount":99},[],{"trials":10091,"activeCount":99},[],{"trials":10093,"activeCount":99},[],{"trials":10095,"activeCount":99},[],{"trials":10097,"activeCount":99},[],{"trials":10099,"activeCount":99},[10100],{"nctId":10077,"briefTitle":10078,"status":534,"phases":10101,"primaryCompletion":3687,"start":4141,"enrollment":228,"conditions":10102,"interventions":10103},[92],[10081],[10062,10083,10084,10085],{"intervention":10084,"totalTrials":171,"cells":10105},{"EARLY_PHASE1":10106,"PHASE1":10108,"PHASE2":10110,"PHASE3":10112,"PHASE4":10114,"NA":10116},{"trials":10107,"activeCount":99},[],{"trials":10109,"activeCount":99},[],{"trials":10111,"activeCount":99},[],{"trials":10113,"activeCount":99},[],{"trials":10115,"activeCount":99},[],{"trials":10117,"activeCount":99},[10118],{"nctId":10077,"briefTitle":10078,"status":534,"phases":10119,"primaryCompletion":3687,"start":4141,"enrollment":228,"conditions":10120,"interventions":10121},[92],[10081],[10062,10083,10084,10085],{"intervention":10085,"totalTrials":171,"cells":10123},{"EARLY_PHASE1":10124,"PHASE1":10126,"PHASE2":10128,"PHASE3":10130,"PHASE4":10132,"NA":10134},{"trials":10125,"activeCount":99},[],{"trials":10127,"activeCount":99},[],{"trials":10129,"activeCount":99},[],{"trials":10131,"activeCount":99},[],{"trials":10133,"activeCount":99},[],{"trials":10135,"activeCount":99},[10136],{"nctId":10077,"briefTitle":10078,"status":534,"phases":10137,"primaryCompletion":3687,"start":4141,"enrollment":228,"conditions":10138,"interventions":10139},[92],[10081],[10062,10083,10084,10085],{"intervention":10141,"totalTrials":171,"cells":10142},"Bendamustine",{"EARLY_PHASE1":10143,"PHASE1":10145,"PHASE2":10147,"PHASE3":10149,"PHASE4":10151,"NA":10153},{"trials":10144,"activeCount":99},[],{"trials":10146,"activeCount":99},[],{"trials":10148,"activeCount":99},[],{"trials":10150,"activeCount":99},[],{"trials":10152,"activeCount":99},[],{"trials":10154,"activeCount":99},[10155],{"nctId":10156,"briefTitle":10157,"status":534,"phases":10158,"primaryCompletion":9433,"completion":9433,"start":3353,"enrollment":645,"conditions":10159,"interventions":10160},"NCT04127916","Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL)",[],[5501],[10141],{"intervention":10162,"totalTrials":171,"cells":10163},"high dose proton pump inhibitor",{"EARLY_PHASE1":10164,"PHASE1":10166,"PHASE2":10168,"PHASE3":10170,"PHASE4":10172,"NA":10174},{"trials":10165,"activeCount":99},[],{"trials":10167,"activeCount":99},[],{"trials":10169,"activeCount":99},[],{"trials":10171,"activeCount":99},[],{"trials":10173,"activeCount":99},[],{"trials":10175,"activeCount":99},[10176],{"nctId":10177,"briefTitle":10178,"status":534,"phases":10179,"primaryCompletion":1274,"completion":1274,"start":1784,"enrollment":10180,"conditions":10181,"interventions":10183},"NCT01179724","Comparison of Proton Pump Inhibitor and H2 Receptor Blocker on Prevention of Bleeding From Iatrogenic Ulcer After Endoscopic Submucosal Dissection for Gastric Neoplasms: A Prospective Randomized Controlled Trial",[92],206,[10182],"Delayed Bleeding",[10162,10184],"H2RB",{"intervention":10184,"totalTrials":171,"cells":10186},{"EARLY_PHASE1":10187,"PHASE1":10189,"PHASE2":10191,"PHASE3":10193,"PHASE4":10195,"NA":10197},{"trials":10188,"activeCount":99},[],{"trials":10190,"activeCount":99},[],{"trials":10192,"activeCount":99},[],{"trials":10194,"activeCount":99},[],{"trials":10196,"activeCount":99},[],{"trials":10198,"activeCount":99},[10199],{"nctId":10177,"briefTitle":10178,"status":534,"phases":10200,"primaryCompletion":1274,"completion":1274,"start":1784,"enrollment":10180,"conditions":10201,"interventions":10202},[92],[10182],[10162,10184],{"intervention":10204,"totalTrials":171,"cells":10205},"Vancomycin HCL",{"EARLY_PHASE1":10206,"PHASE1":10208,"PHASE2":10210,"PHASE3":10212,"PHASE4":10214,"NA":10216},{"trials":10207,"activeCount":99},[],{"trials":10209,"activeCount":99},[],{"trials":10211,"activeCount":99},[],{"trials":10213,"activeCount":99},[],{"trials":10215,"activeCount":99},[],{"trials":10217,"activeCount":99},[10218],{"nctId":10219,"briefTitle":10220,"status":134,"phases":10221,"primaryCompletion":2759,"completion":2759,"start":1222,"enrollment":1440,"conditions":10222,"interventions":10224},"NCT01623817","Effectiveness of Vancomycin Loading Therapy",[92],[10223],"Infection",[10204],{"intervention":8942,"totalTrials":171,"cells":10226},{"EARLY_PHASE1":10227,"PHASE1":10229,"PHASE2":10231,"PHASE3":10233,"PHASE4":10235,"NA":10237},{"trials":10228,"activeCount":99},[],{"trials":10230,"activeCount":99},[],{"trials":10232,"activeCount":99},[],{"trials":10234,"activeCount":99},[],{"trials":10236,"activeCount":99},[],{"trials":10238,"activeCount":99},[10239],{"nctId":8935,"briefTitle":8936,"status":134,"phases":10240,"primaryCompletion":3382,"completion":8938,"start":5643,"enrollment":228,"conditions":10241,"interventions":10242},[92],[8827,8940],[1887,8942],{"intervention":8965,"totalTrials":171,"cells":10244},{"EARLY_PHASE1":10245,"PHASE1":10247,"PHASE2":10249,"PHASE3":10251,"PHASE4":10253,"NA":10255},{"trials":10246,"activeCount":99},[],{"trials":10248,"activeCount":99},[],{"trials":10250,"activeCount":99},[],{"trials":10252,"activeCount":99},[],{"trials":10254,"activeCount":99},[],{"trials":10256,"activeCount":99},[10257],{"nctId":8959,"briefTitle":8960,"status":134,"phases":10258,"primaryCompletion":2197,"completion":2554,"start":6164,"enrollment":1648,"conditions":10259,"interventions":10260},[92],[8963],[8944,8965],{"intervention":10262,"totalTrials":171,"cells":10263},"Visium, Whole Genome Sequencing",{"EARLY_PHASE1":10264,"PHASE1":10266,"PHASE2":10268,"PHASE3":10270,"PHASE4":10272,"NA":10274},{"trials":10265,"activeCount":99},[],{"trials":10267,"activeCount":99},[],{"trials":10269,"activeCount":99},[],{"trials":10271,"activeCount":99},[],{"trials":10273,"activeCount":99},[],{"trials":10275,"activeCount":99},[10276],{"nctId":10277,"briefTitle":10278,"status":534,"phases":10279,"primaryCompletion":80,"completion":80,"start":10280,"enrollment":1717,"conditions":10281,"interventions":10285},"NCT05910710","Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer",[],"2023-03-02",[10282,10283,1240,10284],"Triple Negative Breast Cancer","Neoadjuvant Chemotherapy","Tumor Microenvironment",[10262],{"intervention":10287,"totalTrials":171,"cells":10288},"human umbilical cord blood derived mesenchymal stem cells",{"EARLY_PHASE1":10289,"PHASE1":10291,"PHASE2":10293,"PHASE3":10295,"PHASE4":10297,"NA":10299},{"trials":10290,"activeCount":99},[],{"trials":10292,"activeCount":99},[],{"trials":10294,"activeCount":99},[],{"trials":10296,"activeCount":99},[],{"trials":10298,"activeCount":99},[],{"trials":10300,"activeCount":99},[10301],{"nctId":10302,"briefTitle":10303,"status":534,"phases":10304,"primaryCompletion":10305,"completion":3910,"start":10306,"enrollment":614,"conditions":10307,"interventions":10308},"NCT04954534","Exploratory Efficacy Study of NEUROSTEM® in Subjects Who Control Group of NEUROSTEM®",[92],"2022-01-31","2021-07-12",[3738],[10287],{"intervention":10310,"totalTrials":171,"cells":10311},"Mirtazapine",{"EARLY_PHASE1":10312,"PHASE1":10314,"PHASE2":10316,"PHASE3":10318,"PHASE4":10320,"NA":10322},{"trials":10313,"activeCount":99},[],{"trials":10315,"activeCount":99},[],{"trials":10317,"activeCount":99},[],{"trials":10319,"activeCount":99},[],{"trials":10321,"activeCount":99},[],{"trials":10323,"activeCount":99},[10324],{"nctId":10325,"briefTitle":10326,"status":534,"phases":10327,"primaryCompletion":1049,"completion":1750,"start":8344,"enrollment":1933,"conditions":10328,"interventions":10329},"NCT01039740","Pharmacogenetic Study of Mirtazapine Response in Depressed Patients",[92],[8336],[10310],{"intervention":587,"totalTrials":171,"cells":10331},{"EARLY_PHASE1":10332,"PHASE1":10334,"PHASE2":10336,"PHASE3":10338,"PHASE4":10340,"NA":10342},{"trials":10333,"activeCount":99},[],{"trials":10335,"activeCount":99},[],{"trials":10337,"activeCount":99},[],{"trials":10339,"activeCount":99},[],{"trials":10341,"activeCount":99},[],{"trials":10343,"activeCount":99},[10344],{"nctId":577,"briefTitle":578,"status":534,"phases":10345,"primaryCompletion":580,"completion":581,"start":582,"enrollment":583,"conditions":10346,"interventions":10347},[92],[585],[587,588,589],{"intervention":10349,"totalTrials":171,"cells":10350},"administration of hydroxyehtyl starch",{"EARLY_PHASE1":10351,"PHASE1":10353,"PHASE2":10355,"PHASE3":10357,"PHASE4":10359,"NA":10361},{"trials":10352,"activeCount":99},[],{"trials":10354,"activeCount":99},[],{"trials":10356,"activeCount":99},[],{"trials":10358,"activeCount":99},[],{"trials":10360,"activeCount":99},[],{"trials":10362,"activeCount":99},[10363],{"nctId":10364,"briefTitle":10365,"status":534,"phases":10366,"start":8480,"conditions":10367,"interventions":10369},"NCT00518544","Hemostatic Effect of Various Colloid Solutions",[92],[10368],"Laminectomy",[10349],{"intervention":10371,"totalTrials":171,"cells":10372},"EGFR TKIs",{"EARLY_PHASE1":10373,"PHASE1":10375,"PHASE2":10377,"PHASE3":10379,"PHASE4":10381,"NA":10383},{"trials":10374,"activeCount":99},[],{"trials":10376,"activeCount":99},[],{"trials":10378,"activeCount":99},[],{"trials":10380,"activeCount":99},[],{"trials":10382,"activeCount":99},[],{"trials":10384,"activeCount":99},[10385],{"nctId":10386,"briefTitle":10387,"status":534,"phases":10388,"primaryCompletion":2995,"completion":3532,"start":1222,"enrollment":112,"conditions":10389,"interventions":10391},"NCT01776684","Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis",[92],[10390],"EGFR Mutation Positive Non-small Cell Lung Cancer",[10371],{"intervention":10393,"totalTrials":171,"cells":10394},"PPI",{"EARLY_PHASE1":10395,"PHASE1":10397,"PHASE2":10399,"PHASE3":10401,"PHASE4":10403,"NA":10405},{"trials":10396,"activeCount":99},[],{"trials":10398,"activeCount":99},[],{"trials":10400,"activeCount":99},[],{"trials":10402,"activeCount":99},[],{"trials":10404,"activeCount":99},[],{"trials":10406,"activeCount":99},[10407],{"nctId":10408,"briefTitle":10409,"status":534,"phases":10410,"primaryCompletion":581,"completion":80,"start":10411,"enrollment":10412,"conditions":10413,"interventions":10414},"NCT06241833","Emulation of Randomized Clinical Trial in Cardiovascular Disease",[],"2023-05-30",118420,[277,18],[10393],{"intervention":10416,"totalTrials":171,"cells":10417},"oral contraceptive",{"EARLY_PHASE1":10418,"PHASE1":10420,"PHASE2":10422,"PHASE3":10424,"PHASE4":10426,"NA":10428},{"trials":10419,"activeCount":99},[],{"trials":10421,"activeCount":99},[],{"trials":10423,"activeCount":99},[],{"trials":10425,"activeCount":99},[],{"trials":10427,"activeCount":99},[],{"trials":10429,"activeCount":99},[10430],{"nctId":10431,"briefTitle":10432,"status":534,"phases":10433,"primaryCompletion":1223,"start":3220,"enrollment":7035,"conditions":10434,"interventions":10436},"NCT01414530","Oral Contraceptive During Menopausal Transition",[92],[10435],"Perimenopause",[10416,10437],"NSAID",{"intervention":10437,"totalTrials":171,"cells":10439},{"EARLY_PHASE1":10440,"PHASE1":10442,"PHASE2":10444,"PHASE3":10446,"PHASE4":10448,"NA":10450},{"trials":10441,"activeCount":99},[],{"trials":10443,"activeCount":99},[],{"trials":10445,"activeCount":99},[],{"trials":10447,"activeCount":99},[],{"trials":10449,"activeCount":99},[],{"trials":10451,"activeCount":99},[10452],{"nctId":10431,"briefTitle":10432,"status":534,"phases":10453,"primaryCompletion":1223,"start":3220,"enrollment":7035,"conditions":10454,"interventions":10455},[92],[10435],[10416,10437],{"intervention":10457,"totalTrials":171,"cells":10458},"Tamsulosin 0.4mg",{"EARLY_PHASE1":10459,"PHASE1":10461,"PHASE2":10463,"PHASE3":10465,"PHASE4":10467,"NA":10469},{"trials":10460,"activeCount":99},[],{"trials":10462,"activeCount":99},[],{"trials":10464,"activeCount":99},[],{"trials":10466,"activeCount":99},[],{"trials":10468,"activeCount":99},[],{"trials":10470,"activeCount":99},[10471],{"nctId":10472,"briefTitle":10473,"status":534,"phases":10474,"primaryCompletion":2851,"completion":8515,"start":6672,"enrollment":2736,"conditions":10475,"interventions":10476},"NCT01404637","Effects of Tamsulosin 0.4mg on Clinical Outcomes in Korean Men With Severe Symptomatic Benign Prostatic Hyperplasia (BPH)",[92],[33],[10457,10477],"Tamsulosin 0.2mg",{"intervention":10477,"totalTrials":171,"cells":10479},{"EARLY_PHASE1":10480,"PHASE1":10482,"PHASE2":10484,"PHASE3":10486,"PHASE4":10488,"NA":10490},{"trials":10481,"activeCount":99},[],{"trials":10483,"activeCount":99},[],{"trials":10485,"activeCount":99},[],{"trials":10487,"activeCount":99},[],{"trials":10489,"activeCount":99},[],{"trials":10491,"activeCount":99},[10492],{"nctId":10472,"briefTitle":10473,"status":534,"phases":10493,"primaryCompletion":2851,"completion":8515,"start":6672,"enrollment":2736,"conditions":10494,"interventions":10495},[92],[33],[10457,10477],{"intervention":10497,"totalTrials":171,"cells":10498},"P2Y12 inhibitor",{"EARLY_PHASE1":10499,"PHASE1":10501,"PHASE2":10503,"PHASE3":10505,"PHASE4":10507,"NA":10509},{"trials":10500,"activeCount":99},[],{"trials":10502,"activeCount":99},[],{"trials":10504,"activeCount":99},[],{"trials":10506,"activeCount":99},[],{"trials":10508,"activeCount":99},[],{"trials":10510,"activeCount":99},[10511],{"nctId":10512,"briefTitle":10513,"status":534,"phases":10514,"primaryCompletion":10515,"completion":10516,"start":6961,"enrollment":10517,"conditions":10518,"interventions":10519},"NCT01701453","Safety of 6-month Duration of Dual Antiplatelet Therapy After Acute Coronary Syndromes (SMART-DATE)",[92],"2017-11","2019-11",2712,[10081],[10497],{"intervention":10521,"totalTrials":171,"cells":10522},"Anticoagulation treatment.",{"EARLY_PHASE1":10523,"PHASE1":10525,"PHASE2":10527,"PHASE3":10529,"PHASE4":10531,"NA":10533},{"trials":10524,"activeCount":99},[],{"trials":10526,"activeCount":99},[],{"trials":10528,"activeCount":99},[],{"trials":10530,"activeCount":99},[],{"trials":10532,"activeCount":99},[],{"trials":10534,"activeCount":99},[10535],{"nctId":10536,"briefTitle":10537,"status":534,"phases":10538,"primaryCompletion":1750,"completion":1750,"start":3265,"enrollment":1785,"conditions":10539,"interventions":10540},"NCT02743052","Anticoagulation in Cancer Related Stroke",[],[6782,15],[10521],{"intervention":10542,"totalTrials":171,"cells":10543},"Dapagliflozin Propanediol Hydrate 12.3 mg",{"EARLY_PHASE1":10544,"PHASE1":10546,"PHASE2":10548,"PHASE3":10550,"PHASE4":10552,"NA":10554},{"trials":10545,"activeCount":99},[],{"trials":10547,"activeCount":99},[],{"trials":10549,"activeCount":99},[],{"trials":10551,"activeCount":99},[],{"trials":10553,"activeCount":99},[],{"trials":10555,"activeCount":99},[10556],{"nctId":10557,"briefTitle":10558,"status":534,"phases":10559,"primaryCompletion":10560,"completion":10561,"start":10562,"enrollment":773,"conditions":10563,"interventions":10565},"NCT05686616","SGLT2 Inhibitor for Severe Tricuspid Regurgitation",[92],"2024-04-13","2025-03-03","2022-04-13",[10564],"Tricuspid Regurgitation",[10542],{"intervention":10567,"totalTrials":171,"cells":10568},"Hyaluronic Acid and Chondroitin Sulfate",{"EARLY_PHASE1":10569,"PHASE1":10571,"PHASE2":10573,"PHASE3":10575,"PHASE4":10577,"NA":10579},{"trials":10570,"activeCount":99},[],{"trials":10572,"activeCount":99},[],{"trials":10574,"activeCount":99},[],{"trials":10576,"activeCount":99},[],{"trials":10578,"activeCount":99},[],{"trials":10580,"activeCount":99},[10581],{"nctId":10582,"briefTitle":10583,"status":134,"phases":10584,"primaryCompletion":10585,"completion":5031,"start":10586,"enrollment":3122,"conditions":10587,"interventions":10588},"NCT03463499","The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis\u002FBladder Pain Syndrome Patients",[92],"2019-09-30","2017-09-22",[9750],[10567],{"intervention":10590,"totalTrials":171,"cells":10591},"galantamine",{"EARLY_PHASE1":10592,"PHASE1":10594,"PHASE2":10596,"PHASE3":10598,"PHASE4":10600,"NA":10602},{"trials":10593,"activeCount":99},[],{"trials":10595,"activeCount":99},[],{"trials":10597,"activeCount":99},[],{"trials":10599,"activeCount":99},[],{"trials":10601,"activeCount":99},[],{"trials":10603,"activeCount":99},[10604],{"nctId":10605,"briefTitle":10606,"status":134,"phases":10607,"primaryCompletion":3265,"completion":3265,"start":8488,"enrollment":4708,"conditions":10608,"interventions":10609},"NCT01029132","Characteristics of Treatment Responders to Galantamine",[92],[8579],[10590],{"intervention":10611,"totalTrials":171,"cells":10612},"Candesartan",{"EARLY_PHASE1":10613,"PHASE1":10615,"PHASE2":10617,"PHASE3":10619,"PHASE4":10621,"NA":10623},{"trials":10614,"activeCount":99},[],{"trials":10616,"activeCount":99},[],{"trials":10618,"activeCount":99},[],{"trials":10620,"activeCount":99},[],{"trials":10622,"activeCount":99},[],{"trials":10624,"activeCount":99},[10625],{"nctId":10626,"briefTitle":10627,"status":534,"phases":10628,"primaryCompletion":10629,"completion":10630,"start":10631,"enrollment":8470,"conditions":10632,"interventions":10636},"NCT04429633","Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer",[92],"2022-07-18","2023-07-18","2019-07-19",[10633,21,10634,10635,1119],"Cardiotoxicity","Prevention","Adjuvant",[10611],{"intervention":10638,"totalTrials":171,"cells":10639},"Atorvastatin, pre-treatment 80 mg\u002Fday for 4 days before PCI",{"EARLY_PHASE1":10640,"PHASE1":10642,"PHASE2":10644,"PHASE3":10646,"PHASE4":10648,"NA":10650},{"trials":10641,"activeCount":99},[],{"trials":10643,"activeCount":99},[],{"trials":10645,"activeCount":99},[],{"trials":10647,"activeCount":99},[],{"trials":10649,"activeCount":99},[],{"trials":10651,"activeCount":99},[10652],{"nctId":10653,"briefTitle":10654,"status":534,"phases":10655,"primaryCompletion":4254,"completion":4254,"start":2759,"enrollment":2387,"conditions":10656,"interventions":10657},"NCT01751295","Statin and Post-interventional Coronary Microcirculation Dysfunction",[92],[18],[10638],{"intervention":10659,"totalTrials":171,"cells":10660},"Isoflurane",{"EARLY_PHASE1":10661,"PHASE1":10663,"PHASE2":10665,"PHASE3":10667,"PHASE4":10669,"NA":10671},{"trials":10662,"activeCount":99},[],{"trials":10664,"activeCount":99},[],{"trials":10666,"activeCount":99},[],{"trials":10668,"activeCount":99},[],{"trials":10670,"activeCount":99},[],{"trials":10672,"activeCount":99},[10673],{"nctId":10674,"briefTitle":10675,"status":134,"phases":10676,"primaryCompletion":2759,"completion":2759,"start":4301,"enrollment":10677,"conditions":10678,"interventions":10680},"NCT02222142","Volatile Versus Propofol Anesthesia in OPCAB",[],1080,[10679],"Off Pump Coronary Artery Bypass Graft",[10659],{"intervention":10682,"totalTrials":171,"cells":10683},"tissue biopsy, blood sample",{"EARLY_PHASE1":10684,"PHASE1":10686,"PHASE2":10688,"PHASE3":10690,"PHASE4":10692,"NA":10694},{"trials":10685,"activeCount":99},[],{"trials":10687,"activeCount":99},[],{"trials":10689,"activeCount":99},[],{"trials":10691,"activeCount":99},[],{"trials":10693,"activeCount":99},[],{"trials":10695,"activeCount":99},[10696],{"nctId":10697,"briefTitle":10698,"status":534,"phases":10699,"primaryCompletion":10700,"completion":7210,"start":10701,"enrollment":1933,"conditions":10702,"interventions":10704},"NCT03401359","The Resistance and Immune Response to Palbociclib in Breast Cancer",[92],"2020-10-31","2017-10-24",[10703],"Breast Cancer Stage IV",[10682],{"intervention":10706,"totalTrials":171,"cells":10707},"iv-PCA",{"EARLY_PHASE1":10708,"PHASE1":10710,"PHASE2":10712,"PHASE3":10714,"PHASE4":10716,"NA":10718},{"trials":10709,"activeCount":99},[],{"trials":10711,"activeCount":99},[],{"trials":10713,"activeCount":99},[],{"trials":10715,"activeCount":99},[],{"trials":10717,"activeCount":99},[],{"trials":10719,"activeCount":99},[10720],{"nctId":10721,"briefTitle":10722,"status":134,"phases":10723,"primaryCompletion":10724,"completion":10724,"start":1156,"enrollment":1842,"conditions":10725,"interventions":10727},"NCT02491385","Thoracic Epidural for Postoperative Ileus",[92],"2015-03",[10726],"Ileus",[10706],{"intervention":10729,"totalTrials":171,"cells":10730},"tacrolimus",{"EARLY_PHASE1":10731,"PHASE1":10733,"PHASE2":10735,"PHASE3":10737,"PHASE4":10739,"NA":10741},{"trials":10732,"activeCount":99},[],{"trials":10734,"activeCount":99},[],{"trials":10736,"activeCount":99},[],{"trials":10738,"activeCount":99},[],{"trials":10740,"activeCount":99},[],{"trials":10742,"activeCount":99},[10743],{"nctId":10744,"briefTitle":10745,"status":134,"phases":10746,"primaryCompletion":1859,"completion":1859,"start":10747,"enrollment":10748,"conditions":10749,"interventions":10752},"NCT00777933","Randomized Trial of Cyclosporine and Tacrolimus Therapy With Steroid Withdrawal in Living-Donor Renal Transplantation",[92],"2000-07",131,[10750,10751],"Kidney Transplantation","Living Donors",[10729,10753],"cyclosporine",{"intervention":10753,"totalTrials":171,"cells":10755},{"EARLY_PHASE1":10756,"PHASE1":10758,"PHASE2":10760,"PHASE3":10762,"PHASE4":10764,"NA":10766},{"trials":10757,"activeCount":99},[],{"trials":10759,"activeCount":99},[],{"trials":10761,"activeCount":99},[],{"trials":10763,"activeCount":99},[],{"trials":10765,"activeCount":99},[],{"trials":10767,"activeCount":99},[10768],{"nctId":10744,"briefTitle":10745,"status":134,"phases":10769,"primaryCompletion":1859,"completion":1859,"start":10747,"enrollment":10748,"conditions":10770,"interventions":10771},[92],[10750,10751],[10729,10753],{"intervention":10773,"totalTrials":171,"cells":10774},"Proton pump inhibitor",{"EARLY_PHASE1":10775,"PHASE1":10777,"PHASE2":10779,"PHASE3":10781,"PHASE4":10783,"NA":10785},{"trials":10776,"activeCount":99},[],{"trials":10778,"activeCount":99},[],{"trials":10780,"activeCount":99},[],{"trials":10782,"activeCount":99},[],{"trials":10784,"activeCount":99},[],{"trials":10786,"activeCount":99},[10787],{"nctId":10788,"briefTitle":10789,"status":534,"phases":10790,"primaryCompletion":4230,"start":10791,"enrollment":1933,"conditions":10792,"interventions":10794},"NCT00539786","The Proton Pump Inhibitor (PPI) Test for the Extraesophageal Manifestation of GERD",[92],"2006-03",[10793],"Gastroesophageal Reflux Disease",[10773],{"intervention":10796,"totalTrials":171,"cells":10797},"Ion AmpliSeq BRCA 1\u002F2 Panel (Life Technologies, Carlsbad, CA, USA) ,Ion PGM platform",{"EARLY_PHASE1":10798,"PHASE1":10800,"PHASE2":10802,"PHASE3":10804,"PHASE4":10806,"NA":10808},{"trials":10799,"activeCount":99},[],{"trials":10801,"activeCount":99},[],{"trials":10803,"activeCount":99},[],{"trials":10805,"activeCount":99},[],{"trials":10807,"activeCount":99},[],{"trials":10809,"activeCount":99},[10810],{"nctId":10811,"briefTitle":10812,"status":134,"phases":10813,"primaryCompletion":1098,"completion":1098,"start":4301,"enrollment":10814,"conditions":10815,"interventions":10817},"NCT02963688","BRCA 1\u002F2 Mutation in Korean Patients With Epithelial Ovarian Cancer",[],298,[10816],"To Investigate the Prevalence of BRCA 1\u002F2 Mutation Among Ovarian Cancer",[10796],{"intervention":10819,"totalTrials":171,"cells":10820},"Doxazosin",{"EARLY_PHASE1":10821,"PHASE1":10823,"PHASE2":10825,"PHASE3":10827,"PHASE4":10829,"NA":10831},{"trials":10822,"activeCount":99},[],{"trials":10824,"activeCount":99},[],{"trials":10826,"activeCount":99},[],{"trials":10828,"activeCount":99},[],{"trials":10830,"activeCount":99},[],{"trials":10832,"activeCount":99},[10833],{"nctId":10834,"briefTitle":10835,"status":134,"phases":10836,"primaryCompletion":2760,"completion":2760,"start":2198,"enrollment":1157,"conditions":10837,"interventions":10838},"NCT00730418","Effects of Chronic Use of Doxazosin in Men With Benign Prostatic Hyperplasia",[92],[33],[10819,10819],{"intervention":10840,"totalTrials":171,"cells":10841},"choline alphoscerate",{"EARLY_PHASE1":10842,"PHASE1":10844,"PHASE2":10846,"PHASE3":10848,"PHASE4":10850,"NA":10852},{"trials":10843,"activeCount":99},[],{"trials":10845,"activeCount":99},[],{"trials":10847,"activeCount":99},[],{"trials":10849,"activeCount":99},[],{"trials":10851,"activeCount":99},[],{"trials":10853,"activeCount":99},[10854],{"nctId":10855,"briefTitle":10856,"status":534,"phases":10857,"primaryCompletion":1074,"completion":5105,"start":1206,"enrollment":10858,"conditions":10859,"interventions":10861},"NCT05257902","Clinical Effectiveness of Choline Alphoscerate for Older Adults With Major Depression and Subjective Memory Complaints",[92],120,[10860],"Major Depression",[10840],{"intervention":10863,"totalTrials":171,"cells":10864},"genotype",{"EARLY_PHASE1":10865,"PHASE1":10867,"PHASE2":10869,"PHASE3":10871,"PHASE4":10873,"NA":10875},{"trials":10866,"activeCount":99},[],{"trials":10868,"activeCount":99},[],{"trials":10870,"activeCount":99},[],{"trials":10872,"activeCount":99},[],{"trials":10874,"activeCount":99},[],{"trials":10876,"activeCount":99},[10877],{"nctId":10878,"briefTitle":10879,"status":534,"phases":10880,"primaryCompletion":612,"start":1223,"enrollment":112,"conditions":10881,"interventions":10883},"NCT02747654","Isoniazid Dosage Prediction Model Development",[92],[10882],"NAT2 Genotype",[10863],{"intervention":10885,"totalTrials":171,"cells":10886},"trigger point",{"EARLY_PHASE1":10887,"PHASE1":10889,"PHASE2":10891,"PHASE3":10893,"PHASE4":10895,"NA":10897},{"trials":10888,"activeCount":99},[],{"trials":10890,"activeCount":99},[],{"trials":10892,"activeCount":99},[],{"trials":10894,"activeCount":99},[],{"trials":10896,"activeCount":99},[],{"trials":10898,"activeCount":99},[10899],{"nctId":10900,"briefTitle":10901,"status":134,"phases":10902,"primaryCompletion":4230,"completion":7187,"start":3220,"enrollment":4614,"conditions":10903,"interventions":10905},"NCT02293083","Hyaluronidase for Trigger Point Injection in Myofascial Pain Syndrome",[92],[10904],"Myofascial Pain Syndrome",[10885]]